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Abstract
Distinctions in the biological features of human herpesvirus-6A (HHV-6A) and -6B (HHV-6B)
have recently led to their reclassification from variants to distinct viral species. Unique for
human herpesviruses, these viruses also exist in an endogenous form in ~1% of the human
population, resulting from germ-line chromosomal integration. Chromosomally integrated
human  herpesvirus-6A  (CI-HHV-6A)  and  -6B  (CI-HHV-6B)  genomes  are  inherited  in  a
Mendelian manner, leading to the potential for viral gene expression and/or reactivation in
every cell of the body. As yet, the effects of these integrated viral genomes on health and
their  relationship  to  circulating  viral  strains  remain  unclear.  To  address  this,  next
generation  sequencing  (NGS)  methods  were  established,  to  define  a  readily  utilisable
pipeline  for  genomic  sequencing  of  these  herpesviruses  directly  from  cell  or  tissue
samples. This was first tested to derive the complete genome sequence of a third HHV-6A
strain, AJ. This showed close conservation with a recent North American isolate despite
distinct  geographic  origins,  which  may  reflect  highly  evolved  viral  status  or  recent
emergence. Subsequently, using this defined NGS methodology, supplemented by Sanger
sequencing,  integrated  viral  genomes  were  characterised.  Integration  site  analyses
revealed a high prevalence of integration on chromosome 17, all with a shared junctional
architecture,  indicative  of  a  single  ancestral  germ-line  integration  event  at  this
chromosome.  Genomic  analyses  revealed  CI-HHV-6A  retains  the  full  HHV-6A  gene
complement, with no interrupted open reading frames, and important  cis acting signals
likely  required  for  any  viral  replication/reactivation  mechanism.  Deep  sequencing  with
minority  variant  analysis  suggested  a  potential  reactivation mechanism,  resulting  from
superinfection with circulating viral strains. CI-HHV-6A was also found to diverge at a set of
genes  which  have  been  used  as  markers  of  speciation  amongst  roseoloviruses,  while
retaining many of the features of HHV-6A. One of the key viral immunomodulatory genes,
the  chemokine  receptor  U51,  was  investigated  further.  This  showed  specific  coding
changes and a panel of viral-human chimeric and viral mutant receptor expression vectors
were  generated  to  investigate  this.  Initial  structural  modelling  and  functional
characterisations  were  made  showing  distinctions.  Overall,  the  results  identify  unique
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Chapter 1: Introduction
Herpesviruses are a group of large DNA viruses capable of causing infections in a wide 
range of vertebrate hosts, as well as some invertebrate hosts. Nine members of this group
of viruses infect humans as their primary host; and it is the two most recently classified of 
these human herpesviruses, the betaherpevirus roseoloviruses: human herpesvirus-6A 
(HHV-6A) and human herpesvirus-6B (HHV-6B) [King et al., 2012; Ablashi et al., 2014], that 
are the subject of this thesis. A major defining trait of the herpesviruses is their ability to 
establish life-long latent infection in the host, with periodic reactivation in the face of 
strong anti-viral immune responses. Therefore this failure of the host to completely 
eliminate these viruses makes it clear that herpesviruses must be particularly adept at 
establishing molecular genetic forms and mechanisms for evading or countering the host's
immune responses. Indeed, a number of herpesviruses have even evolved means to 
manipulate host immune responses to aid viral replication.
One mechanism employed by herpesviruses to permit this persistence is the 
establishment of a latent state, whereby the viral genome is maintained in the host cell in 
the absence of infectious virion production. The primary mode of latency for many 
herpesviruses is maintenance  of the viral genome as a nuclear episome in the infected 
cell; with the expression of a limited subset of viral latency genes to permit the replication 
and persistence of the episomes [Grinde, 2013]. However, recent findings with HHV-6A 
and HHV-6B suggest a new paradigm. Unique amongst the human herpesviruses, both 
HHV-6A and -6B can integrate into telomeric regions of the host cell chromosome and it 
has been proposed that this integration provides an alternative mechanism of somatic 
latency [Arbuckle et al., 2010; 2013]. Irrespective of whether this represents a natural 
latency mechanism, in vivo integration of these viruses can, and has occurred. This is 
exemplified by the integration of both HHV-6A and -6B into the germ-line which has 
resulted in an endogenous form of these viruses in ~1% of populations studied to date 
[Pellett et al., 2012]. As yet, the effects of these integrated viral genomes on health and 
their relationship to circulating viral strains remain unclear. A major aspect of this thesis 
concerns the characterisation of the integrated forms of these viruses with comparisons 
to circulating viral strains.
Herpesviruses also extensively employ another strategy to achieve this persistence, that of
immunomodulation. They dedicate significant amounts of their genomes to encoding 
products which can directly interfere with a wide array of innate and adaptive immune 
responses. As they cause infection and establish latency in key effector immune cells, the 
betaherpesvirus subfamily, to which HHV-6A and -6B belong, are particularly accomplished
in this regard. One central immunomodulatory strategy employed most extensively by the 
betaherpesviruses is subversion of the host chemokine system, a key aspect in immune 
response signalling and leukocyte movement during an inflammatory response [McSharry 
et al., 2013; Dagna et al., 2013]. A number of the betaherpesvirus specific genes encode 
homologues of both chemokines and chemokine receptors. When expressed from 
infected cells these viral homologues modulate cellular signalling both to escape immune 
surveillance and assist viral replication, thereby contributing to persistence. This thesis 
investigates both the nature of the germ-line chromosomally integrated forms of HHV-
6A/-6B. As well as an encoded immunomodulatory component, the virally encoded 
chemokine receptor U51, affecting the chemokine system.
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1.1 The Herpesviridae
1.1.1 Classification & Nomenclature
Herpesviruses have been classified into the order Herpesvirales by the International 
Committee on Taxonomy of Viruses (ICTV) [Davison et al., 2009; King et al., 2012]. 
Historically, the primary characteristic for inclusion in the Herpesvirales is the possession of 
a distinct virion morphology. However, the establishment of latency following the 
resolution of acute primary infection, high level of adaption to their natural hosts, 
profound immunomodulatory effects and to a lesser extent the genome organisation can 
also be considered as defining features of the Herpesvirales.
The order Herpesvirales is divided into three families: 
i. Alloherpesviridae – encompassing herpesviruses primarily of bony fish and frogs;
ii. Malacoherpesviridae – containing the viruses of invertebrates;
iii. Herpesviridae – containing the mammal, bird and reptilian herpesviruses.
The latter of these families is the largest, containing ~90 viral species. The viruses within 
this Herpesviridae family are further divided into three subfamilies based originally on 





In addition to their classification, the ICTV have also outlined a formal naming convention 
for herpesvirus species. Under this scheme all designated virus species have an official 
nomenclature, named by the Family (or in some cases Subfamily) taxonomic name of its 
primary natural host followed by 'herpesvirus' and an arabic number [Roizmann et al., 
1992]. However, a number of herpesviruses, especially those infecting humans, possessed 
names which were widely adopted before the introduction of this formal naming 
convention. Therefore these virus names are regarded as synonymous with the formally 
assigned named, although they are generally referred to with dual nomenclature e.g. 
Human cytomegalovirus/Human herpesvirus 5.
1.1.2 General characteristics of Herpesviridae subfamilies
Herpesviruses of humans are present in all three of the Herpesviridae subfamilies, table 
1.1. 
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Table 1.1 The nine members of the Herpesviridae with humans as a primary host.
Alphaherpesvirinae
The Alphaherpesvirinae are primarily defined by their replication and latency in neuronal 
cells [Efstathiou & Preston, 2005]. Three members of the subfamily are regarded as having
a human host. Firstly, herpes simplex virus 1 (HSV-1)/human herpesvirus 1 (HHV-1) which is
primarily known for the clinical presentation of recurrent small blisters/sores around 
mouth known as herpes labialis/cold sores, as a result of episodes of reactivation [Roizman
et al., 2013]. HSV-1 can be regarded as the prototypic virus of the Herpesviridae as a result 
of its use to elucidate much the basic molecular biology of the family. The closely related 
Herpes simplex virus 2 (HSV-2)/human herpesvirus 2 (HHV-2) causes a highly similar 
disease presentation to HSV-1 but with a differing tissue tropism, giving rise to recurrent 
genital lesions [Roizman et al., 2013]. Finally, varicella-zoster virus (VZV)/human 
herpesvirus 3 (HHV-3) causes a primary infection, often acquired during childhood, 
resulting in a acute vesicular rash on the torso known as varicella or chickenpox. In around 
15% of cases, and especially seen in immunocompromised individuals, the latent virus can 
reactivate causing a painful skin rash known as zoster or shingles [Arvin & Gilden, 2013].
Gammaherpesvirinae
The Gammaherpesvirinae are unified by their establishment of latency in lymphocytic cells,
as well as their association with lymphoproliferative diseases and other non-lymphoid 
cancers [Coleman et al., 2010; Amon & Farrell, 2005]. Two members of this subfamily cause
widespread infection in humans. Epstein-Barr virus (EBV)/human herpesvirus 4 infecting 
epithelial and B-cells and is primarily known as an aetiological agent for infectious 
mononucleosis/glandular fever. However, it is also associated with certain types of cancers
including Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma 
[Longnecker et al., 2013]. The second of these is Kaposi's sarcoma-associated herpesvirus 
(KSHV)/human herpesvirus 8 which is associated with Kaposi's sarcoma and primary 
effusion lymphoma [Damania & Cesarman, 2013].
Betaherpesvirinae
This thesis concerns the third subfamily of the Herpesviridae, the Betaherpesvirinae which 
share the general characteristics of slow growth in comparison to the Alphaherpesvirinae 
14
Formal Name Common Name Subfamily
HHV-1 α
HHV-2 α
HHV-3 Varicella zoster virus (VZV) α






Herpes simplex virus 1 (HSV-
1)




Kaposi's sarcoma associated 
herpesvirus (KSHV)
and the distinctive cytopathic effects of multinucleated, 'ballooning' cells which can be 
observed in infected cells. Latency is also established in subsets of haematopoietic cells, 
including bone marrow progenitor and monocytic lineage cells [Sinclair, 2008; Luppi et al., 
1999; Miyake et al., 2006]. Four human herpesviruses are found within this subfamily: 
Human cytomegalovirus (HCMV)/human herpesvirus 5 (HHV-5) a member of the 
Cytomegalovirus genus; human herpesvirus 6A (HHV-6A); human herpesvirus 6B (HHV-6B) 
and human herpesvirus 7 (HHV-7), all members of the Roseolovirus genus. 
HCMV is regarded as the prototypic virus for this subfamily. It possesses a genome which 
at ~235 kbp is substantially larger than those found amongst the roseoloviruses. HCMV is a
ubiquitous infection worldwide, but has received most notoriety as one of the leading 
causes of congenital viral infection following intrauterine transmission of the virus to the 
foetus in approximately 1% of pregnancies [Kenneson & Cannon, 2007]. This can result in 
severe sequelae for the infant such as hearing loss, cognitive impairment and mental 
retardation [Whitley, 2004]. Like HCMV, HHV-6A and -6B also cause congenital infections at
a similar prevalence, however, recent evidence has suggested these HHV-6A/-6B infections
occur by a different mechanism to that of HCMV involving chromosomally integrated 
forms of these viruses [Hall et al., 2008; 2010], a feature discussed further in section 1.3. 
Primary infection with HCMV has long been regarded as asymptomatic, rarely giving rise 
to a mononucleosis-like disease in older children and adults [Grundy, 1990]. Subsequently 
the virus predominantly establishes latency in cells of myeloid lineage, periodically 
reactivating, but may also cause chronic low level infection predominantly at endothelial 
and epithelial sites [Goodrum et al., 2012]. However, increasingly links are being 
established between HCMV infection and developmental impairment in infants and 
immunosenescence [Pawelec et al., 2009; Whitley, 2004; Gompels et al., 2012]. 
The three members of the Roseolovirus genus, HHV-6A, HHV-6B and HHV-7, are T-
lymphotropic viruses [Lusso et al., 1988; Takahashi et al., 1989; Berneman et al., 1992]. 
Primary infection with members of this genus is associated with fever and occasionally a 
rash, exanthem subitum/roseola infantum [Tanaka et al., 1994; Ward, 2005]. For these 
viruses, both lytic replication and the establishment of latency is achieved in effector cells 
of the immune system [Kondo et al., 1991; Miyake et al., 2006]; therefore these viruses are
under close surveillance by the host's immune system. As such they have evolved a variety 
of means to directly evade via latency or indirectly interfere with innate and adaptive 
immune responses. 
Chromosomal integration/latency, speciation and immunomodulatory capabilities of HHV-
6A and -6B are addressed in this thesis and discussed in sections 1.2, 1.3 and 1.4. However, 
as mentioned above the Herpesviridae are grouped together due to a number of shared 
characteristics, such as virion morphology and the establishment of latency. Indeed, 
homology between members of this family has been key to the elucidation of much of the 
basic molecular biology of these viruses. Therefore the remainder of this section is 
devoted to the discussion of a number of general aspects of the Herpesviridae which relate
to the HHV-6A and -6B topics in this thesis.
1.1.3 Virion Morphology
The advent of nucleic acid sequencing and vast advances in high-throughput sequencing 
technology within the last decade have led to sequence based phylogeny emerging as a 
major influence on classification. However, historically herpesviruses were identified 
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through the possession of a distinct morphology of their mature infectious virion. It 
consists of linear double-stranded DNA (dsDNA) genome packaged into a T = 16 
icosahedral capsid. This highly organised capsid structure consists of a total of 162 
capsomeres, 150 hexameric capsomeres and 11 pentameric capsomeres, with the final 
pentameric position being occupied by a portal complex required for entry and exit of the 
genomic DNA [Brown & Newcomb, 2011]. The ~125 nm capsid structure is then coated in a
much less ordered proteinaceous matrix known as the tegument. The tegument is 
composed from a large number of different viral proteins important for virion egress and 
the very early stages of host cell infection [Pellett & Roizman, 2013; Guo et al., 2010]. 
Finally the tegument is in turn wrapped in a host-derived lipid envelope producing a ~200 
nm in diameter virion, figure 1.1 [Mettenleiter et al., 2009]. A number of viral 
glycoproteins protrude through the lipid envelope which are essential for viral replication. 
These contribute to the processes of virion attachment, cell entry as well as the 
envelopment and maturation of viral particles and thus are a major contributing factor to 
biological differences that define herpesvirus speciation [Eisenberg et al., 2012]. 
Figure 1.1 Schematic representation of the herpesvirus (HSV-1) virion [Figure from Hulo et al.,
2011].
1.1.4 Genome
Densely packaged into the capsid core of the mature infectious herpesvirus virion is the 
viral genomic DNA. Which despite large differences in size, composition and sequences 
retain a number of distinct characteristics. Herpesviruses possess linear, dsDNA (Baltimore 
classification group I) genomes, which contain a number of direct or inverted repeats and 
possess unpaired nucleotides at their termini, as seen in figure 1.2 [Pellett & Roizman, 
2013]. 
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Figure 1.2 Herpesvirus genome classes. Unique regions shown as horizontal lines. Repeat regions
shown as boxes with arrows indicating orientation. (A) Class A consists of a unique sequence
flanked by direct repeats. (B) Class B again consists of a unique region flanked by repeats, but
these repeats consist of tandemly repeated sequence. (C) Class C resembles the class B genome
structure with an additional internal set of direct repeats. (D) Class D contain two unique regions
(long and short) each flanked by inverted repeats. (E) Class E resembles class D but with larger
inverted repeats.  (F) Class F is represented by a single member of the Betaherpesvirinae, which
lacks the repeat structures found in other herpesviruses [Figure adapted from Davison, 2007].
The relationship between the genomes of members of three families that make up the 
Herpesvirales can be difficult to ascertain, due to the large amount of divergence time 
since the last common ancestor. In fact, only three genes display clear nucleotide 
sequence homology between the three families: the DNA polymerase (HSV-1 UL30), 
dUTPase (HSV-1 UL50) and the terminase (HSV-1 UL15). Even then, for two of these genes,
the DNA polymerase and dUTPase, independent gene capture events or convergent 
evolution in the different families cannot be ruled out [McGeoch et al, 2006]. However, 
within the relatively closer related Herpesviridae family, an increasing amount of distinctive
genomic features can be observed. These three subfamilies possess a number of 'core' 
genes, representing those which appear to be from a common ancestor [Davison, 2007]. 
Generally speaking these core genes encode products required to make a virus particle 
and are essential for growth in cell culture. They tend to be positioned towards the centre 
of the genomes, while genes obtained since the respective divergence events occupy 
positions nearer the termini of the genomes. In addition to their central location, they are 
found within seven so called 'gene blocks' of conserved genes (figure 1.3), which in most 
cases are ordered in the same manner in members of the same subfamily [Gompels et al., 
1995; Davison, 2007]. There are 43 Herpesviridae core genes, however, three of these 
genes, the thymidine kinase, helicase and the small subunit from the ribonucleotide 
reductase, have been lost from certain lineages [McGeoch et al, 2006].
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Figure 1.3 Arrangement of conserved gene blocks in the Herpesviridae subfamilies. Genomic
unique regions are designated a solid line, repeat regions as shaded boxes and gene block
locations labelled I-VII [Adapted from Gompels et al., 1995].
1.1.5 General Characteristics of Lytic Replication
The replication cycle of all herpesviruses share notable similarities, with HSV-1 used as the 
general model for herpesvirus replication. Primary attachment of the virion to the host cell
surface occurs through relatively non-cell type specific and reversible interactions 
between viral envelope glycoproteins and glycosaminoglycans (GAGs) [Shukla & Spear, 
2001]. This is followed by higher affinity cell type specific interaction(s) with the viral entry 
receptor(s). Within the Herpesviridae three envelope glycoproteins are conserved which 
include, gH and gL, which form the gH/gL complex and gB. These have been shown to be 
core components in the viral entry machinery for members of all three subfamilies [Reske 
et al., 2007; Ryckman et al., 2008; Isaacson & Compton, 2009; Liu et al., 1993; Chou & 
Marousek, 1992; Hutt-Fletcher, 2007]. However, many herpesviral species possess 
additional glycoproteins and accessory proteins which are essential to the attachment and 
entry process, the diversity in which plays a large part in determination of the distinct cell 
tropisms of each species [Krummenacher et al., 2013; Mori et al., 2003a, 2004].
 
While endocytosis and viral fusion with the endosomal membrane has been noted for 
some species in vitro, the primary mechanism of entry in vivo appears to be fusion of the 
viral envelope with the plasma membrane of the host cell [Nicola et al., 2003; Spear & 
Longnecker, 2003]. Following the fusion event, the viral capsid and associated tegument 
proteins are deposited into the cytoplasm of the host cell, from where they must gain 
access to the nucleoplasm to continue the replication cycle. As diffusion of molecules 
larger than ~500 kDa is subject to restrictions in the cytoplasm, the capsid requires an 
active transport mechanism to reach the nuclear pore complexes for nuclear entry [Sodeik,
2000]. For this, the herpesvirus capsids utilise components of the hosts cytoskeletal 
transport machinery to traverse the cytoplasm on microtubule networks. The capsids 
associate with ATP catalysing dynein/dynactin motor complexes, to move to microtubule 
organising centres anchored in close proximity to the nucleus [Dohner et al., 2002; Dohner
& Sodeik, 2005]. Once at this site they bind filaments associated with the nuclear pore 
complexes; interactions which lead to destabilisation of the capsid, release of the viral 
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DNA and its transport through the nuclear pore to the nucleoplasm [Ojala et al., 2000; 
Radtke et al., 2006]. 
Once in the nucleoplasm, covalent linkage of the termini of the linear genome results in a 
circularised form [Garber et al., 1993]. Subsequently, with the aid of tegument proteins, 
host derived transcription machinery is utilised for transcription of viral genes. This gene 
transcription is tightly regulated and follows a 'cascade' mechanism, in which viral proteins
are transcribed and translated in three groups sequentially, with expression of members 
of the next kinetic class of genes being dependent on expression of genes from the 
previous class. Firstly, the immediate early (IE) group comprising genes predominantly 
involved in regulation of viral gene expression and establishment of a suitable replication 
environment. This is followed by the early (E) group, primarily including those genes 
responsible for DNA replication. Finally the late (L) gene group, possessing genes for the 
structural components and glycoproteins of the virions [Honess & Roizman, 1974; Tsao et 
al., 2009; Jenner et al., 2001].  
DNA replication is initiated through DNA rearrangements which permit the access of a 
number of virally encoded initiator proteins to the origin of lytic replication(s) (oriLyt). 
Subsequently a virally encoded polymerase/elongation complex is formed and genomic 
replication proceeds via 'rolling circle' replication, in which the circularised parental 
genome results in the production of head-to-tail full length genomic concatemers [Jacobs 
et al., 1979; Deiss et al., 1986; Thomson et al., 1994a; Turner et al., 2002; Zimmermann & 
Hammerschmidt, 1995]. Formation of the precursor capsid structures occurs concurrent 
with DNA replication. Such that following rolling circle replication, the concatameric units 
are cleaved into unit length genomes and packaged into precursor capsids through their 
portal complexes; due to the action of virally encoded terminase proteins on highly 
conserved cleavage and packaging sequences (pac1 and pac2) at the termini of the unit 
length genomes [Homa & Brown, 1997; Thomson et al., 1994a; Turner et al., 2002; 
Zimmermann & Hammerschmidt, 1995]. 
The current prevailing model suggests the nucleocapsids undergo an envelopment-de-
envelopment process in order to traverse the nuclear membrane. This is mediated by 
primary tegument proteins and non-structural proteins, resulting in deposition of the 
nucelocapsid in the cytoplasmic compartment [Mettenleiter, 2002]. This nucleocapsid then
associates with remaining tegument proteins before a secondary envelopment process 
then occurs on endosomal/Golgi complex membranes. Utilisation of the host's vesicular 
transport and exocytic machinery then permits egress of the mature virion by budding at 
the plasma membrane [Mettenleiter, 2002; Torrisi et al., 1999; Mori et al., 2008].
1.1.6 General Characteristics of Latency
Productive lytic infection cycle, as described above, is not the only possible outcome of 
host cell infection. Importantly, the establishment of latency following the resolution of 
acute primary infection can also be considered a major defining feature of the 
Herpesvirales. This latent state refers to maintenance of the viral genome in the absence of
infectious virion production, thereby allowing for life-long persistence of the virus in the 
host. The ability to reactivate from this latent state to the lytic replication cycle, being the 
prerequisite that defines latency from abortive infection. Throughout the life of the host 
this pool of latently infected cells permits sporadic instances of viral reactivation; allowing 
for the initiation of lytic replication from the latent genomes and thus production of 
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infectious virions, primarily based upon the immune status of the host. [Pellett & Roizman, 
2013]. 
The establishment of latency is highly cell type specific, a feature which plays a key role in 
the classification of members of the Herpesviridae. However, for all subfamilies the primary
mode of latency has long been believed to be the maintenance of the genome as a nuclear
episome associated with cellular histones. This episomal structure displays a highly 
restricted pattern of gene expression maintained by both host and viral factors. Those 
genes which are expressed mainly involve factors contributing to maintenance of latency, 
immune evasion, and reactivation [Grinde, 2013]. 
However, recent findings with some members of the Herpesviridae, including HHV-6A and 
-6B, suggest that this central dogma may not be true for all herpesviruses [Delecluse & 
Hammerschmidt, 1993; Delecluse et al., 1993; Kaufer et al., 2011; Arbuckle et al., 2010; 
2013]. Both HHV-6A and -6B can integrate into telomeric regions of the host cell 
chromosome and it has been proposed that this integration may also provide an 
alternative mechanism of latency [Arbuckle et al., 2010; 2013]. Uniquely amongst 
herpesviruses, in ~1% of populations studied to date, integration of HHV-6A and -6B has 
occurred in the germ-line [Pellett et al., 2012]. Not only is viral genomic DNA present in 
every nucleated cell of the body, the integrated form of the virus can be transmitted 
vertically between generations in a Mendelian manner, as originally shown by Daibata and 
colleagues [Daibata et al., 1998b; Daibata et al., 1999c]. These chromosomally integrated 
forms of HHV-6A and -6B are a major topic in the work presented here. Therefore 
extensive discussion of this viral integration will be discussed in its own section below 
(section 1.3).
1.2 Human Herpesvirus-6A & -6B
1.2.1 Introduction
In 1986, during the cultivation of peripheral blood mononuclear cells (PBMCs) from AIDS 
patients and other lymphoproliferative disorders, the existence of large, refractile mono- 
or binucleated cells often with nuclear and/or cytoplasmic inclusion bodies, was noted. 
Examination of these cells led to the isolation of a novel virus possessing herpesvirus-like 
morphology, initially named human B-lymphotropic virus (HBLV) [Salahuddin et al., 1986]. 
Subsequent studies showed it was predominantly a T lymphotropic herpesvirus, therefore 
the name of this virus was revised to Human Herpesvirus-6 (HHV-6) to reflect this and to 
adhere to the ICTV classification scheme used for other herpesviruses [Ablashi et al., 
1987]. As such this represents the first recorded isolation of one of the HHV-6 species 
(now known as HHV-6A strain GS). This was closely followed by isolation of further strains, 
HHV-6A U1102 and AJ [Downing et al., 1987; Tedder et al., 1987] and HHV-6B strains Z29 
and HST [Lopez et al., 1988; Yamanishi et al., 1988]. The first complete clones of the 
genome were then derived for HHV-6A strain U1102 [Martin et al., 1991a]. Followed by 
derivation of the complete genome sequence [Gompels et al., 1995]. This combined with 
better replicative properties in cell culture, led to the establishment of HHV-6A strain 
U1102 as the prototype for the Roseoloviruses.
Soon after the initial isolation of HHV-6, it became clear that notable differences in the 
restriction endonuclease cleavage patterns, the ability to replicate in certain T cell lines, 
reactivity to a number of monoclonal antibodies and nucleotide sequence, could be 
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observed among the HHV-6 strains isolated [Wyatt et al., 1990; Schirmer et al., 1991; 
Ablashi et al., 1991; Aubin et al., 1991]. These distinctions led to the classification of HHV-6
strains into two variant groups: A and B [Ablashi et al., 1993]. However, as data was 
accrued on the strains of HHV-6 falling into these two variant categories, the distinction 
between the them with regards to epidemiology, disease associations and biological 
features became clearer. This in combination with a lack of data suggesting recombination
between the variants implied the two groups occupy different ecological niches [Ablashi 
et al., 2014]. As such, despite strains in the two variants sharing in the region of 90% 
overall nucleotide sequence homology, the clear distinctions between these variant 
groups has meant that they have recently been reclassified as distinct viral species, HHV-
6A and HHV-6B, by the ICTV [King et al., 2012; Ablashi et al., 2014]. The prototypic strains 
for each species are now strain U1102 for HHV-6A and strain Z29 for HHV-6B. 
1.2.2 Genome 
Currently, complete genome sequences for two HHV-6A strains, the 159 kbp U1102 strain 
and the 157 kbp GS strain, and also two HHV-6B strains, the 162 kbp Z29 strain and the 
162 kbp HST strain, have been deposited in the GenBank sequence database (accession 
numbers X83413.1, KC465951.1, AF157706.1 and AB021506.1, respectively) [Gompels et 
al., 1995; Gravel et al., 2013a; Dominguez et al., 1999; Isegawa et al., 1999]. HHV-6A strain 
U1102 was isolated from reactivated infection in an adult HIV/AIDS patient from Uganda, 
while GS is from a mixture of American/Jamaican patients with lymphoproliferative 
disorders, including a HIV/AIDS patient [Downing et al., 1987; Salahuddin et al., 1986]. For 
HHV-6B, Z29 was isolated from a HIV/AIDS patient from Zaire (now Democratic Republic of
the Congo) [Lopez et al., 1988], while strain HST was isolated from a Japanese infant 
during primary infection [Yamanishi et al., 1988], representing the only childhood primary 
infection strain sequenced to date.
A conserved genome architecture can be observed between HHV-6A and HHV-6B. This 
consists of a large ~144 kbp central unique region, which is interrupted by three repeat 
regions (R1-R3), as well as being flanked by two ~8 kbp direct repeats (DRs) located at the 
left (DRL) and right (DRR) termini of the genome. Predicted ORFs in the DRs are designated
DR followed by an arabic number. Both DRs are flanked by herpesviral conserved genome 
cleavage and packaging signals (pac) as well as vertebrate telomeric repeat arrays which 
appear to play a role in integration of HHV-6A and -6B genomes into chromosomal DNA 
[Thomson et al., 1994a; Gompels & Macaulay 1995; Achour et al., 2009; Arbuckle et al., 
2010]. Variation in the size of these DR and R1-R3 regions, is predominantly responsible 
for the size difference observed between the two species [Dominguez et al., 1999; 
Isegawa et al., 1999]. Differences in these repeat regions are also a major contributor to 
the sequence variation observed between the two species. The overall nucleotide 
sequence identity of HHV-6A and HHV-6B is in the region of 90% [Dominguez et al., 1999; 
Isegawa et al., 1999]. But further analyses shows the divergence includes these 
mismatched repetitive sequences as well as a number of hypervariable genes, such as 
those coding for the envelope glycoproteins, involved in immnomodulation and those 
important in the early stages of infection (U86-U95, excluding U94) [Gompels & Kasolo, 
2006 ]. Therefore, much of the rest of the unique region of the genome displays a higher 
level of sequence conservation, averaging ~95%.
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Figure 1.4 HHV-6A genome organisation. Human herpesvirus conserved genes (black),
betaherpesvirus conserved genes (shaded), HHV-6A unique (white). Direct repeat regions are
labelled TR and internal repeat regions are labelled R1-R3. [Figure from Gompels & Kasolo, 2006].
The central unique region of HHV-6A and HHV-6B contains at least 100 genes, ORFs 
designated U1 – U100, with a minority encoding multiple exons. HHV-6B has been 
suggested to contain nine additional ORFs (119 ORFs) compared to HHV-6A (110 ORFs), 
which have been termed B1 – B9. However, the protein coding status of a number of these
ORFs has yet to be determined [Megaw et al., 1998; Dominguez et al., 1999]. Comparisons 
of related genomes suggests a verified list of 85 genes [Megaw et al., 1998]. The unique 
region displays some further general subdivisions. The left end of the genome contains 
predominantly betaherpesviral conserved genes, totalling around 27 genes. The central 
region contains 41 of the 43 core genes, that is those conserved among the Herpesviridae 
family, which are found in the characteristic seven gene blocks, in a betaherpesviral 
conserved arrangement [Gompels & Kasolo, 2006]. While the right end of the genome 
contains predominantly Roseolovirus and HHV-6A and -6B specific genes, figure 1.4.  
Interestingly, HHV-6A and -6B appear to encode a number of genes which share some 
homology to cellular and other viral family genes. As such it seems gene acquisition, or 
possibly convergent evolution, have played an important role in HHV-6A and HHV-6B 
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evolution. A number of these genes are of note with regard to the topic of this work. U83 
encodes a functional chemokine homologue, while U12 and U51 encode functional 
chemokine receptor homologues. All of which may contribute an immunomodulatory role 
to HHV-6A and -6B. U94 encodes a protein with homology to the Adeno-associated 
parvovirus type 2 (AAV-2) Rep 68/78 proteins and as such has been strongly implicated as 
playing a role in HHV-6A and -6B chromosomal integration events, discussed further in 
section 1.3.
1.2.3 Cellular & Tissue Tropism 
Both HHV-6 species display a broad cellular tropism in vitro, presumed to be due to the 
ubiquitous expression of their primary cellular receptor, CD46; however, productive lytic 
infection of HHV-6A and -6B, both in vitro and in vivo, predominantly occurs in non-naive 
CD4+ T lymphocytes [Lusso et al., 1988; Takahashi et al., 1989; Grivel et al., 2003; De Bolle 
et al., 2005a]. In vitro differences in the ability of HHV-6A and -6B to infect certain T-cell 
lines and other cell types was a major basis for the classification of both viruses as 
separate species [Ablashi et al., 2014]. Notably, HHV-6A has a wider cellular tropism with 
productive infection in a range of cytotoxic effector cells: CD8+ T cells [Lusso et al., 1991; 
Grivel et al., 2003], natural killer cells [Lusso et al., 1993], and gamma/delta T cells [Lusso 
et al., 1995]. In addition HHV-6A also appears to replicate more efficiently in a variety of 
neuronal cells, potentially providing a basis for increased neuropathology of HHV-6A: 
neural stem cells [De Filippis et al., 2006], astrocytes [Donati et al., 2005] and 
oligodendrocytes [Ahlgvist et al., 2005]. 
A number of factors have been proposed to contribute to the differential cell tropism 
observed between HHV-6A and -6B. Variation in the affinity of HHV-6A and -6B for CD46 
has been noted, with HHV-6B displaying a lower affinity than HHV-6A [Santoro et al., 1999]
and the potential utilisation of additional or alternative cellular receptors, exemplified by 
the recent identification of CD134 as a specific receptor for HHV-6B [Tang et al., 2013], 
discussed further in section 1.2.4. Closely linked to this is the large sequence variation 
observed between a number of the HHV-6A and HHV-6B envelope glycoprotein 
homologues, gO and gQ [Mori, 2009a]. While, the sequence variation in the viral 
chemokine, U83, between the species and the subsequent ability to chemoattract 
different cell populations has also been implicated in determining cell tropism [Luttichau 
et al., 2003; Dewin et al., 2006; Catusse et al., 2007; 2009; Clark et al., 2013].
Latent infection has been demonstrated to occur within bone marrow progenitor cells 
[Luppi et al., 1999]; monocytes/macrophages [Kondo et al., 1991]; as well as reports in 
myeloid, astrocytoma and oligodendrocyte cell lines [Yasukawa et al., 1999; Yoshikawa et 
al., 2002; Ahlqvist et al., 2005]. However, again the greater appreciation of the differential 
target cells of these viral species, means the definition of the true latency reservoirs of 
these viral species requires further clarification. In addition, the recognition of germ-line 
chromosomally inherited HHV-6A and -6B (CI-HHV-6A/-6B), discussed further in section 
1.3, could be considered to cloud this distinction in a subset of the population, depending 
on the reactivation capabilities in certain cell types.
HHV-6A and -6B DNA can also frequently be detected in an array of both healthy and 
pathological human tissues [Di Luca et al., 1996; De Bolle et al., 2005b]. Of note, the 
salivary glands and adenoid tissue have been identified as a site of viral replication and 
persistence for HHV-6B [Jarrett et al., 1990; Fox et al., 1990; Di Luca et al., 1995; Roush et 
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al., 2001; Sato et al., 2009], which is consistent with the major route of transmission of 
HHV-6B being salival secretions from close contacts. In addition, while both HHV-6A and 
HHV-6B are considered neurotropic viruses, evidence suggests HHV-6A replicates more 
readily in the CNS and is associated with increased neuropathology [Hall et al., 1998; Chan 
et al., 2001; Ablashi et al., 2014].
1.2.4 Replication Cycle & Latency
In many respects the replication cycles of HHV-6A and -6B follow the generalised 
Herpesviral cycle outlined in section 1.1.5 and 1.1.6. However, an exception to this may 
arise in the possible mode for the establishment and maintenance of latency. Recent 
evidence has suggested integration of the viral genome into the host cell chromosome 
may provide an alternative mechanism for latency in HHV-6A and -6B, instead of nuclear 
episomal maintenance as predominantly observed in the rest of the Herpesvirales 
(discussed in detail in section 1.3). The following will therefore focus on supplementing 
the discussion of the replication cycle previously outlined with features specific to HHV-6A 
and -6B.
Initial reports identified the cellular receptor for both HHV-6A and HHV-6B as the human 
complement regulator protein CD46, also known as membrane cofactor protein (MCP)  
[Santoro et al., 1999]. CD46 is a type I transmembrane glycoprotein primarily noted as an 
inhibitor in the complement system, but which has also been found to possess important 
roles in T cell regulation and fusion during fertilisation. It has also been identified as a 
receptor for a diverse array of human viral and bacterial pathogens, including measles 
virus, a number of adenoviruses, Streptococcus pyogenes, Neisseria gonorrhoeae, and 
Neisseria meningitidis [Cardone et al., 2011]. Structurally it consists of four short consensus 
repeats (SCR1 – 4) at the N-terminus, followed by a serine, threonine and proline rich 
domain, a transmembrane domain and a short C-terminal cytoplasmic domain [Liszewski et
al., 1991]. It is expressed on all nucleated cells, which provides some insight into the 
relatively broad in vitro human cell tropism of HHV-6A and -6B. In the initial reports of the 
HHV-6 cellular receptor, an anti-CD46 mAb as well as a soluble form of CD46 were shown 
to inhibit HHV-6A and -6B-mediated cell fusion (HHV-6A strain GS and HHV-6B strains Z29 
and PL1). In addition, gain of function was demonstrated through the expression of 
human CD46 rendering non-human cells susceptible to HHV-6A and -6B entry [Santoro et 
al., 1999]. Subsequently, the viral ligand important for HHV-6A and -6B fusion and entry 
was found to be a glycoprotein complex consisting of the gH/gL/gQ1/gQ2 glycoproteins 
(U48, U82 and U100), gH being primarily responsible for CD46 binding [Santoro et al., 
2003; Mori et al., 2003b; Tang et al., 2011; Kawabata et al., 2011; Tanaka et al., 2013; 
Jasirwan et al., 2014]. This complex was found to be interacting with at least the SCR2 and 
SCR3 domains, and possibly also the SCR4 domain, of CD46 in the case of HHV-6A [Mori et 
al., 2002; Greenstone et al., 2002; Santoro et al., 2003]. 
However, HHV-6A and -6B may utilise additional receptors, or especially with regard to 
HHV-6B, utilise an alternative receptor(s). Firstly, for the HHV-6B strain HST the 
gH/gL/gQ1/gQ2 was found not to bind CD46 [Mori et al., 2004] and did not mediate fusion
from without in cells expressing human CD46 [Mori et al., 2002]. Secondly, variability in the
ability of HHV-6A strain GS to infect a panel of CD4+ T-cell lines was observed, even with 
the transfection of CD46 into the cell lines to account for different isoforms of CD46 
[Santoro et al., 1999]. 
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Thirdly, both HHV-6A and -6B have been found to possess another viral envelope 
glycoprotein complex, gH/gL/gO (U48, U82 and U47), also containing the Herpesviridae 
conserved glycoproteins gH and gL [Mori et al., 2004]. Since these glycoproteins have 
been implicated as participants in herpesvirus cell fusion and entry, a number of attempts 
are currently being made to characterise the role of this gH/gL/gO glycoprotein complex 
[Paterson et al., 2002]. Also of note is that the products of the gO gene from HHV-6A and 
-6B only share ~77% amino acid sequence identity, much lower than that found amongst 
the other envelope glycoproteins. Therefore interactions of the gH/gL/gO complex have 
been postulated to be involved in the different cell tropisms observed for the two viral 
species [Mori et al., 2004]. Indeed, recently it has been suggested that at least HHV-6B 
strains HST and KYO utilise CD134, also known as OX40, as the cellular receptor [Tang et 
al., 2013]. CD134 is a member of the tumour necrosis factor receptor superfamily which is 
preferentially expressed on the surface of activated CD4+ T cells, but also present on 
activated CD8+ T cells  and other T cell subsets at lower levels [Croft, 2010]. Interestingly, 
CD134 is rarely present on glial cells [Croft, 2010], which may play a role in the increased 
neurotropic capacity of HHV-6A over that of HHV-6B, which has been observed. 
Another envelope glycoprotein, gB, also appears to have a role in the entry process 
[Takeda et al., 1996; Mori et al., 2002]. While the mechanism of action for gB in HHV-6A 
and -6B currently remains undetermined, identification of its role in other herpesviruses 
combined with high conservation of the gene among the Herpesviridae suggests it likely 
plays a role in the membrane fusion event [Pereira, 1994; Isaacson & Compton, 2009].
 
Entry results in release of the capsid and associated tegument proteins in the cytoplasm of
the host cell. Cytoplasmic transport of the capsid and nuclear entry has received little 
attention for HHV-6A/-6B. But it is presumed to undertake a mechanism similar to that of 
HCMV which utilises the hosts microtubule network to reach the nucleus and entry of the 
viral genome via nuclear pore complexes [Ogawa-Goto et al., 2003; Dohner & Sodeik, 
2005]. Subsequently lytic replication proceeds almost immediately following viral entry via
'cascade' gene expression, DNA replication and capsid packaging and assembly, as outlined
in section 1.1.5. There are however, notable differences in the egress pathway. Unlike the 
other herpesviruses which have received extensive study, HHV-6A/-6B glycoproteins were 
found to be undetectable at the plasma membrane in lytically infected cells [Cirone et al., 
1994]. Instead it was found they accumulate predominantly in lipid rafts in ER/Golgi 
apparatus membranes [Cardinali et al., 1998; Kawabata et al., 2009], as such it is believed 
that association with the viral envelope glycoproteins occurs during a secondary 
envelopment on these structures prior to egress via the host's vesicular transport system 
[Torrisi et al., 1999].
Lytic replication of HHV-6A and -6B has profound effects on host cells. The most readily 
identifiable of these are the cytopathic effect of multinucleated, ballooning cells and 
apoptosis of cells [Inoue et al., 1997; Yasukawa et al., 1998; Ichimi et al., 1999]. But lytic 
infection also produces notable effects on the production of cytokines, upregulation of 
IFN-α [Kikuta et al., 1990], IL-1β [Flamand et al., 1991], TNF-α [Flamand et al., 1991] and IL-
15 [Flamand et al., 1996], downregulation of IL-2 [Flamand et al., 1995] and IL-12 [Smith et 
al., 2003] and modulation of CCL5 production [Milne et al., 2000; Caruso et al., 2003], 
which have been linked to roles in both immunomodulation and viral infection control 
[Takahashi et al., 1992; Smith et al., 2003; Milne et al., 2000; Caruso et al., 2003]. As well as 
affecting the expression of cell surface markers, most notably the induction of CD4 
expression permitting infection of cells by HIV-1 [Lusso et al.,, 1991; Furukawa et al., 1994].
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Following initial infection, lytic replication and seroconversion, the persistence of HHV-6A 
and -6B has long been thought to occur either through entering a true latent state due to 
the formation of circular genomic episomes as observed among other herpesviruses or 
possibly through low level replication at distinct sites. However, recent findings have led 
to the suggestion that HHV-6A and -6B may in fact utilise an alternative or additional 
mechanism for latency, that of chromosomal integration [Arbuckle et al., 2012, 2013]. 
Since the integration of HHV-6A and -6B is a major theme of the work presented in this 
thesis, extensive discussion of this feature has been moved to it's own section below 
(section 1.3).
Latency associated transcripts and latency associated gene expression have been detected
for HHV-6A and HHV-6B. The U94 gene product was found to be expressed at higher 
levels during latency. Stable expression of U94 in a lymphoid cell line permitted HHV-6 
infection but restricted viral replication, and as such a role in the establishment and/or 
maintenance of latency was proposed [Rotola et al., 1998; Caselli et al., 2006]. While, due 
to their expression at higher levels prior to reactivation four latency associated transcripts 
located in the IE1/IE2 gene region, have been implicated in the promotion of reactivation 
[Kondo et al., 2002; Kondo et al., 2003]. Expansion of these IE1/IE2 latency associated 
transcripts, and subsequent reactivation, was associated with cellular stimuli [Kondo et al., 
2003]. But superinfection with HHV-7 has also been shown to reactivate latent HHV-6B, 
presumed to be by a transactivating function [Katsafanas et al., 1996; Tanaka-Taya et al., 
2000].
1.2.5 Transmission and Epidemiology
In those populations studied to date primary infection with a HHV-6 species, most 
commonly HHV-6B, occurs within the first two years of life [Okuno et al., 1989; Enders et 
al., 1990; Zerr et al., 2005a] coinciding with a decline in the levels of maternal antibodies, 
which are believed to confer at least some level of protection against infection [Farr et al., 
1990; Hall et al., 1994]. Despite some variance in the estimates, possibly in part due to 
geographic variation but also likely due to the different methodologies employed, the 
overall prevalence of HHV-6A and -6B infection is now believed to be >90%, but there 
appear to be geographic differences [Enders et al., 1990; Di Luca et al., 1994; Zerr et al., 
2005a].
In most populations, HHV-6B has been identified as the initial HHV-6 species acquired and 
predominantly responsible for fever and exanthem subitum disease associated with 
primary infection [Yamanishi et al., 1988; Dewhurst et al., 1993; De Bolle et al., 2005a]. 
Primary infection with HHV-6A is rare, but symptomatic cases have been noted [Ward et 
al., 2005; Hall et al., 2006]. Instead HHV-6A is thought to occur asymptomatically later in 
life [De Bolle et al., 2005a]. Co-infection with multiple HHV-6B strains, as well as HHV-6A 
and HHV-6B together has also been observed in adult populations [Cone et al., 1996]. It 
has been shown that there may be geographic differences in primary infection and species
prevalence. Studies in Zambia show HHV-6A is equally prevalent with HHV-6B in 
symptomatic febrile infant infection and predominant in a population study of 
asymptomatic children [Kasolo et al., 1997; Bates et al., 2009]. Global seroprevalance 
studies will require specific reagents to further explore relative distributions, but these are
not yet available since immunodominant proteins in the two HHV-6 species are cross-
reactive.
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As highlighted, primary infection with either HHV-6A or -6B primarily occurs due to 
horizontal transmission in the first years of life. Indicative of transmission from close 
contacts during this period. The frequent detection of HHV-6A and/or -6B DNA in saliva [Di
Luca et al., 1995; Tanaka-Taya et al., 1996; Zhao et al., 1997] has led to suggestions that 
asymptomatic shedding of HHV-6A and -6B in the saliva of close family members likely 
represents the main route of transmission. However, while HHV-6B is frequently detected 
in saliva/salivary gland tissue, detection of HHV-6A has been limited [Collot et al., 2002]. 
Therefore, alternative routes of transmission may exist. Recent demonstration of the 
presence of HHV-6A and -6B DNA in the nasal cavity, has led to suggestions that this site 
represents an in vivo reservoir which could permit host to host transmission [Harberts et 
al., 2011]. Detection of HHV-6A and -6B in the cervix [Leach et al., 1994; Okuno et al., 
1995] and stool samples [Suga et al., 1998] have been used to implicate the possibility of 
perinatal and faecal-oral transmission routes, however, evidence for such routes remains 
limited. 
Congenital HHV-6A and -6B infections can also occur, albeit with a much rarer occurrence 
of approximately 1% of the population, similar to that of HCMV. This can be due to 
transplacental passage of maternal HHV-6A or -6B, however, recent findings suggest this 
detection is most frequently from the inheritance of chromosomally integrated form of 
these viral species, discussed in section 1.3 [Hall et al., 2008; Hall et al., 2010].
1.2.6 Primary Infection, Reactivation & Reinfection
Primary infection with one of the HHV-6 species in infants is associated with an acute 
febrile illness, lasting 3-7 days [Asano et al., 1994; Hall et al., 1994]. In a subset of patients 
(~25%), the initial high temperature fever, is followed by the development of a 
maculopapular rash, clinically referred to as exanthem subitum/roseola infantum/sixth 
disease, initially on the torso but later spreading to the extremities [Asano et al., 1994]. In 
the majority of populations studied, HHV-6B has been found to be the causative agent of 
symptomatic primary infections [Yamanishi et al., 1988; Dewhurst et al., 1993; De Bolle et 
al., 2005a], however, the opposite has been found to be true in a Sub-Saharan African 
population [Kasolo et al., 1997; Bates et al., 2009]. As highlighted by epidemiological 
studies, primary infection in immunocompetent adults is a rare occurrence, but where 
studied there has been suggestions of an increased severity compared to the infant 
infection, with presentations of extended lymphadenopathy and mononucleosis-like 
disease noted [Niederman et al., 1988; Akashi et al., 1993]. In immunocompetent 
individuals these primary infections are generally regarded as benign and self-limiting. 
However, in rare cases, and also more frequently amongst immunosuppressed individuals, 
complicated primary infections may occur associated with much more severe disease 
manifestations, such as liver dysfunction/hepatitis, myocarditis, thrombocytopenia, 
gastrointestinal symptoms and central nervous system complications [De Bolle et al., 
2005a]. 
As with all members of the Herpesviridae, primary infection with HHV-6A/-6B results in life-
long persistence of the virus. The virus remains in a latent state, with the ability to 
reactivate periodically. This reactivation is primarily associated with immunosuppression 
and again in immunocompetent individuals is most frequently asymptomatic and self-
limiting [Caserta et al., 2004]. However, in cases of prolonged immunosuppression such as 
seen in transplant recipients and HIV positive individuals, symptomatic reactivation occurs 
27
at high frequency, often associated with severe disease manifestations [Clark & Griffiths, 
2003]. In addition, following primary infection, reinfection with further HHV-6A/-6B strains
and associated disease manifestations remains a possibility, however, to date the effects 
of these secondary acquisitions remains poorly defined [Agut, 2011].  
1.2.7 Diagnosis
As in much of virology, the gold standard for diagnosis for active infection by HHV-6A/-6B, 
be that primary, reactivated or re-infection, remains virus isolation and culture. However, 
this method is both time and resource intensive, as well as being less useful in the 
detection of latent and chromosomally integrated infections. As such methods based on 
serology, antigen detection and DNA/RNA detection tend to be more readily employed, 
yet due to the similarity between HHV-6A and -6B these assays possess a number of 
limitations. 
Serologic methods that have been employed include indirect immunofluorescence assays 
(IFA), enzyme-linked immunosorbent assays (ELISA) and antibody avidity assays. However, 
these methods provide difficulties in the diagnosis of reactivations and have the potential 
for cross-reactivity with other betaherpesviruses [Nakagawa et al., 1997]. But most 
importantly, due to the high level of similarity observed between the antigens in HHV-6A 
and -6B, all of these serological assays currently lack of ability to discriminate between 
HHV-6A and HHV-6B [Flamand et al., 2010].
Detection of viral DNA/RNA by means of quantitative (qPCR) and/or reverse transcriptase 
(RT-PCR) has provided highly sensitive methods which also allow for the typing of the 
species and genotype strains. However, in the case of qPCR issues still remain in the 
discrimination of active infection from CI-HHV-6A/-6B, as there can be considerable 
overlap between the viral loads obtained from samples in each of these cases [Flamand et 
al., 2010; Caserta et al., 2010]. Such issues have been shown to lead to unnecessary 
administration of antiviral therapy [Lee et al., 2012] and also have the potential for causing
delays in the diagnosis/intervention of active HHV-6A or -6B infection. Accurate diagnosis 
of CI-HHV-6A/-6B currently relies on the use of fluoresence in situ hybridisation (FISH) 
analysis or qPCR on hair follicle samples [Pellet et al., 2012]. However, FISH analysis where 
available, is time intensive and hair follicle samples are not routinely obtained. The recent 
development of a CI-HHV-6A/-6B specific droplet digital PCR assay may provide a means of
rapid diagnosis from readily obtained and stored cellular samples [Sedlak & Jerome, 2013; 
Sedlak et al., 2014]. Indeed recent evidence suggests this third generation PCR technology
allows for accurate discrimination between the HHV-6 species, as well as more accurate 
detection of co-infection [Leibovitch et al., 2014]. 
1.2.8 Disease Associations
Due to the latent nature of the HHV-6A/-6B and propensity to reactivate under times of 
immunosuppression, the ability to demonstrate causality of a disease represents a difficult
task. In addition to the now well established clinical symptoms of primary infections 
described above, numerous disease associations have been attributed to infections with 
HHV-6A and/or -6B. The evidence for some of these provide compelling arguments for the
involvement of the HHV-6 species, while for others the associations still remain 
controversial.
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Central Nervous System & Neuroinflammatory Disease 
Both HHV-6A and HHV-6B have been demonstrated to infect a variety of neuronal cells in 
vitro, see section 1.2.3, where they may establish persistent infections. In addition, DNA 
and mRNA transcripts from both viruses can also be readily detected in the brain tissue 
and cerebrospinal fluid (CSF) of healthy immunocompetent adults [Chan et al., 2001; Luppi
et al., 1998a; Cuomo et al., 2001; Opsahl & Kennedy, 2005]. Therefore, it seems clear that 
the central nervous system (CNS) represents a site of replication and latency for both HHV-
6 species. This complicates attempts to definitively attribute neurological pathologies to 
these viruses and has led to much debate about involvement of the HHV-6 species in such 
diseases. However, it also clearly demonstrates the neuroinvasive properties of these 
viruses, which in addition to its noted proinflammatory properties provide a potential 
mechanism for neuropathology. This in combination with a large number of association 
studies and the recent demonstration of HHV-6A as a trigger for neurological disease in an
marmoset (Callithrix jacchus) model; and HHV-6A also responsible for viral persistence and 
production of proinflammatory chemokines via TLR9 signalling in the brain tissue of CD46 
transgenic mice [Leibovitch et al., 2013; Reynaud et al., 2014], strongly suggest a role of 
HHV-6A and HHV-6B in at least some of these pathologies. However, there do seem to be 
some differences between the two species and their neurotropism and pathological 
outcomes. HHV-6A possesses a greater propensity to replicate and cause cytopathic 
effects in a number of the neuronal cell types [Ahlgvist et al., 2005; Donati et al., 2005; De 
Filippis et al., 2006; ]. Also, HHV-6B has been detected more frequently in  the brain tissue, 
likely as a consequence of its higher prevalence in the populations sampled [Chan et al., 
2001], however, association studies and the recent animal models have implicated a 
greater role for HHV-6A in neuropathology [Hall et al., 1998; Akhyani et al., 2000; Soldan et
al., 2000; Leibovitch et al., 2013; Reynaud et al., 2014]. 
The most well defined neurological disease associations are those of febrile seizures, 
encephalopathy. Similarly, strong links have been established between HHV-6A/-6B 
reactivation in immunocompromised populations and these neurological complications 
[Zerr et al., 2001]. Links between HHV-6A/-6B and encephalopathy in immunocompetent 
adults remain difficult to prove. However, HHV-6A/-6B has been detected in cerebrospinal 
fluid samples from immunocompetent patients suffering encephalitis and there have 
been case reports of the successful treatment of such patients with antiherpesviral drugs 
[Isaacson et al., 2005; Birnbaum et al., 2005].
Infections with HHV-6 viral species also have some less well defined links to a number of 
other neurological pathologies. The most notable being that due to the proinflammatory 
properties of HHV-6A and -6B, these viruses have frequently been cited as a causative 
agent or progression factor in the inflammatory neurological disease multiple sclerosis 
(MS). These links have been determined by a variety of methods. The more frequent 
amplification of HHV-6A/-6B DNA and immunohistochemical detection of HHV-6A/-6B 
antigens in the brain tissue and especially the MS lesion samples of MS patients [Wilborn 
et al., 1994; Challoner et al., 1995; Chapenko et al., 2003; Goodman et al., 2003]. Increased 
detection of both HHV-6A/-6B DNA and specific antibody titres in the sera and CSF of MS 
patients [Soldan et al., 1997; Chapenko et al., 2003; Ablashi et al., 1998a].  Increased 
lymphoproliferative responses to HHV-6A antigens in MS patients [Soldan et al., 2000]. The
increased detection of HHV-6A/-6B DNA and HHV-6A/-6B specific antibody titres in 
relapsing remitting MS patients, undergoing relapse [Alvarez-Lafuente et al., 2004; 
Simpson et al., 2012]. While potential links to MS can also be made from the observation 
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that HHV-6A infection in the marmoset animal model caused myelin abnormalities in some
of the marmosets that displayed both clinical symptoms and anti-HHV-6A antibody 
responses [Leibovitch et al., 2013]. So while there appear to be strong links between MS 
and HHV-6A/-6B infection, the true role of the involvement of the HHV-6 species, be it 
causative agent, progression factor or consequence of MS, remain to be determined. 
Transplantation Complications
HHV-6A/-6B infection is detected with high frequency, incidence rate estimated to be 30-
50%, in the setting of transplantation, with HHV-6B accounting for the majority of these 
infections [Ljungman & Singh, 2006; De Bolle et al., 2005a; Zerr, 2012; Drobyski et al., 
1993; Wang et al., 1999; Ogata et al., 2013; Inazawa et al., 2015]. Generally occurring 
within a month post transplantation, this infection is often asymptomatic or produces the 
fever and rash manifestations observed during primary infection [Griffiths et al., 1999; 
Ablashi et al., 2010]. However, complications are reported with higher frequency than 
seen in immunocompetent hosts, and more often the complications are associated with 
fatality [Ablashi et al., 2010; Ohashi et al., 2008; Ogata et al., 2013; Inazawa et al., 2015]. 
These infections are thought to predominantly arise from the reactivation of latent 
endogenous virus as a result of the prolonged immunosuppression induced through the 
utilisation of immunosuppressive drugs to maximise the success of transplantation. 
However, primary infection or reinfection with a secondary strain due to transfer of virus 
from host to recipient during transplantation remain a possibility [De Bolle et al., 2005a]. 
In haematopoietic stem cell transplant recipients, encephalopathy is the most frequently 
reported complication and the available reports include both cases of fatalities and 
successful treatment with anti-herpesviral drugs [Drobyski et al., 1994; Rieux et al., 1998; 
Yoshida et al., 2002; MacLean & Douen, 2002; Ogata et al., 2013; Inazawa et al., 2015]. 
Delayed engraftment or graft rejection are also often reported [Rosenfeld et al., 1995; 
Ljungman et al., 2000; Zerr et al., 2005b; Dulery et al., 2012]. While in solid organ 
transplant recipients, disease similar to acute primary infection is most frequently 
observed [Griffiths et al., 1999; Humar et al., 2002]. However, encephalopathy [Montejo et 
al., 2002; Paterson et al., 1999; Ljungman & Singh, 2006], hepatitis [Griffiths et al., 1999] 
and graft dysfunction/rejection [Acott et al., 1996; Tong et al., 2002] are also reported 
complications.
HIV/AIDS Interactions
Since its original isolation from an AIDS patient [Salahuddin et al., 1986], HHV-6A/-6B has 
long been associated with HIV-1 infection. Indeed HHV-6A/-6B infection is frequently 
detected in AIDS patients [Knox & Carrigan, 1994; Secchiero et al., 1995; Ablashi et al., 
1998b]. In addition, HHV-6A, HHV-6B and HIV-1 all have a tropism for lytic replication in 
CD4+ T-cells and productive co-infections with accelerated cytopathic effects have been 
observed in vitro [Lusso et al., 1989]. As such it has been proposed that while HHV-6A/-6B 
active infection may be a consequence of the immunosuppression induced by HIV-1 
infection, it could also play a role in the progression of HIV-1 to AIDS.
A number of lines of evidence point towards interplay between HHV-6A/-6B and HIV-1. 
Some of these have suggested a negative impact of HHV-6A/-6B infection on HIV-1. Firstly,
the HHV-6A viral chemokine, U83, has been demonstrated to be a high affinity ligand for 
the important HIV-1 co-receptor CCR5. Its action at CCR5 inhibits the infection of CCR5 
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expressing cells by CCR5 tropic HIV-1 at nanomolar concentrations [Catusse et al., 2007]. 
Also, early in the lytic cycle, HHV-6A infection has also been found to upregulate the 
production of CCL5 [Grivel et al., 2001]. CCL5 binds CCR5 with high affinity, albeit a lower 
affinity than U83A, and has been demonstrated to be a potent inhibitor of CCR5 tropic 
HIV-1 [Cocchi et al., 1995], thereby providing another mechanism for the inhibition of HIV-
1 replication. However, as to be outlined shortly, these features may in fact promote the 
evolution of HIV-1 strains towards CCL5 resistance or alternative co-receptor usage, 
therefore actually aiding in the progression to AIDS.
A greater body of evidence supports a role of HHV-6A/-6B infection in the the progression 
to AIDS. Firstly, infection of cells with HHV-6A/-6B leads to transactivation of the CD4 
promoter by a mechanism involving the immediate early genes U86 and U89 [Flamand et 
al., 1998]. Not only does this infection upregulate CD4 expression on CD4+ cells 
potentially making them more susceptible to HIV-1 infection, it also induces the surface 
expression of CD4 on normally CD4- cells (CD8+ T-cells, γδ T-cells and NK cells), thereby 
rendering them susceptible to HIV-1 infection [Lusso et al., 1991; 1993; 1995]. HHV-6A 
also has the ability to transactivate the HIV-1 LTR promoter resulting in stimulation of HIV-
1 gene expression [Ensoli et al., 1989; Horvat et al., 1989; McCarthy et al., 1998]. This 
transactivation is via a region which is distinct from that required for HIV-1's own 
transactivating protein Tat [Ensoli et al., 1989]. There is evidence of a synergistic 
interaction of HHV-6A/-6B proteins with Tat, as well as some suggestion that Tat may in 
fact reciprocally enhance HHV-6A/-6B gene expression [Di Luca et al., 1991; Garzino-Demo 
et al., 1996; Sieczkowski et al., 1995]. HHV-6A infection also increased the production of a 
number of proinflammatory cytokines, notably  TNF-α and IL-1β [Flamand et al, 1991], 
which have been implicated in the activation of HIV-1 gene expression [Duh et al., 1989; 
Swingler et al., 1992; Copeland, 2005]. While in a pig-tailed macaque (Macaca nemestrina) 
model co-infection with HHV-6A and simian immunodeficiency virus (SIV) accelerated the 
progression of disease through the depletion of CD4+ T-cells [Lusso et al., 2007]. Thereby 
providing the first in vivo links of HHV-6A/-6B to AIDS progression. Further work with this 
macaque model has demonstrated that SIV isolates obtained from HHV-6A and SIV co-
infected animals one year post infection had developed resistance towards CCL5 
inhibition, which was not seen in singly SIV infected animals [Biancotto et al., 2009]. 
Thereby implicating the evolution of the SIV strains to CCL5 resistance, as a result of the 
HHV-6A mediated generation of high levels of CCL5 and potentially providing an 
explanation for the rapid progression of SIV disease.
Myocarditis & Cardiomyopathy
A viral agent is often cited in myocardits and cardiomyopathy, and parvovirus B19 and 
HHV-6A/-6B are the three most frequently found viruses in the heart muscle [Bultmann et 
al., 2005; Kuhl et al., 2005]. This link is extended by a number of case reports of both HHV-
6A and HHV-6B associated myocarditis and even the recent successful treatment of 
myocardits in an infant, with the promising anti-herpesviral drug candidate artesunate 
[Bigalke et al., 2007; Chang et al., 2009; Leveque et al., 2011; Ashrafpoor et al., 2013; 
Hakacova et al., 2013].
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1.2.9 Therapy
In immunocompetent hosts, HHV-6A/-6B primary infection, reactivation or reinfection 
represent self-limiting infections and therefore does not require treatment. However, 
where individuals present with some of the more severe disease manifestations outlined 
above, intervention strategies are attempted. Currently there are no formally approved 
vaccines or drugs for the treatment of HHV-6A or -6B, therefore intervention involves the 
use of drugs originally developed as anti-HCMV compounds (or anti-HSV in the case of 
acyclovir/valaciclovir) which have subsequently been demonstrated to have some efficacy 
against HHV-6A and -6B [Agut et al., 1989; Manichanh et al., 2000; De Clercq et al., 2001; 
De Clerq & Naesens, 2006]. All of these drugs specifically inhibit the catalytic site of the 
viral DNA polymerase that (with the exception of cidofovir) result in premature chain 
termination, with acyclovir/valaciclovir, ganciclovir/valganciclovir and cidofovir acting as 
nucleotide/nucleoside analogues which are activated by viral kinases and foscarnet 
directly binding the DNA polymerase to bring about these effects [Wagstaff & Bryson, 
1994; Reardon & Spector, 1989; De Clerq, 2003]. In an in vitro analysis cidofovir was the 
most potent in cord blood lymphocytes, while in the T-cell lines HSB-2 and MOLT-3, 
foscarnet was the most potent [De Bolle et al., 2004]. This study also demonstrated that 
generally, all of the drugs are more potent against HHV-6A than HHV-6B. 
Ganciclovir/valganciclovir appear to be the most readily utilised drugs, resulting in 
successful resolutions, in case reports [Flamand et al., 2010]. 
However, the efficacy of these drugs has yet to be assessed in controlled clinical trials, 
they frequently have strong adverse effects associated with their use, and the potential 
prolonged use required to control HHV-6A/-6B infection in immunocompromised settings,
opens up the possibility of the development of resistance [De Clerq & Naesens, 2006]. As 
such there remains a search for new anti-HHV-6 drugs, especially those which do not 
target the viral DNA polymerase. From this search two non-nucleoside analogues have 
emerged as promising candidates. Firstly, CMV422, presumed to target a cellular protein 
tyrosine kinase, has been shown to exhibit a high level of activity and selectivity for HCMV 
and HHV-6A/-6B [Snoeck et al., 2002; De Bolle et al., 2004]. While artesunate, a derivative 
of artemisinin often used in the treatment of Plasmodium falciparum malaria, has also 
proven to have broad activity against herpesviruses, including HHV-6A/-6B  [Efferth et al., 
2008; Milbradt et al., 2009] and has recently been successfully utilised in a clinical setting, 
for suspected HHV-6B myocarditis [Hakacova et al., 2013].
1.3 Chromosomal Integration of Human Herpesvirus-6A & -6B
1.3.1 Inherited Chromosomally Integrated HHV-6A and -6B
In 1993, analysis of uncultured peripheral blood mononuclear cells (PBMCs) from three 
patients, two suffering lymphoproliferative disorders and the third multiple sclerosis (MS), 
led to the discovery of a high copy number of HHV-6 specific sequences present in the 
samples. Following up this finding, the discovery of higher than expected molecular 
weights for the viral DNA during restriction analysis of the patients PMBCs indicated that 
the viral genomic sequences were linked to cellular DNA [Luppi et al., 1993]. These 
findings provided the first indication that HHV-6A/-6B DNA may integrate into the human 
genome. Subsequently, Gardella gel, fluorescent in situ hybridisation (FISH), and PCR 
analysis was used in a number of different studies to confirm chromosomal integration of 
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viral genomic DNA (or the high DNA copy number indicative of integration) in a number of 
different tissue types including hair follicles, brain, lymph nodes and cardiac tissues 
[Daibata et al., 1998a; Morris et al., 1999; Ward et al., 2006; Nacheva et al., 2008; Hall et al.,
2008; Strenger et al., 2010; Arbuckle et al., 2010]. It has now been demonstrated that in 
these individuals HHV-6A and/or HHV-6B genomic DNA has been inherited through an 
integration event(s) into the chromosome of germ-line cells, hence the apparent presence 
of CI-HHV-6A/-6B in every nucleated cell of the body. Therefore, CI-HHV-6A/-6B can be 
transmitted vertically between generations in a Mendelian manner, with integration at the
same chromosomal sites in parent and child [Daibata et al., 1998b; Hall et al., 2008; 
Morissette & Flamand, 2010; Arbuckle et al., 2010]. As such, this inherited CI-HHV-6A/-6B 
represents a unique mechanism among human herpesviruses for the vertical transmission 
of HHV-6 genomic DNA, in addition to the horizontal transmission through viral shedding 
in saliva which is believed to be the major route of acquiring HHV-6A/-6B. The prevalence 
of this CI-HHV-6A/-6B in the worlds population has been estimated to be in the region of 
0.8 – 1% [Tanaka-Taya et al., 2004; Leong et al., 2007; Hubacek et al., 2009; Potenza et al., 
2009].
Even prior to the acquisition of the complete genome sequences for strains of HHV-6A 
and -6B, it was noted that human telomeric repeat sequences were present in the 
genomes of both species, close to the termini [Thomson et al., 1994a; Gompels & Macaulay
1995]. Within each of the direct repeats (DR) located at the left (DRL) and right (DRR) 
termini of the genome is a left terminal (pac1 adjacent) imperfect human telomeric repeat
array and a right terminal (pac2 adjacent) perfect repeat array, each with variable copy 
numbers ranging from 15-180 repeats between different isolates which have been 
examined [Thomson et al., 1994a; Gompels & Macaulay 1995; Achour et al., 2009; Arbuckle
et al., 2010]. Soon after the initial indications that HHV-6A/-6B could integrate into human 
chromosomal DNA, it was hypothesised that these telomeric repeat sequences may be 
involved in the integration event [Luppi et al., 1998b]. Support for this gathered as 
mapping of the integration sites demonstrated they were all localised to telomeric regions
(1q44 [Watanabe et al., 2008], 9q34.3 [Nacheva et al., 2008; Ward et al., 2006], 10q26.3 
[Nacheva et al., 2008; Huang et al., 2013], 11p15.5 [Nacheva et al., 2005; Clark et al., 
2006b; Ward et al., 2006], 17p13.3 [Nacheva et al., 2008; Ward et al., 2006; Clark et al., 
2006b; Arbuckle et al., 2010; Luppi et al., 1993; Morris et al., 1999; Torelli et al., 1995], 
18p11.3 [Hubacek et al., 2009], 18q23 [Arbuckle et al., 2010], 19q13.4 [Nacheva et al., 
2008; Ward et al., 2006] and 22q13.3 [Arbuckle et al., 2010; Daibata et al., 1999b]). 
Anecdotally, it seems there may be some preference for integration into the telomeric 
region of  chromosome 17p13.3, however, further study is needed to confirm this, this is 
also one of only two sites for which integration has been observed for both HHV-6A and 
HHV-6B [Morris et al., 1999; Torelli et al., 1995; Morissette & Flamand, 2010]. This 
telomeric integration was confirmed through the in vitro demonstration that single copy 
full length genomic DNA of both HHV-6A and -6B can integrate into the telomeres of 
human chromosomes at a location close to the subtelomere [Arbuckle et al., 2010; 
Arbuckle et al., 2013]. The integration event results in insertion of the HHV-6A or -6B 
genome (figure 1.5) in an orientation, where U100 is located towards the centromere and 
U1 towards the telomeric cap, as well as the loss of the pac2 site from the DRR [Arbuckle et
al., 2010].
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Figure 1.5 CI-HHV-6A/-6B chromosomal integration. Direct repeats (DRL and DRR), retained pac
sites (pac1 and pac2) and gene locations (U1 and U100) labelled in relation to key telomeric
features [Figure adapted from Prusty et al., 2013b].
1.3.2 Somatic Integration of HHV-6A & HHV-6B
The recent work by Arbuckle and colleagues has also led to the hypothesis that HHV-6A 
and -6B may be using chromosomal integration after primary infection of somatic cells as a
means of achieving latency in a different manner to that observed in other human 
herpesviruses [Arbuckle et al., 2010; Arbuckle et al., 2013]. Arbuckle et al. were able to 
demonstrate the maintenance of viral genomic DNA in the apparent absence of episomal 
DNA, following infection of cell lines with HHV-6A and -6B (JJHan, Molt3 and HEK 293 
cells). This was found to be due to the ability of a single copy of the viral genome to rapidly
integrate into the chromosomes of some cells within a population of lytically competent 
cells, with the resultant cells remaining viable [Arbuckle et al., 2010; Arbuckle et al., 2013]. 
As such they proposed that integration represents an alternative mechanism of achieving 
latency upon primary infection of somatic cells, with telomeric integration providing an 
good site for latency due to comparatively limited active transcription [Arbuckle et al., 
2010; Morissette & Flamand 2010; Arbuckle & Medveczky, 2011; Arbuckle et al., 2013]. 
With inherited CI-HHV-6A/-6B being a result of the rare occurrence of integration into the 
germ-line resulting from the broad cellular tropism of HHV-6A/-6B. In the case of somatic 
integration the number of cells harbouring CIHHV-6 would be relatively small, therefore 
not detected by conventional assays. Further compelling evidence for this hypothesis is 
added due to the suggestion that CI-HHV-6A/-6B can reactivate, discussed below. 
1.3.3 Reactivation from Chromosomally Integrated HHV-6A & -6B
Increasing evidence is emerging with regard to the reactivation of CI-HHV-6A and -6B, 
both that of the inherited and somatic integration forms. Treatment of PBMCs from CI-
HHV-6 patients and a CI-HHV-6 cell line with trichostatin A (TSA) and to a lesser extent 12-
O-tetradecanoyl-13 acetate (TPA), compounds known to reactivate latent herpesviruses, 
could reactivate both CI-HHV-6A and -B to produce infectious virions [Arbuckle et al., 2010;
Arbuckle & Medveczky, 2011; Arbuckle et al., 2013]. The sequence of the gB gene in 
transplacentally acquired HHV-6A cases was shown to be identical to that of mothers CI-
HHV-6A yet divergent from other known HHV-6 isolates, implicating transmission of 
reactivated CI-HHV-6A [Gravel et al., 2013b].
At the start of this thesis, the relationship of these chromosomally integrated forms of 
HHV-6A/-6B to those of their circulating counterparts was unknown. This addition of more 
than 150 kb of viral DNA into the host chromosome, if intact, leads to the possibility of 
viral gene expression and/or reactivation in every nucleated cell of the body; as well as 
potentially significant effects on host chromosome function and integrity. Furthermore, 
along with the presence of the genome in every cell of the body, germ-line integrated 
virus can be transmitted vertically following the laws of Mendelian inheritance, as a 





regulation of the immune system, as well as infant development. Therefore part of this 
thesis concerns characterisation of the CI-HHV-6A/-6B genomes with comparison to 
circulating viral strains. Focusing on genetic variation which may define phenotypic and 
pathogenic variation between circulating viral strains and the inherited chromosomally 
integrated forms.
1.4 HHV-6A/-6B and the Chemokine System
1.4.1 Immunomodulation by HHV-6A and -6B
Mechanisms of immunomodulation by HHV-6A/-6B are important for virus persistence 
since they cause both primary and latent infection in key effector immune cells [Lusso et 
al., 1988; Takahashi et al., 1989; Kondo et al., 1991]. As such they have evolved a variety of 
means to interfere with immune responses. These include modulation of both innate and 
adaptive immunity.
Antigen presentation
Both HHV-6A and -6B have evolved means of specifically targeting antigen presentation 
pathways. Briefly, for antigen presentation in the MHC class I pathway, proteasomal 
degradation of cytosolic proteins leads to the generation of antigenic peptides. These 
antigenic peptides are translocated to the endoplasmic reticulum (ER) through the action 
of an ATP-dependent transporter protein known as transporter associated with antigen 
presentation (TAP), where they are loaded onto MHC class I complexes. Proper loading of 
the peptide on the complex permits vesicular transport and subsequent presentation at 
the cell surface. HHV-6A and -6B U21 specifically associates with newly synthesised MHC 
class I diverting them to lysosomal compartments, thereby reducing surface-expression. 
While both HHV-6A and -6B utilised this mechanism, and despite 90% similarity between 
the pU21 of HHV-6A and -6B, HHV-6B was shown to be much less efficient at 
downregulation [Hirata et al., 2001; Glosson & Hudson, 2007].
T cell responses
For HHV-6A it has also been shown that the product of ORF U24 posses a role in 
modulating T cell interactions. pU24 downregulated surface expression of both the T-cell 
receptor complex and CD3, targeting them to endosomal compartments for degradation. 
Thereby interfering with the activation of the T-cells by antigen presenting cells and 
potentially having profound effects on the development of adaptive immune responses 
[Sullivan & Coscoy, 2008].
Cytokine responses
Pattern recognition receptor (PRR) mediated recognition of pathogen-associated 
molecular patterns (PAMPs) with the subsequent cellular signalling and gene transcription 
involved in a multitude of immune processes, represents one of the earliest responses by 
the host to pathogen challenge. In the case of viral infection, the upregulation of 
cytokines known as interferons (IFNs), their signalling and induction of interferon 
stimulated genes (ISGs) is the key player in early host immune responses. As such this 
represents another vital target of herpesvirus immunomodulation. Interferon regulatory 
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factors (IRFs) are important in both the regulation of IFN and ISG transcription, while signal
transducers and activators of transcription (STATs) are important in upregulating ISGs. 
While not specifically a immunomodulation mechanism the general host protein synthesis 
shutdown that occurs upon infection by a number of herpesviruses, including HHV-6A/-6B 
[Di Luca et al., 1990], likely inhibits many immune responses. Additionally HHV-6B and to a 
lesser extent -6A, encode a means of directly interfering with IFN responses. HHV-6B 
infected cells are resistant to IFN-α and -β due to effects on the expression of IFN-
stimulated genes. While the effects were much less pronounced in HHV-6A infected cells, 
representing a clear biological difference between the strains [Jaworska et al., 2007; 
2010]. This effect was found to be mediated by IE1 expression, which interacts with STAT2 
sequestering it to the nucleus. Thereby preventing the binding of the ISGF3 transcription 
factor to IFN-responsive gene promoters [Jaworska et al., 2010]. The differences between 
HHV-6A and HHV-6B with regard to IE1 mediated IFN resistance were found to map to a 
41 amino acid region present in IE1B yet absent in IE1A [Jaworska et al., 2010]. 
1.4.2 The Chemokine System
Another immunomodulatory strategy employed most extensively by the 
betaherpesviruses is subversion of the host chemokine system, a key aspect in immune 
response signalling and leukocyte movement during an inflammatory response [McSharry 
et al., 2013; Dagna et al., 2013]. The human chemokine system, reviewed in appendix 7.1, 
is complex with multiple ligands and receptors expressed on specific leukocyte 
populations, figure 1.6 and table 1.2. The betaherpesviruses encode homologues of both 
chemokines and chemokine receptors. When expressed from infected cells these viral 
homologues modulate cellular signalling both to escape immune surveillance and assist 
viral replication. 
Table 1.2 Chemokine receptors and their expression. Abbreviations: N, neutrophil; Mo, monocyte;
MC, mast cell; Ba, basophil; DC, dendritic cell; EC, endothelial cell; pDC, plasmacytoid DC; NHC,




CCR1 N, Mo/MΦ, Th1, Tmem, NHC
CCR2 Mo/MΦ, Th1, iDC, Ba, NK
CCR3 Eo, Ba, Th2, MC, MG, DC, PC, NHC
CCR4 Th2, Th17, Treg, iDC, Mo, B, CD4+ & CD8+ T
CCR5 DC, Mo/MΦ, NK, Th1, Th17, Treg, CTL, NHC
CCR6 Th17, NK, NKT, Treg
CCR7 mDC, B, naïve T
CCR8 DC, Mo/MΦ, Th2, CD8+ T, Tregs, NHC
CCR9 Gut-homing T, B, DC
CCR10 Skin-homing T, skin Fb, EC
CXCR1 N, Mo, NK, MC, Ba, DC, CD8+ T, Treg, EC
CXCR2 N, Mo, NK, MC, Ba, DC, T, EC
CXCR3 B, Th1, CD8+ T, pDC, NK, NKT, Treg
CXCR4 Most leukocytes, NHC
CXCR5 B, CD8+ T
CXCR6 Th1, Th17, NKT, NK, PC
XCR1 DC
CX3CR1 Mo/MΦ, Th1. CTL, DC, NK, MG, neuron
Figure 1.6 Chemokine ligands and their receptors. Both common and systematic nomenclature
are included. Colours denote functional classification of the chemokines. [Figure from Nomiyama
et al. 2013].
A number of viruses have developed methods to subvert or exploit the chemokine system 
as a means of establishing a niche or evading immune detection. Arguably, the most 
famous being the chemokine co-receptor usage by the HIV virus [Haggani &  Tilton, 2013]. 
Additionally, some members of the Poxviridae and most notably the Herpesviridae, possess 
genes which can directly interfere with the chemokine system. The poxviruses seem to 
have predominantly adopted a strategy of encoding  soluble chemokine binding proteins 
[Epperson et al., 2012]. While the herpesviruses, tend to encode homologues of cellular 
chemokines and chemokine receptors, likely pirated from the host during their co-
evolution. Of the herpesviruses, those found within the Betaherpesvirinae subfamily make 
extensive use of these virally encoded chemokine component homologues. While most of 
these vGCPRs are dispensable for growth in tissue culture, their significance in vivo is 
increasingly being recognised. HHV-6A and -6B both encode a chemokine homologue, U83
and two chemokine receptor homologues, U12 and U51 [Gompels et al., 1995; Dominguez 
et al., 1999; Isegawa et al., 1999].  
1.4.3 HHV-6A and -6B Chemokines
U83
HHV-6A and HHV-6B both encode a single chemokine homologue, U83 [Zou et al., 1999; 
Dewin et al, 2006]. This is one of the few genes which is unique to the HHV-6 species but 
absent from other betaherpesviruses. Original annotation of the genomes of HHV-6A and 
-6B noted that these ORF encoded a protein with homology to mammalian CC chemokines
[Gompels et al., 1995; Dominguez et al., 1999; Isegawa et al., 1999]. Subsequent analysis of
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the ORF in a number of strains from both species identified the hypervariable nature of 
this gene. Not only are large differences observed between the two species, U83 also 
displays a high level of variation between different strains from the same species [French 
et al., 1999; Sjahril et al., 2009]. Due to the variation of U83 observed between the two 
species and its association with an immunomodulatory role, U83 was proposed to be a 
prime candidate for many of the biologic and pathogenic differences observed between 
the two species.
Subsequently, the U83 genes from HHV-6A [Dewin et al., 2006; Catusse et al., 2007] and 
HHV-6B were functionally characterised. This did indeed highlight a number of differences
between the gene in the two species. U83B was found to be an agonist of CCR2 capable of
inducing chemotaxis in CCR2 expressing leukocytes [Zou et al., 1999; Luttichau et al., 2003;
Clark et al., 2013]. In contrast U83A was a high potency agonist for CCR1, CCR4, CCR5, 
CCR6 and CCR8, capable of inducing chemotaxis of leukocytes [Dewin et al., 2006; Catusse
et al., 2007; Clark et al., 2013]. Additionally, in contrast to human chemokines, U83A does 
not interact with the atypical chemokine receptors ACKR1/DARC or ACKR2/D6 [Catusse et 
al., 2009], receptors which play a vital role in regulation of the chemokine system [Nibbs & 
Graham, 2013]. Initially U83 was described to be expressed as a late kinetic class gene [Zou
et al., 1999]. But soon after it was found that while the full length U83 protein was only 
expressed with late kinetics, U83 transcripts can be detected at early times. These 
transcripts, however, undergo splicing leading to introduction of an early stop codon 
resulting in the generation of truncated peptide, termed U83-N [French et al., 1999]. This 
N-terminal peptide form of U83 retained the receptor binding properties of the full length
chemokine, however, acted as an antagonist at the receptor instead of an agonist as seen 
with the full length chemokine [Dewin et al., 2006; Catusse et al., 2007]. These properties 
led to suggestions of a role of inhibition of proinflammatory responses during the early 
stages of infection, followed by chemoattraction of susceptible cell types for latency 
and/or dissemination during the later stages of infection. It has also been shown that both 
the full length and truncated forms of U83A are highly potent inhibitors of HIV-1 infection 
[Catusse et al., 2007].
1.4.4 HHV-6A and -6B Encoded Chemokine Receptors
U12
Both HHV-6A and -6B also encode two GPCRs, U12 and U51, with homology to mammalian
chemokine receptors. To date, information regarding the U12 ORFs of HHV-6A and HHV-
6B remains sparse. Functional analysis of the U12 ORF and its products has only occurred 
for the HHV-6B species (strain HST) [Isegawa et al., 1998; Isegawa et al., 1999]. The U12 
ORF was found to be expressed as a spliced transcript with late kinetics in HHV-6B 
infected cells [Isegawa et al., 1998]. While generation of stably expressing human 
erythroleukemic cell line, allowed for initial attempts at functional characterisation of 
pU12. Using these cell lines pU12 was found to bind the β-chemokine ligands CCL2, CCL3, 
CCL4 and CCL5, and be activated by these same ligands as measured by mobilisation of 
intracellular Ca2+, with CCL2 and CCL5 acting as more effective Ca2+ mobilising agonists 
than CCL3 and CCL4 [Isegawa et al., 1998]. The U12 ORF of HHV-6B strain Z29 contains a 
deletion, respective to that of strain HST and other clinical isolates examined, which is 
predicted to result in the production of a truncated protein, implying U12 is dispensable 
for in vitro culture [Dominguez et al., 1999].
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U51
The HHV-6A (strains U1102, GS) and HHV-6B (strains Z29 and HST) pU51 ORFs predict 
protein products of 301 amino acids in length, which show ~94% sequence identity with 
one another [Gompels et al., 1995; Gravel et al., 2013a; Dominguez et al., 1999; Isegawa et 
al., 1999]. A couple of particular features of note from examination of the U51 ORF were 
that the predicted N-terminal domain of the 7TM structure of these vGPCRs is unusually 
short in comparison to the human chemokine receptors with which it shares homology 
(~15 amino acids in comparison to ~30-40 amino acids), while the highly conserved DRY 
motif is actually ERI in the viral receptor.
Initial characterisation of HHV-6A (strain U1102) pU51 identified it as an early lytic gene 
[Menotti et al., 1999]. This initial study also led to suggestions that HHV-6 may modulate 
the surface expression of pU51 in a cell type dependent manner, since they found the 
expressed protein was retained in intracellular vesicles unless expressed in cells of T-
lymphocytic lineage [Menotti et al., 1999]. However, later work has found that pU51 of 
HHV-6A, is also surface expressed in non-lymphoid cells, with the implication that the virus
may be exploiting codon usage for variable surface expression of pU51 [Milne et al., 2000; 
Bradel-Tretheway et al., 2003]. The data from these studies also suggests that HHV-6A 
pU51 can form homodimers, however, while the importance of homo- and 
heterdimerisation of GPCRs is increasingly being recognised, the functional significance of 
this dimerisation (if any) with regard to pU51 function still remains unclear [Menotti et al., 
1999; Milne et al., 2000; Bradel-Tretheway et al., 2003]. 
Initial attempts at characterising the ligand binding properties of HHV-6A pU51 led to the 
identification of its ability to bind a broad range of β-chemokines (CCL2, CCL5, CCL7, 
CCL11 and CCL13) and the KSHV viral chemokine homologue vMIP-II [Milne et al., 2000; 
Fitzsimons et al., 2006]. While later a further β-chemokine ligand (CCL19) as well as the  γ-
chemokine, XCL1, were found to bind at physiologically relevant concentrations [Catusse 
et al., 2008]. Thus, HHV-6A pU51 combined binding profile overlaps that of the 
predominantly inflammatory human chemokine receptors CCR1 (CCL5, CCL7), CCR2 (CCL2,
CCL7, CCL13), CCR3 (CCL5, CCL7, CCL11 and CCL13), CCR5 (CCL2, CCL5, CCL7, CCL11, 
CCL13), CCR7 (CCL19) and XCR1 (XCL1). 
With regards to the signalling capabilities, HHV-6A pU51 has been found to signal in a 
constitutive fashion through the Gα subunits, but not Gβγ subunits, of G proteins of the 
the Gαq/11 family activating PLC and inhibiting CRE-mediated gene transcription [Fitzsimons
et al., 2006; Catusse et al., 2008]. In addition the constitutive signalling activity of the viral 
receptor can be differentially modulated through the binding of the human chemokine 
ligands [Fitzsimons et al., 2006; Catusse et al., 2008]. CCL5 was found to promote 
trafficking of the receptor signal to G proteins of both the Gαq/11 and Gαi/o (specifically Gαi3 
and Gαo1) families; while CCL2 and CCL11 trafficked the signal to only Gαi/o family G 
proteins (Gαi1/i2/i3 and Gαi1/i2, respectively) [Fitzsimons et al., 2006]. This modulation of the 
receptor-G protein coupling resulted in decreased PLC activation and a abolishment of the 
inhibition of CRE-mediated gene transcription, compared to levels seen for the 
constitutively active receptor state [Fitzsimons et al., 2006].
The constitutive signalling activity exhibited by HHV-6A pU51 has been shown to 
specifically lead to the transcriptional down-regulation of two cellular targets. The first of 
these is CCL5, which has been demonstrated in both epithelial and haematopoietic cell 
39
lines, where its roles have been hypothesised to include immune evasion or modulation of 
recruitment of circulating inflammatory cells for systemic spread of the virus [Milne et al., 
2000; Caruso et al. 2003; Catusse et al., 2008]. The second cellular target specifically down-
regulated by HHV-6A pU51 is FOG-2 in a haematopoietic cell line, FOG-2 is a transcriptional
repressor which may have a role in influencing the Th1/Th2 balance by repressing Th2 
development, but it is also hypothesised that this dysregulation may contribute to cardiac 
and inflammatory complications [Catusse et al., 2008]. Currently, the broader ranging 
functional consequences of the differential ligand dependent signalling remain unclear.
Finally, RNAi knockdown of HHV-6A pU51 was found to result in a reduction of viral 
replication and virally induced cytopathic effects, with the same study also suggesting 
pU51 may also be involved in direct cell-cell fusion mediated by viral proteins thus 
potentially providing a mechanism for this inhibition of viral replication [Zhen et al., 2005].
U51 has complex regulatory signalling, resembling properties of the vGPCR US28 from the
closely related HCMV, which also combines constitute and inducible signalling. 
Furthermore, US28 is expressed during latency and is a key immunomodulator [Beisser et 
al., 2001; Miller et al., 2012]. Expression of such potent immunomodulators such as the 
chemokine receptor U51 and chemokine U83 could affect many pathological processes. In 
the context of germ-line integrated CI-HHV-6A/-6B there could be profound effects, given 
possible gene expression in every cell. In this thesis the genetic relationship between the 
integrated genomes and that of infectious virus are investigated and then also evaluated 
for possible effects of any strain variation on potential immunomodulatory properties.
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1.5 Aims
Therefore in order to investigate the nature of the CI-HHV-6A/B genomes and their 
potential effects, three major aims were established for the research presented here:
1. In order to avoid issues related to genomic changes resulting from laboratory culture 
and to be able to characterise clinical material directly, the thesis aimed to develop 
methods for the enrichment of Roseolovirus genomic DNA directly from clinical samples 
to permit whole genome characterisation of these viral species by NGS, with validation 
through sequencing of HHV-6A/-6B genomes. Thereby establishing methods to permit 
characterisation of the chromosomally integrated forms of these viral species to allow in 
depth investigation of the genetic variation between circulating and integrated genomes.
2. To compare the integrated viral genomes to exogenous infectious HHV-6A/-6B 
genomes. Through the application of the established NGS methods, to the recently 
defined germ-line chromosomally integrated forms of HHV-6A/-6B, in order to analyse any
differences or similarities. With a focus on genetic variation which may define phenotypic 
and pathogenic variation between circulating viral strains and the inherited 
chromosomally integrated forms.
3. To characterise a key immunomodulatory gene from the CI-HHV-6A/-6B genomes, that 
of the virally encoded chemokine receptors, U51. Focussing on the molecular basis of the 




2.1 DNA Samples, Vectors and Reference Sequences
2.1.1 Virus Reference Strains and Infected Cell DNA
HHV-6A strain U1102 was isolated from a reactivated infection in a Ugandan HIV/AIDS 
patient [Downing et al., 1987] and strain AJ was originally isolated in the UK from a 
reactivated infection in an adult HIV/AIDS patient from the Gambia [Tedder et al., 1987]. 
Strain U1102 and AJ infected cell DNA was extracted previously in this laboratory from 
infected JJhan T leukaemic cell lines, as described by Dr. D. Clark [Clark, 2011].
2.1.2 CI-HHV-6A and -6B Patient DNA
Two cohorts of CI-HHV-6A/-6B samples were collected in collaboration with Dr. D. Lassner 
at the Institute of Cardiac Diagnostics and Therapy, Berlin, Germany and Dr. P. Hubacek at 
Motol University Hospital, Prague, Czech Republic. CI-HHV-6A/-6B was identified as 
described in Kuhl et al., 2005, Boutolleau et al., 2006 and Hubacek et al., 2013, with 
additional samples described in Tweedy et al., 2015a. Samples were DNA extracted from 
endomyocardial biopsies (EMB) or peripheral blood leukocytes (PBL). These were from 
European patients with haematological disorders, malignancy or inflammatory disease in 
the Czech Republic and cardiac disease in Germany where germline CI-HHV-6A/-6B had 
been indicated by diagnostic viral loads, with positive identification from hair or nail 
samples in some instances.
In the German cardiac cohort, viral load was quantified through real-time PCR screening of
the conserved U94 locus, with comparison to human genome copy number calculated 
from the molecular mass of extracted blood DNA sample. In a subset of the PBL or EMB 
samples, RNA was extracted and cDNA prepared using Trizol reagent and reverse 
transcriptase as described previously [Kuhl et al., 2005; 2015]. 
In the Czech inflammatory disease cohort, relative copy number was determined following
real-time PCR screening of the viral U65/66 locus and human albumin genes using a HHV-
6A/B-specific Taqman assay, as described previously [Boutolleau et al., 2006]. Germline 
integration was also confirmed by Taqman detection of virus genomes in DNA extracted 
from hair or nail samples, as described by Hubacek et al. 2013.
2.1.3 Virus Genome Reference Sequences
Reference sequences used for HHV-6A and -6B were those where complete genomic 
sequences are available. The HHV-6A prototype strain U1102 as sequenced by Gompels et 
al., 1995 (Accession X83413/RefSeq NC_001664). Two reports, from different passaged 
cultures, of the HHV-6A strain GS isolated from a reactivated infection in an American 
patient with lymphoproliferative disease [Salahuddin et al., 1986] and as sequenced by 
Gravel et al., 2013a (Accession KC465951) and Bhattacharjee et al., 2014 (Accession 
KJ123690).
HHV-6B strain Z29 isolated from a reactivated infection HIV/AIDS patient from Zaire 
[Lopez et al., 1988] and sequenced by Dominguez et al., 1999 (Accession 
AF157706/RefSeq NC_000898). HHV-6B strain HST isolated from a Japanese infant during 
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primary infection [Yamanishi et al., 1988] and sequenced by Isegawa et al., 1999 (Accession
AB021506).
2.1.4 Plasmid DNA
An amino-terminally haemagglutinin (HA)-epitope tagged human chemokine receptor 
CCR3 construct inserted into the pcDNA3 vector [Comabadiere et al., 1995; Auger et al., 
2002], designated HA-CCR3, was generously donated by Dr. J. Pease (Imperial College 
London, London, UK). A HHV-6A strain U1102 chemokine receptor U51 coding sequence 
construct (designated pcDNA3-U51) and an amino-terminally HA-epitope tagged U51 
construct cloned in pcDNA3 (designated U51D) as described in Milne et al., 2000 were 
obtained from Dr. U.A. Gompels (London School of Hygiene and Tropical Medicine, 
London, UK) of this laboratory. A human chemokine receptor CCR5 clone in pcDNA3 was 
obtained from the cDNA Resource Centre (Rolla, Missouri, USA). All vector construct 
identities were confirmed by Sanger capillary sequencing, as described in section 2.7, 
before use.
2.2 Primer Design
The primer design program Primer3Plus [Untergasser et al., 2007] was primarily used to 
aid design of primers. Due to location and mutational requirements, some primers were 
designed manually adhering as closely as possible to the generalised concepts of PCR 
primer design [Dieffenbach et al., 1993]. Multiple alignment programs ClustalW2 [Larkin et
al., 2007] and Clustal Omega [Sievers et al., 2011] were used to confirm specificity and 
sequence identity between viral strains. Unless otherwise stated, all oligonucleotide 
primers were synthesised by Sigma-Aldrich (Gillingham, UK).
2.3 Primer Sequences
2.3.1 Long Range PCR Amplicons
Primer sets were designed based on the HHV-6A strain U1102 genome, with comparison 
to related HHV-6A strains. These primers sets were designed to generate 36 overlapping 
amplicons, ranging in size from 1-7 kbp, spanning the entire HHV-6A genome (table 2.1). 
Primer design was by Maria-Alexandra Spyrou, an MSc student in the laboratory, and 
described in our subsequent publications Tweedy et al., 2015a; 2015b.
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Table 2.1 LPCR amplicon primer sequences and expected sizes. Primers were designed based on
the HHV-6A strain U1102 genome. Size indicates the expected base pair size of amplicons from
LPCR reactions with HHV-6A strain U1102 template DNA.
2.3.2 AJ genomic Sequence Gap Filling
The following primer sets were used for the amplification and subsequent Sanger capillary
sequencing of contig gaps, ambiguities and repetitive regions. For the DRL -UL junction: 
DRL_ULF 5' CGTACACACGCAGACACACA 3' and DRL_ULR 5' GTATCCTCGTCTGCCCTCTG 3'. 
For the R2 region: R2F 5' GTGCTTTTTGTGTATGTCTCTATG 3' and R2R 5' 
CTCTATCTCTCTATTTGTTTCCCTC 3'. For the R3 region R3F 5' 
GTACCCACTGATCTTTATCTTTATG 3' and R3R 5' CTAAAATCTGCTAACGGGG 3'. For the UL-
DRR junction: UL_DRRF1 5' TACTCTGACGCTCATCTTTTC 3', UL_DRRR1 5' 
GTTGTCTTGTTATACAGGGGTAAC 3', UL_DRRF2 5' GGGCCGAGACTCCTTTTT 3' and 
UL_DRRR2 5' TGGAGGAAGAAGGTGAAGTTG 3'.
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Amplicon Forward Primer (5'-3') Reverse Primer (5'-3') Amplicon Size (bp)
DR1 ACAACCGCATCTTCTTCAG ATGAACGGAGATCTGGGAG 1750
DR1DR6 CCTCATCTGTTATTCCCTTCC ACTCACCGCAGTCTTGAAC 2872
DR6 TCCAAACTGTACGGCTATG TGGCGTCTAATCCAGGTAC 1858
DR_UL CATGAGAGGACACTGGACGTACTC GACATCTGTGGACCATGCA 2339
0203 ACCATGTGCGGAGAAAGTTG ACGAGAATGAATATGCCGATG 2174
0306 ACTCCTATCCGTCTAAACTGCT ATTTCTCACGCCGGTATTC 4417
0611 ATGCCAAATCTAGCTGCTG GAATCGGAGGAAGCTAACGT 4757
1114 TCTTCAGGTGTCTCAACCTTC TGATGATCTGCTGTTGGAAC 5737
1419 TTGAGATGCAGAGCCTCTC ACGTGGTGGATAATTCTTCAG 5370
1923 CTACATCATCGGTTGCCATA TACAGAAGTTTCGGCAACTG 5216
2328 TAGTCGCTGGATGTCGATAC GAGGAATTGTGGACAACGCT 4721
2830 CATCCAACTCCTTGTCCGT TCGTTCGACGTGTCTGAC 5753
3031 GACACTGTCCAACGCATCT CTCTTGGGCATAAGTCCAGTA 6552
3134 ACAGAGCGACACCCAATATTC AGCTGTGTCGATGTCTTGCTA 2787
3439 TGCATTCTCTCACAGCATG TGTTTCCTTATGCCACCAATC 6309
3941 TGAGGCATGAGACTCAGAAG AGCGGCATCCATAATGCTTA 4796
4142 AGCATCGTTTGAAGACACC GAGTTGTTGTTCGCTGGTCT 2810
4142INT TTGTTTCAGGCCAGCATC ATACCGAAAACTCAGGCAAC 2983
4245 AGACCGCATTCGTATCGCT CACGATCAAGTTCGAATCGTA 5092
4549 GAGTGCTCGGATAAGTTCATT ACGATACAATCCGGAATGC 5922
4953 TGGAACTCGGAATTGTTTCT GTTTGAGACTGTATCTGCGCA 4282
5357 TATGGTGAAGAACCGTCG TCCGCAGATAACAGAATGG 4707
5758 CAGTGCCATCTGTTATGAATAG AGTCGCAGTAAGGTCCACGT 6792
5864 TGCTGAAATTACCTCAGTGAG CCATTCAGTATAATGCATCC 4229
6469 CTGTATCAATATCAAGGCGG ACCACTGAATACGAACGCTC 5111
6974 GCGATTGTTCTGCGATAGAG CTTATATCCGAGCCTTGCAGT 6472
7476 GAGAACATGCTAGACAATTGG CAAGAACTGCGACTCAATCC 2668
7679 GTTGCTAGTTGTATGACTTGG CAATATCCACCGTTAGAGAAC 7681
7984 AGATGTATGCTGAAGAACGTG GGATCGTCAACCGTTAGTG 5109
8486 CACAGTGTGTTCGCCGGAAG ACAGACAATGCACATCCTCTG 4773
8690 AGGTTGATACGGCAACGAG GCAATCATTAGCATACAGATG 3326
8690INT TGAGGAATCACGTGTTTG ATCGAATCTATCCATGAAGATG 1746
90R3 CATCATTGTTATCGCTTTCAC GCAACCGCAGTTCCTGTT 4912
R395 GCGGTACCCACTGATCTT AGTCTACCAGGCATTCCGT 6250
95100 GAGGAGGGTCTGTCTAGATGT TCGGAGATATCATAATCTGCGT 4031
100DR TTATAGTTGCTCCCGAAAGC AAGAAGATGCGGTTGTCTTG 2358
2.3.3 CI-HHV-6A/-6B Gene Amplification 
Primers used to amplify a fragment of the U38 gene, and the complete coding sequences 
of U46 and U83 were provided by Dr U.A. Gompels and described in Tweedy et al., 2015a; 
by Bates et al., 2009 or by Clark et al., 2013. These were: MaSU38F 5' 
AAGACGGGTTATTATGCTGTG 3' and MaSU38R 5' ACAGACATAAAGATGCTATCC 3'; U46F 5' 
TGTCTGCTGTTAATCACGTC 3' and U46R 5' GCGATCTAATAACCCTTCAC 3'; BHU83F1 5' 
GAAGGATCCTAATATGAGTGACATTAC 3', 
ERU83R1 5' TTCGAATTCTTTCATGATTCTTTGTC 3', U83FP1 5' 
AAGTTAACACGACGGGAACAA 3' and U83RP1 5' TGCCATATCACACATCGAG3'.
To amplify the U83 locus, a semi-nested PCR procedure was used for some samples 
using primers BHU83F1 and U83RP1, then a second step using primers U83FP1 and 
U83RP1.
The complete coding sequences of U47, U51 and U65, were amplified using the following 
primers: U47aF 5' ATGTGTGATGCGTTGCATTT 3', U47aR 5' TCAGCGTCTCTCACATCACC 3', 
U47bF 5' TTCCGTTGTTTGCGTTGTTA 3' and U47bR 5' GTAATCGCGGTCCAACACA 3'; 
IU51SF1 5' GTCAATACGGATGGGGTTTTG 3' and IU51SR2 5' CAGCGCCGAAGATCTATTCT 3'; 
U65F 5' CAATCACCGGTAAATTCG 3' and U65R 5' CAGCTGCTACAATACACACG 3'.
2.3.4 Viral Chromosomal Integration Site Junction Amplifications
Primers for the amplification of the integration site junctions of HHV-6A at specific human 
chromosomal subtelomeric regions were as previously described by Britt-Compton et al., 
2006 and Arbuckle et al., 2010. The 17p subtelomeric primer was 5' 
AACATCGAATCCACGGATTGCTTTGTGTAC 3' and the HHV-6 DRR primer was 5' 
CATAGATCGGGACTGCTTGAAAGCGC 3'. Further chromosomal subtelomeric region 
primers, described in Huang et al., 2014 were also trialled in conjunction with the above 
HHV-6 DRR primer. These included chromosome 10q 5' ATCCTTCCTCTTTGCAGCCG 3', 
chromosome 11q 5' CAGACCTTGGAGGCACGGCCTTCG 3', chromosome 18q 5' 
CTCATGTCCTCGGTCTCTTGCCTC 3' and an alternative chromosome 17p primer: SubT17 5' 
CCCAATTTACTGGTAATGGACT 3'. 
Nucleotide sequencing of these amplicons was performed with the primer sequences 
above and a custom nested primer set designed as follows. For this, a ClustalW2 [Larkin et 
al., 2007] alignment of the previously published CI-HHV-6A and -6B, known and suspected 
17p integration sites [GenBank accession numbers: GU784872.1, KF366419.1 and 
KF366420.1, respectively] was generated, then used to design primers located at a 
conserved region within the subtelomeric region of the amplicon, designated 17Tel-
DR_IntF 5' TGTCGTTTCATTCCATTTATTCC 3', and a semi conserved region (1bp difference 
across 22bp between CI-HHV-6A and -6B) of the DRR, designated 17Tel-DR_IntR 5' 
GGAAGACGACAACAGGTTT 3'.
2.3.5 U51A Chimeric and Mutant Construct Generation
2.3.5.1 U51NCCR3M
For the U51NCCR3M construct, the PCR-driven overlap extension protocol devised by 
Heckman & Pease, 2007 was utilised (summarised in section 2.11.1 and figure 2.2). For this,
amplification of the predicted amino-terminal domain of U51A used, U51NF1 5' 
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TTAGAATTCCTGGAGAAAGAAACGAAGTCTTTGG 3' to add an EcoRI restriction site 
(italicised) to the amino-terminal end of the amplicon and U51NR1 5' 
GTACAGCGGGGGCACAAACTGGGCCATAAACTCCGCAGTGGCTGG 3' to add sequence 
complementary to the required CCR3 chimeric junction site (underlined) to the carboxyl-
terminus of the amplicon. To amplify the coding sequence of CCR3 minus its predicted 
amino-terminal domain, CCR3MF1 5' ATGGCCCAGTTTGTGCCC 3' and CCR3MR1 5' 
CGTCTCGAGCTAAAACACAATAGAGAGTTCCGGC 3' were used to add a XhoI restriction site 
(italicised) to the 5' end of the amplicon. Amplification products from both of these PCR 
reactions were used as template along with the U51NF1 and CCR3MR1 primers to 
generate the final chimeric construct.
2.3.5.2 HA-U51NCCR3
The T7 primer 5' TAATACGACTCACTCTAGGG 3' and the U51DNR1 primer 5' 
ACCATAGAATTCCGCAGTGGCTGG 3' were used to amplify the HA tagged U51 amino-
terminal domain from the U51D vector with the introduction of an EcoRI restriction site 
mutation at the carboxyl-terminus of the amplicon, figure 2.1.
Figure 2.1 Generation of the U51NCCR3 receptor construct. Expanded section shows mutation to
an EcoRI restriction site with maintenance of the amino acid sequence.
2.3.5.3 HA-U51ΔE2G
The generation of a U51A amino-terminal domain reflecting that of HHV-6A strains GS and
AJ, and CI-HHV-6A utilised a primer to add a XhoI site (italicised) to the 3' end of the U51 
CDS: U51MR1 5' ACTCTCGAGTCATTTTAACATTTTTATTCCAACCTCTAAATCC 3' in 
conjunction with a primer to add an EcoRI site (italicised), HA tag (underlined) followed by 




For alanine scanning mutagenesis of the amino-terminal region of U51A the U51MR1 
primer described above was used in conjunction with 14 mutagenic primers for the amino-
terminal addition of an EcoRI site (italicised) and HA tag (underlined) followed by alanine-













































    2.3.6 Vector Sequencing
Vector inserts were sequenced prior to use to confirm identities, as well as following 
cloning of newly generated inserts. The pGEM-T (Promega, Southampton, UK) and 
pcDNA3 (Life Technologies, Paisley, UK) vectors were used for cloning. Primers designed 
against the T7 and SP6 promoter sequences contained in these vectors, T7: 5' 
TAATACGACTCACTCTAGGG 3' and SP6: 5' ATTTAGGTGACACTATAG 3', were used to 
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sequence multiple cloning site inserts, as described in section 2.7.
2.4 Polymerase Chain Reaction (PCR)
2.4.1 General
Except for the specific cases outlined in sections 2.4.2 and 2.4.3, PCR amplifications were 
performed using 25 μl reactions with GoTaq green mastermix (Promega, Southampton, 
UK), following the accompanying protocol. For these, 12 μl GoTaq DNA polymerase green 
mastermix (Promega, Southampton, UK) was combined with 7 μl nuclease-free water 
(Sigma-Aldrich, Gillingham, UK), 2.5 μl forward primer (10 μM for a final concentration of 1 
μM), 2.5 μl reverse primer (10 μM for a final concentration of 1 μM) and 1 μl of template 
DNA (at concentration of 50 ng/μl). A negative control (1 μl  nuclease-free water, 
described above, as template) and positive control (1 μl of relevant DNA at concentration 
of 50 ng/μl) was included per 10 reactions, for all reaction preparations. Reaction 
preparation, DNA template addition, amplification and amplicon analyses were 
undertaken in separate facilities to prevent contamination. 
Amplification reactions were performed on a DYAD PTC-220 peltier thermal cycler (MJ 
Research, now Bio-Rad, Hemel Hempstead, UK). Thermocycling conditions were: a hot-
start of 95°C for 2 minutes, followed by 35 cycles of 95°C for 20 seconds denaturation 
step, 58°C for 30 seconds annealing step, 72°C for 2 minutes extension step, and a final 
elongation at 72°C for 5 minutes. 
2.4.2 Long Range PCR Amplicons
PCR amplifications were performed using 50 μl reactions with GoTaq Long PCR mastermix 
(Promega, Southampton, UK), following the accompanying protocol. For these, 25 μl 
GoTaq Long PCR DNA polymerase mastermix (Promega, Southampton, UK) was combined 
with 13 μl nuclease-free water (Sigma-Aldrich, Gillingham, UK), 5 μl forward primer (10 μM 
for a final concentration of 1 μM), 5 μl reverse primer (10 μM for a final concentration of 1 
μM) and 2 μl of template DNA (242-460 ng of DNA). A negative control (2 μl  water as 
template) and positive control (2 μl of relevant DNA corresponding to 200 ng of DNA) was 
included per 10 reactions, for all reaction preparations. Reaction preparation, DNA 
template addition, amplification and amplicon analyses were undertaken in separate 
facilities to prevent contamination. 
Amplification reactions were performed on a DYAD PTC-220 peltier thermal cycler (MJ 
Research, now Bio-Rad, Hemel Hempstead, UK). Thermocycling conditions were: a hot-
start of 95°C for 2 minutes, followed by 35 cycles of 95°C for 20 seconds denaturation 
step, 59°C for 30 seconds annealing step, 70°C for 6 minutes extension step, and a final 
elongation at 72°C for 10 minutes. 
2.4.3 Chromosome 17p Integration Site PCR Amplification
Reaction set up was performed as in section 2.4.1, with amplification reactions again 
performed on a DYAD PTC-220 peltier thermal cycler (MJ Research, now Bio-Rad, Hemel 
Hempstead, UK). However, template DNA was increased from 50 ng to 242-460 ng of DNA
depending on the CI-HHV-6A/B sample.  Additionally, thermocycling conditions were 
based on those described in Britt-Compton et al., 2006 and Arbuckle et al, 2010, with 
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adjustments to account for different polymerases and amplicon sizes. These included of 
hot-start 94°C for 5 minutes, followed by 25 cycles of 94°C for 15 seconds denaturation 
step, 59°C for 30 seconds annealing step, 72°C for 5 minutes extension step, and a final 
elongation at 72°C for 10 minutes. 
2.5 Agarose Gel Electrophoresis and DNA Purification
Separation of DNA was performed by agarose gel electrophoresis using 1.5% or 0.7% (the 
latter for the LPCR amplicons) agarose gels. The gels were prepared from 1.5 g or 0.7 g 
agarose (Fisher Scientific, Loughborough, UK) dissolved in 100 ml TBE buffer (made as a 
10X stock solution: 108 g Tris base, 55 g Boric acid and 7.5 g EDTA disodium salt all from 
Sigma-Aldrich, Gillingham, UK dissolved in 1 L deionised water. Further diluted to 1X 
solution with deionised water prior to use) supplemented with 5μg/ml ethidium bromide 
(Sigma-Aldrich, Gillingham, UK) for DNA visualisation. Restriction digested and PCR 
reaction DNA were mixed with blue loading dye (New England Biolabs, Hitchin, UK), where
necessary, prior to gel loading. Electrophoresis was carried out using a Sunrise 96 
Horizontal Electrophoresis Apparatus (Gibco BRL, now Life Technologies, Paisley, UK) with 
100 volts supplied by a BioRad Model 200/2.0 Electrophoresis Power Supply (Bio-Rad, 
Hemel Hempstead, UK). All samples were run with a relevant DNA ladder for the expected 
size of the amplicon, either a 100 bp or 1 kb DNA ladder (both from New England Biolabs, 
Hitchin, UK). DNA bands were visualised under UV light (365 nm) using a Gene Genius 
Bioimaging machine in conjunction with GeneSnap Image Acquisition software (Syngene, 
Cambridge, UK).
After confirmation of correct size, DNA bands were excised from the gel using a clean 
scalpel and DNA was extracted using silica membrane spin columns either the PureLink 
Quick Gel Extraction Kit (Life Technologies,  Paisley, UK), Wizard SV Gel and PCR Clean-Up 
System (Promega,  Southampton, UK) or the Zymoclean Gel DNA Recovery Kit (Zymo 
Research, Freiburg, Germany) and their accompanying protocols, respectively. While the 
exact specifics vary, all follow a generalised protocol whereby the extracted gel slice was 
weighed and in turn incubated with 3 volumes of a gel solubilisation buffer for 10 minutes 
at ~50°C, until completely dissolved. The dissolved solution was then applied to a silica 
spin column and centrifuged at >12,000 g for 1 minute using a Micro Centaur Plus 
microcentrifuge (MSE, Lower Sydenham, UK). Run-through was discarded, and two rounds 
of a wash step were performed, whereby a wash buffer was applied to the column and 
centrifuged at >12,000 g for 1-5 minutes, with run-through being discarded after each 
washing round. Sample DNA was then eluted into a fresh microcentrifuge tube, through 
the addition of 30 μl nuclease-free water (Sigma-Aldrich, Gillingham, UK) to the column, 
which was left to stand for 1 minute prior to a final centrifugation step at >12,000 g for 1 
minute. Eluted DNA was then either used immediately or stored at -20°C. 
2.6 DNA Quantification
2.6.1 General 
Except in the case highlighted in section 2.6.2, DNA concentrations and purity were 
calculated using 1 μl of sample DNA on a Nanodrop 1000 spectrophotometer 
(ThermoFisher Scientific, Loughborough, UK), according to the manufacturers guidelines.
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2.6.2 Long Range PCR Amplicon DNA Quantification
Prior to equimolar pooling, long range PCR (LPCR) purified amplicon DNA concentrations 
were quantified as in section 2.6.2. Both LPCR amplicon and SureSelect enriched DNA 
library concentrations were calculated post-shearing and post-library preparation using 
the Agilent High Sensitivity DNA Kit and 2100 Bioanalyzer Instrument (both Agilent, 
Stockport, UK), in accordance with the manufacturers guidelines.
2.7 Sanger Nucleotide Sequencing and Resolution
Sanger capillary DNA sequencing was performed either using the BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, now Life Technologies, Paisley, UK) and 
resolved on an ABI Prism 3730 DNA Analyzer (Applied Biosystems, now Life Technologies, 
Paisley, UK) at LSHTM or purified and sent for Sanger sequencing by Source Bioscience 
(Nottingham, UK). 
The BigDye Terminator v3.1 Cycle Sequencing Kit was utilised according to the 
accompanying protocol. Briefly, 10 μl reactions were prepared consisting of 1 μl BigDye 
termination mix, 3 μl dilution buffer, 1 μl sequencing primer, 1 μl template DNA and 4 μl 
nuclease free water (Sigma-Aldrich, Gillingham, UK). Unless otherwise stated, the PCR 
amplification primers were used in the sequencing reactions. Amplification reactions were 
performed on a DYAD PTC-220 peltier thermal cycler (MJ Research, now Bio-Rad, Hemel 
Hempstead, UK). Thermocycling conditions were: a hot-start of 96°C for 4 minutes, 
followed by 25 cycles of 96°C for 20 seconds denaturation step, 50°C for 10 seconds 
annealing step, 60°C for 2 minutes extension step, and a final elongation at 60°C for 5 
minutes. DNA from the sequencing reactions were precipitated through the addition of a 
0.1M sodium acetate/70% ethanol solution and incubation on ice for 20 minutes, followed
by centrifugation at 4°C and 3000 g for 30 minutes and removal of the supernatant. The 
DNA was then subjected to two rounds of a wash step, involving resuspension in 70% 
ethanol and centrifugation at 4°C and 3000 g for 10 minutes, prior to removal of the 
supernatant. DNA was then resuspended in Hi-Di Formamide (Life Technologies, Paisley, 
UK) and resolved on an ABI Prism 3730 DNA Analyzer (Applied Biosystems, now Life 
Technologies, Paisley, UK).
Resulting sequence traces from both methods were visualised and manually corrected 
using ChromasPro version 1.7.6 (Technelysium, Brisbane, Australia). Sequences were 
resolved from both forward and reverse primers and combined to generate consensus 
sequences. Consensus sequences were compared to National Centre for Biotechnology 
Information (NCBI) and European Bioinformatics Institute (EBI) archived sequences using 
their respective Basic Local Alignment Search Tools (BLAST) [Camacho et al., 2009; Lopez 
et al., 2003]. 
2.8 Illumina MiSeq NGS Sequencing, Assembly and Annotation
2.8.1 Target Enrichment using Agilent SureSelect Target Enrichment 
The solution hybrid selection of HHV-6A genomic DNA was performed as described 
previously [Gnirke et al., 2009; Depledge et al., 2011], using the SureSelect Target 
50
Enrichment System (Agilent Technologies, Stockport, UK). Briefly, HHV-6A, strain U1102 or
AJ, infected cell total DNA was sheared to an average size of 200 bp (6x60 seconds: duty 
cycle 10%, intensity 5 and 200 cycles per burst) using a Covaris E210 focused-
ultrasonicator (Covaris, Brighton, UK), followed by end repair, dA-tailing, adapter ligation 
and PCR enrichment according to the manufacturers guidelines with all required 
purification steps performed using Agencourt AMPure XP beads (Beckman Coulter, High 
Wycombe, UK). Overlapping, 120-mer biotinylated RNA baits, custom designed against the
HHV-6A strain U1102 genome sequence (Accession X83413, RefSeq NC_001664) were 
then hybridised to the viral DNA component of this total cellular fragmented DNA library 
for 36 hours. Before streptavidin magnetic beads were used to capture HHV-6A genomic 
DNA. This was followed by a limited number of rounds of PCR to amplify the captured 
library. 
2.8.2 Target Enrichment using LPCR Amplicons
Long-range PCR (LPCR) amplicon based sequencing was performed as described 
previously [Depledge et al., 2011]. For this, primer sets (synthesised by Sigma-Aldrich, 
Gillingham, UK), described in section 2.3.1, were designed against the HHV-6A strain 
U1102 reference genome [Gompels et al., 1995] (Accession X83413, RefSeq NC_001664) 
in overlapping 1-7kb amplicons. 36 overlapping PCR amplicons were generated using 
GoTaq Long PCR mastermix  (Promega, Southampton, UK) and nuclease-free H2O (Sigma-
Aldrich, Gillingham, UK) with thermocycling using a hot start 95°C for 2 minutes, then 35 
cycles of 95°C for 20 seconds, 59°C for 30 seconds, 70°C for 6 minutes, and a final 
elongation step of 72°C for 10 minutes. Amplicons were size-selected on 0.7% agarose 
gels, then purified using the Wizard SV gel and PCR clean-up kit (Promega, Southampton, 
UK). Pooled equimolar amplicons were sheared using an E210 focused-ultrasonicator 
(Covaris, Brighton, UK) to an average size 200 bp. End repair, dA-tailing, adapter ligation, 
and PCR enrichment used NEBNext DNA library prep master mix set for Illumina with 
multiplex oligos (New England Biolabs, Hitchin, UK). Again all required purification steps 
were performed using Agencourt AMPure XP beads (Beckman Coulter, High Wycombe, 
UK).
2.8.3 Illumina MiSeq Sequencing
DNA quality and quantification of prepared libraries was assessed as described in section 
2.6.2. Final, indexed DNA libraries were denatured, diluted, then loaded onto a MiSeq v2 
reagent cartridge following the MiSeq guide (Illumina, Little Chesterford, UK) for 2 x 250 
bp paired-end sequencing. Post-sequencing, raw sequence data quality was assessed with 
FastQC (Babraham Bioinformatics, Cambridge, UK). The Fastq file reads had adapters 
removed and quality trimming using a phred score of 33 and minimum length of 100 base 
pairs with trimmomatic version 0.32 [Bolger et al., 2014]. 
2.8.4 NGS Bioinformatics: Sequence Assembly
For mapped assemblies, trimmed read-pairs were mapped to the HHV-6A strain U1102 
reference genome [Gompels et al., 1995] (Accession X83413, RefSeq NC_001664) using 
the BWA-MEM alignment algorithm of BWA version 0.7.10 and SAMtools version 1.0 [Li 
and Durbin, 2009; Li et al., 2009]. Average read coverage was calculated using the  
DepthOfCoverage tool from the Genome Analysis Toolkit (GATK) software version 3.3 
[McKenna et al., 2010] and alignment quality was assessed using Qualimap version 2.0 
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[Garcia-Alcade et al., 2012]. Variant calling used both a SAMtools version 1.0 mpileup, 
BCFtools, vcfutils varFilter pipeline [Li et al., 2009; Danecek et al., 2011] and the GATK 
version 3.3 UnifiedGenotyper tool [DePristo et al., 2011]. For de novo assemblies a 
VelvetOptimiser version 2.2.5, Velvet version 1.2.10 [Zerbino & Birney, 2008], ABACAS 
version 1.3.1 [Assefa et al., 2009] pipeline was used to optimise assembly and contig 
ordering using HHV-6A strains U1102 [Gompels et al., 1995] (Accession X83413; RefSeq 
NC_001664) and GS [Gravel et al., 2013a] (Accession KC465951), with manual adjustments 
using Artemis version 16 [Rutherford et al., 2000; Carver et al., 2005; 2012]. Gaps, 
ambiguities and repetitive regions were confirmed by PCR and Sanger capillary 
sequencing as described in section 2.4 and 2.7. 
2.8.5 NGS Bioinformatics: Annotations
Initial annotations were transferred onto generated consensus sequences using the Rapid 
Annotation Transfer Tool (RATT) [Otto et al., 2011] and the annotation of the prototypical 
HHV-6A strain U1102 [Gompels et al., 1995] (Accession X83413, RefSeq NC_001664). 
These were in turn updated and manually corrected in Artemis version 16 [Rutherford et 
al., 2000] guided by GeneMark ORF predictions [Besemer et al., 2001] and the 
experimentally determined annotation corrections found in more recently sequenced 
HHV-6A and HHV-7 strains [Megaw et al., 1998; Donaldson et al., 2013; Gravel et al., 
2013a]. 
2.8.6 NGS Bioinformatics: Minor Variant SNP Analyses
Variant calling was performed as described in section 2.8.4. As described in our 
subsequent publication [Tweedy et al., 2015a] “A cut-off for SNP sensitivity was applied 
using an database control, a CG>GC inversion in the U83 CDS, previously identified and 
corrected [French et al., 1999; Dewin et al., 2006] but still present on the archived NCBI 
database sequence. At this site, the correct sequence was called to a depth of 6148 reads 
with a level of detection of 0.02 %; a cut-off 1 log above this was applied to verify SNPs, 
with a sensitivity of 0.2 %, and SNPs confirmed by Sanger capillary sequencing.”
2.9 Sequence Alignments and Phylogenetic Relationships
Multiple alignments of nucleotide and encoded amino acid sequences were calculated 
using either Clustal W [Larkin et al., 2007] or MUSCLE [Edgar, 2004] using the Molecular 
Evolutionary Genetics Analysis (MEGA) software version 6.0.5 [Tamura et al., 2013]. For 
nucleotide alignments, translated amino acid sequences were aligned before back-
translation. For gene subset alignments, amino acid sequences or nucleotide coding 
sequences were concatenated and aligned as described above, after which any gaps were 
removed prior to downstream analysis.   
Phylogenetic relationships were calculated by Maximum Likelihood statistical method 
[Felsenstein, 1981] using MEGA version 6.0.5 [Tamura et al., 2013]. Nucleotide sequence 
trees were constructed using the Tamura–Nei model [Tamura & Nei, 1993], with uniform 
rates, close neighbour interchange, invariant sites allowance, and checked with 1050 
bootstrap replicates. Amino acid sequence trees were constructed using the Jones–
Taylor–Thornton model [Jones et al., 1992], again using close neighbour interchange, 
invariant site allowance, and tested with 1050 bootstrap replicates.
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2.10 Molecular Modelling of U51A-CCL2 Interaction
Secondary structure predictions were made using RaptorX [Kallberg et al., 2012], JPred 
[Cole et al., 2008] and SOPMA [Geourjon & Deleage, 1995] web servers. All viral receptor 
amino-terminal domain peptide structures were prepared using HyperChem (Hypercube 
Inc, Gainesville, Florida, USA). Helices were modelled with ionic ends removed and 
optimised in Amber99 force field in vacuo for 8000 cycles (utilising the following 
parameters: Constant dielectric scale factor: 1; Switched cut-offs, outer: 14Å, inner: 10Å; 
Electrostatic scale factor: 0.8333Van der Waals scale factor: 0.5) [Cornell et al., 1995]. The 
X-ray crystal structure of the CCL2 I-form refined to 2.40Å [Lubkowski et al. 1997] was 
obtained from the RCSB protein data bank (PDB ID: 1DOL). Modelled viral amino-terminal 
peptides were docked to the CCL2 crystal structure using the AutoDock Vina software 
(search space parameters: centre x 29.451, y 45.273, z 23.508; size x 20Å, y 40Å, z 16Å) 
[Trott & Olson, 2010].
2.11 Plasmid Cloning
2.11.1 PCR-driven Overlap Extension
For the generation of chimeric constructs, PCR-driven overlap extension was performed 
following the protocol devised by Heckman and Pease, 2007 (figure 2.1), except that the 
expand high fidelity PCR system was substituted for the KOD Hot Start DNA Polymerase 
system (Merck Millipore, Watford, UK) with the accompanying protocol being followed. 
The primers  U51NF1 and U51NR1 (section 2.3.5) and a vector containing a U51 construct 
were used to amplify the predicted amino-terminal domain of the U51 gene coding 
sequence. Amplification with these mutagenic primers was also designed to add an EcoRI 
restriction site before the amino-terminus domain sequence and a section of sequence 
complementary to the required chimeric joining site of CCR3. In addition, two further 
primers CCR3MF1 and CCR3MR1 and a vector containing a HA tagged-CCR3 construct 
were used to amplify the coding sequence of CCR3 minus its amino-terminal domain. This 
included the addition of a XhoI restriction site at the carboxyl-terminus. Subsequently, 
these two PCR products were both utilised in a second round of PCR, along with the 
primers U51NF1 and CCR3MR1 to allow for the generation of a chimeric receptor 
construct. The generated chimeric construct was then purified and inserted into a HA tag 
containing pcDNA3 vector using the EcoRI and XhoI restriction sites, as described in 
sections 2.11.3 – 2.11.6, to generate a vector designated HA-U51NCCR3M.
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Figure 2.2 PCR-mediated overlap extension to generate an N-terminally swapped chimeric
receptor. The first round of PCRs generates two PCR products with overlapping sequences due to
the inclusion of nucleotides in the internal primers, b and c, that span the junction of segments AB
and CD. Here AB is used to signify the N terminal region of the U51 gene and CD signifies the CCR3
gene minus the N terminus. These two products are then used as the template for a second PCR to
generate the hybrid gene product AD. The inclusion of restriction enzyme site in the sequences of
the two external primers then allows for insertion of this chimeric receptor construct into an
expression vector [Figure adapted from Heckman & Pease, 2007].
2.11.2 HA-U51NCCR3
The HA-U51NCCR3 was generated using the T7 and U51DNR1 primers to amplify the 
amino-terminal domain of U51A with a HA tag and an EcoRI restriction site at the 3' end. 
This construct was in turn inserted into the HA-CCR3 vector using the HindIII and EcoRI 
restriction sites.
2.11.3 Alanine-scanning Mutagenesis
For alanine-scanning mutagenesis of the entire amino-terminal domain of U51A, the 
Heckman and Pease, 2007 protocol described above was adapted to allow for the 
generation of mutant constructs with a single PCR step. The primers HA-U51ΔM1A – HA-
U51ΔY17A described in section 2.3.5.4, which were designed to contain the entire amino-
terminal domain of U51A with relevant mutations for alanine scanning, plus the addition 
of an amino-terminal HA tag and EcoRI restriction site, were used in conjunction with the 
U51MR1 primer and the U51A vector to amplify alanine-scanning mutant constructs. 
These constructs were inserted into pGEM-T as a transfer vector, a selection of these 
constructs (U51A-ΔE2G, -ΔE2A, -ΔK3A, -ΔE4A, -ΔK6A and -ΔE15A) were then transferred to
a HA tagged pcDNA3 expression vector using the EcoRI and XhoI restriction sites, as 
described in sections 2.11.3 – 2.11.6, to generate vectors designated HA-U51ΔE2G, HA-
U51ΔE2A, HA-U51ΔK3A, HA-U51ΔE4A, HA-U51ΔK6A and HA-U51ΔE15A.
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2.11.4 Restriction Digestion
All restriction digestions were performed using restriction enzymes from New England 
Biolabs (Hitchin, UK), following the accompanying protocols. For double digestions 50 μl 
reactions were prepared as follows: 1 μl restriction enzyme 1 (10 enzyme units), 1 μl 
restriction enzyme 2 (10 enzyme units), 5 μl relevant digestion buffer, X μl of sample DNA 
corresponding to 1 μg total DNA, Y μl nuclease-free water (Sigma-Aldrich, Gillingham, UK) 
to make up to 50 μl total reaction volume. Digestion reactions were incubated at 37°C for 
1 hour. Subsequently, restriction enzymes were heat inactivated by incubation at 65°C (in 
some cases 80°C) for 20 minutes. Reaction DNA was separated, visualised and gel purified, 
as described in section 2.5. 
For single restriction enzyme digestions, the volume of nuclease-free water was increased 
accordingly. In addition, where necessary, post-digestion DNA was treated with 1 μl 
Antarctic Phosphatase (1 enzyme unit) (New England Biolabs, Hitchin, UK) and incubated 
at 37°C for 15 minutes prior to heat inactivation in order to prevent self-ligation.
2.11.5 Ligation
All ligations were performed using T4 DNA ligase (New England Biolabs, Hitchin, UK), in 
accordance with the manufacturers guidelines. Briefly, the size and DNA concentration of 
purified digested DNA, quantified as described in section 2.5, was used to calculate the 
mass of insert required for a 3:1 molar insert:vector ratio. 20 μl ligation reactions were 
then set up as follows: 1 μl T4 DNA ligase (1 enzyme unit), 2 μl ligation buffer, X μl insert 
DNA corresponding to 3:1 molar insert:vector ratio, Y μl vector DNA corresponding to 3:1 
molar insert:vector ratio, Z μl nuclease-free water (Sigma-Aldrich, Gillingham, UK) to make 
up to 20 μl total reaction volume. Ligation reactions were then incubated at room 
temperature for 1 hour or at 16°C overnight, followed by incubation at 65°C for 10 
minutes for enzyme heat inactivation.
2.11.6 Transformation
Vectors were transformed into competent Escherichia coli (E. coli) strain JM109 cells. Either
commercially prepared cells: JM109 Competent Cells >107 cfu/μg (Promega, 
Southampton, UK) or MAX Efficiency DH5α Competent Cells (Life Technologies, Paisley, 
UK) following their accompanying protocols, respectively. Or prepared according to the 
protocol outlined by Chung et al., 1989. For this, E. coli strain JM109 cells were grown in 
LB broth (10g tryptone, 5g yeast extract and 10g NaCl dissolved in 1L de-ionised water, all 
from Sigma-Aldrich, Gillingham, UK) to the early exponential phase as estimated by 
absorbance at 600 nm (OD600). Cells were then diluted 1:1 with transformation and storage
solution (TSS) (LB broth containing 10% (wt/vol) PEG, 5% (vol/vol) DMSO and 50 mM MgCl2
all from Sigma-Aldrich, Gillingham, UK) and stored at -80°C for long-term storage.
Transformation competent cells were thawed on ice, up to 50 ng of sample DNA is mixed 
with the cells and incubated on ice for 10 minutes. The cells were then heat-shocked for 
45 seconds by immersion in a water bath at 42°C, followed by a further 2 minute 
incubation on ice. Cells were then mixed with 900 μl of SOC medium (Life Technologies, 
Paisley, UK) and incubated for 60 minutes at 37°C with shaking. Followed by plating onto 
LB/ampicillin agar plates (LB medium prepared as above, supplemented with 15 g/L agar 




Streaking of picked colonies on LB/ampicillin plates, prepared as described in section 
2.11.5, was performed for single colony isolation. Individual colonies were then grown 
overnight in LB broth, also as described in section 2.11.5, supplemented with 100 µg/mL 
ampicillin (Sigma-Aldrich, Gillingham, UK), at 37°C with shaking. Plasmid DNA was then 
purified using either the PureLink Quick Plasmid Miniprep Kit or the PureLink HiPure 
Plasmid Maxiprep Kit (both Life Technologies, Paisley, UK). In general, the overnight 
LB/ampicillin cultures were harvested by centrifugation at 5000 g for 10 minutes and the 
supernatant removed, followed by cell lysis using a modified version of the alkaline lysis 
method [Birnboim & Doly, 1979], with isotonic resuspension buffer supplemented with 
RNase, and an alkaline lysis buffer containing a detergent, followed by incubation at room 
temperature for 5 minutes. A precipitation/neutralisation buffer was added to the lysed 
cell mixture and the lysate is centrifuged for 10 minutes at >12,000 g. The plasmid DNA 
containing supernatant was then transferred to either a silica membrane spin column, or 
in the case of maxiprep purification an anion-exchange resin column with solutions passing
through the column by gravitational instead of centrifugal force, for purification as 
described in section 2.5. Plasmid DNA insert identities were confirmed by Sanger capillary 
sequencing as described in section 2.7.
2.12 Cells and Cell Culture
2.12.1 Cell Types
The human lymphoblastic K562 cell line (derived from chronic myelogenous leukemia) 
[Klein et al., 1976] was obtained from Dr. U.A. Gompels (London School of Hygiene and 
Tropical Medicine, London, UK) and maintained in RPMI 1640 media (Sigma Aldrich, 
Gillingham, UK) supplemented with 10% v/v Fetal Bovine Serum (Life Technologies, 
Paisley, UK), 50 IU/ml penicillin, 50 μg/ml streptomycin and 2 mM glutamine (all Life 
Technologies, Paisley, UK), as described by Milne et al., 2000. The human monocytic THP-1 
cell line (derived from monocytic leukemia) [Tsuchiya et al., 1980] was also obtained from 
Dr. U.A. Gompels (London School of Hygiene and Tropical Medicine, London, UK) and 
maintained in RPMI 1640 media with GlutaMAX-I and 25 mM HEPES pH 7.4 (from Sigma 
Aldrich, Gillingham, UK) supplemented with 10% v/v Fetal Bovine Serum (Life 
Technologies, Paisley, UK), 2 mM glutamine, 50 IU/ml penicillin, and 50 μg/ml streptomycin
(all Life Technologies, Paisley, UK), as described by Dewin et al., 2006. The murine pre-B 
(derived from Abelson murine leukemia virus transformation of adult C57L mouse cells) 
were generously donated by Dr. J. Pease (Imperial College London, UK) and maintained in 
RPMI 1640 media with GlutaMAX-I and 25 mM HEPES (Sigma Aldrich, Gillingham, UK) 
supplemented with 10% v/v Fetal Bovine Serum (Life Technologies, Paisley, UK), 50 IU/ml 
penicillin, 50 μg/ml streptomycin, 1x non-essential amino acids, 1 mM sodium pyruvate and
50 μM 2-mercaptoethanol (all Life Technologies, Paisley, UK), as described by Vaidehi et al.,
2009.
Cells were grown at 37°C, 5% CO2 in a Sanyo MCO-15 incubator (Sanyo Electric Biomedical,
Loughborough, UK). Cells were counted every 36 hours, as described in section 2.12.3, and
maintained at log phase, at a concentration between 2 x 105 and 1 x 106 cells/ml. This was 
performed by centrifugation of sufficient total viable cells numbers at 125 g for 5 minutes 
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in a Mistral 3000i centrifuge (MSE, Lower Sydenham, UK), supernatant removal and 
resuspension in fresh media, as described above. Cultures exceeding 1.5 x 106 cells/ml 
were discarded due to reported suboptimal expression, post transfection [Vaidehi et al., 
2009].
2.12.2 Resuscitation of Cells and Storage
All procedures were carried out in a sterile environment using a class II safety Heraeus 
LaminAir HB 2436 laminar flow hood (ThermoFisher Scientific, Loughborough, UK). All 
surfaces, bottles and equipment were cleaned with 70% ethanol prior to their use or 
addition to the flow hood. 
For resuscitation, cells from liquid nitrogen storage were thawed in a pre-warmed 37°C 
water bath, added to 9 ml of pre-warmed culture media, and centrifuged at 125 g for 6 
minutes in a Mistral 3000i centrifuge (MSE, Lower Sydenham, UK). The supernatant was 
carefully removed before resuspension in fresh pre-warmed media and transfer to a T25 
tissue culture flask (Corning Life Sciences, Kennebunk, Maine, USA) which was incubated at
37°C, 5% CO2 in a Sanyo MCO-15 incubator (Sanyo Electric Biomedical, Loughborough, UK).
For the production and storage of cell stocks, cultured cells were counted as described in 
section 2.12.3. Media containing 5 x 106 cells was centrifuged at 125 g for 5 minutes in a 
Mistral 3000i centrifuge (MSE, Lower Sydenham, UK) and the supernatant removed. Cells 
were then resuspended in 1 ml 90% Fetal Bovine Serum (Life Technologies, Paisley, 
UK)/10% DMSO (Sigma Aldrich, Gillingham, UK), transferred to a cryotube, frozen slowly at
-80°C before transfer to liquid nitrogen storage.
2.12.3 Cell Counting
Viable cell number per ml and total viable cell number were estimated using a Neubauer 
haemocytometer. For this cultured cell suspension and trypan blue (Sigma Aldyrich, 
Gillingham, UK) were mixed in a 1:1 ratio then added to the haemocytometer chambers. 
On the basis of trypan blue exclusion, viable cell counts per ml were calculated, which in 
turn was multiplied by total cell suspension volume to estimate total viable cell numbers.
2.12.4 Expression Vector Transfection
DNA electroporation of L1.2 cells was performed as described by Vaidehi et al., 2009. 24 
hours prior to electroporation cells were split to 0.5 x 106 cells/ml so they would be in 
logarithmic growth phase (approximately 1 x 106 cells/ml) prior to electroporation. Cells 
were counted as described in section 2.12.3, then a cell suspension corresponding to 10 x 
106 cells was centrifuged at 300 g for 5 minutes and resuspended in 800 μl RPMI 1640 
media with GlutaMAX-I and 25 mM HEPES (Sigma Aldrich, Gillingham, UK). These cells were
added to an 0.4-cm electrode gap electroporation cuvette (VWR, Lutterworth, UK) along 
with 0.5 mg/ml tRNA ( Sigma Aldrich, Gillingham, UK) and 1 μg expression plasmid DNA 
before incubation at room temperature for 30 minutes. Cells were then electroporated at 
330 volts and 975 μF using a Gene-Pulser electroporator (BioRad, Hemel Hempstead, UK) 
and incubated at room temperature for a further 30 minutes. Cells were then transferred 
to a T25 tissue culture flask (Corning Life Sciences, Kennebunk, Maine, USA) and 
resuspended in complete media, as described in section 2.12.1 , at a final concentration of 
1 x 106 cells/ml and incubated for 3 hours at 37°C/5% CO2 in a Sanyo MCO-15 incubator 
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(Sanyo Electric Biomedical, Loughborough, UK) before addition of sodium butyrate to a 
final concentration of 10 mM. Cells were then incubated for a further 24 - 48 hours to 
allow gene expression.
K562 and THP-1 were electroporated based on an adaptation of the protocol described by
Milne et al., 2000. These electroporation were performed as described above except that 
cells were added to the cuvette along with 0.1 mM Dithiothreitol, 10 mM Glucose (both 
Sigma Aldrich, Gillingham, UK) along with 20 μg expression plasmid DNA and sodium 
butyrate induction was omitted.
2.13 Chemokines and Chemotaxis Assay
2.13.1 Chemokines
All chemokines were purchased from Peprotech (Rocky Hill, New Jersey, USA), and 
prepared according to the manufacturers guidelines. Lyophilised chemokines were 
reconstituted in nuclease-free water (Sigma Aldrich, Gillingham, UK), working aliquots 
were prepared by dilution with RPMI 1640/0.1% BSA (both Sigma Aldrich, Gillingham, UK) 
and stored at -20°C.
2.13.2 Calcein-AM Staining
Receptor expressing cells were centrifuged for 5 minutes at 300 g in a Mistral 3000i 
centrifuge (MSE, Lower Sydenham, UK) and resuspended in RPMI 1640/0.1% BSA (both 
Sigma Aldrich, Gillingham, UK) with 4 μM calcein-AM (Life Techologies, Paisley, UK) for live 
cell staining. Cells were then incubated for 30 minutes at 37°C, before being washed twice
by centrifugation for 5 minutes at 300 g in a Mistral 3000i centrifuge (MSE, Lower 
Sydenham, UK) and resuspension in RPMI 1640/0.1% BSA (both Sigma Aldrich, Gillingham, 
UK) prior to use in the chemotaxis assay, described in section 2.13.3. Post chemotaxis, 
remaining cell suspension was removed from the top of the chemotaxis filter and live cell 
migration was assessed using a Wallac Victor 1420 Multilabel Counter (Perkin Elmer, Seer 
Green, UK) with an excitation wavelength of 485 nm and an emission wavelength of 535 
nm.
2.13.3 Chemotaxis Assay
Chemotaxis was performed as described by Vaidehi et al., 2009. The Neuroprobe 
ChemoTX chemotaxis plate wells (Receptor Technologies, Warwick, UK) were blocked with
RPMI 1640/1% BSA (both  Sigma Aldrich, Gillingham, UK) and incubated for 30 minutes, 
then rinsed with de-ionised water. Dilutions of chemokines, prepared in RPMI 1640/0.1% 
BSA together with controls containing chemokine buffer only, were placed in the lower 
wells of the chemotaxis plate in triplicate at a volume of 31 μl per well. The 5 μm pore size 
filter was then overlayed on the well plate. 50 μl resuspended calcein-AM stained cells at a 
cell density of 3 x 106 cell/ml, prepared as described in section 2.13.2, were then applied 
atop the chemotaxis filter above each well. The lid of the plate was fitted and the entire 
plate was incubated at 37C/5% CO2 for 3-5 hours. Live cell migration was calculated as 
described in section 2.13.2.
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2.14 Flow Cytometry
Cells were counted as described in section 2.12.3, 2 x 105 cells were collected, centrifuged 
at 400 g for 4 minutes in a Mistral 3000i centrifuge (MSE, Lower Sydenham, UK), with 
supernatant removed before resuspension in PBS/0.1% BSA (both Sigma Aldrich, 
Gillingham, UK). Cells were then stained with relevant fluorescently labelled antibodies (all
from R&D Systems, Abingdon, UK, except for anti-HA-FITC which was from Roche, Burgess 
Hill, UK) and incubated for 30 minutes at 4°C. Subsequently, cells were washed with 
PBS/0.1% (both Sigma Aldrich, Gillingham, UK) with centrifugation at 400 g for 4 minutes 
and fixed through resuspension in PBS/2% PFA (both Sigma Aldrich, Gillingham, UK) and 
incubation at room temperature for 15 minutes. Cells were then subjected to a further 
wash step as described above. Stained cells were run on a FACS Calibur flow cytometer 
(BD Biosciences, Oxford, UK). 
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Chapter 3: Next Generation Sequencing of Roseoloviruses
3.1 Introduction
The dideoxy or chain termination method developed by Sanger and colleagues [Sanger et 
al., 1977] has underpinned DNA sequencing technology for the past three decades. 
Advances in the chemistry and technology associated with this technique [Prober et al., 
1987; Panussis et al., 1998; Marsh et al., 1997], allowed automation which has increased 
throughput to a level that allows large complex genomes, such as the human genome, to 
be sequenced [Lander et al., 2001]. However, for whole genome sequencing this method 
suffers from a number of limitations. Requirements for the amplification of DNA 
fragments prior to sequencing typically involves bacterial cloning and electrophoretic 
separation of chain terminated fragment libraries before base detection; placing 
limitations on the throughput potential of this method. Therefore, whole genome Sanger 
sequencing remains a laborious and expensive process. 
Attempts to overcome these limitations led to the development of next generation 
sequencing (NGS). NGS describes a group of diverse technologies unified by the rapid, low 
cost per base generation of large volumes of sequence read data when compared to 
traditional Sanger sequencing. In the decade since these technologies became 
commercially available, five major platforms have emerged: 454, Illumina, Ion Torrent, 
PacBio and SOLiD. While all of these platforms have their relative advantages and 
disadvantages [Reviewed in Mardis et al., 2013; van Dijk et al., 2014], the lowest cost per 
base and highest per run throughput displayed by the Illumina platform has contributed 
greatly to a dominant share in the NGS marketplace [Liu et al., 2012; Loman et al., 2012; 
van Dijk et al., 2014]. The introduction of Illumina MiSeq in 2011, a benchtop high-
throughput sequencing platform, allowed this technology to become a viable option for 
smaller laboratory and in clinical settings. As such advances in these second-generation 
sequencing technologies have revolutionised DNA sequencing and are now beginning to 
allow such data to be available to a much wider user base. Which in turn has permitted 
much greater consideration of species at the whole genome level.
Due to their small size, sequencing of viral genomes is well within the remit of a single run 
from many NGS technologies. However, if this sequencing is performed directly from 
infected tissue samples, the presence of host genomic nucleic acid vastly complicates the 
process. In such cases, the levels of viral nucleic acid may be in a minority compared with 
host nucleic acid; proportions which will be reflected in resultant sequence reads. For 
certain applications this may represent sufficient viral sequence reads. However, in other 
cases, such as viral genomic sequencing, this will affect the ability to achieve the levels of 
read coverage required for accurate sequence resolution. This is especially an issue with 
restricted tissue infections or in characterisation of latent infections, such as that observed
in herpesviruses. As well as for characterisation of the recently defined germ-line 
chromosomally integrated form of HHV-6A/-6B (CI-HHV-6A/-6B), under investigation in 
this thesis.
In these cases, methods for the isolation of viral DNA from the host nucleic acids prior to 
sequencing are advantageous [Mamanova et al., 2010; Radford et al., 2012]. This 
enrichment is typically achieved by in vitro viral culture, long-range PCR (LPCR) 
amplification of viral genomic DNA or hybridisation capture. Each of which have their 
relative advantages and disadvantages mostly centring around time, cost, failure to detect
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large genomic changes or the introduction of mutations [Reviewed in Mertes et al., 2011]. 
However, of particular note in this regard, in vitro culture of the betaherpesvirus HCMV has
been shown to rapidly alter the genetic content of the viral population [Dargan et al., 
2010]. Which may have implications for attempts to sequence Roseoloviruses utilising this 
enrichment method. While all of these enrichment methods have been successfully 
utilised for the next-generation sequencing (NGS) of whole genomes of various other 
members of the Herpesviridae [Lin et al., 2013; Szpara et al., 2014; Cunningham et al., 2010;
Donaldson et al., 2013; Depledge et al., 2011; Depledge et al., 2014; Renzette et al., 2011],
at the start of this thesis, these technologies had not been applied to Roseoloviruses. 
Additionally, different methods for the assembly of NGS sequencing reads can affect their 
interpretation. If a suitable reference genome is available, the sequencing reads may be 
aligned/mapped onto this genome and any variants used to generate a consensus 
sequence. Whilst this method has time advantages and less computational resource 
requirements. Issues arise with read alignment at regions of high divergence and novel 
genes/sequence may be missed [Scheibye-Alsing et al., 2009]. Alternatively reads can be 
subjected to de novo assembly whereby specific algorithms are used to identify 
overlapping sequence in the reads permitting their assembly into larger contigs. This 
allows for better resolution of novel sequences, but also requires greater computational 
power and read depth coverage [Scheibye-Alsing et al., 2009]. Additionally both of these 
sequence assembly methods suffer with the resolution of repetitive sequences [Treangen 
& Salzberg, 2011; Lee & Schatz, 2012], which can be found at a number of locations 
throughout HHV-6A/-6B genomes, most notably the T1 and T2 regions in the direct repeat
(DR) regions of the genomic termini, the origin of lytic replication (oriLyt) towards the 
centre of the unique long (UL) region,  and the R1, R2 and R3 regions located towards the 
right end of the UL region, indicated in figure 1.4. As with enrichment strategies, at the 
start of this thesis the utility of these NGS short read assembly methods for use in 
Roseoloviruses had not been determined. 
In order to assess the effects of different NGS methods, comparisons were made between
different enrichment and sequence assembly methods for the Illumina platform based 
NGS of HHV-6A genomic DNA. The aim was to establish a readily utilisable pipeline for viral
genomic sequencing directly from cell or tissue samples. This would also be widely 
applicable to HHV-6A/-6B strains, and key to determine genomic sequences of the 
previously uncharacterised integrated forms of these viruses, CI-HHV-6A/-6B. These 
methods were first validated by resequencing the HHV-6A reference strain U1102. Before 
further validation through the application of this technology for the sequencing of a 
second previously unsequenced strain of HHV-6A, AJ. Also one of the first Roseolovirus 
isolates.
Available reports of complete HHV-6A/-6B genomes are currently limited. Complete 
genome sequences of two HHV-6B strains, the 162 kbp Z29 strain and the 162 kbp HST 
strain, have been determined (accession numbers AF157706 and AB021506, respectively) 
[Dominguez et al., 1999; Isegawa et al., 1999]. Z29 was also isolated from a HIV/AIDS 
patient from Zaire, now Democratic Republic Congo [Lopez et al., 1988], while strain HST 
was isolated from a Japanese infant during primary infection [Yamanishi et al., 1988], and 
represents the only primary childhood infection strain currently sequenced. 
To date, genomes have been derived from HHV-6A strains isolated from reactivated 
infections in immunosuppressed patients. The first to be sequenced was strain U1102, 
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originally isolated from a Ugandan HIV/AIDS patient [Downing et al., 1987]. This was 
sequenced by Gompels and colleagues (accession number X83413) [Gompels et al., 1995] 
and subsequently has become the prototypical reference sequence for HHV-6A. After the 
start of this thesis, two versions of strain GS were derived (accession numbers KC465951 
and KJ123690), only one of which (KC465951) was reported [Gravel et al., 2013a]. With GS 
originally being isolated from American/Jamaican patients with lymphoproliferative 
disease [Salahuddin et al., 1986]. HHV-6A strain AJ, was also one of the original HHV-6A 
isolates and was characterised in the UK from an adult HIV/AIDS patient from the Gambia 
[Tedder et al., 1987], however, at the start of this thesis the sequence of its genome had 
not been resolved.
Although the sequencing projects that gave rise to the strain GS genome sequences 
utilised NGS technologies, methods were not explicitly described. Importantly, no viral 
target enrichment methods were described, meaning these methods could not be readily 
applied to the sequencing of CI-HHV-6A/-6B genomes directly from clinical samples. 
Comparisons were made between all these fully sequenced HHV-6A and -6B genomes and 
the resequenced U1102 and strain AJ derived here.
3.2 Establishment of Next Generation Sequencing Protocols for HHV-6A Genomes
3.2.1 SureSelect Target Enrichment System
Solution hybrid selection has previously been utilised for the specific capture and 
subsequent second-generation sequencing of viral genomic DNA [Matranga et al., 2014]. 
Including from some members of the Herpesviridae, namely VZV, EBV and KSHV [Depledge 
et al., 2011]. However, its use for the enrichment of HHV-6A genomic DNA has not been 
reported. Therefore, initially attempts were made to investigate the validity of the use of 
solution hybrid selection to specifically capture HHV-6A genomic DNA from an infected 
cell, total DNA fragment library and then to compare it to a long-range PCR amplicon 
method of target enrichment. The enriched fragment libraries were then used for the 
determination of whole viral genomic sequence by Illumina MiSeq based NGS and read 
assembly. Initially the SureSelect methodology was applied to resequencing of the 
prototypical HHV-6A strain, U1102 (Accession X83413/RefSeq NC_001664), originally 
sequenced by Gompels et al., 1995 from plasmid, cosmid and lambda bacteriophage 
clones containing fragments covering the entire genome [Martin et al., 1991a]. This 
allowed an assessment of the accuracy of the solution hybrid selection and NGS 
methodology for HHV-6A strains. It also provided a means for confirmation of the strain 
U1102 genome sequence, confirmation of previously reported errors in the U1102 
sequence (three substitutions in the DR6, U83 and U86 ORFs) [Schleimann et al., 2014; 
French et al., 1999; Dewin et al., 2006; Papanikolaou et al., 2002] and identification of any 
further errors or minor strain variants.
The SureSelect Target Enrichment System, was used due to its proven ability in the whole 
genome sequencing of other human herpesviruses from clinical samples [Depledge et al., 
2011]. Briefly, following sequence library generation, overlapping, 120-mer biotinylated 
RNA baits, custom designed against known HHV-6A/-6B and HHV-7 genomes [Depledge et
al., 2011; Donaldson et al., 2013] were used to capture HHV-6A strain U1102 genomic DNA
from the JJhan infected cell total DNA sequence library, followed by a limited number of 
rounds of PCR to generate sufficient quantities of nucleic acid [Gnirke et al., 2009]. The 
enriched sequence library was then subjected to paired-end sequencing on an Illumina 
62
MiSeq. Post-sequencing, quality trimmed read-pairs were mapped to the strain U1102 
genome using Burrows-Wheeler Aligner-MEM algorithm (BWA-MEM) [Li & Durbin, 2009], 
with variant calling, read coverage analysis and consensus sequence generation  
performed using the Genome Analysis Toolkit (GATK) [McKenna et al., 2010; DePristo et 
al., 2011] as well as a SAMtools/BCFtools/vcfutils pipeline [Li et al., 2009; Danecek et al., 
2011]. In addition, a VelvetOptimiser, Velvet [Zerbino & Birney, 2008] and ABACAS [Assefa 
et al., 2009] pipeline was also used to optimise de novo assembly of the trimmed read-pairs
and subsequent contig assembly against the U1102 reference genome. 
For the consensus sequences generated by both assembly methods, the Rapid Annotation 
Transfer Tool (RATT) [Otto et al., 2011] was used to transfer the annotation of the 
prototypical HHV-6A strain U1102 onto the assembled genomes sequences, these initial 
annotations were in turn corrected and updated using a combination of GeneMark ORF 
predictions [Besemer et al., 2001] and further annotation corrections found on HHV-6A 
and HHV-7 strains derived during the work towards this thesis [Donaldson et al., 2013, 
Gravel et al., 2013a; Megaw et al., 1998]. In addition, the original annotation of the HHV-6A
strain U1102 (Accession X83413, RefSeq NC_001664) was also updated to reflect these 
corrections and thereby allowing for accurate comparisons between the archived and 
experimental genome sequences.
A total of 1,444,266 reads were generated from the MiSeq run, with a mean read length 
of 220.89 bp post trimming. For the read mapped assemblies 1,403,841 of these reads 
(97.20%) could be mapped to the U1102 reference genome with a mean mapping quality 
score, a Phred-scaled quality score of the mapping, of 52.95, 1,396,309 (96.68%) of which 
were properly paired. Unmapped read pairs were subjected to BLASTn searches [Camacho 
et al., 2009], which revealed they were of human genomic origin. Of the 40,425 unmapped
reads, 97.4% shared homology with some of the viral bait sequences used for DNA 
capture, presumed to have been captured along with viral DNA due to the presence of 
human genomic-like sequences within the HHV-6A genome. The remaining 2.6% of 
unmapped reads were believed to result from incomplete post-hybridisation wash steps. 
Read depth coverage across the entire genome is shown in figure 3.1A. The mean read 
depth coverage across the genome was 1,557.36 (SD 481.21), with 100% of the genome 
covered at a read depth coverage greater than 10, and 99.95% at greater than 100 depth. 
Read mapping quality scores were also compared across the genome, figure 3.1B. Regions
with lowest read depth and mapping quality scores were predominantly found in the 
direct repeats (DR) at the genomic termini and in the R2 and R3 regions within the unique 
long (UL) section of the genome. These included regions with higher G+C content, which 
are know to be under-represented in Illumina sequencing results [Benjamini & Speed, 
2012].
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Figure 3.1 Coverage and mapping quality of SureSelect enriched HHV-6A strain U1102 sequence
reads across the X83413 reference genome. (A) Coverage of SureSelect HHV-6A strain U1102
reads across the reference genome. SureSelect target enriched libraries from infected cell DNA
were sequenced by Illumina MiSeq and mapped to the U1102 reference genome using the BWA
MEM algorithm. (B) Mapping quality scores of sequence reads across the U1102 genome. Direct
repeat regions of the genome are shaded and labelled DRR and DRL, accordingly. 
The de novo assembly of read pairs resulted in contigs covering 95.24% (151743 bp) of the 
U1102 reference genome, with gaps occurring in repetitive sequences: a 1233 bp gap in 
R2, a 2287 bp gap in R3 and the remaining gaps in the DR around the T1 and T2 human 
telomeric repeat-like sequences. All previously predicted open reading frames were 
covered by the assembled contigs.
Consensus sequences generated from both the reference mapped and de novo assemblies
were compared to each other and the NCBI genome reference sequence (HHV-6A strain 
U1102, accession X83413). The mapped assembly consensus sequence showed 99.98% 
identity with that of the NCBI reference sequence. The de novo assembly consensus 
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sequence shared an overall nucleotide identity of 99.62% with that derived from the 
mapping assembly. The main sequence variation was in the repetitive sequence regions, 
including the human telomere-like repeat regions of the DRs and in R2 and R3. Since these
repetitive sequences confound assembly from reads shorter than the repeat units, these 
regions were removed to check assembly of unique sequence. Following this, the mapped 
and de novo assemblies shared 99.99% nucleotide identity, providing validation of this NGS
method for the derivation of HHV-6A genomes. This consensus was then compared to the 
NCBI HHV-6A reference genome and showed 99.98% identity, some of this variation was 
expected due to the identification of previously defined or suggested corrections to DR6, 
U83 and U86 [Schleimann et al., 2014; French et al., 1999; Dewin et al., 2006; Papanikolaou
et al., 2002] still present in the NCBI reference genome. However, these did not account 
for all the variation observed, additional SNPs were identified which are discussed further 
in section 3.3.
3.2.2 Long-range PCR amplicons
Since the SureSelect Target Enrichment System (Agilent Technologies) relies on previously 
determined sequence to bait new genomes, an additional method of enrichment was 
established to allow checks for further sequence variation in HHV-6A/-6B genomes. This 
was particularly important for the goal of sequencing CI-HHV-6A/-6B genomes, since at 
the outset of this thesis the genetic distance of these integrated viral forms to infectious 
virus genomes was not known. Therefore, an alternative method was also used which 
involved a whole genome long-range PCR (LPCR) amplicon based approach for the 
enrichment of viral genomic DNA. Both methods were compared to derive the complete 
genome of the previously unsequenced HHV-6A laboratory strain, AJ. The SureSelect 
Target Enrichment System was performed as described above. For the LPCR approach, 
enrichment of HHV-6A viral genomic DNA from JJhan infected cell DNA involved the use 
of primer sets, designed against the U1102 genome sequence, to generate 36 overlapping
amplicons, ranging in size from 1 – 7 kbp, spanning the entire HHV-6A genome (methods 
section 2.3.1). These amplicons were then purified and pooled in equimolar ratios, prior to 
shearing and sequence library preparation. Again, cluster generation and sequencing was 
performed on an Illumina MiSeq. With consensus sequences generated by both mapping 
to the HHV-6A strain U1102 reference sequence and de novo assembly as described for the
resequencing of strain U1102 above.
Paired-end sequencing of the SureSelect enriched AJ library generated a total of 
1,937,791 reads, with a mean read length of 196.49 bp. For mapped assemblies, 1,914,498
(98.8%) of these reads mapped to the U1102 reference genome with a mean mapping 
quality of 52.52, 1,912,009 (98.7%) which were properly paired. Mean read coverage 
across the reference genome was 2,119.84 (SD 719.95), with 99.7% and 98.4% of the 
genome covered at read depths greater than 1 and 100, respectively (figure 3.2). De novo 
assembly of these reads generated contigs covering 90.2% of the U1102 reference 
genome. 
The LPCR library generated 2,790,709 reads, with a mean read length of 224.31 bp. 
2,787,945 (99.9%) of these reads mapped to the U1102 reference genome with a 
mapping quality of 52.67, where 2,787,689 (99.9%) of these reads were properly paired. 
The mean read coverage was 2,581.51 (SD 1,439.74), with 99.5% and 95.5% of the 
genome covered at read depths greater than 1 and 100, respectively (figure 3.3). Although
the mapping quality scores across the genome from both the SureSelect and LPCR 
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methods were similar, there was greater read coverage variance across the genome with 
the LPCR generated library, predominantly coinciding with genomic amplicon locations. 
This appeared to be from variances in the equimolar pooling of the genomic amplicons 
prior to sequence library generation. However, despite these differences, coverage was 
still sufficient to allow determination of the genomic sequence. De novo assembly of these
read pairs generated contigs covering 90.35% of the U1102 reference genome, with gaps 
primarily from the repeat regions described.
Figure 3.2 Coverage and mapping quality of SureSelect enriched HHV-6A strain AJ sequence
reads across the HHV-6A strain U1102 reference genome. (A) Coverage of SureSelect HHV-6A
strain AJ reads across the U1102 reference genome. SureSelect target enriched libraries from
infected cell DNA were sequenced by Illumina MiSeq and mapped to the U1102 reference genome
using the BWA MEM algorithm. (B) Mapping quality scores of reads across the U1102 genome.
Direct repeat regions of the genome are shaded and labelled DRR and DRL, accordingly. 
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Figure 3.3 Coverage and mapping quality of LPCR enriched HHV-6A strain AJ sequence reads
across the HHV-6A strain U1102 reference genome. (A) Coverage of LPCR HHV-6A strain AJ reads
across the U1102 reference genome. LPCR derived libraries from infected cell DNA were
sequenced by Illumina MiSeq and mapped to the U1102 reference genome using the BWA MEM
algorithm. (B) Mapping quality scores of reads across the U1102 genome. Direct repeat regions of
the genome are shaded and labelled DRR and DRL, accordingly.  
The accuracy of both enrichment methods was compared. For this each method was 
compared separately to a combined consensus sequence determined using all available 
reads from both methods and additional Sanger sequencing verification of divergent or 
gap regions, as described in below in section 3.4. Using U1102 reference mapping, the 
consensus sequences derived from mapping of the SureSelect enriched and LPCR strain 
AJ sequencing reads to the U1102 genome shared 99.2% and 99.3% identity with the final
consensus AJ genome, respectively. Using de novo assembly, the SureSelect and LPCR 
reads shared 98.1% and 98.3% identity, respectively. Again discrepancies between the 
mapped and de novo assemblies were confined to repetitive regions: the DRs and R3. With 
the exclusion of these repetitive regions, the SureSelect reference mapped and de novo 
assemblies shared 100% identity with each other. Similarly, the LPCR enrichment method 
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also shared 100% identity between the reference mapped and de novo assemblies. This 
showed both enrichment methods assembled equally well using both reference mapped 
and de novo assembly. However, in both cases the sequencing pipeline depended on 
Sanger sequencing of gaps and repetitive regions for completion of the full genome 
sequence.
Finally, to determine whether all previously defined genes could be resolved accurately by 
mapping assemblies, CDS nucleotide identity comparisons were made between the 
different reference mapped assemblies and the final resolved sequence of AJ. For this, all 
consensus sequences were again annotated to reflect recent experimentally defined 
annotation corrections, as described in section 3.2. Before pairwise comparisons and 
calculations of read coverage were made between all gene CDS, table 3.1. This indicated 
mapped assemblies from both SureSelect and LPCR libraries could accurately resolve all 
gene CDS across the UL region of the genome, even in genomic regions with increased 
variation, at the right end of the genome [Gompels & Kasolo, 2006]. As a further control, a 
number of these genes, including a set of defined variable genes, were compared to 
sequences determined by Sanger capillary sequencing (partly described in sections 5.2 and
as subsequently published in full in Tweedy et al., 2015a). These also shared 100% identity 
with those generated by the mapped assemblies from both library generation methods. 
Therefore, SNP differences identified in the strain AJ sequence were confirmed using all 
three methods.
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Table 3.1 Percentage identity between HHV-6A CDS features from mapped assemblies methods
with the complete  sequence of HHV-6A strain AJ. Comparison of CDS with final AJ sequence
resolved below. Emboldened denotes also Sanger sequenced with 100% identity.
Taken together, these results show that solution hybrid capture and LPCR both represent 
viable means for target enrichment of HHV-6A genomic DNA. As for assembly, the 
relatively low level of diversity observed to date amongst HHV-6A strains permits a 
reference based mapping assembly of the UL region of the genome. However, with this 
method issues are encountered with resolution of a number of repetitive regions. At these
sites a de novo assembly method provides better, albeit incomplete, sequence resolution. 
However, currently determining the sequence of these variable and repetitive regions will 
require complementary Sanger sequencing to ensure accurate resolution. Because of 
these repetitive regions and the additional analyses required, this remains a bottleneck to 
the routine use of NGS for whole genome sequencing of HHV-6A strains.
3.3 Resequencing of HHV-6A Strain U1102 Sequence
During resequencing of the HHV-6A strain U1102 genome, section 3.2, it was noted a 
number of discrepancies existed between the NCBI archived U1102 reference sequence 
and the NGS derived consensus sequences. Some of these confirmed sequencing errors 
previously identified in DR6, U83 and U86 [Schleimann et al., 2014; French et al., 1999; 
Dewin et al., 2006; Papanikolaou et al., 2002]. These corrections were all identified during 
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AJ LPCR mapped AJ SureSelect mapped AJ LPCR mapped AJ SureSelect mapped
CDS % Identity % Identity CDS % Identity % Identity
DR1 95.75 1616.45 0 95.75 1494.26 0 U47 100 4427.41 1490 100 3117.86 1467
DR6 95.81 4027.05 18 95.81 1464.84 1 U47A 100 3766.19 2954 100 2216.86 1758
U2 100 9505.95 5644 100 2416.51 1755 U48 100 4502.69 3929 100 2440.31 1842
U3 100 9321.60 601 100 2224.82 219 U49 100 4714.56 2430 100 2589.36 1852
U4 100 5820.74 4498 100 1884.06 1484 U50 100 2540.71 1446 100 2376.88 1256
U7 100 5545.52 1823 100 1973.61 926 U51 100 2769.28 2427 100 2965.15 2005
U10 100 4700.43 3084 100 1989.17 1629 U52 100 2589.15 2154 100 2055.14 1626
U11 100 5076.88 2145 100 1586.60 928 U53 100 7550.19 2361 100 2624.11 1921
U12 100 5042.46 4236 100 1690.05 1368 U53.5 100 7509.09 6653 100 2825.59 2508
U13 100 4382.09 4003 100 1543.87 1270 U54 100 6824.40 2798 100 2992.98 1821
U14 100 5388.61 2460 100 1868.92 1351 U55 100 7732.69 977 100 2702.88 1540
U15 100 4112.03 1157 100 1263.47 1110 U56 100 8619.75 5835 100 2512.97 1598
U17 100 4625.00 3697 100 2084.87 1463 U57 100 7594.49 2720 100 2601.16 1282
U18 100 4397.42 3878 100 1688.72 799 U58 100 9268.91 5134 100 2211.52 1359
U19 100 5208.70 2517 100 2639.69 1698 U59 100 9204.25 7576 100 2985.29 2281
U20 100 4491.90 2927 100 2003.99 1134 U60 100 6411.49 3996 100 2348.60 1559
U21 100 4631.86 1814 100 2539.66 1276 U62 100 7991.17 7236 100 2538.09 2258
U22 100 4785.69 4199 100 2563.95 2217 U63 100 8359.30 7321 100 2479.87 1645
U23 100 5136.92 1320 100 2095.59 1030 U64 100 5774.55 3553 100 2266.40 1318
U24 100 5417.96 5004 100 2509.66 1894 U65 100 4425.32 4026 100 2560.70 2059
U24A 100 5514.00 5296 100 3266.36 3179 U67 100 4423.31 3832 100 2454.01 1962
U25 100 5027.83 4400 100 2477.28 1928 U68 100 4956.52 4618 100 2897.55 2323
U26 100 5521.15 4685 100 2726.60 1959 U69 100 6141.39 3140 100 2753.28 1556
U27 100 5424.07 3986 100 2382.95 1547 U70 100 5276.62 4143 100 2461.10 1756
U28 100 5805.10 2539 100 2130.84 1130 U71 100 5341.32 5079 100 2833.85 2555
U29 100 5560.68 4887 100 2239.81 1759 U72 100 5366.70 4400 100 2486.93 1997
U30 100 5845.46 4036 100 2489.21 1715 U73 100 5950.11 3671 100 2454.06 1665
U31 100 4672.35 2744 100 2361.73 1468 U74 100 6995.05 5427 100 2729.20 2137
U32 100 4939.60 3748 100 2185.78 1636 U75 100 7722.06 2058 100 2347.65 1849
U33 100 6107.34 5187 100 2653.77 2037 U76 100 1929.96 1375 100 2030.75 1022
U34 100 7167.45 5360 100 2685.18 2181 U77 100 1707.88 787 100 2190.08 1303
U35 100 5955.16 5483 100 1962.09 1702 U79 100 6757.10 1652 100 2629.25 1268
U36 100 6071.62 5107 100 2227.00 1605 U81 100 5944.96 5067 100 2691.77 1983
U37 100 6667.73 6297 100 2437.44 1685 U82 100 6073.80 5451 100 2261.54 1725
U38 100 6001.78 2240 100 2166.27 694 U83 100 5477.55 5088 100 2307.49 2123
U39 100 7785.20 3348 100 2272.09 1629 U84 100 5978.56 52 100 2209.75 1355
U40 100 7174.70 6335 100 1945.55 1372 U85 100 7669.00 28 100 2048.19 109
U41 100 5667.65 2491 100 2093.45 1262 U86 100 5193.77 4450 100 1881.77 128
U42 100 7272.84 2549 100 2735.82 1503 U90 100 5287.02 3040 100 1331.07 644
U43 100 8212.30 7262 100 2050.77 1189 U91 100 4419.95 2939 100 1737.33 1156
U44 100 8861.19 8134 100 2452.38 1981 U94 100 2986.21 2250 100 1936.06 1052
U45 100 8024.43 3774 100 3065.64 2331 U95 100 4080.97 2229 100 2528.45 1744

















the re-sequencing, as shown in figure 3.4. However, for DR6 the corrections reported by 
Schleimann et al., 2014, were only identified by the de novo assembly resulting from the 
issues already identified relating to the mapping of reads to repetitive regions as 
exemplified by the mapping quality scores across these regions, figures 3.2 and 3.3.  This 
shows a combination of de novo and reference mapping is required to determine the 
sequence of Roseolovirus genomes.
Figure 3.4 Confirmation of previously identified corrections to the HHV-6A strain U1102 genome
sequence. (A) DR6 - G addition at positions 6664 and 6666 resulting in frame shift early stop codon
as seen in other HHV-6A strains and HHV-6B, could only be identified from the de novo assembly
consensus sequence (B) U83 – GC inversion at position 123740. (C) U86 – G addition as position
128132, subsequently corrected in Refseq version (NC_001664), brings originally defined ORFs
U86 and U87 into one long ORF. Encoded on minus strand, CDS shown 5' to 3' here.
A further five differences were noted between the archived nucleotide sequence and the 
NGS generated consensus sequences. These were located within the coding sequences of 
the U40, U42, U57, U58 and U100 open reading frames, figure 3.5. Blast searches 
[Camacho et al., 2009] of these re-sequenced open reading frames revealed sequences 
with 100% nucleotide identity to two of them, U40 and U42, were already present on the 
NCBI database. These were from genomic fragment sequencing of strain U1102 predating
the publication of the complete genome sequence found under the accession numbers 
L20954 [Jones & Teo, 1993] and X92436 [Jones, unpublished], respectively. These were all 
nonsynonymous mutations and may represent mixed populations in the original isolate 




















Figure 3.5 Further sites of variation identified by resequencing of HHV-6A strain U1102. (A) U40 -
AC to CA at position 63873 (B) U42 – ACTGT to AACTGGAT starting at position 70451 (C) U57 – G to
C at position 92149 (D) U58 – A to G at position 94068 (E) U100 – CG to GC at position 149552. All
shown as CDS 5' to 3'. Amino acid sequence changes shown below nucleotide sequences.
3.4 Construction of the Complete Genome Sequence of HHV-6A Strain AJ
To generate the final consensus, sequence reads from both SureSelect and LPCR 
enrichment methods were combined to increase sequence read coverage across any low 















































then used to generate consensus sequences by both de novo and reference mapped 
assembly, with comparisons made between the consensus sequences for validation. De 
novo assembly resulted in a total of 93.6% sequence resolution (as compared to strain 
U1102), with gaps only in the repetitive regions. The de novo consensus sequence of the 
UL region shared 100% identity with that of the reference mapped consensus with no 
gene insertions or deletions identified.
Remaining gaps and ambiguous regions were resolved by Sanger sequencing, using the 
primers described in section 2.3.2. Also, due to the locations of the primers used for 
generation of the long range PCR amplicons, noted difficulties with de novo assembly of 
repetitive sequences from short read generating NGS technologies and the inability to 
amplify a concatemeric junction sequence for strain AJ; the first 715 bp of direct repeat 
left (DRL) and the final 1381 bp of direct repeat right (DRR) could not be resolved using 
conventional methods. However, these could be determined due to the direct repeat 
nature of the genomic termini, as summarised in figure 1.4. The expected sequences of 
these regions were derived from the corresponding fully sequenced region from the 
opposite termini. The addition of these sequences to the de novo assembled draft genome
allowed for resolution of the complete strain AJ genome sequence. In turn, the original 
sequencing read-pairs were mapped to the newly generated AJ genome sequence using 
BWA-MEM and SAMtools [Li & Durbin, 2009; Li et al., 2009], with BLAST searches 
[Camacho et al., 2009] of unmapped read-pairs revealing only human genomic and 
bacterial sequences and nothing with significant homology to herpesviral sequences. This 
demonstrated that no insertions had been missed during assembly. Annotations were 
derived as described in section 3.2, but also guided by GeneMark ORF predictions 
[Besemer et al., 2001]. The complete genome sequence of HHV-6A strain AJ, was 
subsequently reported in Tweedy et al., 2015b, and has been deposited in GenBank under 
the accession number KP257584 (a gene table is also in  appendix 7.2).
3.5 Analyses of the Complete Genome of HHV-6A Strain AJ
The AJ genome is 156,714 bp in length, maintaining a typical class A herpesviral genomic 
organisation consisting of a 140,401 bp unique long region flanked by 8156 bp direct 
repeats (DRR and DRL). During determination of this genomic sequence, two reports of 
HHV-6A strain GS was published. These were included in the comparisons of HHV-6A/-6B 
strains. Strain AJ is the shortest of the HHV-6A strains sequenced to date (strain U1102 
159,322 bp; strain GS_1 KC465951 156,864; strain GS_2 KJ123690 156,885 bp). Most of 
the sequence length disparity is from deletions of repetitive sequences in the R2 and R3 
repeat regions of the genome. Phylogenetic analyses showed strain AJ shares the closest 
overall nucleotide identity with the low passage North American HHV-6A isolate GS 
(99.1%), followed closely by HHV-6A strain U1102 (98.42%). While the HHV-6B strains Z29 
and HST share 92.41% and 91.79% identities, respectively, figure 3.6. 
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Figure 3.6 Phylogentic analyses of HHV-6A strain AJ to compared to sequenced HHV-6A/-6B
strains. Whole genome comparisons using maximum likelihood estimation and bootstrapping
(1050 replicates). Accession numbers of all HHV-6A/-6B strains used included in the figure.
Branch length scale represents number of nucleotide substitutions per site.
All 85 genes previously identified in HHV-6A strains, U1102 and GS were present in AJ. 
ORF prediction software did not indicate the presence of additional genes, using a cut-off 
ORF size of 100 amino acids. Nucleotide comparisons between gene CDS of strains AJ and 
GS (table 3.2), revealed divergence at genes encoding glycoproteins, products involved in 
DNA replication and immunomodulation. However, a number of these, DR1 and DR6 
[Borenstein et al., 2010], U21 and U24 [Jasirwan et al., 2015], are known to be dispensable 
for viral replication in vitro. Therefore effects resulting from passage of virus in tissue 
culture cannot be ruled out. Thus, despite their distinct geographic origins in the USA and 
Africa, HHV-6A strains AJ and GS are very closely related. 
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HHV-6A GS_2 KJ123690 
HHV-6A GS_1 KC465951 
HHV-6A AJ KP257584 
HHV-6A U1102 X83413 
HHV-6B Z29 AF157706 
HHV-6B HST AB021506 
Table 3.2 Percentage identity between defined CDS of HHV-6A strain AJ and sequenced HHV-6A
strains.
Of particular note, was variation observed in the DNA polymerase gene, U38. Comparisons
with U38 from the other fully sequenced HHV-6A genomes, strains U1102 and GS, 
identified variation, figure 3.7, at a site which has been used to develop a HHV-6 subtype-
specific, probe-based, real-time PCR (SSPBRT-PCR) species typing assay [Lou et al., 2011]. 
While the real-time PCR probe site was identical for all fully sequenced HHV-6A strains, 
variation was noted in both GS and AJ at both primer amplification sites. Thus the 
potential for reduced primer binding affinity, could confound the results of this assay 
through under diagnosis of HHV-6A infection. 
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Pairwise comparisons to HHV-6A AJ
GS_1 GS_2 U1102 GS_1 GS_2 U1102
CDS % % % CDS % % %
DR1 98.15 98.29 95.75 U47 99.59 99.59 98.16
DR6 97.88 98.13 95.81 U47A 100.00 100.00 100.00
U2 100.00 99.91 98.64 U48 99.95 99.95 99.90
U3 99.73 98.48 98.93 U49 99.87 99.87 99.60
U4 100.00 100.00 99.75 U50 99.76 99.76 99.40
U7 99.92 99.92 99.32 U51 99.67 99.67 99.45
U10 99.69 99.62 99.01 U52 99.87 99.87 99.74
U11 99.66 99.66 97.86 U53 99.75 99.75 99.62
U12 99.90 99.90 98.95 U53.5 99.86 99.86 99.59
U13 100.00 100.00 99.69 U54 98.84 98.84 99.27
U14 99.89 99.89 99.56 U55 99.38 99.38 99.38
U15 100.00 100.00 97.57 U56 100.00 100.00 100.00
U17 99.70 99.70 98.71 U57 99.80 99.78 99.01
U18 99.77 99.77 98.07 U58 99.48 99.48 99.22
U19 99.83 99.91 97.86 U59 99.81 99.81 99.15
U20 99.92 99.92 98.90 U60 99.85 99.85 99.75
U21 98.39 98.39 99.46 U62 99.61 99.61 98.45
U22 99.67 99.67 99.84 U63 99.69 99.69 98.77
U23 98.73 98.73 99.02 U64 99.17 99.17 99.17
U24 98.48 98.48 98.48 U65 99.70 99.70 99.50
U24A 100.00 100.00 100.00 U67 99.81 99.81 99.81
U25 99.58 99.58 99.47 U68 99.42 99.42 99.71
U26 99.55 99.55 99.55 U69 99.11 99.11 99.23
U27 99.07 99.07 99.07 U70 99.73 99.73 99.52
U28 99.79 99.79 99.30 U71 100.00 100.00 99.15
U29 99.89 99.89 100.00 U72 99.90 99.90 99.61
U30 99.85 99.85 99.38 U73 99.74 99.70 99.57
U31 99.82 99.82 99.49 U74 99.85 99.85 99.40
U32 100.00 100.00 100.00 U75 99.87 99.87 99.73
U33 99.65 99.65 99.93 U76 99.79 99.79 99.79
U34 99.04 98.92 99.76 U77 99.68 99.68 99.72
U35 100.00 100.00 100.00 U79 96.62 96.70 98.46
U36 99.52 99.52 99.66 U81 99.74 99.74 99.22
U37 99.87 99.87 99.50 U82 99.34 99.34 99.34
U38 99.74 99.74 99.05 U83 98.61 98.61 98.30
U39 99.60 99.60 99.36 U84 98.25 98.25 98.15
U40 99.22 99.22 99.17 U85 98.74 98.74 98.40
U41 99.91 99.91 99.32 U86 98.85 98.85 98.58
U42 99.94 99.94 98.71 U90 98.69 98.69 97.81
U43 99.81 99.81 99.65 U91 99.35 99.35 97.19
U44 99.84 99.84 99.35 U94 99.52 99.52 99.05
U45 99.82 99.82 99.56 U95 98.90 98.90 97.77
U46 99.61 99.61 98.04 U100 98.02 98.17 98.07
Figure 3.7 Variation in the DNA polymerase genes of HHV-6A strains and potential effects on the
SSPBRT-PCR species typing assay. (A) SSPBRT-PCR primer and probe sequences (B) Alignment of
U38 genes of fully sequenced HHV-6A strains at the SSPBRT-PCR expected amplification site.
Primer locations are labelled with solid arrows, probe location is labelled as a dashed line. 
3.6 Discussion
In recent years, the advances in second generation sequencing technologies have 
permitted its widespread use for the low cost (per base) generation of large volumes of 
sequence read data, due to its massively parallel throughput approach [Koboldt et al., 
2013]. Along with advances in an array of areas of biological research, the availability of 
this data has begun to allow much greater consideration of the genetic variation of viral 
species at the whole genome level. The small size of viral genomes compared to the high 
levels of sequence read data achievable by even a single sequencing run by NGS 
technologies, suggests that whole genome sequencing should be a straight forward task. 
However, the obligate intracellular nature of viruses complicates such sequencing 
attempts due to the presence of host cell nucleic acid. While the viral genome copy 
number per millilitre in clinical samples can be in the millions for actively replicating virus, 
this is still in a minority when compared to levels of host nucleic acid. Therefore simply 
generating a NGS total DNA fragment library from such a sample results in high 
proportions of host nucleic acid and low proportions of viral nucleic acids; which is 
reflected in resultant sequencing reads. Thus issues can be encountered with achieving 
the levels of sequence read coverage across the viral genome required to permit whole 
genome assembly. Such problems can be overcome through in vitro viral culture to 
increase quantities of viral nucleic acid. However, in vitro culture may not be possible, and 
even if possible has the potential to rapidly alter the genetic content of a viral population, 
a feature which is observed extensively in a number of herpesviruses, including the closely 
related betaherpesvirus HCMV [Tyler et al., 2007; Dargan et al., 2010]. Thus potentially 
confounding the identification of genetic characteristics of the virus that define its 
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biological and health effects. The relative amounts of viral to host nucleic acid can be even 
further skewed towards the host in cases of restricted tissue infections or in the 
characterisation of latent infections, such as that observed in herpesviruses. Including the 
potentially latent germ-line integrated form of HHV-6A and -6B, CI-HHV-6A and -6B, that is 
the major subject of this thesis. In these cases methods for the enrichment of viral 
genomic DNA from cellular samples are often a prerequisite in order to achieve accurate 
viral sequence data, as well as helping to minimise reagent, computational resource and 
time costs. This is especially important where sample is limited or viral culture is not 
possible, again an issue with the characterisation of CI-HHV-6A/-6B from clinical samples 
from patients with integrated viral genomes. In order to accurately characterise these 
integrated genomes new methodology is required. 
Here the use of two of the major approaches for target enrichment, in solution hybrid 
capture and long range PCR, were employed and assessed for use in the Illumina MiSeq 
mediated sequencing of HHV-6A strains. The aim being that these methods could then be 
used to characterise other Roseoloviruses directly from tissue samples, in particular to 
begin to allow characterisation of CI-HHV-6A and -6B. The results presented here 
demonstrate that both these methods could accurately determine HHV-6A genomic 
sequences. The accuracy was demonstrated with almost 100% identity of the resequenced
U1102 genome with that of the NCBI reference genome [Gompels et al., 1995]. There 
were only 13/159,321 bp differences (99.99% identity). Three of the sites of difference 
agreed with previously reported base substitutions, two causing frame-shifts and one a GC
inversion which currently remain in the NCBI archived reference genome sequence 
[Schleimann et al., 2014; French et al., 1999; Dewin et al., 2006; Papanikolaou et al., 2002]. 
Further differences were identified within 5 additional ORFs. These could represent 
sequencing errors from either the NGS or Sanger methods utilised. Or may be minor 
variants in the original isolate strain of U1102. Additional analyses of passaged U1102 
would be required to verify this.
Difficulties in the resolution of repetitive regions, a common problem encountered in the 
assembly of short-read NGS sequence data [Treangen & Salzburg, 2011], meant that 
complete genome sequences could not be obtained by NGS methods alone. Genome 
completion required directed PCR amplification combined with nucleotide sequence 
determination using Sanger capillary sequencing. Therefore the pipeline for determining 
complete genome sequences still requires a combination of NGS combined with Sanger 
sequencing for HHV-6A/-6B strains. In contrast, genomes of the related betaherpesvirus, 
HCMV, while possessing a complex herpesviral class E genome structure have fewer 
repetitive regions sharing the complexity observed in the HHV-6A/-6B genomes, as such 
NGS methodologies have been rapidly applied to HCMV genomics [Sijmons et al., 2014]. 
Nonetheless, almost all of the 85 identified ORFs of HHV-6A can be rapidly determined by 
these NGS methodologies. Therefore these methods could be utilised to faithfully 
determine and characterise HHV-6A/-6B genomes directly from tissue samples. 
Importantly, these methods can now be applied to determine the genome of the germline
chromosomally integrated form of these viruses.
There are some differences between these two enrichment approaches. Using the same 
amount of input DNA, the mean read coverage observed from sequencing of the LPCR 
generated library was greater than that seen with the SureSelect library (2,581.51 vs 
2,119.84). However, there was much greater variance in the read coverage across the 
genome (SD 1,439.74 vs 719.95 and figure 3.2 vs 3.3), due to the genomic amplicon 
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locations. This was most likely due to minor differences in relative molarity of the 
individual amplicons, since NGS is extremely sensitive to DNA quantitiy. Prior to equimolar 
pooling of the LPCR genomic amplicons estimates of amplicon size were made based on 
U1102 with confirmation/adjustments made by comparison with standards following 
agarose gel electrophoretic separation. While DNA quantification of purified amplicons 
was estimated by UV absorbance on a spectrophotometer. Calculations for the equimolar 
pooling of the genomic amplicons for DNA sequencing library generation were based on 
these measurements. It seems likely that the inherent error levels in these measurement 
procedures, most notably the UV-absorbance based DNA quantification where 
contaminant absorbance at 260 nm can lead to inaccuracies in DNA quantification 
[Manchester, 1996], had a significant impact on sequence uniformity. In the case of the 
sequencing of HHV-6A strain AJ, this variability had no major consequences since variation 
amongst HHV-6A strains is relatively low and the level of coverage was still sufficiently 
high enough for genome assembly. In order to improve relative quantification and 
resulting sequence coverage, fluorometer based assays could be used which rely on the 
specific binding of dyes to dsDNA in order to achieve high levels of fluorescence which in 
turn can be more accurately quantified [Rye et al., 1993]. A number of commercially 
available applications of this technology are now available, the use of which should help to
improve target DNA quantification. 
The percentage of the genome which could be resolved was almost identical for both 
enrichment methods. Similarly, consensus sequences generated from both methodologies
were again identical, when inaccuracies in the assembly of repetitive regions were taken 
into account. Thus, from a technical standpoint there is little to distinguish these 
enrichment methods for the NGS sequencing of HHV-6A strains for this application. 
Instead, the choice of method will likely rely on other factors such as time, cost and sample
limitations. Given that both methods rely on Sanger sequencing to complete the genomic 
sequences, the LPCR amplicon method could show advantages in that an archived 
amplicon pool is created which can be used to complete the genomic sequence. In 
contrast, using the SureSelect system all starting material is used in library preparation.
The second aim here was to compare two different sequence read assembly methods. In 
many of the comparative studies performed to date the findings suggest that the exact 
choice of assembler has to be considered on a genome by genome basis [Ekblom & Wolf, 
2014]. This comparison was performed through the use of two publicly available and most 
frequently used assembly programs, one utilising a reference genome mapping approach 
and the other a de novo assembly approach. The reference genome based mapping 
assembly used the BWA-MEM alignment algorithm [Li & Durbin, 2009] with subsequent 
SAMtools mediated variant calling for consensus sequence generation [Li et al., 2009]. 
While the de novo assembly utilised a De Bruijn graph mediated de novo assembly of 
contigs followed by reference genome based scaffolding, using a Velvet optimiser, Velvet, 
ABACAS pipeline [Zerbino & Birney, 2008; Assefa et al., 2009]. These particular programs 
are easily installed with low computational time and resource usage, are widely utilised 
and have extensive literature and community support surrounding their use, accuracy and 
limitations [Shang et al., 2014; Zhang et al., 2011]. As such the results here should be 
widely applicable to other roseolovirus genomes, in particular the chromosomally 
integrated forms of HHV-6A/-6B which are analysed in this thesis.
Comparisons between the consensus sequences generated from both assembly methods 
and with Sanger sequencing characterised regions suggested either target enrichment 
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method in conjunction with either assembly methods could be utilised for accurate 
sequencing of the complete UL region of the HHV-6A genome. Indicating the low level of 
diversity observed amongst HHV-6A strains, to date, permits a reference based mapping 
assembly of the UL region of the genome. This may be of use where time or 
computational resources required for a de novo assembly are not available. However, 
where possible the complementary information provided by both assembly methods 
should be used to to guide genome assembly. This is especially important in cases where 
the target genome may be unknown, such as the integrated forms of HHV-6A/-6B. The 
resolution of repetitive regions outside of the UL region of the genome was confounded 
using the reference mapped assembly approach. This was particularly apparent in the DR 
regions of the genome where due to the multiple repeat iterations, sequence reads could 
map to multiple sites on the reference genome. This lowered the mapping quality score of
a read to levels which would exclude it from consensus sequence assemblies due to cut-
off limits imposed to prevent misaligned reads. For these regions a de novo assembly 
approach was best. Indeed, the previously identified DR6 substitution [Schleimann et al., 
2014] was only identified by the de novo assembly method. However, although the use of 
paired end sequencing can be used to aid the resolution of these regions [Cahill et al., 
2010], a feature incorporated into the Velvet assembler [Zerbino et al., 2008], errors were 
noted in the number of repeats when compared to sequence resolved in some of the 
Sanger sequencing used for gap filling. In this regard, while some alternative assembly 
methods utilise different assembly algorithms and thus have the potential to provide 
better estimates of repeat structures [Breseler et al., 2012; Ruan et al., 2013]; it seems 
that until Illumina based sequencing technology allows for improvements in read length, 
repetitive sequences still pose a problem to genome assembly. Here for HHV-6A, these 
gaps could be addressed using directed PCR amplifications combined with Sanger capillary
sequencing. But this stage still represents a bottleneck and would need to be improved to 
enable high throughput HHV-6A/-6B whole genome sequencing. However, the bulk of the 
genome could be determined using the NGS methods alone, including all coding 
sequence, which would be sufficient for many purposes.
This work on identifying an approach for the NGS sequencing of HHV-6A lead to the 
resequencing of the prototypical HHV-6A strain U1102, as well as determination of the 
complete genome sequence of the third HHV-6A strain to be sequenced, that of AJ. The 
resequencing of strain U1102 identified five new potential sites of variation, two of which 
were represented in previously reported sequence fragments. All newly identified sites of 
variation represented minor changes to the amino acid sequence. But were in genes 
involved in many crucial processes for the replicative cycle: U40 in DNA packaging [Jones &
Teo, 1993], U42 in viral mRNA export from the nucleus [Zielke et al., 2011], U57 the major 
structural capsid protein [Littler et al., 1990], U100 (gQ) in virion attachment [Mori et al., 
2003], and U58, the function of which is currently unknown in HHV-6A/-6B. These are 
differences to the HHV-6A strain U1102 genome sequence which has been utilised as the 
reference genome for two decades. These could be minor variants from mixed infection in
the original isolated virus or result from sequencing errors due to the low genome 
coverage from many of the original Sanger shotgun sequencing projects. More strain 
comparisons would be required to determine the extent of divergence at these sites.
HHV-6A strain AJ was originally isolated from an adult HIV/AIDS patient from the Gambia 
[Tedder et al., 1987]. Along with strains U1102 and GS, strain AJ is one of the earliest 
isolates and subsequently most readily utilised laboratory strains of HHV-6A in the three 
decades since the discovery of the species. Thus the sequencing of this third HHV-6A strain
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has provided more insight into genomic variation within the species, which should help to 
understand its role in pathogenesis. Strain AJ showed closest relation to the recently 
sequenced isolate of strain GS (Accession KC465951) [Gravel et al., 2013a]. This could be 
reflecting a highly evolved virus status or potentially a recent emergence. Both virus 
genomes were determined from tissue cultured virus, yet the high nucleotide identity 
observed between these two genomes, their different geographic isolation and culture, 
the retention in AJ of the full gene complement identified in strain GS and similarities in 
the overall architecture of the genome sequences between strains AJ and GS, suggest 
that in vitro passage of HHV-6A strains may not significantly alter the genetic content of 
the viruses in the same extent as observed amongst some other betaherpesviruses such as
HCMV [Dargan et al., 2010]. Although it has been noted in HHV-6B that the genomes of 
laboratory adapted strains can be up to several kb shorter in length than wild strains, 
these are not due to the gene deletion and rearrangements shown in HCMV, but primarily 
due to the loss of repetitive sequences from the DR regions upon viral passage 
[Lindquester & Pellet, 1991]. Indeed these passage effects could contribute to the 
genome length disparity observed between strains AJ and GS, since the majority of the 
differences were in the DR region. Comparisons of the two GS strains reported, one early 
passage and one late, also showed limited differences [Gravel et al., 2013a].
The report on strain GS from a North American mixture of donors commented on the 
distinct differences to strain U1102, of African origin. The study suggested that these 
result from the different geographic origins [Gravel et al., 2013a]. However, strain AJ was 
also from African origin, yet it shares greatest similarity with the North American isolate. 
Additionally, sequence analyses noted variation in the DNA polymerase gene, U38. Due to 
its high level of conservation amongst the herpesviruses, motifs within this gene have 
been extensively utilised for diagnosis and in determination of relationships between 
herpesviral species [Minjolle et al., 1999; Tafreshi et al., 2005; McGeoch et al., 2006]. In the 
case of the HHV-6 species, amplification of regions of this gene is frequently used as a 
means of species typing. The variation noted here in strain AJ, but also present in strain GS
potentially confounds one commonly utilised diagnostic assay, and where it has been 
applied, low prevalence of HHV-6A has been reported, potentially due to the lack of 
specificity in the primer sequences [Lou et al., 2011; Oakes et al., 2013; Tembo et al., 
2015]. 
In summary, comparisons were made on methods for the enrichment and accurate NGS of 
HHV-6A genomes. These methods permitted enrichment and characterisation of 
herpesvirus genomes separate from the human host; methodology which can be used to 
allow accurate whole genome sequencing directly from tissue samples. Validation of 
methods resequenced the prototypical HHV-6A strain, U1102, identifying 5 new sites of 
variation. Application of the methods was then used to derive  the complete genome 
sequence of the third HHV-6A strain to be sequenced, AJ. A robust NGS pipeline was 
established which could be applied to characterise the germline chromosomally 
integrated forms of HHV-6A/-6B. 
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Chapter 4: Genomic Analyses of CI-HHV-6A and Reactivation
4.1 Introduction
At the start of this thesis the genetic relationships between the germ-line integrated viral 
forms and circulating strains of HHV-6A/-6B was unknown. In order to understand their 
relationship to infectious viral strains, attempts were made to characterise the 
chromosomally integrated form of these viruses, using both Sanger sequencing and the 
next-generation sequencing pipeline established in the previous chapter. 
Initially, PCR screens followed by Sanger sequencing were performed to characterise the 
junction of the viral integration site into the host chromosome from a panel of samples 
from patients with confirmed CI-HHV-6A and -6B. Subsequently, NGS was used to 
sequence three CI-HHV-6A genomes from clinical samples. This enabled comparisons of 
coding capacity of the CI-HHV-6A strains to that of exogenous viral strains, as well as the 
assessment of cis acting sequences likely important for viral reactivation/replication. 
Finally, deep sequencing with minor variant analysis was utilised to further investigate the 
reactivation potential of CI-HHV-6A.
4.2 Characterisation of a Common Integration Site at Chromosome 17p
A panel of 70 CI-HHV-6A/-6B patient DNA samples were collected for analyses. These were
identified following screening of patients reporting to a diagnostic facility in Berlin, 
Germany, with cardiac complications and a hospital in Prague, Czech Republic with 
lymphoproliferative or inflammatory disease (see methods section 2.1.2). 44 samples were
from the German diagnostic facility and the remaining 26 from the Czech Republic. These 
confirmed CI-HHV-6A/-6B samples were then assayed further in order to characterise the 
site of viral integration into the human genome. To do this a set of specific oligonucleotide
primers were used to PCR amplify the sequence of the viral genome-human subtelomere 
integration site junctions.
CI-HHV-6A and -6B has been previously shown to insert into the sub-telomeric region of 
human chromosomes, in an orientation where U100 is located towards the centromere 
closest to subtelomeric sequences and U1 closest to the telomeric cap [Arbuckle et al., 
2010, 2013; Huang et al., 2014]. As such a primer was utilised to specifically amplify from a 
HHV-6A and -6B conserved site in the DRR of the viral genome (designated DRR) [Arbuckle 
et al., 2010] in conjunction with primers previously utilised to specifically amplify from 
subtelomeric sequences from human chromosomes 10, 11, 17 and 18 (designated 10qF, 
11q, 17p and 18q, respectively) [Britt-Compton et al., 2006; Arbuckle et al., 2010; Huang et
al., 2014], which have been observed as CI-HHV-6A and/or -6B integration sites [Nacheva 
et al., 2008; Arbuckle et al., 2010, 2013; Huang et al., 2014]. Based on these previous 
analyses the primer pairs were predicted to amplify a products approximately 1-2 kbp in 
length. However, variation in the number of telomeric repeats between the viral 
integration site and the human subtelomere had the potential to alter this. 
Trials with all primer sets only identified integration sites at chromosome 17. With no 
specific products amplified from chromosomes 10, 11 and 18, as determined by Sanger 
sequencing of minor amplification products. In 25/70 (36%) of the samples an amplicon of 
approximately 1.5 kbp, as previously observed, was generated utilising the 17p primer. 
12/44 (27%) of these from the German myocarditis/cardiomyopathy patient set and 13/26 
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(50%) from the Czech inflammatory disease set. To confirm these represented CI-HHV-6A 
or -6B integration site junctions and obtain the nucleotide sequence of the junctions, a 
nested primer set was designed for use in sequencing reactions. For this, a ClustalW2 
[Larkin et al., 2007] alignment of previously published CI-HHV-6A and -6B 17p integration 
sites (GenBank accession numbers: GU784872.1, KF366419.1 and KF366420.1, 
respectively) was used to design primers located at a conserved site within the 
subtelomeric region of the amplicon (designated 17Tel-DR_IntF) and a semi conserved 
region, 1 bp difference across 22 bp between CI-HHV-6A and -6B, of the DRR (designated 
17Tel-DR_IntR). From the 25 amplicons, the nucleotide sequence of the complete 
integration junction could be resolved for 12. Sequence comparisons confirmed the 
relationship of all of these with the HHV-6A DR regions, indicating all were CI-HHV-6A 
(complete sequences in appendix 7.3). While partial junctional sequences were resolved 
from a further 9 amplicons, 6 CI-HHV-6A and 2 CI-HHV-6B. This confirmed the ability of 
both CI-HHV-6A and -6B to integrate at this chromosomal subtelomeric site [Nacheva et 
al., 2008; Ward et al., 2006; Clark et al., 2006b; Arbuckle et al., 2010; Luppi et al., 1993; 
Morris et al., 1999; Torelli et al., 1995]. This is the largest group of integration sites 
characterised to date, showing a marked preference within these patient groups for 
integration on chromosome 17.
Analysis of the viral DRR region of the junctional sequences in isolation showed that 
despite HHV-6A and -6B  strains sharing 94-97% nucleotide homology with each other in 
this region (HHV-6B HST 97% with Z29, HHV-6A U1102 95% and 94% with GS and AJ 
respectively), the CI-HHV-6A sequences amplified here shared 100% homology with one 
another in this region which was distinct from that seen in available circulating strains 
(94% to U1102 and 92% to GS and AJ), figure 4.1A. The CI-HHV-6A sequences also shared 
99% nucleotide identity with two other previously characterised CI-HHV-6A chromosomal 
integration site junctions, with evidence for integration at chromosome 17p13.3, figure 
4.1A. The first of these an isolate (accession KF366419.1) of CI-HHV-6A from the Negev 
region of Israel [Cann et al., 2002; Huang et al., 2014] and the second an isolate (accession 
GU784872) of undefined, possibly US, origin [Arbuckle et al., 2010]. Yet they were distinct 
from the DRR region of CI-HHV-6A samples from in vitro integration into the JJhan T cell 
line at chromosomes 11 and 18 (accessions GU784871 and GU784873, respectively) 
[Arbuckle et al., 2010]. Both CI-HHV-6B sequences amplified here also shared 100% 
nucleotide homology in this region, which was identical to another previously 
characterised CI-HHV-6B isolate, HGDP0628 from Sardinia [Cann et al., 2002; Huang et al., 
2014] as well as HHV-6B strain HST, but distinct from strain Z29, figure 4.1B. Similarly, the 
sequences of the readily identifiable 17p subtelomeric region adjacent to the integration 
junctions of all the CI-HHV-6A and CI-HHV-6B samples shared 100% nucleotide identity 
with one another.  As well as 100% identity with both the previously identified 17p CI-
HHV-6A and -6B chromosomal integration sites (data not shown).
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Figure 4.1 Phylogenetic analyses of viral DRR sequence from viral chromosomal integration site
junction amplifications. (A) CI-HHV-6A isolates compared to HHV-6A strains (B) CI-HHV-6B isolates
compared to HHV-6B strains. Comparisons made using maximum likelihood estimation. Accession
numbers of all HHV-6A/-6B strains and previous CI-HHV-6A/-6B integration site junctions, included
in the figure. Branch length scale represents number of nucleotide substitutions per site.
Complete junctional sequences of the CI-HHV-6A isolates amplified here, included in appendix 7.3.
Analysis of the complete junctions confirmed the loss of nucleotide sequence from the far 
right end of the genome, starting in the T2 perfect telomere-like repeat region of the DRR, 
during the viral integration event [Arbuckle et al., 2010, 2013; Huang et al., 2014; Ohye et 
al., 2014]. Importantly, including loss of the highly conserved pac 2 DNA packaging motif. 
Analyses of the repeat structure showed these consisted of a short subterminal sequence, 
followed by a varying copy number of perfect telomeric repeats, telomeric repeat variants 
commonly found in human telomeres [Baird et al., 1995], before returning to perfect 
telomeric repeats of human or viral origin, then readily identifiable viral DRR sequence. 
Therefore the integration site junctions did not consist of solely perfect telomeric repeat 
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subunits, but had a complex structure suggesting retention of host telomeric repeat 
variants.
In addition to this generalised architecture, large similarities could be observed in the 
repeat structures of the junctions from the samples examined. All the CI-HHV-6A junctions
shared a characteristic pattern of perfect and imperfect repeats immediately after the 
readily identifiable 17p subtelomeric sequence. In addition to a pattern of imperfect 
repeats followed by 6 perfect telomeric repeats immediately prior to the viral DRR 
sequence, figure 4.2. The only divergence was in the number of perfect repeats between 
these two signatures, which varied from 5 up to 67 here (mean 39, median 52). This 
indicated a specificity to the integration site, not previously observed.
Figure 4.2 Alignments of CI-HHV-6A integration site junctions at chromosome 17p13.3 show
common perfect and imperfect telomeric repeat structures. (A) Yellow highlighted sequence
indicates the end of the readily identifiable chromosome 17p subtelomeric sequence. (B) Yellow
highlighted sequence indicates start of readily identifiable viral DRR sequence. Complete junctional
sequences of the CI-HHV-6A isolates amplified here, included in appendix 7.3
This structure is distinct from the integration sites defined at other chromosomes, from 
both germ-line CI-HHV-6A (Chromosome 10; Accession KF366418) and in vitro cell line 
integrations, (Chromosome 11; accession GU78487 and chromosome 18; accession 
GU784873), summarised in figure 4.3. While still distinct, more substantial similarities 
could be observed between the repeat structure of chromosome 17p subtelomeric record
from human genome sequencing (accession AC240565) as well as a previously defined 
integration junction (accession KF366419) from a distinct geographic origin, potentially 
also integrated at chromosome 17p. A further CI-HHV-6A isolate also integrated at 
chromosome 17p (accession GU784872), shared similar repeat structures adjacent to the 
viral  DRR, but the characteristic structure adjacent to the human subtelomeric region of 
the junction was absent. The common architecture of the human-viral integration site 





Figure 4.3 Comparison of sub-telomere adjacent repeat structure between CI-HHV-6A integrated
at chromosome 17p and other defined chromosomal integration sites. Imperfect repeats derived
from the human subtelomeric region are shaded. Number of repeat structures indicated in
subscript. Accession numbers indicated in brackets. Full alignment of the junctional sequences of
the CI-HHV-6A isolates amplified here, is included in appendix 7.3.
4.3 Genomic Analysis of CI-HHV-6A
4.3.1 CI-HHV-6A Genome Determination
Previous work on the phylogenetic relationships between CI-HHV-6A and -6B isolates 
through multiple loci genotyping, described in part in section 5.2 and fully in Tweedy et al.,
2015a, suggested the greatest diversity of CI-HHV-6A and -6B was shown in CI-HHV-6A 
sequences. Therefore, these CI-HHV-6A genomes were investigated further. For this, the 
Illumina MiSeq NGS methodology determined in chapter 3 was applied for the whole 
genome sequencing of three CI-HHV-6A samples, isolates 2284/4305, 5055/1624 and 
5814 from the German myocarditis/cardiomyopathy cohort. One of which, 5055, had 
evidence for integration into chromosome 17.
As detailed in the previous chapter, a long-range PCR method was used to amplify viral 
genomic DNA, described in section 3.2. The same 36 overlapping primer sets designed 
[against HHV-6A strain U1102, Accession X83413.1, RefSeq NC_001664.2] were used to 
produce amplicons, which were subsequently purified and pooled in equimolar ratios. 
These genomic DNA preparations were then sheared and DNA libraries generated for 
paired end sequencing. Sample multiplexing, cluster generation and sequencing was 
performed on an Illumina MiSeq sequencer. Read assembly, consensus sequence 
generation and genome annotation were all performed as previously described in section 
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HHV-6A DRR
HHV-6A Strain U1102 DRR telomeric repeats (X83413):
(GGGTTA)59-DRR




Chromosome 17p CI-HHV-6A DRR integration site (14 CI-HHV-6A isolates: 5055-43670 and KF366419):
(GGGTTA)2(GGGTT)1(GGGGTTA)1(GGGTTA)5-67(GGGTT)1(GGGGTT)4-8(GGGGTTA)2(GGGTTA)6 -DRR 
Chromosome 17p CI-HHV-6A DRR integration site (GU784872): 
(GGGTTA)6-DRR




Chromosomes 11q in vitro integration (GU784871):
(GGGTTA)41-DRR
Chromosomes 18q in vitro integration (GU784873):
(GGGTTA)54-DRR
3.2. For the CI-HHV-6A samples, a mapped assembly was performed, with comparisons 
made to de novo assembled contigs for validation purposes. As highlighted in section 3.2, 
resolution of repetitive regions of the genome again were confounded since read lengths 
were shorter than these repeat regions. Therefore, these repeat containing regions, R2, 
R3 and the DR's were initially excluded from the consensus sequences generated by the 
reference mapped assemblies. The resolution of these regions was instead performed by 
targeted de novo assembly. Again BLAST searches [Camacho et al., 2009] were performed 
on non-aligning read pairs with no indication of major insertions missed by the mapped 
assemblies, annotation of the genomes was performed as described in section 3.2. 
Table 4.1 Sequence read and coverage statistics for the CI-HHV-6A genomes subjected to NGS.
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Total Reads
2284/4305 2626303 96.40 1907.51 (SD 4,479) 99.92 91.67 40.13
5055/1624 20446080 98.31 19882.10 (SD 11,491) 98.37 66.72 83.10
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Figure 4.4 Sequence read coverage of CI-HHV-6A genomes across the HHV-6A strain U1102
reference genome following mapped assemblies. (A) CI-HHV-6A isolate 2284 (B) CI-HHV-6A isolate
































Sequence reads mapped to all currently defined HHV-6A CDS features, validating the use 
of this methodology for the enrichment of CI-HHV-6A genomic DNA. While also indicating 
that all currently defined CDS features are retained in CI-HHV-6A genomes. However, it 
was clear that variance existed in the coverage observed between the amplicons, as 
highlighted in section 4.3.1 and table 4.1. Some of the genomic amplicons were under-
represented in the DNA pooling prior to sequencing library generation, resulting in low 
read coverage across CDS features within these genomic regions. Measures were taken to 
determine the practical level of read coverage required for accurate sequence resolution, 
described in appendix 7.4. This indicated a read depth of greater than 7 allowed for 
accurate sequence resolution across the CDS features. Therefore to minimise the 
potential for sequencing errors to confound downstream analyses, any genes where the 
read coverage from one or more of the CI-HHV-6A genomes was below this cut-off, 
indicated in table 4.2, were excluded from further analyses.
For sample 2284 coverage across the CDS regions was a minimum of 7 fold. Only two 
genes were at this minimal cut-off, U50, a capsid associated tegument protein and U76, 
the capsid portal protein. In total there were 11 nucleotide positions at a depth of 7 reads 
across these two conserved structural proteins. Thus, while at the limit of accurate 
sequence resolution this indicated that overall there were no major deletions or defects in
the viral exome of CI-HHV-6A respective to HHV-6A, and all 85 genes could be identified. 
With analysis of non-aligning read pairs also indicating no major insertions. This represents 
the first report of whole genome sequencing from the germ-line integrated form of HHV-
6A.
Taken together these results confirmed the methodology utilised for viral enrichment of 
HHV-6A genomic DNA from culture samples is also applicable for the enrichment of CI-
HHV-6A genomic DNA from clinical samples. Furthermore, the viral genome as currently 
described for HHV-6A is also retained in CI-HHV-6A. 
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Table 4.2 Read coverage across CI-HHV-6A CDS from the UL genomic region. Red colour denotes
coverage across the CDS was at or fell below the defined cut-off for accurate sequence resolution,
see appendix 7.4, for one or more CI-HHV-6A isolates. Stars denote sequenced obtained by Sanger
capillary sequencing and utilised in further analysis. CDS of the DR regions are omitted here as
they were determined by de novo assemblies.
4.4 CI-HHV-6A Variation
The utilisation of concatenations of highly conserved core genes has previously been 
utilised extensively to investigate the relationships between members of the Herpesviridae
[McGeoch et al., 2006]. Therefore, initially the relationship between the CI-HHV-6A isolates
and other human herpesviruses was examined using concatenations of a set of these 
homologues found in representative members of human herpesviral species from the 
three Herpesviridae sub-families, figure 4.5. These showed that the CI-HHV-6A strains 
clustered together, tightly linked but separate to the currently sequenced HHV-6A strains.
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2284_U1102 5055_U1102 5814_U1102 2284_U1102 5055_U1102 5814_U1102
CDS Mean Minimum Mean Minimum Mean Minimum CDS Mean Minimum Mean Minimum Mean Minimum
U2 1522.7 421 38397.16 19944 6648.13 4203 U47A 167.76 146 4.35 2 3817.66 3382
U3 1290.19 219 40268.08 16512 4917.9 1243 U48 187.9 153 8.02 1 3921.58 3427
U4 234.55 180 18630.46 14476 1351.02 1046 U49 93.4 12 8.42 1 1194.16 0
U7 1401.69 187 40521.37 16686 3103.38 1183 U50 20.18 7 4.29 0 0.62 0
U10 1938.56 1257 48657.89 32441 3722.55 2355 U51* 18.06 10 3.57 0 1.04 0
U11 437.79 18 10101.01 69 1093.68 166 U52 18.3 9 4.05 1 0.38 0
U12 54.36 33 127.88 99 342.1 291 U53 391.56 17 22324.03 1967 7913.16 6920
U13 57.33 47 130.8 112 328.95 309 U53.5 378.58 326 22974.94 21408 7650.02 7040
U14 80.38 15 129.16 19 375.83 17 U54 288.86 29 20436.73 2189 6094.24 817
U15 41.15 22 42.16 13 41.92 23 U55 446.21 254 22986.71 3969 8426.56 4950
U17 40.51 23 15.65 10 33.36 14 U56 392.12 302 2460.21 13 5745.84 4935
U18 43.66 31 16.53 12 34.1 24 U57 322.11 96 22.51 13 5084.06 1754
U19 126.6 24 16781.17 23 1866.8 22 U58 300.72 107 24.32 15 4402.83 1190
U20 135.02 15 20853.52 11655 2190.27 1135 U59 133.89 100 23.24 16 1326.17 1130
U21 142.45 48 19912.85 8514 2160.75 951 U60 120.59 40 7.02 0 649.48 14
U22 125.77 99 20568.85 18519 2182.35 1811 U62 140.57 122 13.06 9 1419.8 1345
U23 1082.59 46 36582.05 6121 3768.7 722 U63 135.79 95 8.68 3 1499.62 1269
U24 3444.47 3137 71347.85 68842 6322.49 5905 U64 121.49 65 8.89 0 231.46 24
U24A 3725.95 3495 71901.76 66626 6776.1 6455 U65* 100.41 72 5.64 0 40.03 26
U25 3398.25 2878 70545.89 61687 6398.75 5490 U67 99.17 71 5.7 0 32.75 13
U26 3609.93 3274 74937.3 65796 6763.7 6061 U68 105.46 81 1.98 0 35.73 21
U27 3534.74 230 72295.38 54787 6682.31 394 U69 92.33 46 21999.51 21 411.69 20
U28 1329.09 286 22196.27 1696 4631.76 2759 U70 69.07 49 26742.35 23336 450.61 341
U29 351.17 280 3512.05 3343 3081.17 2839 U71 65.42 51 27424.14 26209 454.56 386
U30 352.58 89 5644.25 2735 3207.83 1158 U72 68.85 48 25926.13 24087 441.75 379
U31 2229.94 47 19705.43 8636 2311.38 679 U73 161.68 35 26524.34 9937 1521.64 275
U32 25238.25 17559 76063.43 53823 14209.49 10163 U74 860.85 640 12008.06 9761 8958.07 7808
U33 29798.2 26482 88526.41 80231 16266.52 14937 U75 618.04 13 9935.16 0 6329.93 16
U34 22519.67 94 68676.93 6362 12926.78 1465 U76 19.55 7 2.35 0 23.66 10
U35 125.54 104 7500.97 7098 1582.35 1482 U77 16.59 9 2.38 0 21.86 13
U36 121.29 99 7343.97 6762 1609.29 1410 U79 437.68 56 1169.68 18 9097.3 180
U37 126.28 94 7544.6 6615 1663.36 1411 U81 420.23 324 1149.03 949 8545.88 7475
U38 119.46 44 7710.53 2614 1566.01 628 U82 412.27 346 1225.59 1052 9232.35 7992
U39 730.16 98 25650.22 7186 11675.13 1502 U83 407.04 336 1158.37 1031 8417.23 7788
U40 774.02 686 26818.13 24015 12540.79 11502 U84 392.98 264 1184.52 904 8902.64 6920
U41 9994.14 659 80248.54 23788 10114.11 1451 U85 182.79 31 9530.33 958 3389.09 299
Ori-lyt 9970.73 9180 41881.65 34014 1777.28 1649 U86 76.87 10 9179.27 27 565.95 14
U42 5806.72 568 65420.33 41001 8986.5 1568 U90 17653.28 30 18810.7 14 7625.66 16
U43 719.76 605 66903.68 61063 12820.57 11768 U91 40.42 23 21.96 13 18.25 13
U44 766.15 689 70249.33 66744 13544.07 12298 U94 51.29 34 16.74 11 629.89 513
U45 540.6 144 41477.45 35280 9497.74 3266 U95 538.39 21 8873.08 16 2169.54 13
U46* 202.74 182 7.04 4 4124.52 3774 U100 2096.9 14 50326.9 304 7600.19 90
U47* 184.77 51 7.61 2 3707.86 1396
Figure 4.5 Phylogenetic analyses of CI-HHV-6A compared to prototypical human herpesvirus
species from all three Herpesviridae sub-families. Maximum likelihood estimations, with
bootstrapping (1050 replicates), from concatenations of Herpesviridae conserved genes: capsid
triplex subunit 1 (HHV-6A/-6B U29), small capsid protein (U32), large tegument protein (U3), large
tegument binding protein (U30), cytoplasmic egress tegument protein (U71), cytoplasmic egress
facilitator-1b (U44), glycoproteins gB, gL, gM (U39, U82, U72), multifunctional expression regulator
(U42), DNA polymerase catalytic subunit (U38), DNA polymerase processivity subunit (U27),
helicase-primase RNA polymerase subunit (U43), helicase primase subunit (U74), single-stranded
DNA-binding protein (U41), alkaline deoxyribonuclease (U70), uracil DNA glycolase (U81),
ribonucleotide reductase large subunit (U28), capsid transport nuclear protein (U36), DNA
packaging terminase subunit 2 (U40), terminase binding protein (U35), nuclear egress membrane
protein (U34), nuclear egress lamina protein (U37). Accession numbers of all strains used included
in the figure. Branch length scale represents number of nucleotide substitutions per site.
Subsequently, relationships of the CI-HHV-6A isolates to HHV-6A strains were investigated 
further. To compare the relationships, classes of conserved and divergent genes were 
compared amongst CI-HHV-6A, HHV-6A and HHV-6B with the aim of subjecting these to 
phylogentic analyses. This allowed the determination of the relationships, while taking 
into account the possibility of different evolutionary rates in highly conserved and non-
conserved genes [Pond et al., 2010; Subramanian & Lambert, 2012]. To achieve this, the 
complete genome sequences of HHV-6A strains U1102 (modified version of accession 
X83413/NC_001664 with the corrections outlined in section 3.3), GS (accession KJ123690) 
and HHV-6B strains Z29 (accession AF157706) and HST (accession AB021506) were all re-
annotated to reflect the experimentally defined corrections noted in the recent HHV-6A 
strain GS (accession KC465951) and AJ (accession KP257584) annotations. Thereby 
allowing for direct comparisons between genes of all the genomes using the same CDS 
definitions and splice donor/acceptor sites. Subsequently, pairwise comparisons were 
performed between all the defined CDS with all noted in relation to the prototypical HHV-
6A strain U1102, table 4.3. 
89






HHV-6B Z29 AF157706/NC_000898 




HHV-8 GK18 AF148805/NC_009333 
HHV-3 Dumas X04370/NC_001348 
HHV-1 17 X14112/NC_001806
HHV-2 HG52 Z86099/NC_001798 
Table 4.3 Pairwise comparisons of the CDS features of HHV-6A/-6B strains and CI-HHV-6A isolates
to HHV-6A strain U1102. 'i' denotes incomplete CDS sequence available. Red colour indicates read
coverage across this CDS was below the defined cut-off for accurate sequence resolution.
Using these comparisons, mean percentage divergence was calculated across HHV-6A and 
CI-HHV-6A genes. The mean divergence observed between HHV-6A and CI-HHV-6A genes 
was 1.5%. Therefore to determine conserved genes, a cut-off of those with a mean 
divergence of lower than 1% was applied. These parameters defined a gene set comprised
primarily of previously defined Herpesviridae core genes [McGeoch et al. 2006], with the 
addition of the Roseolovirus conserved genes U4, U22, U24A, U25, U51 and U73, table 4.4.
Similarly, for the definition of divergent genes a cut-off of greater than 2% was applied, 
table 4.4, these included all of the genes which define the speciation of HHV-6A and HHV-
6B [Dominguez et al., 1999; Gompels & Kasolo, 2006; Ablashi et al., 2013] in addition to 
genes U13 and U15 which remain to be fully characterised. This gene set includes 
abundant tegument proteins which are CD4 and CD8 T cell targets, as well as membrane 
envelope glycoproteins, targets for neutralising antibody. In addition to genes whose 
products are involved in gene expression, cell cycle and immune regulation. The 
immediate early gene, U90, in all CI-HHV-6A isolates also retained the deletion observed in
HHV-6A strains which renders them susceptible to type I interferons [Jaworska et al., 2007;
2010]. Furthermore, the U54 of the three CI-HHV-6A isolates contained the divergent 
motif observed in HHV-6A strains,  U54293-297 GISTT, that distinguishes inhibition of 
transactivation of NFAT and subsequent IL-2 gene expression in HHV-6B from HHV-6A 
[Iampietro et al., 2014]. Greater diversity could be observed in CI-HHV-6A, with 6 genes 
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Pairwise comparisons to HHV-6A U1102
HHV-6A CI-HHV-6A HHV-6B HHV-6A CI-HHV-6A HHV-6B
GS_1 GS_2 AJ 2284 5055 5814 Z29 HST GS_1 GS_2 AJ 2284 5055 5814 Z29 HST
CDS % % % % % % % % CDS % % % % % % % %
DR1 96.98 96.59 95.75 95.41i 96.18 95.75i 89.90 89.90 U47 98.47 98.47 98.16 97.70 97.70 97.70 88.50 88.60
DR6 96.41 96.15 95.81 95.09i 96.50 96.15 88.87 89.97 U47A 100.00 100.00 100.00 100.00 100 100.00 90.91 90.91
U2 98.64 98.55 98.64 98.82 98.82 99.00 92.31 92.49 U48 99.95 99.95 99.90 99.81 100 99.81 95.30 95.40
U3 99.11 97.86 98.93 98.48 98.48 98.48 92.25 92.07 U49 99.74 99.74 99.60 99.74 99.74 100 96.97 96.84
U4 99.75 99.75 99.75 99.69 99.19 99.69 96.89 96.89 U50 99.52 99.52 99.40 99.4 99.58 99.89 96.28 96.28
U7 99.35 99.35 99.32 99.51 98.91 99.54 95.03 95.03 U51 99.56 99.56 99.45 99.45 99.45 99.78 94.92 94.92
U10 99.01 98.93 99.01 99.31 99.31 99.31 94.28 94.28 U52 99.87 99.87 99.74 99.74 99.74 99.74 96.65 96.65
U11 97.78 97.78 97.86 97.97 98.08 97.82 89.25 89.25 U53 99.50 99.50 99.62 98.36 98.36 98.36 96.22 96.16
U12 99.04 99.04 98.95 98.95 99.04 98.95 93.23 93.30 U53.5 99.46 99.46 99.59 97.96 97.96 97.96 95.92 95.92
U13 99.69 99.69 99.69 99.69 97.48 97.48 96.26 96.57 U54 98.77 98.77 99.27 97.24 97.24 97.24 88.60 88.82
U14 99.67 99.67 99.56 99.45 96.45 95.96 90.55 90.71 U55 99.69 99.69 99.38 98.31 98.31 98.31 95.07 95.07
U15 97.57 97.57 97.57 97.57 97.57 99.65 94.44 94.79 U56 100.00 100.00 100.00 99.55 100.00 99.55 98.09 97.98
U17 99.00 99.00 98.71 98.71 98.71 99.30 94.63 94.63 U57 99.11 99.13 99.01 99.11 99.11 99.11 96.61 96.61
U18 98.07 98.07 98.07 98.07 98.07 98.30 93.65 93.65 U58 99.57 99.57 99.22 99.09 99.27 99.09 95.77 95.69
U19 97.69 97.69 97.86 97.86 97.69 98.03 94.27 94.27 U59 99.15 99.15 99.15 99.15 99.15 98.67 95.63 95.54
U20 98.82 98.82 98.90 98.97 99.84 98.89 94.25 94.25 U60 99.80 99.80 99.75 99.55 99.8 99.50 97.75 97.70
U21 98.31 98.31 99.46 98.39 98.39 98.39 93.24 93.24 U62 98.45 98.45 98.45 98.84 98.45 99.22 98.06 97.67
U22 99.84 99.84 99.84 99.18 99.18 99.18 95.40 96.39 U63 99.08 99.08 98.77 98.77 98.77 99.23 97.54 96.93
U23 98.87 98.87 99.02 99.30 99.30 99.30 92.83 92.83 U64 99.40 99.40 99.17 98.42 99.4 98.72 95.56 95.56
U24 97.73 97.73 98.48 98.11 98.08 98.11 93.18 92.42 U65 99.60 99.60 99.50 97.42 97.52 97.52 92.86 92.86
U24A 100.00 100.00 100.00 100.00 98.85 98.85 93.68 93.68 U67 99.62 99.62 99.81 99.53 99.81 99.53 96.70 96.89
U25 99.68 99.68 99.47 99.16 99.89 99.26 97.37 97.37 U68 99.13 99.13 99.71 99.42 99.71 99.13 95.94 95.65
U26 99.55 99.55 99.55 98.87 99.32 98.87 95.15 95.05 U69 99.76 99.76 99.23 99.47 98.93 98.82 94.85 95.03
U27 99.49 99.49 99.07 98.47 99.75 98.47 95.55 95.83 U70 99.39 99.39 99.52 99.52 99.39 99.11 95.91 95.98
U28 99.50 99.50 99.30 99.09 99.59 99.09 95.82 95.78 U71 99.15 99.15 99.15 99.15 95.30 95.30 92.74 92.31
U29 99.89 99.89 100.00 99.22 99.89 99.22 96.00 96.00 U72 99.52 99.52 99.61 99.61 99.61 99.42 96.62 96.71
U30 99.48 99.48 99.38 98.68 99.72 98.68 94.86 94.49 U73 99.57 99.53 99.57 99.53 99.62 99.45 97.27 97.06
U31 99.47 99.47 99.49 99.37 99.37 99.23 94.83 94.69 U74 99.45 99.45 99.40 99.04 98.99 99.04 96.13 96.28
U32 100.00 100.00 100.00 99.25 99.25 99.25 95.88 95.88 U75 99.87 99.87 99.73 99.33 99.33 99.07 96.13 96.00
U33 99.58 99.58 99.93 99.01 99.29 99.01 97.10 97.24 U76 99.69 99.69 99.79 99.79 99.95 99.38 97.17 97.58
U34 99.04 98.92 99.76 99.40 99.16 99.40 95.19 94.71 U77 99.72 99.72 99.72 99.72 99.84 99.68 97.29 97.29
U35 100.00 100.00 100.00 99.38 99.07 99.38 97.82 97.17 U79 96.55 96.62 98.46 96.63 96.85 96.12 90.74 90.67
U36 99.59 99.59 99.66 99.11 99.18 99.04 96.63 96.41 U81 99.48 99.48 99.22 98.96 98.96 98.96 95.05 95.05
U37 99.37 99.37 99.50 99.25 99.37 99.25 96.98 97.11 U82 99.73 99.73 99.34 98.94 99.47 98.94 95.48 95.48
U38 99.05 99.05 99.05 99.11 99.08 99.11 96.18 96.12 U83 98.96 98.96 98.30 98.64 98.64 98.64 92.52 92.52
U39 99.20 99.20 99.36 99.48 99.44 99.48 95.67 95.75 U84 99.32 99.32 98.15 99.22 99.42 99.22 94.27 94.56
U40 99.04 99.04 99.17 99.08 98.95 99.08 96.88 96.84 U85 98.97 98.97 98.40 98.97 99.20 99.20 94.73 94.62
U41 99.29 99.29 99.32 99.29 99.24 99.29 97.35 97.32 U86 98.14 98.09 98.58 97.57 95.45 94.94 85.70 85.35
U42 98.77 98.77 98.71 99.29 99.29 99.29 95.47 95.47 U90 97.66 97.66 97.81 97.38 97.59 97.35 85.67 85.42
U43 99.46 99.46 99.65 99.61 99.65 99.61 97.33 97.33 U91 97.19 97.19 97.19 97.19 97.40 97.62 77.27 75.76
U44 99.51 99.51 99.35 99.35 99.35 99.35 95.95 95.95 U94 99.39 99.39 99.05 99.05 99.25 99.05 96.54 96.54
U45 99.56 99.56 99.56 99.29 99.29 99.29 95.76 95.76 U95 97.59 97.53 97.77 97.23 96.46 95.71 83.96 84.14
U46 98.43 98.43 98.04 100.00 99.61 100.00 95.29 95.29 U100 97.87 98.02 98.07 97.02 97.12 97.02 88.65 88.65
(DR1, DR6, U71, U79, U86 and U95) displaying greater than 3% divergence, compared to 
only two restricted to the DR region in HHV-6A. The sequences of both the conserved and 
divergent genes of CI-HHV-6A are in appendices 7.5 and 7.6.
Table 4.4 CI-HHV-6A conserved and variable gene sets. Star denotes not part of defined
Herpesviridae gene set, however, all are part Roseolovirus conserved genes [McGeoch et al. 2006]. 
Concatenations of these gene sets were multiply aligned. Subsequently, regions of 
sequence were removed and loci with gapping characters before the calculation of 
phylogenetic relationships amongst the CI-HHV-6A strains and their relationship to HHV-
6A and HHV-6B strains, figure 4.6. Analysis of the conserved gene set showed that the  CI-
HHV-6A strains clustered independently from circulating viral strains, while there was 
evidence for recombination in some of the divergent genes, which showed mixed 
branching relative to the HHV-6A strains. Overall these analyses show that CI-HHV-6A 
genomes diverge at a set of genes which encode products involved in gene regulation, 
host infection, cellular tropism and immune regulation. Many of these genes are involved 
in the speciation of herpesviruses.
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Conserved Variable
CDS Gene Function CDS Gene Function
U4* Maribavir resistance DR1 Tegument protein; Putative DNA directed RNA polymerase
U22* Glycoprotein DR6 Binds p41 DNA processivity factor U27, inhibits replication, G2/M arrest
U24A* Glycoprotein U11 Tegumument phosphoprotein
U25* Tegument protein U13
U27 Processivity subunit of DNA polymerase complex U14 Virion tegument protein, p53 interaction cell cycle
U28 Large subunit of ribonucleotide reductase U15
U29 Component of intercapsomeric triplex between hexons and pentons U19 IE-B protein
U30 Interacts with U31 protein U47 Membrane glycoprotein gO complexes with gH/gL
U31 U54 Virion transactivator, U54A transactivates NFAT
U32 Small capsid protein; Capsid transport U65 Tegument protein
U34 Inner nuclear membrane protein; nuclear egress U71 Myristylated tegument protein
U35 DNA packaging U79 DNA replication
U36 Capsid transport U86 IE2, IE-A protein; interacts with transcriptional material
U37 Nuclear matrix protein U90 IE1, IE-A transactivator; enhances activation by IE2
U38 DNA polymerase catalytic subunit U91 Membrane glycoprotein
U39 Membrane glycoprotein gB U95 IE gene
U40 Terminase subunit U100 Membrane glycoprotein gQ complexes with gH/gL binds CD46
U41 Single-stranded DNA-binding protein
U42 Tegument protein
U43 Component of DNA helicase-primase
U44 Tegument protein
U45 Deoxyuridine triphosphatase
U46 Membrane glycoprotein gN complexes with gM
U51* Chemokine receptor
U53 Protease; Capsid scaffold protein maturation
U56 Capsid protein
U57 Major capsid protein
U69 Serine-threonine protein kinase
U70 Deoxyribonuclease
U72 Membrane glycoprotein gM complexes with gN
U73* Origin binding protein
U74 Component of DNA helicase-primase
U81 Uracil DNA glycosylase
U82 Memebrane glycoprotein gL complexes with gH and gO
Huge virion protein; interacts with U30 protein; influences release of 
DNA from capsids during entry
Figure 4.6 Phylogenetic analyses of CI-HHV-6A and HHV-6A/-6B conserved and variable gene sets.
Maximum likelihood estimation on gene set concatenations with bootstrapping (1050
replicates). (A) CI-HHV-6A conserved genes (B) CI-HHV-6A variable genes. Gene sets as defined in
Table 4.5. Accession numbers of all strains used included in the figure. Branch length scale
represents number of nucleotide substitutions per site.
4.5 Cis-acting Sites Required for DNA Packaging, Genome replication and Gene 
Regulation are Conserved in CI-HHV-6A
While not conclusive, evidence supporting the in vivo reactivation of CI-HHV-6A and -6B 
has been suggested by a number of means [Hall et al., 2010; Gravel et al., 2013a; Endo et 
al., 2014; Arbuckle et al., 2010; Prusty et al., 2013b; Huang et al., 2014]. Here, the 
reactivation potential of CI-HHV-6A was further assessed. As highlighted in section 4.3, all 
85 genes previously defined for HHV-6A strains could all be identified in the CI-HHV-6A 
samples with no major indels. As the gene complement for genome 
reactivation/replication appeared to be present in the genomes, attempts were initially 
made to identify and characterise a number of the other highly conserved requirements 
for genome reactivation/replication and signatures of actively replicating genomes. 
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replication (oriLyt), this motif, located between U40 and U41 ORFs in the UL region of 
HHV-6A and -6B, contains sequences bound by the viral origin binding protein, U73, to 
initiate the recruitment of the core DNA replication machinery [Inoue et al., 1994; Krug et 
al., 2001; Turner et al., 2002]. The 1.3kb Mori oriLyt [Turner et al., 2002] consists of two 
main regions, the first contains two origin binding sequences (OBP1,2) which share 
homologues with alpha- but not CMV herpesviruses [Dykes et al., 1997]. The second 
domain includes imperfect direct repeats (IDR). These are present as a tandem duplicated 
array in HHV-6B (IDR1,2). HHV-6A strains contain a tripartite array (IDR1,2,3), with a third 
IDR which is divergent from IDR1/2 and specific to HHV-6A [Turner et al., 2002]. 
Phylogenetic analyses of the CI-HHV-6A oriLyts with HHV-6A strains, figure 4.7, revealed all
CI-HHV-6A Mori sequences clustered within the HHV-6A strains (5055 with U1102; 2284 
and 5814 with GS/AJ). Closer inspection of alignments of this region, shown in appendix 
7.7, demonstrate that all the CI-HHV-6A samples possessed OBP sequences which are 
identical to HHV-6A and -6B. In addition to the three IDR sequences of HHV-6A with only 
three SNPs across these sequences. Together this indicates the structure of the functional 
efficient origin of lytic replication is maintained and despite the repetitive structure 
observed here, it is among the most conserved regions of the genomes.
Figure 4.7 Phylogenetic analyses of the origin of lytic replication (Mori) of CI-HHV-6A isolates and
HHV-6A/-6B strains. Maximum likelihood estimation with bootstrapping (1050 replicates) on
the maximally efficient origin of replication defined for HHV-6A strain U1102 [Turner et al., 2002].
Accession numbers of all strains used included in the figure. Branch length scale represents
number of nucleotide substitutions per site. Full alignment shown in appendix 7.7.
The DNA packaging motifs, pac1 and pac2, which flank the DR regions at the genomic 
termini are required for the cleavage of whole genome length subunits from rolling-circle 
generated concatemers and their subsequent capsid packaging [Deiss et al., 1986; 
Thomson et al.,1994a; Gompels & Macaulay, 1995; Deng & Dewhurst, 1998; Turner et al., 
2002]. The pac sites closest to the UL genome region could be accurately resolved (pac2 
site from DRL and pac1 site from DRR). But those located directly adjacent to the genomic 
termini could not be resolved. However, as found previously [Arbuckle et al., 2010; Huang 
et al., 2014] and confirmed for a number of CI-HHV-6A and -6B samples including 5055 
(section 4.2), the pac2 site at immediate end of the DRR is absent in CI-HHV-6A and -6B 
genomes believed to result from the mechanism of chromosomal integration during the 
viral integration event. In addition, attempts at mapping the DRL termini of CI-HHV-6A and 
-6B have indicated that the pac1 site at the immediate end of the opposite side of the 
genome is also absent [Ohye et al., 2014; Huang et al., 2014]. The identifiable CI-HHV-6A 
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pac sequences were aligned with those of HHV-6A and -6B strains, figure 4.8. This showed 
both pac sites are retained in the CI-HHV-6A genomes with only a single SNP observed in 
the pac1 site, similar to that observed between circulating viral strains.
Figure 4.8 Alignment of CI-HHV-6A and HHV-6A/-6B pac sites with those of the prototypical strain
HHV-6A U1102. (A) pac 1 site. (B) pac 2 site. Embolden sequence indicates the defined HHV-6A
strain U1102 pac sites. HHV-6A strain GS genome sequences, GS_1 = accession KC465951, GS_2 =
accession KJ123690.
Localised CpG suppression across the immediate early (IE) gene region, observed amongst 
a number of betaherpesviruses [Gompels et al., 1995], is also indicative of gene regulation 
by methylation [Honess et al., 1989; Martin et al., 1991b; Gompels et al., 1995]. CpG plots 
across the CI-HHV-6A genomes, figure 4.9, indicated that these were also present in all the
CI-HHV-6A samples. While, all four of the recently defined microRNAs (miRNAs) of HHV-6B 
[Tuddenham et al., 2012], conserved at the structural and sequence levels in HHV-6A, also 
appear to be retained in CI-HHV-6A genomes, figure 4.10. However, issues with the 
assembly of the DRs due to the nature of their repeat sequences, as discussed in section 
4.3, meant all the miRNAs could not be resolved for all samples. Taken together, the 
presence of these features imply that the CI-HHV-6A genomes may be competent for 
reactivation and viral replication.
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Figure 4.9 CpG frequency plots across the CI-HHV-6A genomes. (A) CI-HHV-6A isolate 2284 (B) CI-
HHV-6A isolate 5055 (C) CI-HHV-6A isolate 5814. Arrows indicate CpG suppression at IE gene





Figure 4.10 Conservation in CI-HHV-6A of the pre-miRNA sequences identified in HHV-6B
[Tuddenham et al., 2012]. (-) denotes negative strand sequence. GS_1 = accession KC465951, GS_2
= accession KJ123690. Emboldened sequence indicates mature miRNA sequences.
4.6 Deep Sequencing Shows Minor Variants in CI-HHV-6A Genomes with Gene 
Expression
Previous work in this group, described fully in Tweedy et al., 2015a, made attempts to 
analyse cDNA samples from the German and Czech CI-HHV-6A and -6B patient cohorts, for 
gene expression from the integrated genomes. For this, seven patients from a German 






specific for a select group of HHV-6A, -6B genes, primer sequences also outlined in section
2.3.3. From this subset, four displayed evidence for gene expression, from multiple loci, at 
certain bleeds, but not at others. With sequencing showing these were identical to the 
integrated genotypes and distinct from known circulating HHV-6A and HHV-6B strains. The
cDNA observed from one of these, the U83 gene, was the complete unspliced gene, which
is only expressed after DNA replication [French et al., 1999].
Samples from two of these patients, CI-HHV-6A 2284 and 5055 (section 4.2), were also 
those which had been subjected to whole genome sequencing by NGS described above. 
With one patient, 2284, showing evidence for gene expression from integrated virus, 
while the other, 5055, appeared silent. This provided an opportunity to investigate the 
relationship between viral gene expression and reactivation, through deep sequencing 
analysis. For this minor variant analysis was performed on the CI-HHV-6A genomes and 
HHV-6A strain AJ (section 3.4) at two loci, U38 and U83, which had previously been 
sequenced by Sanger capillary sequencing [Tweedy et al., 2015a]. SNPs were called in 
comparison to the HHV-6A strain U1102 reference genome, with all SNPs identified 
reflecting those observed by Sanger capillary sequencing. To investigate minor variants a 
cut-off for SNP sensitivity was applied using an internal database control of a CG>GC 
inversion in the U83 gene CDS, identified by Dewin et al., 2006 and confirmed here in 
section 3.3, was still present in the U1102 reference sequence. Here, the original 
reference sequence was not called at read depths up to 6148, indicating a level of 
detection of at least 0.02%; a cut-off of 1 log above this was applied to verify minor 
variants, table 4.5.
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Table 4.5 Minor variants in CI-HHV-6A isolates identified by deep sequencing. Table shows the
position of SNPs in the CI-HHV-6A sequence reads. Total sequence read depth at the site (TR). The
number of sequence reads calling a single nucleotide polymorphisms (SNPs) different from the
reference strain HHV-6A U1102 (SNP). The number and percentage of sequence reads calling a
SNP the same as the reference (REF). (17p) indicates chromosome 17p telomere integration.
Shading shows minor variant SNPs above the defined cut off of 0.2 % (see methods section 2.8.6).
The results showed minor variants were identified in samples with evidence for virus gene 
expression, both strain AJ infected cells and the CI-HHV-6A sample positive for cDNA, 
isolate 2284. But there were no minor variants identified where cDNA was negative, in CI-
HHV-6A isolate 5055. Although the minor variants shared similarities to the strain U1102 
reference genome, SNP patterns across the entire CDS indicated they were distinct. 
Overall, these results indicated HHV-6A superinfection in CI-HHV-6A patients may lead to 
gene expression from the CI-HHV-6A genomes, as the detected cDNA was identical to the 
integrated genotype. Furthermore, the detection of the full length unspliced form of U83 




5055 (17p) 2284 cDNA+ AJ
U38A Polymerase
Position SNP TR SNP REF TR SNP REF TR SNP REF
57357 G-A 7431 7422 8 (0.1%) 126 79 47 (37%) 6559 6559 -
57392 C-T 7537 7537 - 124 73 51 (41%) 6856 6856 -
57426 A-G 7541 7541 - 124 124 - 6959 6941 18 (0.3%)
57498 T-C 7811 7811 - 128 80 48 (31%) 7172 7172 -
57561 C-T 7125 7125 - 108 74 34 (32%) 7098 7098 -
57564 G-A 7070 7070 - 109 109 - 7063 7049 14 (0.2%)
57702 C-T 6973 6973 - 119 119 - 7369 7351 16 (0.2%)
57722 T-C 7053 7045 8 (0.1%) 125 125 - 7406 7406 -
57752 C-T 7133 7133 - 124 124 - 7300 7280 20 (0.3%)
U83 Chemokine
123484 G-A 1281 1281 - 406 406 - 5273 5249 23 (0.4%)
123504 G-GTT-long / 1269 1105 0 (0%) 388 361 6 (2%) 5088 4748 7 (0.1%)
G-GT-short G-GTT-long G-GT-short G-GTT-long
123590 G-T 1101 1096 0 (0%) 347 346 0 (0%) 5162 5158 1 (0.02%)
123633 C-T 1063 1063 - 361 361 - 5420 5388 31 (0.6%)
123687 A-G 1093 1093 - 406 406 - 5683 5653 30 (0.5%)
123733 A-G 1101 1096 0 (0%) 429 395 34 (9%) 6419 6419 -
123740-41 CG-GC* 1108 1108 0 (0%) 411 411 0 (0%) 6148 6145 0 (0%)
4.7 Discussion
This chapter confirms the integration of both HHV-6A and -6B into the subtelomeric 
region of chromosome 17p13.3 and suggests this is a prevalent integration site. The 
observation of a conserved structure to the integration site junctions of the CI-HHV-6A 
samples at this chromosomal location suggests they likely originated from a single rare 
ancestral germ-line integration event which was subsequently expanded in the human 
populations studied here as a polymorphism. The apparent high prevalence of integration 
at this chromosomal location implicates either some preference for integration at this site 
and/or that the ancestral germ-line integration event pre-dates that seen at other 
chromosomal locations. Whole exome analyses of CI-HHV-6A genomes determined by NGS
suggested divergence at a set of genes which encode products involved in gene 
regulation, host infection, cellular tropism and immune regulation, all markers previously 
used for herpesvirus speciation. Key genomic features required for viral replication, and 
likely any reactivation mechanism, were also retained in the CI-HHV-6A genomes. Finally, 
the identification of minor variants in CI-HHV-6A samples with previous evidence for gene 
expression, indicated a mechanism by which superinfection with circulating viral strains 
may permit gene expression and potentially reactivation from the chromosomally 
integrated form.
Initially attempts were made to identify CI-HHV-6A and -6B chromosomal integration site 
junctions. For this, a minority of the subtelomeric sites where viral integration has been 
observed to occur were chosen as potential targets (10q, 11q, 17p and 18q). These were 
chosen as either anecdotally the prevalence of integration at these sites appeared higher, 
or as they represented sites with well defined subtelomeric sequences for which validated 
primer sequences were available. Of those chromosomal locations trialled expected 
amplicons were only obtained utilising the primers designed to amplify integrated viral 
genomes from the subtelomeric region of chromosome 17p. Thus the integration sites of 
those not on chromosome 17 within this sample group, remains to be elucidated. 
Similar to previous findings, the results here suggest both HHV-6A and -6B have integrated
into the subtelomeric region of chromosome 17 (17p13.3) [Morris et al., 1999; Torelli et 
al., 1995; Morissette & Flamand, 2010; Nacheva et al., 2008; Ward et al., 2006; Clark et al., 
2006b; Arbuckle et al., 2010; Luppi et al., 1993]. Furthermore, the results provided 
evidence that chromosome 17p13.3 was a prevalent site for HHV-6A integration. This was 
in agreement with anecdotal observations from previous studies, where chromosome 
17p13.3 has often been identified as a site of CI-HHV-6 integration. Since chromosome 
17p13.3 is frequently found to be one of the shortest telomeres in somatic cells [Martens 
et al., 1998], suggestions have been made that the apparent preference for this 
chromosomal location may result from an evolutionary advantage conferred by 
integration there, such as to viral reactivation potential. In this regard, in vitro integration 
experiments have noted integration at chromosome 17p during productive infection 
[Arbuckle et al., 2010]. However, at least 8 other chromosomal integration sites have been 
identified to date for inherited CI-HHV-6A [Watanabe et al., 2008; Nacheva et al., 2008; 
Ward et al., 2006; Huang et al., 2014; Clark et al., 2006b; Hubacek et al., 2009; Arbuckle et 
al., 2010; Tanaka-Taya et al., 2004], and at least two (11q and 18q) others during in vitro 
work [Arbuckle et al., 2010]; many of which are longer both in overall length and, despite 
heterogeneity, also in the telomeric region [Lander et al., 2001; Lansdorp et al., 1996]. This
suggests that integration into the shortest chromosome may not be a requirement for the
virus. However, observations have been made that the virally integrated chromosome is 
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frequently the shortest in somatic cells, even when compared to the length of that of 
chromosome 17p [Huang et al., 2014]. Thus the viral integration event itself may result in 
telomere shortening, regardless of chromosomal location either merely as a consequence 
of the integration or should such shortening aid viral reactivation. So while integration into
this site on chromosome 17 may still provide some advantage or result from a 
characteristic of the still undefined integration mechanism, there may be other factors 
involved.
The identification of a common integration site junction architecture in the CI-HHV-6A 
samples appearing to be integrated at chromosome 17p13.3; sharing specific sub-
telomeric repeat structures plus identical adjacent sequences from the human sub-
telomere and virus DR-R termini; indicates an alternative, although not wholly 
incompatible, explanation for the apparent high prevalence of integration at this site 
observed in inherited CI-HHV-6A. Amongst HHV-6A strains the DR regions represent sites 
displaying some of the highest levels of variation, 5-8%, in the genome. Indeed it is 
variability in the repeat structures here which contribute greatly to the different genome 
sizes observed amongst HHV-6A strains. Furthermore, subtelomeres are known to possess
complex degenerate repeat structures [Ambrosini et al., 2007] and in the limited 
information available regarding the chromosome 17p13.3 subtelomeric region, variation 
could be observed in these telomeric repeat structures. Thus the shared integration site 
junction structure in the CI-HHV-6A samples appears to indicate a common integration 
event which has given rise to some of the CI-HHV-6A genomes observed within the 
samples examined here. This could potentially be attributed to close ancestral relationship
between the individuals in this sample panel, resulting from their similar geographic 
origins, Germany and the Czech Republic. The fact that the integration junction sequences 
shared notable similarities to one previously identified for CI-HHV-6A, also suspected to be
at this chromosomal location and from distinct geographic origin, Israel [Cann et al., 2002; 
Huang et al., 2014]; suggested this viral integration event potentially occurred earlier in 
human history with inheritance through a number of generations. Thus the apparent high 
prevalence of integration at this chromosomal location in inherited CI-HHV-6A could result
from an integration event into the germ-line which predates those seen at other 
chromosomal locations, followed by a subsequent expansion as a polymorphism by 
Mendelian inheritance. The acquisition of further genome and integration site junction 
data, either directly from CI-HHV-6A samples or alternatively as a by product of human 
genomic sequencing, will help to clarify this.
The sequence of the integration site junctions, confirmed the loss of nucleotide sequence 
from far right end of genome including the pac 2 site. This is consistent with models for a 
role of homologous recombination between the perfect telomeric-like repeats of the T2 
region of the DRR and chromosomal telomeric repeat sequences, in the viral integration 
event [Arbuckle et al., 2010, 2013; Huang et al., 2014]. In addition to this, there are also 
accounts of the loss of the pac 1 site from the far left end of the genome following 
integration [Ohye et al., 2014; Huang et al., 2014]. The loss of these specific signals for 
DNA cleavage and packaging from the ends of the genome have implications for the 
mechanism of viral integration as well as potential models of reactivation. Indeed models 
have been proposed in which two pac sites may represent the minimal complement 
required for reactivation via a t-loop formation mechanism [Huang et al., 2014; Prusty et 
al., 2013b]. Expansion of the T1 imperfect telomeric repeat regions, respective to that 
observed in circulating viral strains, has been noted for the CI-HHV-6A and -6B [Ohye et al., 
2014; Huang et al., 2014]. While this could be a feature of the virus which resulted in the 
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germ-line integration events. Suggestions have also been made that this expansion results
from erosion of viral sequence from the genomic termini, which activates a homology 
directed DNA repair mechanism as a prerequisite for the viral integration event [Ohye et 
al., 2014]. Therefore, any potential reactivation mechanisms must in some way account for
the loss of these pac sites if replication competent virus is to be produced. 
Preliminary work on characterisation of the these CI-HHV-6A and -6B samples, at 4 loci, 
discussed partly in section 5.2 and fully in Tweedy et al., 2015a, suggested CI-HHV-6A 
genomes may show greater diversity than those of CI-HHV-6B. This was investigated 
further through the NGS of three of CI-HHV-6A samples, for which sufficient template was 
available. An LPCR approach for viral genomic enrichment was employed as a result of 
sample limitations. However, the variability in coverage observed between the amplicons 
for HHV-6A, described in section 3.2, was much more pronounced for the CI-HHV-6A 
samples. As highlighted previously inaccuracies in the quantification and equimolar 
pooling of the amplicon DNA likely had an effect on sequence uniformity. However, the 
greater variance implicated additional factors contributed. The primer sets used for the CI-
HHV-6A samples were the same used for HHV-6A, where optimisation had been 
performed for HHV-6A species. While results of the PCR reactions for CI-HHV-6A did not 
show clear signs of amplification difficulties; optimisation for each viral strain would be of 
benefit with this target enrichment approach adding further time consuming steps to the 
process in comparison to alternative methods. 
However, through the use of both NGS and gap filling with Sanger sequencing, the 
complete coding complement of the genome could be determined for CI-HHV-6A isolate 
2284, as well as sufficient genome sequence from CI-HHV-6A isolates 5055 and 5816 to 
assess conserved and divergent gene sets. This showed the integrated virus genomes 
possess the full gene complement required for viral replication. Analysis of the integrated 
genomes showed retention of many of the cis acting signals required for viral reactivation,
with a high level of conservation. So in addition to the full genome complement, the 
integrated genomes also retain many of the genomic features likely required for any viral 
reactivation mechanism. 
Analysis of the conserved gene set showed that the CI-HHV-6A strains clustered 
independently from circulating viral strains, while there was evidence for recombination in
some of the divergent genes, which showed mixed branching with HHV-6A strains (a 
feature which is further investigated in Tweedy et al., 2015a). The divergent gene set 
consisted of 17 genes encoding products involved in roles in transcriptional regulation, 
virus infection, cell cycle and immune modulation. These are often features which are 
regarded as markers of speciation amongst herpesviruses. Indeed, the CI-HHV-6A 
divergent gene set included all of the genes which defined the recent speciation of HHV-
6A and -6B [Dominguez et al., 1999; Gompels & Kasolo, 2006; Ablashi et al., 2014]. 
Together, the integration site junction and gene divergence analyses indicate integration 
of an ancestral HHV-6A/6B variant into the germline at this chromosomal location. While 
the reactivation/gene expression with possible recombination suggest that expansion of 
the integrated form in the human population could serve as source of emergent infection 
or contribute to gene divergence.
Finally, the depth of the NGS read coverage in some regions permitted analysis of minor 
variants in the CI-HHV-6A samples. This allowed for comparison between a sample with 
noted integrated gene expression, as identified by cDNA analysis, and one without. These 
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results suggested superinfection with HHV-6A strains, in the sample with evidence for 
integrated virus gene expression. This is consistent with a model where superinfection 
with HHV-6A or -6B has the potential to result in gene expression from/reactivation of the 
integrated virus. There is evidence of superinfections causing reactivation of latent and 
integrated virus. Reactivation of latent HHV-6B has been noted following superinfection 
with HHV-7 [Katsafanas et al., 1996; Tanaka-Taya et al., 2000]. Furthermore co-infection 
with Chlamydia trachomatis, has also been suggested to cause reactivation of CI-HHV-6A 
via a t-circle excision mechanism [Prusty et al., 2013a; Prusty et al., 2013b]. As new 
methods allowing for greater accuracy in distinguishing between the viral species, such as 
ddPCR [Sedlak et al., 2014; Leibovitch et al., 2014], and deep sequencing becoming a 
viable solution for detection of viral populations [Beerenwinkel & Zagordi, 2011; 
Giallonardo et al., 2014], the involvement of superinfection in integrated genome gene 
expression/reactivation should become clearer.
In summary, analysis of the integration site junctions of CI-HHV-6A at chromosome 17p 
indicated a shared genetic lineage between virally integrated genomes. The application of 
NGS methodologies investigated in the previous chapter allowed characterisation of three
CI-HHV-6A genomes. These revealed CI-HHV-6A genomes are intact, possessing the full 
complement of genes identified for HHV-6A strains, in addition to key cis acting signals 
important for reactivation. Comparisons of these integrated genomes to circulating viral 
strains highlighted divergence at a set of genes which have been used previously to mark 
herpesvirus species. The minor variant analysis supported a mechanisms by which HHV-
6A/-6B superinfection may result in gene expression from, or reactivation of the 
integrated CI-HHV-6A genome.
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Chapter 5: Variation and Functional Analysis of the Viral Chemokine Receptor 
U51
5.1 Introduction
Both HHV-6A and -6B have been associated with a variety of inflammatory pathologies, 
such as myocarditis and encephalitis. Therefore, the encoded chemokine modulatory 
capabilities of these viruses may represent important virulence factors mediating viral 
replication and inflammatory pathology. Expression of these genes from the integrated 
genomes, could affect inflammatory pathology in general since every nucleated cell would
have potential for expression.
These viruses encode two GPCRs, U12 and U51, which have been demonstrated to interact
and signal in response to key inflammatory ligands [Gompels et al., 1995; Dominguez et al.,
1999; Isegawa et al., 1999; Isegawa et al., 1998; Milne et al., 2000; Fitzsimons et al., 2006; 
Catusse et al., 2008]. In cases of the germ-line integrated forms of these viruses, 
immunomodulatory effects may be more pronounced through expression in a greater 
range of cells or potentially even affects on immune system development. In this regard, 
other work in this laboratory on cDNA analysis from CI-HHV-6A/-6B samples presented 
evidence for gene expression from U51 and the viral chemokine, U83 [Tweedy et al., 
2015a]. Furthermore, this work also showed that in the integrated form of the viruses, the 
viral chemokine, U83, was found to be predominantly in a long active form, less frequently
observed in circulating viral strains. Indicating differences existed between inflammatory 
modulators in the integrated form of the virus when compared to that observed in 
circulating viral strains. Therefore, here the viral chemokine receptor, U51, from CI-HHV-
6A/-6B was investigated further.
U51 represents a relatively conserved gene, sharing 99% homology amongst strains of 
each of the HHV-6 species and 95% homology between the species (accession numbers: 
X83413, KC465951, KP257584, AF157706 and AB021506). Despite this, the determination
of the HHV-6A strain AJ genome sequence, described in chapter 3 of this thesis, and 
recent reports of the HHV-6A strain GS genome sequence [Gravel et al., 2013a; 
Bhattacharjee et al., 2014] indicated the presence of variation in the amino acid sequence 
of the amino-terminal region of the U51 gene (U51A) from that seen in the prototypical 
HHV-6A strain U1102. Moreover, there was similar variation identified in the U51 CDS of 
three CI-HHV-6A genomes subjected to NGS analysis, described in chapter 4.
According to current evidence, the amino-terminal domain of a chemokine receptor 
represents a key determinant in the chemokine-receptor interaction, receptor activation, 
and associated signalling properties. Therefore, any variation here could affect specificity 
and function of the receptor. Additionally, U51 also displays a number of unique features, 
when compared to other viral and human chemokine receptors. Most notably, an 
unusually short amino-terminal domain in comparison to other chemokine receptors; 
predicted to be 17 amino acids in U51 compared to a range from 26 amino acids, CX3CR1, 
to 65 amino acids, DARC, for human chemokine receptors. This combined with a broad 
ligand binding profile showing a combination of constitutive and ligand-inducible 
signalling [Milne et al., 2000; Fitzsimons et al., 2006; Catusse et al., 2008], which outgroups
the entire human CC chemokine receptor group. Therefore, changes to this domain as 
shown in the integrated genomes, could have large immunomodulatory effects. As such 
analyses were initiated at this gene to start to evaluate the consequences of the variation 
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observed in the integrated genomes and circulating virus.
To examine any functional differences, firstly, variation in the U51 gene was investigated 
further through the screening of a panel of samples from patients with CI-HHV-6A or -6B. 
Subsequently, molecular modelling software was employed to guide mutagenesis of the 
U51A amino-terminal domain and for the generation of chimeric receptor constructs with 
the human chemokine receptor CCR3. Generated constructs were expressed in 
mammalian expression systems and subjected to preliminary functional analysis. These 
included measurement of surface expression, as well as activation using chemotaxis and 
actin polymerisation assays. 
5.2 U51 Variation in CI-HHV-6A and -6B
A panel of 57 CI-HHV-6A and -6B samples previously examined in this thesis (31 from 
patients reporting to a diagnostic facility in Berlin, Germany, with cardiac complications 
and 26 from patients reporting to a hospital in Prague, Czech Republic with 
lymphoproliferative or inflammatory diseases) were screened by PCR to amplify the 
complete CDS of the U51 gene from CI-HHV-6A and -6B strains, followed by nucleotide 
sequence analysis.
Firstly, conserved oligonucleotide primer sets were designed to amplify the U51 gene. 
Utilising a ClustalW2 [Larkin et al., 2007] alignment of the nucleotide sequences of the 
reference HHV-6A and HHV-6B genomes (strain U1102: accession X83413/RefSeq 
NC_001664 and strain Z29: accession AF157706/RefSeq NC_000898, respectively) species 
conserved sites flanking the protein coding sequence of the U51 gene were identified. 
Oligonucleotide primers, derived from these conserved sites, were used for both PCR 
amplification and Sanger sequencing of the complete protein coding sequence of the U51 
gene from the CI-HHV-6A and -6B samples (methods section 2.3.3).
These primers amplified a predicted product of 1008 bp. Amplicons of the predicted size 
were amplified from 44/57 (77%) of the samples. The negative samples appeared mainly 
due to limited clinical sample since other regions had been previously amplified and 
sequenced in the laboratory in our subsequent publication which included the U51 data 
[Tweedy et al., 2015a]. Sanger sequencing was used to both confirm the correct identity of
the PCR products and determine the complete CDS. 20/31 of the amplicons were from the
German myocarditis/cardiomyopathy patient cohort and 24/26 from the Czech 
inflammatory disease set. BLAST searches [Camacho et al., 2009] of the nucleotide 
sequences, allowed species typing of the chromosomally integrated samples. Overall 
26/44 (59%) of the amplicons were CI-HHV-6A and 18/44 (41%) of the amplicons 
represented CI-HHV-6B. For U51A, 19/26 (73%) were from the Czech cohort and 7/31 
(23%) from the German cohort. For U51B, 5/26 (19%) were from the Czech cohort and 
13/31 (42%) from the German cohort.
Subsequently, phylogenetic analyses were performed on these CI-HHV-6A and -6B 
sequences with comparisons made to available U51 sequences from circulating HHV-6A 
(U1102 accession X83413, GS accessions KC465951 and KJ123690 and AJ accession 
KP257584) and HHV-6B strains (Z29 accession AF157706 and HST accession AB021506). 
The CI-HHV-6A and -6B sequences shared 99-100% identity within each virus species and 
95% between the two species. All CI-HHV-6B sequences were identical to HHV-6B strain 
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HST, and distinct from Z29. Whereas, all the CI-HHV-6A U51A sequences showed greater 
divergence than CI-HHV-6B, with all being distinct from known circulating HHV-6A strains.
105
Figure 5.1 Phylogenetic analyses of U51 gene from CI-HHV-6A/-6B isolates with HHV-6A/-6B
strains. Maximum likelihood estimation with bootstrapping (1050 replicates). Accession numbers
of all strains used included in the figure. Branch length scale represents number of nucleotide
substitutions per site.
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To ascertain whether the observed divergence represented synonymous or non-
synonymous substitutions, the translated amino acid sequences of U51 from HHV-6A, 
HHV-6B, CI-HHV-6A and CI-HHV-6B were aligned, figure 5.2. The coding region of U51B in 
the CI-HHV-6B samples were 100% identical to U51B of circulating HHV-6B strains, Z29 
and HST. However, for the CI-HHV-6A strains there were 4 sites of amino acid variation in 
comparison to circulating HHV-6A strains, with the integrated forms differing from strain 
AJ at one site and strain U1102 at 3 sites. These non-synonmyous SNPs encoded serine to 
proline (S156P) and tyrosine to histidine (Y167H) substitutions within the predicted 
second extracellular loop (ECL2), an isoleucine to leucine (I188L) substitution at the end of 
transmembrane domain five (TM5) and a glutamic acid to glycine (E2G) substitution in the 
amino-terminal domain. Of particular interest were the E2G and Y167H mutations as these
represented charge changes in predicted extracellular domains. These small amino acid 
substitutions could have large effects, since these are external regions involved in 
receptor-ligand binding and the interactions involved in this binding are believed to rely 

























































Figure 5.2 U51A amino acid sequence variation. Alignment of U51 amino acid sequences for CI-HHV-6A/-6B
and HHV-6A/-6B strains. All CI-HHV-6A amino acid sequences were identical, similarly all CI-HHV-6B
sequences were identical, so both have been condensed to representative sequences here. Amino acid
differences between HHV-6A strains and CI-HHV-6A have been highlighted yellow. Predicted locations of the
extracellular domains have been coloured green: amino-terminal domain (N-term) and extracellular loops I –
III (ECL I – III). Predicted transmembrane domains (TM I – VII) coloured black. Predicted intracellular domains
(ICL I – III) and the C-terminal domain (C-term) have been coloured blue. Domain locations predicted from
previous alignments by Milne et al., 2000, and updated using adjustments from GPCRHMM prediction
software [Wistrand et al., 2006].
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In the prevalent model of chemokine receptor activation, the “two-site” model, charge 
interactions are believed to play a key role in ligand binding specificity of a chemokine 
receptor [Szpakowska et al., 2012; Liou et al., 2014]. The E2G mutation observed in all the 
CI-HHV-6A genomes and a subset of circulating HHV-6A strains, represents the loss of a 
charged residue from the amino-terminal domain of pU51, thereby resulting in the loss of 
a net negative charge across the amino-terminal domain. As such, it was hypothesized that
this substitution may be of functional significance to receptor-ligand interactions 
particularly in regard to ligand binding specificity. In addition, the variation in ECL2 could 
potentially play roles in receptor activation and the variation in TM5 may affect receptor 
activation and/or downstream signalling from the receptor. The functional effects of the 
N-terminal substitution were first investigated, since this could affect ligand specificity and
alter cellular responses to chemokines.
5.3  Molecular Modelling of U51A Amino-terminal Domain-CCL2 Interaction
Molecular modelling was used initially to investigate the potential ligand specificity effects
of the observed variation. To do this a model of the interaction of the receptor's amino-
terminal domain with that of its most extensively characterised chemokine ligand, 
CCL2/MCP-1, was generated. The advantage of this was that both the tertiary structure of 
CCL2 and receptor interaction interfaces have previously been determined [Handel & 
Domaille, 1996; Lubkowski et al., 1997; Chakravarty et al., 1998; Paavola et al., 1998; 
Jarnagin et al., 1999; Hemmerich et al., 1999; Lau et al., 2004]. In contrast, the structure of 
U51, like most human and viral chemokine receptors, has yet to be resolved resulting from
the complexities of membrane association in the structural determination of GPCRs. In 
those cases where structural information is available for large protein binding GPCRs such 
as chemokine receptors, data on the amino-terminal domain is limited. It is often only 
present with a 5' truncation, if at all, which is believed to stem from either a disordered 
structure or the flexible nature of at least the immediate 5' end of this region of the 
protein [Wu et al., 2010; Park et al., 2012; Tan et al., 2013; Qin et al., 2015]. Indeed studies 
on the structures of N-terminal peptides of chemokine receptors complexed to 
chemokines also suggest a predominantly irregular loop structure to the amino terminal 
domain of the receptor, at least in the bound state, which binds a hydrophobic groove 
along the surface of the chemokine ligand [Skelton et al., 1999; Mizoue et al., 1999; Ye et 
al., 2000; Love et al., 2012]. 
To investigate possible similar structures in U51 of HHV-6A, a selection of bioinformatic 
software programs, utilising a variety of different prediction methods, were employed to 
model the secondary structure of amino-terminal domain. These predicted the 5' end of 
the domain had a disordered structure with an alpha-helical structure towards the 3' end 
of the N-terminal domain, figure 5.3A-C. Additionally a helical wheel plot [Schiffer & 
Edmundson, 1967] indicated that if modelled as an alpha helical structure the acidic 
residues of the domain would be clustered on one side of the helix with basic residues 
found on opposite face figure 5.3D. Since it was not possible to model a random coil 
structure for the U51 N-terminal domain and there was some indication of an alpha helical 
structure at least at the 3' end. An alpha helical structure was used to initiate a model 
investigating potential interactions with the chemokine. Wild type and mutant receptors 
were modelled as alpha helices using HyperChem software, figure 5.5. 
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Figure 5.3 Secondary structure predictions of amino-terminal domain of U51A. (A) RaptorX web
server [Kallberg et al., 2012] (B) JPred web server [Cole et al., 2008] (C) SOPMA web server
[Geourjon & Deleage, 1995] (D) Helical wheel plot, red colouring indicates acidic residues and blue
colouring indicates basic residues. 
Docking was performed with CCL2 since this ligand of U51 has crystal structures resolved 
in a number of forms, in addition to extensive functional characterisation of interaction 
sites of the chemokine [Handel & Domaille, 1996; Lubkowski et al., 1997; Chakravarty et 
al., 1998; Paavola et al., 1998; Jarnagin et al., 1999; Hemmerich et al., 1999; Lau et al., 
2004]. These structures showed that like the majority of other chemokines CCL2 can form 
higher order oligomers. However, the obligate dimeric forms of CCL2 were unable to bind 
or activate CCR2 [Tan et al., 2012], implying the monomeric form is required for receptor 
interaction. Yet obligate monomeric mutants of CCL2 lacked the ability to recruit cells in 
an in vivo intraperitoneal recruitment assay [Proudfoot et al., 2003]. This Suggested that 
oligomerisation is essential for an aspect of chemokine function distinct from direct 
receptor binding. Together this data indicates that the dimerisation interface was unlikely 
to be involved in initial interactions with the N-terminus of chemokine receptors and 
therefore the modelling considered only the monomeric receptor binding interactions.
A number of the surface features of CCL2 identified from the structural data have also 
been investigated via mutational studies to characterise the effect of specific regions in its
known functions: dimerisation, GAG binding and receptor interactions [Chakravarty et al., 
1998; Paavola et al., 1998; Jarnagin et al., 1999; Hemmerich et al., 1999; Lau et al., 2004]. 
With regards to the receptor binding determinants, Arg24, Lys49, Tyr13 and the ligands N-
terminus have all been implicated to play a major role in interactions with the receptor. Of 
these Tyr13 and N-terminal truncations/mutants are predominantly linked to loss of 
receptor signalling or chemotactic activity while still retaining receptor binding abilities 
[Paavola et al., 1998; Jarnagin et al., 1999; Hemmerich et al., 1999], implying they are 
involved more in the secondary interactions with the extracellular loops of the chemokine 
receptor that determine receptor activation in the prevailing 'two-site' model. In contrast, 







[Paavola et al., 1998; Jarnagin et al., 1999; Hemmerich et al., 1999], implying they are 
involved in the primary interactions with the amino-terminal domain of the chemokine 
receptor that are believed to determine the specificity of the interaction. Utilising this 
data allowed the search space used for the docking of the U51A N-terminal peptide to 
CCL2 to be narrowed down, concentrating around a hydrophobic groove running along 
the length of CCL2, figure 5.4A-B.
Figure 5.4 Search space parameters for ligand docking modelling. (A) Key interacting residues of
CCL2 (B) Definition of search space parameters for amino-terminal domain docking.
Subsequently, docking of the helical viral receptor N-terminal peptides to the defined 
CCL2 search space were modelled using the AutoDock Vina software [Trott & Olson, 
2010]; albeit with the actual roles reversed using the software such that the 'receptor' in 
the docking model was played by the crystal structure of CCL2 and the role of the 'ligand' 
by the viral receptor N-terminal domain peptides. The interaction was initially modelled 
with the wild type strain U1102 receptor N-terminal peptide strictly constrained to the 
alpha helical conformation by limiting the rotation of the bonds in the peptide backbone, 
figures 5.5A-B. The optimal predicted binding mode from this docking suggested that the 
viral receptor N-terminal domain would be orientated in a manner that would allow for 
further interactions of the N-terminal domain of CCL2 with the receptor binding pocket 
created by the extracellular loops. Additionally it gave some indication that the glutamic 
acid residue at position 2 of the viral receptors N-terminal domain had the potential to be 
an interacting partner with functionally important arginine residue at position 24 on the 
chemokine ligand. However, the predicted binding affinity was low, possibly from the 
structural constraints put on the rotation of the bonds. Additionally as the current 
evidence suggests a strict helical structure is unlikely to represent the natural form the 
amino-terminal domain of the receptor. The docking procedure was performed again, but 
this time with removal of the parameters constraining bond rotation in the peptide 
backbone, figure 5.5C-D. Again the optimal binding mode from this docking model 
predicted the receptor N-terminal peptide to be orientated in a manner which would be 




suggesting close association of the receptor's Glu2 residue and ligands Arg24 residue. This
model had a much higher predicted binding affinity. Interestingly, this predicted binding 
model also suggested the glutamic acid residue at position 4 of the viral receptor peptide 
may also be interacting with Arg24 of the ligand, figure 5.5E. As well as placing the 
tryptophan residue at position 10 of the viral peptide in an orientation facing away from 
the interactions with the chemokine ligand. In structural studies of other chemokine 
receptors, most notably CXCR1, a tryptophan residue in this orientation found 
approximately half way along the length of the N-terminal domain has been implicated in 
anchoring the domain to the cell membrane, which would be accommodated in the U51 
model [Szpakowska et al., 2012 & Park et al., 2011].
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Figure 5.5 Modelling and predicted affinity of the interaction between the amino-terminal
domain of HHV-6A strain U1102 U51 and the crystal structure of the chemokine ligand CCL2. (A)
Ribbon structure representation of the N-terminus of U51 constrained in an alpha helical structure
docked to a space filling representation of CCL2. (B) Molecular structure representation of the N-
terminus of U51 constrained in an alpha helical structure docked to a space filling representation
of CCL2. (C) Ribbon structure representation of the N-terminus of U51 with the torsional
constraints on the peptide backbone removed, docked to a space filling representation of CCL2.
(D) Molecular structure representation of the N-terminus of U51 with the torsional constraints on
the peptide backbone removed, docked to a space filling representation of CCL2. (E) As (D) but





Next, the model was used to predict effects of the substitutions observed in the amino-
terminal domain of the CI-HHV-6A samples. To do this docking was then performed with a 
viral peptide containing the glutamic acid to glycine mutation at position 2 (ΔE2G) 
encoded in all CI-HHV-6A U51 genes, figure 5.6A-B.  While the overall orientation of the 
viral peptide was the same as that seen for the strain U1102 peptide, the ΔE2G change led 
to distinct conformational differences at the immediate 5' end of the peptide, and notably
a predicted reduction in binding affinity, figure 5.5C-D vs 5.6A-B.
Figure 5.6 Modelling and predicted affinity of the interaction between the amino-terminal
domain of the U51 from the CI-HHV-6A isolates and the crystal structure of the chemokine ligand
CCL2. (A) Ribbon structure representation of the N-terminus of U51 docked to a space filling
representation of CCL2. (B) Molecular structure representation of the N-terminus of U51 docked
to a space filling representation of CCL2. 
These models indicated that variation observed in this domain may alter the ligand binding
dynamics of the receptor. Therefore the integrated U51 could have different function 
from that of some circulating viral strains. Notably, U51 from HHV-6A strain U1102 which 
has been utilised for all functional investigation to date. Based on these models, biological 
evidence for functional differences were next investigated.
5.4 Generation of Chimeric and Mutagenic Receptor Expression Vectors
To investigate the nature of the chemokine binding specificity derived from the amino-
terminal domain of U51A, initially a chimeric chemokine receptor was generated. This 
swapped the amino-terminal domain of the human chemokine receptor CCR3 with the 
wild-type amino-terminal domain of U51A from the prototypical HHV-6A strain, U1102. 
This permitted greater investigation into the viral amino terminal domain in isolation from 
the rest of the receptor, while still being present in a naturally relevant environment of the
cell membrane. This approach was based on chimeric human receptors similarly 
investigated for receptor specificity. These were human CCR1:CCR3 chimeric receptors 
used to demonstrate that specificity could be altered with changes in the amino-terminal 
domain [Pease et al., 1998]. Additionally, since U51 and CCR3 have overlapping but distinct
chemokine ligand binding profiles, table 5.1, these could also be used to investigate the 
relationship between receptor binding specificity and functional activation. Central to this 
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was the interaction of U51A with the CCL2 ligand, distinct from CCR3 which does not 
recognise this chemokine ligand. This initial construct was generated by the gene splicing 
and mutagenesis by PCR-driven overlap extension protocol [Heckman & Pease, 2007] (see 
methods section 2.11.1 for a full description).
Table 5.1 Chemokine binding and chemotaxis properties of HHV-6A U51 and CCR3. Key ligands of
U51 and CCR3 that have reciprocal specificities for investigating the interaction of binding and
signalling.
To further investigate specificity of the amino-terminal domain of U51A, a number of 
other vector constructs were also generated, table 5.2. These utilised either a modified 
version of the gene splicing and mutagenesis by PCR-driven overlap extension protocol or 
mutagenic primers (methods sections 2.11.1 – 2.11.3). A vector was generated with the 
U51A amino-terminal cassette construct which could be utilised for the rapid addition of 
alternative receptor sequences to a HA tagged U51A amino terminal domain. As well as 
vectors based on an HA tagged wild-type U51A receptor, with alanine scanning 
mutagenesis of the entire amino-terminal domain. Allowing for further testing of the 
ligand specificity conferred by the amino-terminal domain of U51A. 





HA tagged receptor construct consisting of the human chemokine receptor CCR3 with the amino-terminal 
domain swapped for that of HHV-6A strain U1102 U51A. Allowing interogation of the amino-terminal domain of 
U51A in isolation from the remainder of the viral receptor. 
HA tagged receptor construct consisting of the complete human chemokine receptor CCR3 with the 5' addition 
of the amino-terminal domain of HHV-6A strain U1102. The nucleotide sequence at the 3' end of the U51 
amino-terminal domain has been mutated to an EcoRI restriction site with maintenance of the amino acid 
sequence. Generated to act as a caseete for the rapid addition of alternative receptor sequences to the HA 
tagged amino-terminal domian of HHV-6A strain U1102 U51A.
HA tagged receptor construct consisting of HHV-6A strain U1102 U51A with a glutamic acid to glycine mutation 
at position 2. Reflecting the amino-terminal variation noted in U51A from CI-HHV-6A and certain HHV-6A strains.
HA-U51ΔM1A – 
HA-U51ΔY17A
A series of HA tagged receptor constructs consisting of the HHV-6A strain U1102 U51A with alanine scanning 
mutagenesis of the entire amino-terminal domain of U51A. For further interogation of specificity determinants 
found in the amino-terminal domain. 
5.5 Surface Expression of U51NCCR3M Receptor Construct
Chemokine receptors must be trafficked to the cell surface for plasma membrane ligand 
interactions and subsequent receptor activation required to mediate signalling and 
chemotaxis. Induction of efficient chemotaxis requires sufficient receptor density on the 
cell surface [Szabo et al., 2001; Desmetz et al., 2006]. To detect surface expression of the 
generated receptors, all constructs were N-terminally tagged with an influenza 
haemagglutinin (HA) epitope. This enabled surface expression to be assayed by labelling 
with fluorescein isothiocyanate (FITC) labelled antibodies directed to the HA epitope and 
detection by flow cytometry. Expression was evaluated in two leukocyte cell lines, the 
human lymphoblastic K562 cell line and the murine pre-B lymphocyte L1.2 cell line, both 
previously used for surface expression of chemokine receptor constructs and chemotaxis 
assays [Catusse et al., 2008; Sabroe et al., 2005]. Therefore, a human leukocyte target of 
the HHV-6A virus was compared to a murine model system efficient for receptor 
expression.
The murine L1.2 cell line offered a significant advantage over the human K562 cell line, 
since it did not express competing human chemokine receptors, minimising the potential 
for interference. Additionally, high levels of surface expression following transfection of 
chemokine receptor constructs and efficient chemotaxis have been noted with this cell 
line [Vaidehi et al., 2009]. However, the use of this cell line with the closely related U51 
receptor of HHV-7 failed to induce chemotaxis [Tadagaki et al., 2007] therefore it was 
important to consider the possibility that HHV-6 U51 may display limited chemotaxis in 
this cell line due to the requirement for host specific factors and look into alternative 
human cell lines. The human erythroleukemia K562 cell line was chosen as it does not 
express the chemokine receptors studied here under normal conditions, yet being of 
human origin the cells are potentially similar to the normal target cells of the virus with 
regards to intracellular factors required for receptor signalling. In addition a HA-tagged 
U51 construct has previously been shown to surface expressed and be able to induce 
chemotaxis in this cell line [Catusse et al., 2008].
Comparisons were made between different methods to optimise surface expression, 
appendix 7.8. As a result cells were subsequently electroporated when cultured cell 
density was ~0.9  x 106 cells/ml, to ensure they were in early log phase since this optimised 
receptor gene expression. Electroporation was conducted with 2 μg of plasmid DNA/1 x 
106 cells, then cells were cultured for a further 48hrs before downstream analysis, to 
permit maximum gene expression and cell surface transport. Electroporation of the 
U51NCCR3M chimeric receptor construct showed detectable but low surface expression 
in both cell lines, figure 5.7.  Similar results were observed for transfection of the CCR3 
and U51D constructs which have previously been utilised for functional analysis where 
similar transfection conditions had been utilised [Catusse et al., 2008; Sabroe et al., 2005].
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Figure 5.7 Surface expression of U51NCCR3M chemokine receptor construct in L1.2 cells.
Histogram plots showing cell counts (y) against relative FITC fluorescence (x). Red shading
indicates mock transfected cells and blue shading indicates experimental transfected cells.   
5.6 Functional Analysis of U51NCCR3M Construct
 
Although surface expression of the receptor constructs was low, since chemotaxis has 
previously been observed at these expression levels, functional analysis by chemotaxis was
investigated. This requires the specific transmigration of live cells across the chemotaxis 
filter in response to a chemotactic stimuli. Thus even if receptor expressing cells were in a 
minority of the total cell population, detection could be possible since only the receptor 
expressing cells could specifically migrate. However, this has to be measured against a 
background of random movements, chemokinesis and gravity flow effects. Experiments 
were performed in triplicate and preliminary results showed CCL2, a native ligand of the 
U51 receptor but not the CCR3 receptor, induced chemotaxis in cells expressing the 
chimeric receptor construct, figure 5.8. However, the chemotaxis levels were low and 
greater expression relative to background migration would be required to verify this 








through the amino-terminal domain switch with the viral chemokine receptor.
Figure 5.8 Chemotaxis of U51NCCR3M cells in response to the chemokine ligand CCL2. All ligand
concentrations run in triplicate. Chemotactic responses are normalised as a chemotactic index,
indicating the fraction of cells moving towards the chemokine ligand respective to buffer. One way
analysis of variance (ANOVA) was used to determine significant chemotaxic response (* = p value <
0.01  ** = p value < 0.05).
5.7 Discussion
The screening here of a key viral immunomodulatory gene from one of the largest groups 
of CI-HHV-6A and CI-HHV-6B samples collated to date shows that the integrated forms of 
these viral species have similar prevalences. This was supported by studies by others in this
laboratory on three further loci, U38, U46 and U83 and subsequently published [Tweedy et
al., 2015a]. As well as previous observations about the prevalence of CI-HHV-6A and -6B 
[Leong et al., 2007; Hubacek et al., 2009; Kuhl et al., 2015]. This is in contrast to the 
prevalence of circulating strains of HHV-6A and HHV-6B in the majority of countries  
studied to date, where HHV-6B is more frequently detected [Hall et al., 2006; 2008]. The 
exception to this being that of Zambia where HHV-6A and HHV-6B are detected at similar 
levels [Bates et al., 2009]. To date CI-HHV-6A has not been detected in screens in this 
southern African population, although one case of CI-HHV-6B has been reported in a north
African population [Faten et al., 2012; Tembo et al., 2015]. Thus clear differences exist 
between the relative prevalences of the circulating and integrated forms of these viruses. 
If integration occurred recently or frequently, the relative prevalence of the integrated 
forms could be expected to reflect that of the circulating viral forms. While a number of 
factors, such as human genetics or differences in germ-line integration efficiency between
HHV-6A and HHV-6B, could account for the differences in relative prevalence. An 
additional explanation may lie in the shared origins of the integrated samples and 
supported by data in the previous chapter. The higher prevalence of CI-HHV-6A could 
result from HHV-6A integration events, which predate those of CI-HHV-6B, allowing a 
greater length of time for expansion in the population. In this regard, the nucleotide 
sequences of the U51A gene from the samples where 17p13.3 chromosomal integration 
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was identified, were all identical (Germany sample ID 1624/5055 and Czech sample IDs 
10593-43670, grouping together in figure 5.1). The same was also found with analyses of 
three further loci from CI-HHV-6A genomes integrated at this chromosomal location 
[Tweedy et al., 2015a]. Providing further support to the notion of shared origins of HHV-6A
integrated at this site. 
The prevalence of CI-HHV-6A in the lymphoproliferative/inflammatory disease cohort from
the Czech Republic was higher than that observed in the German 
myocarditis/cardiomyopathy group. Suggesting the possibility of an association with this 
disease group. Again this was confirmed by studies in three further loci by others in the 
laboratory as included in our subsequent publication, Tweedy et al., 2015a. If such an 
association exists, key players in any viral contribution to disease could be from the virally 
encoded modulators of the chemokine system; which posses binding capabilities implying 
the ability to manipulate the majority of beta-chemokine inflammatory system [Dewin et 
al., 2006; Catusse et al., 2007; 2009; Isegawa et al., 1998; Milne et al., 2000; Fitzsimons et 
al., 2006; Catusse et al., 2008]. Indeed, a recent study in the same German cohort 
examined here, from which gene expression from viral inflammatory mediators including 
U51 has been demonstrated [Tweedy et al., 2015a], found links between persistent 
inflammatory disease, in the form of myocardial complications, and CI-HHV-6A/-6B [Kuhl et
al., 2015]. Furthermore, a recent large scale analysis has also found CI-HHV-6A/-6B to be a 
risk factor in the development of angina, with the prevalence more than three times 
greater in CI-HHV-6A/-6B than control groups [Gravel et al., 2015]. The implication being 
that expression from the integrated viral genome and/or reactivation leads to immune 
activation with cellular damage that promotes myocardial complications.
Other work in this laboratory has found that virally encoded chemokine, U83, is 
predominantly in a long active form, in CI-HHV-6A samples from this inflammatory disease 
cohort [Tweedy et al., 2015a]. Furthermore cDNA analysis indicated gene expression of 
this potent viral chemokine [Dewin et al., 2006; Catusse et al., 2007; Clark et al., 2013; 
Tweedy et al., 2015a]. Gene expression was also suggested from the chemokine receptor 
gene, U51, of these CI-HHV-6A samples [Tweedy et al., 2015a]. Here it was found that 
there is variation in the U51A gene in both HHV-6A and CI-HHV-6A, with amino acid 
sequence comparisons revealing four sites of variation. Of note, two of these represented 
charge changes in predicted extracellular domains, thus having a strong potential to affect
viral receptor ligand specificity and receptor activation Blanpain et al., 1999; Szpakowska 
et al., 2012]. As such it seems important to investigate possible functional significance, 
since the gene could be expressed in every cell and dramatically affect the inflammatory 
response giving dysfunctional cell mobilisation.
The amino-terminal domain was investigated further here, since this domain has a noted 
role in ligand specificity interactions in other chemokine receptors [Pease et al., 1998; 
Monteclaro & Charo, 1997; Blanpain et al., 1999; Wu et al., 1996; Gozansky et al., 2005; 
Mizoue et al., 1999]. Two chimeric receptor construct expression vectors have been 
generated, along with a selection of vectors containing constructs with alanine scanning 
mutations across the amino-terminal domain of the viral receptor. Preliminary attempts at 
functional analysis with the U51NCCR3M viral-human chimeric receptor construct have 
demonstrated transient surface expression, albeit at a limited level. Initial results showed 
that this amino-terminal domain switch may allow changes in both receptor specificity and
activation. Future studies are needed to confirm this result and test the other constructs 
made (table 5.2), but there was not sufficient time to explore this further here. Of 
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interest, amino-terminal chimeric receptor constructs have previously shown to display 
specificity changes, but this did not correspond to chemotaxis activation [Monteclaro & 
Charo, 1996; Pease et al., 1998; Blanpain et al., 2003]. Therefore, these preliminary results 
indicate unusual differences in the viral receptor and mechanisms of chemokine receptor 
activation. Which may have implications for ligand binding specificity differences between 
the integrated and virus encoded forms of U51.
Higher levels of receptor surface expression would facilitate further analyses and many 
factors may contribute to this. It may be that amino-terminal changes in the current 
constructs affect cell surface transport of the receptor constructs or inhibit binding of the 
fluorescently labelled antibody utilised for surface expression analysis. However, chimeric 
CCR3 receptors have previously been expressed at levels sufficient for chemotactic 
analysis [Pease et al., 1998]. Amino-terminally HA tagged U51 receptor constructs have 
also been expressed in the K562 cell line at levels sufficient for chemotactic analysis [Milne
et al., 2000]. Additionally, expression of the wild type CCR3 receptor construct in the L1.2 
cell line is around half of that previously achieved and utilised for chemotactic analysis 
[Duchesnes et al., 2006]. Thus it seems an alternative explanation to mutation affecting 
the surface expression exists. 
As highlighted, a number of factors affecting surface expression have been investigated 
(appendix 7.8), albeit with the human CCR5 chemokine receptor construct, which were 
applied to expression of the U51 and CCR3 constructs here with limited success. This could
be due to different effects on the chimeric receptor. As an alternative means of achieving 
sufficient levels of surface expression, a stably expressing cell line was generated with the 
U51NCCR3M construct, described in appendix 7.9. This method has previously been 
utilised for functional analysis of U51 [Catusse et al., 2008]. While expression levels are 
typically lower in these cell lines, the advantage is that the proportion of expressing cells is
greatly increased. There was not sufficient time to further investigate surface expression 
and functional analysis of these cell lines but this could be a subject for further study. 
Additionally, inconsistencies in the chemotaxis assay have led to considerations for 
alternative means of functional analysis of the receptor constructs. Exploratory 
investigations have been made with an actin polymerisation assay which would be a 
downstream marker for receptor activation [Burger et al., 2005; Udi et al., 2013], methods 
described in appendix 7.10. The actin polymerisation assay therefore gives an alternative 
means of assessing receptor activation, while ligand binding assays using the stable cell 
lines could give greater insight into ligand specificity and affinity changes.
In summary, a key site of amino acid variation was defined in an important 
immunomodulatory gene, U51A, encoded by the chromosomally integrated form of HHV-
6A. This was investigated further by molecular modelling and functional analyses of a 
series of receptor construct expression vectors. Preliminary results showed altered roles 
of the amino-terminal domain of U51A in chemokine ligand binding specificity and 
receptor activation. With potential for changed affinity and response to chemokine CCL2 
therefore restricting its activity. Further studies could confirm these functional changes 




At the start of this thesis there was little understanding of the genetic relationship 
between the chromosomally integrated genomes of CI-HHV-6A/-6B and those of 
infectious HHV-6A/-6B. Evidence from in vitro cell line work has suggested that viral 
integration could represent a new mechanism of latency, which would be unique amongst 
the human herpesviruses [Arbuckle et al., 2010; 2013]. Although to date, in vivo evidence 
for this has not been presented. However, irrespective of the potential role as a latency 
mechanism, it is clear that both HHV-6A and -6B can and have integrated into the human 
germ-line. This has resulted in endogenous forms of these viruses, in approximately 1% of 
populations studied [Tanaka-Taya et al., 2004; Leong et al., 2007; Hubacek et al., 2009; 
Potenza et al., 2009; Pellett et al., 2012]. The pathological significance of these integrated 
forms are only beginning to be determined. Therefore the major intention of this thesis 
was to explore the integrated forms of these viral species to establish their relationship to 
circulating viral strains and begin to establish their biological significance. 
The results presented here firstly established methodology which can be used to allow 
accurate genomic NGS directly from tissue samples. Validation of these methods was 
provided through resequencing of the prototypical HHV-6A strain, U1102. As well as by 
adding to the repertoire of fully sequenced HHV-6A strains through derivation of the 
complete genome sequence of strain AJ. This established a NGS pipeline which could be 
applied to characterisation of the germline chromosomally integrated forms of HHV-6A/-
6B. Additional analyses of 12 viral integration site junctions indicated a shared genetic 
lineage of CI-HHV-6A integrated at chromosome 17p. Whole genome NGS of three CI-
HHV-6A isolates revealed they are intact possessing the full complement of genes 
identified for HHV-6A strains, in addition to key cis acting signals required for 
replication/reactivation. In addition, comparisons of these integrated genomes to 
circulating viral strains highlighted divergence at a set of genes regarded as markers of 
speciation amongst herpesviruses. Minor variant analysis also supported a mechanism by 
which HHV-6A/-6B superinfection may result in gene expression from, and/or reactivation 
of the integrated virus. Finally, variation in the viral chemokine receptor, U51, observed in 
CI-HHV-6A was investigated due to a predicted role in ligand binding specificity affecting 
function. 
6.2 Roseolovirus Next Generation Sequencing
Next generation sequencing technologies have been extensively applied for genomic 
analyses of the closely related betaherpesvirus HCMV [Reviewed in Sijmons et al., 2014]. 
However, at the start of this thesis these technologies had yet to be applied to the 
Roseoloviruses. Therefore, one of the initial aims of the work presented here was to 
investigate genomic NGS and subsequent assembly of HHV-6A/-6B strains, using the 
currently most prevalent commercially available platform. This was with a focus on 
establishing methods which would allow characterisation of the chromosomally 
integrated forms of these viral species, directly from clinical samples. 
The work presented here suggests that both solution hybrid capture and long range PCR 
(LPCR) represent viable options for target enrichment of HHV-6A genomic DNA prior to 
Illumina MiSeq mediated sequencing. Both methods were capable of achieving sufficient 
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read coverage across the genome for whole exome sequencing. Indeed, the percentage of
the genome which could be resolved, and generated consensus sequences, were almost 
identical for both enrichment methods. Thus, from a technical standpoint there is little to 
distinguish between these enrichment methods for the NGS sequencing of HHV-6A strains
for this application. Instead, the choice of method will likely rely on other factors such as 
time, cost and sample limitations. In this regard, the overall time for the completion of 
both target enrichment methods is similar, ~48-72 hours. Although preliminary 
optimisation of amplicon primer and RNA bait library sequences could vary significantly. 
However, even with the possibility of multiplex PCR, the generation and purification of the
genomic amplicons during this time period represent a greater work load than the 
hybridisation and capture steps required for solution hybrid capture based target 
enrichment. Yet LPCR based enrichment has the advantage of reagent cost at the scale 
performed here, approximately 50% cheaper than that of solution hybrid capture, 
although this could change with competition for commercial target enrichment strategies.
LPCR based enrichment could in some regards be a more readily reproducible method 
since it does not rely on custom designed RNA bait libraries and theoretically can capture 
greater divergence. Moreover LPCR also provides an archived reference library of 
amplicons unlike solution hybridisation which depletes the original template. However, 
variability in the read coverage coinciding with the amplicon locations was an issue with 
LPCR enrichment, especially with the CI-HHV-6A samples. An issue where solution hybrid 
selection provided a clear advantage over LPCR enrichment. This variability not only had 
implications for resolution of the CI-HHV-6A genome sequences, but could also affect the 
detection of the signatures of genomic insertions/deletions or the use of software 
utilising read coverage to aid in the determination of repetitive regions [Xi et al., 2011; 
Nowak, 2015]. While amplicon primer optimisation for the CI-HHV-6A genomes may be 
beneficial there was no indication from the post amplification size and yield 
quantifications that this variability arose directly from PCR complications. Instead other 
factors most notably extended storage of the amplicons combined with minor 
inaccuracies in the quantification process seemed more likely to be the cause. Regardless, 
the experience here suggests focus should be placed on the crucial equimolar pooling 
step to ensure less variability thus aiding accurate genome sequencing. 
Comparisons of different assembly methods, indicated that mapping of the read data to 
an appropriate HHV-6A reference genome with subsequent variant calling and consensus 
sequence generation was sufficient for accurate sequencing of the UL region of the 
genome. The most notable advantage of this being a reduction in the time and 
computational resources required for sequencing. However, where possible both a 
mapped and de novo assembly should be utilised as separate lines of evidence to inform 
the generation of the hypothesis for the underlying genome sequence. Problems were 
encountered with the assembly of reads across repetitive regions, which for HHV-6A/-6B 
are in the R1-R3 and DR regions of the genome. The results here suggest that these 
regions cannot be accurately resolved by a mapped assembly resulting from read 
alignment failure at these more diverse regions or mis-alignment of reads complicated by 
repetitive regions. Targetted de novo assembly of these regions permitted incomplete 
sequencing. However, subsequent Sanger PCRs performed for gap filling which 
overlapped with the contigs generated for these regions, indicated that at least for the 
overlapping regions the de novo assembly was generating an accurate representation of 
the sequence. Thus, while de novo assemblies were able to partially sequence these 
regions, the need for Sanger sequencing for gap filling in repetitive sequence assessment 
represent a major bottleneck for the routine use of NGS for HHV-6A whole genome 
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sequencing. Currently the maximum read length achievable on the Illumina MiSeq 
platform is 2x300 bp, yet tandem repeat regions in HHV-6A genomes can extend to more 
than double this size often also surrounded also by imperfect repeats. Therefore, if read 
lengths are extended on the MiSeq platform this may allow a higher throughput by NGS 
for HHV-6A genome sequences..
The issue of repetitive sequences is also complicated by the presence of human telomeric-
like repeat sequences within the genomic termini, thus the potential exists for sequenced 
reads of human origin to confound results. These repetitive areas of the genome are some
of the major areas which define the sequence length variation observed between 
different HHV-6A species. To date the role of the R1-R3 repetitive sequences in the 
genome are largely undefined, however, their retention in all currently sequenced HHV-6A
and -6B strains implies a functionally significant role. The exception to this is the human 
telomeric-like repeat sequences located in the DR at the genomic termini. These 
sequences have been proposed to play dual roles in HHV-6A replication both in integration
of the viral genome into host chromosomal DNA and protection of the integrated viral 
DNA through neo-telomere formation following chromosomal integration [Arbuckle et al.,
2010; Huang et al., 2014; Ohye et al., 2014].
6.3 Resequencing of HHV-6A Strain U1102
The establishment of a methods pipeline for Illumina MiSeq mediated HHV-6A genomic 
sequencing ultimately led to resequencing of the prototypical HHV-6A strain, U1102, 
which showed 99.9% identity with the original sequence. In addition to the three 
previously identified sequencing errors/sites of variation, in the CDS of the DR6, U83 and 
U86 genes [Schleimann et al., 2014; French et al., 1999; Dewin et al., 2006; Papanikolaou et
al., 2002], confirmed by the resequencing here. Five further suggested corrections to the 
archived genome sequence were identified by both assembly methods: U40, U42, U57, 
U58, U100. These could affect the functions of these encoded proteins in viral replication. 
Little experimental information directly from HHV-6A/-6B strains is currently available on 
the majority of these genes. However, homologues of these HHV-6A genes are identified 
in other herpesviruses and indicate potential functions.
HHV-6A/-6B U40 is a homologue of HCMV UL56 and HSV-1 UL28 [Jones & Teo, 1993]. In 
both HCMV and HSV-1 the products of these genes form trimers, UL51-UL56-UL89 for 
HCMV [Borst et al., 2013] and UL15-UL28-UL33 for HSV-1 [Heming et al., 2014], collectively
termed the terminase complex. The UL56/UL28 components possess a nuclear 
translocation signal and the ability to interact with a cellular importin [Giesen et al., 2000a]
to permit transport of the trimeric complex to the nucleus whereupon the complex 
associates with viral DNA replication centres [Giesen et al., 2000b]. Additional sequences 
within the UL56/ UL28 component orchestrate binding to the highly conserved herpesviral
pac sites, nuclease activity, ATP binding and interaction with viral capsid structures 
[Bogner et al., 1998; Tengelsen et al., 1993; Sheaffer et al., 2001; White et al., 2003; Scholz 
et al., 2003]. This is consistent with these complexes acting as molecular motors that 
cleave single unit length viral genomic DNA from its concatemric form and package these 
into preformed capsid structures via the capsid portal. By inferred homology, HHV-6A and 
-6B U40 may interact with the products of U35 and U60 to form the terminase complex. 
HHV-6A and -6B U42 is a homologue of HCMV UL69 and HSV-1 UL54/ICP27 [Winkler et al., 
1994; Gompels et al., 1995], and in turn the ICP27 family of proteins due to the high level 
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of conservation within the Herpesviridae. These are expressed with immediate early/early 
kinetics [Winkler et al., 1994; Winkler & Stamminger, 1996; Sandri-Goldin, 2011], with some
suggestion UL69 may also be present in the tegument of HCMV virions [Winkler & 
Stamminger, 1996]. ICP27 shuttles between the cytoplasm and nucleus [Soliman et al., 
1997] and directly binds viral mRNAs [Corbin-Lickfett et al., 2009]. It acts as a 
transactivator of viral gene expression from the later kinetic classes, with most effect 
being mediated post-transcriptionally [Winkler et al., 1994; Rice & Knipe, 1990; Uprichard &
Knipe, 1996]. These effects are mediated by a variety of different means, the best 
characterised being inhibition of cellular pre-mRNA splicing, the nuclear export of viral 
mRNAs through interactions with cellular mRNA export factors and stabilisation of viral 
mRNAs in the cytoplasmic compartment [Sandri-Goldin, 2011].
HHV-6A and -6B U57 is a homologue of HCMV UL86 and HSV-1 UL19/VP5, which has been 
defined as the major capsid protein in HSV-1 [Olshevsky & Becker, 1970; Brown & 
Newcomb, 2011]. Concurrent with this role as a virion structural protein, the gene is 
expressed in abundance with late kinetics in herpesviruses and as such is frequently used 
as a marker for the detection of viral replication.
HHV-6A and -6B U58 has homologues in the betaherpesviruses, HCMV UL87, and the 
gammaherpesviruses, EBV BcRF1, however, homologues do not appear to be present in 
the alphaherpesviruses. Deletion mutants of both UL87 and BcRF1 suggest these genes 
are expressed with early kinetics, and essential for growth due to their apparent 
involvement in a mechanism required for activation of late viral gene expression, which in 
EBV appears to be as a member of a viral 'preinitiation' complex [Yu et al., 2003; Dunn et 
al., 2003; Isomura et al., 2011; Aubry et al., 2014]. Additionally, recent evidence suggests 
an antisense transcript from the U87 gene region may be expressed during the late phase 
of replication, possessing two predicted reading frames, one of which shows high 
conservation among CMV strains [Ma et al., 2011]. However, currently the products or 
functions of these predicted ORFs functions have not been identified.
While HHV-6A and -6B U100 is unique to the Roseoloviruses. It encodes the envelope 
glycoprotein Q (gQ), two transcripts produce different products (gQ1 and gQ2) from the 
gene via differential splicing. These products associate with glycoproteins H and L (gH and 
gL) form complex which acts as the viral ligand for the cellular receptor CD46 and along 
with glycoprotein B (gB) mediate membrane fusion [Mori et al., 2003a; 2003b; 
Akkapaiboon et al., 2004; Tanaka et al., 2013]. 
Preliminary alignments of the HHV-6A strain U1102 CDS with HCMV homologues indicated
that the sequence variations fell outside of any of the currently defined functional 
domains. However, the crucial role of many of these gene products in herpesviral 
replication, may mean that investigation of these components in HHV-6A and -6B may be 
of interest to produce intervention strategies. In this regard, a number of small organic 
molecules have been found to be interfere with HCMV replication via inhibition of the 
terminase complex [Krosky et al., 1998; Buerger et al., 2001; Goldner et al., 2011]. The 
existence of drugs which abrogate HSV-1 replication, through an indirect action affecting 
ICP27 function [Murata et al., 2001; Park et al., 2013], implies that the members of this 
gene family could represent viral intervention targets. RNA interference (RNAi) of the 
capsid proteins UL18 and UL19 in HSV-1 and -2 has been found to significantly affect the 
replication of acyclovir resistant clinical isolates of these viral species. Suggesting these 
could be a target for RNAi based intervention strategies, especially in the case of strains 
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resistant to the most prevalent herpes antiviral drugs [Jin et al., 2014]. Studies with 
mutant BACs suggest gQ is essential for virus production [Tang et al., 2011]. Also in 
addition to gB and gH, gQ also contains epitopes which are recognised by neutralising 
antibodies [Pfeiffer et al., 1993; 1995], which in combination with significant sequence 
variation between the HHV-6 species at these genes raises the possibility of an 
intervention via variant specific neutralising antibodies. Thus these corrections or sites of 
variation may be of importance for such work. 
6.4 Sequencing of HHV-6A Strain AJ
The established Illumina MiSeq NGS methods were further validated by genomic 
sequencing of HHV-6A strain AJ, adding a third viral strain to the repertoire of fully 
sequenced HHV-6A strains. The recent sequencing and analysis of an isolate of HHV-6A 
strain GS [Gravel et al., 2013a] led the authors to propose that the observed divergence 
between strain GS and the prototypical HHV-6A strain U1102 [Gompels et al., 1995] may 
stem from their distinct geographic origins. Strain GS was first isolated from patients with 
lymphoproliferative disorders, including one with HIV/AIDS, from the United 
States/Jamaica [Salahuddin et al., 1986] and strain U1102, while originally isolated in the 
United Kingdom, was from a Ugandan HIV/AIDS patient [Downing et al., 1987]. However, 
the high degree of relation observed here between strain AJ, originally isolated  from an 
adult HIV/AIDS patient from Gambia [Tedder et al., 1987], and strain GS from the USA imply
alternative explanations must exist for the variation observed between strains U1102, GS 
and AJ. Indeed, despite their distinct geographic origins, strains AJ and GS showed closer 
relations to one another than either did to strain U1102. This may reflect convergent 
evolution of the strains or alternatively a more recent emergence event, possibly related 
to chromosomal integration. Current evidence cannot provide a definitive answer to this 
question. However, the presence of a number of features in the HHV-6A genome may 
favour the latter of these explanations. For example, in contrast to the product of HHV-6B 
IE1/U90, which efficiently evades type I interferon responses, HHV-6A remains sensitive 
resulting from the lack of a specific gene insertion [Jaworska et al., 2007; 2010]. U20A also 
displays signs of unregulated immune surveillance since it downregulates MHC class I 
more efficiently than HHV-6B U20 [Glosson & Hudson, 2007]. Additionally, while U54B 
inhibits  nuclear factor of activated T-cells (NFAT) signalling, through improper 
dephosphorylation and nuclear translocation, U54A actually acts as a transactivator of 
NFAT [Iamietro et al., 2014].
In depth sequence analyses of AJ also noted variation in the DNA polymerase gene, U38. 
Due to its high level of conservation, regions of U38 are often used for HHV-6 species 
typing. However, this variation noted in strain AJ, but also present in strain GS, fell within 
primer site locations used in a real-time PCR based diagnostic assay for the HHV-6 species 
[Lou et al., 2011]. This assay has been readily utilised [Lou et al., 2011; Oakes et al., 2013; 
Tembo et al., 2015] and could confound results through under-detection of HHV-6A 
species, through reduced primer affinity. Such issues can easily be overcome through the 
use of multiple genomic sites for diagnosis in the currently established real-time PCR 
based assays. A number of newer technologies such as ddPCR, which has already been 
employed for the detection of HHV-6A and -6B [Sedlak et al., 2014; Leibovitch et al., 2014],
and ultra-deep sequencing with variant analysis [Barzon et al., 2013; Beerenwinkel et al., 
2011] display promise in the ease of quantification of infections as well as the detection of
multiple or co-infections. However, these may still require a PCR amplification based 
approach, such that the identification of multiple genomic targets from all available 
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sequence available remains a crucial consideration. 
During annotation of HHV-6A strain AJ, ORF prediction software was utilised to confirm 
the location of previously defined genes. These indicated a number of short ORFs (<100 
amino acids) may be present in the AJ, however, due to the lack of evidence indicating any 
transcription and/or translation from these sites these were not been included in the 
current annotation. But short reading frames are increasingly found to be a feature of 
many genomes [Andrews & Rothnagel, 2014]. Indeed, two recent reports utilising 
ribosome profiling in the gammaherpesvirus KSHV and the betaherpesvirus HCMV have 
revealed a large number of new ORFs [Arias et al., 2014; Stern-Ginossar et al., 2012]. These
were from both novel genomic loci and overlapping currently annotated ORFs, including 
numerous examples of leaky scanning and non-AUG initiation. While the cellular function 
of many of these remain to be determined, this implies a currently underappreciated level 
of complexity to expression from herpesviral genomes. This is in addition to recognition of
the increasing role virally encoded microRNAs and long non-coding RNA play in herpesviral
replication [Hook et al., 2014; Tuddenham et al., 2012; Nukui et al., 2015]. Thus currently 
defined annotations will likely require extensive updates as the status of many of these 
features become further defined.
6.5 Germ-line Chromosomal Integration of HHV-6A and -6B
Chromosome 17p Integration
To date, germ-line CI-HHV-6A/B genomes have been identified at 10 different 
chromosomal locations. This indicates there has been a minimum of two separate 
integration events into the germ-line for HHV-6 species, one for HHV-6A and another for 
HHV-6B. The presence of integrated viral genomes from these species at multiple 
chromosomal locations in the germ-line could potentially have arisen from additional 
independent germ-line integration events, interchromosomal translocation of integrated 
viral genomes, or excision and re-integration events within germ-line cells. Currently, 
further study is required to ascertain the relevance of these different scenarios. Vertical 
transmission of CI-HHV-6A and -6B is well established [Mori et al., 2009b; Arbuckle et al., 
2010; Huang et al., 2014; Kuhl et al., 2015]. Indeed integrated genomes account for most 
cases of congenital infections by these viruses [Hall et al., 2010]. This vertical inheritance 
implies that there is some level of expansion of the integrated genomes within 
populations by Mendelian inheritance. However, mechanisms governing the frequency of 
integration at a given chromosomal location need to be established. For example, the 
integration could represent a singular event with extensive expansion in the population or 
frequent separate integration events at preferential integration location each with limited
expansion.
Analysis of the integration site junctions of CI-HHV-6A amplified utilising a chromosome 
17p13.3 specific primer sequence, suggested a shared genetic lineage between the 
integrated viral genomes at this chromosomal location, within the European population 
under investigation here. This was further supported by phylogenetic clustering of isolates
integrated at this chromosomal location in the U51 gene. Indeed, additional work in this 
laboratory utilising multiple loci analysis of CI-HHV-6A isolates from this cohort with 
evidence for integration at chromosome 17p, showed similar phylogenetic clustering, as 
well as retention of a long form of the viral chemokine gene, seen rarely in clinical strains 
[Tweedy et al., 2015a]. This data implies germ-line integration of HHV-6A/-6B may be a 
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series of rare events which have subsequently been expanded as a polymorphism. In line 
with this, recent results analysing CI-HHV-6B in non-familial Japanese patients has also 
noted similarities between integration sites at the same chromosomal location, adding 
support to the notion of ancient origins of these integration events [Ohye et al., 2014]. 
Analyses of the CI-HHV-6A integration site junctions showed a shared structure of 
combined perfect and imperfect telomeric repeats. These shared characteristic repeat 
patterns close to readily identifiable sequence from both the chromosomal subtelomeric 
region and the viral DRR. There was some variance in the number of repeats between 
these two signatures. However, two isolates from independent donors, 25533 and 27355, 
shared identical junctional sequences implying close familial relationship. The variance 
observed between other isolates suggested replication slippage, or homologous 
recombination has occurred, perhaps reflecting accumulative changes since the 
integration event or that viral integration has effects on telomere biology. In this regard, a 
recent report on the length of CI-HHV-6A/-6B associated telomeres in somatic and sperm 
cells suggests elongation of virally associated telomeres can occur in germ-line cells, 
implying active maintenance in these cells, although this is presumed to occur by a 
telomerase mediated mechanism. While virally associated telomeres were frequently the 
shortest in the somatic cell, the implication being that integration may disrupt telomere 
function [Huang et al., 2014].   
The possibility of more than a single CI-HHV-6A integration event at this chromosomal 
location remains, however. CI-HHV-6B was also noted at chromosome 17 in this work, and 
in a number of previous reports [Luppi et al., 1993; Torelli et al., 1995; Morris et al., 1999; 
Ward et al., 2006; Nacheva et al., 2008]. So at least two independent integration events at 
this chromosomal location have occurred, one for each viral species. The previously 
identified 17p CI-HHV-6A junctional sequence of undefined, possibly US, origin (accession 
GU784872) shared similarities to those identified here but lacked the characteristic 
imperfect telomeric repeats identified in the CI-HHV-6A samples here. As suggested 
above, accumulative effects of replication slippage or homologous recombination could 
be a possible explanation for this. Another possibility is that in vitro passage of the 
leukocytes from that patient affected the integration site or its cloning into plasmids prior 
to sequencing. The integration sites investigated in this thesis were amplified directly from
clinical samples. However, it is also possible that this could represent a separate lineage of 
CI-HHV-6A integrated in the germ-line at this chromosomal location. Indeed, all of the 
samples assessed here were from a clustered region in central Europe (Czech Republic and
Germany). But similarities were also noted to a previously defined CI-HHV-6A integration 
site from Sardinia (accession KF366419). Therefore, it would be of interest to investigate 
additional populations, as well as the ethnicity of the individuals with CI-HHV-6A/-6B 
assessed here, to give further insight into the extent and origins of these integration 
events. 
Furthermore, while the viral integration site junction sequences generated here appear to 
share common architectural features and were amplified utilising primer sequences 
designed to amplify viral genomes integrated into the subtelomeric region of 
chromosome 17p; the differences in the number of pure TTAGGG telomeric repeats 
between these common features could also be indicative of integration events in the 
subtelomeric regions of more than one chromosome. In this regard, it is well established 
that the subtelomeric regions of a number of human chromosomes share regions of 
significant homology [Riethman et al., 2004; Ambrosini et al., 2007]. In particular, the 
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distal, telomeric adjacent, regions of the subtelomeres from these different human 
chromosomes contain short repetitive sequences of high homology, which have arisen 
from segmental duplication and interchromosomal translocation events [Mefford & Trask, 
2002; Mewborn et al., 2005; Linardopoulou et al., 2005]. It is also true that the 
subtelomeric and telomeric regions of all human chromosomes remain poorly defined 
when compared to more central regions of the genome, resulting largely from the 
repetitive nature and high levels of sequence homology, which have hampered their 
inclusion in genome sequencing projects [Lander et al., 2001; Riethman et al., 2004]. Such 
that numerous polymorphisms in the subtelomeric regions of the human chromosomes 
are likely yet to be defined, which in combination with segmental duplication and 
chromatid exchange could allow for similar sequences to be present in the subtelomeric 
regions of multiple chromosomes. Thus, there is the possibility that the 17p primer 
sequence utilised in this work could also amplify from regions of significant homology 
located on chromosomes other than at 17p13.3. For true clarification of the chromosomal 
location of these integrated genomes, additional techniques such as that of FISH analysis 
would be of merit. Indeed a defined protocol for the generation of FISH probes which 
permit the high sensitivity detection of CI-HHV-6A/B has recently been published [Ohye et 
al., 2016]. However, owing to the requirement for interphase or metaphase chromosome 
preparations for FISH analysis and the nature of the CI-HHV-6A/B samples available in this 
work, FISH analysis on the individuals included in this work would not be possible without 
the acquisition of further samples. Of note, there was also a distinct clustering of CI-HHV-
6A located on chromosome 22q in seven of the thirteen Japanese patients examined in 
the work generating the CI-HHV-6A/B FISH probes [Ohye et al., 2016]. Which could support
either the notion of a minority of integration events with expansion in the population, as 
argued for chromosome 17p in the European populations studied here or perhaps that 
chromosome 22q represents an additional preferential site of integration. However, 
sequences of the integration site junctions at chromosome 22q or genomic data from the 
CI-HHV-6A samples which could determine the relationship of these integrated viral 
genomes has yet to be determined. 
As such, it does remain a possibility that the integration sites amplified here could 
originate from multiple integration events at the same chromosomal location or different 
homologous subtelomeric locations. However, a number of distinct features support the 
interpretation here of a shared genetic lineage between CI-HHV-6A genomes integrated 
at chromosome 17p in the populations studied here. The observation that the readily 
identifiable viral DR sequences from all of these amplified integration site junctions was 
identical, despite the DRs being amongst the most variable regions of HHV-6A/-6B 
genomes. The shared degenerate repeat structures preceding both readily identifiable 
subtelomeric and viral DR sequences. Plus the distinct phylogentic grouping of nucleotide 
sequences from these CI-HHV-6A genomes believed to be integrated at 17p, when 
compared to CI-HHV-6A/-6B samples where integration site junctions could not be 
amplified utilising the 17p primer; shown here for U51 and further in more recent work 
utilising concatenations of both conserved and variable genes (U38, U46, U51 and U83) 
from throughout these CI-HHV-6A genomes [Tweedy et al., 2016]. However, without 
confirmation of the chromosomal locations of integration or further genomic data from 
these CI-HHV-6A samples, the possibility of multiple integration events remains. As 
greater characterisation of these integrated viral forms emerges, relationships between 
the isolates integrated at different chromosomal locations should become clearer.
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Prevalence of Germ-line Integration
Integration of CI-HHV-6A at chromosome 17p appears prevalent in the samples examined 
here, in agreement with similar previous anecdotal suggestions of a high prevalence of 
integration at this chromosomal location [Morissette & Flamand, 2010]. As above, CI-HHV-
6B was found to be integrated at this chromosomal location both here and previously. This
suggest there may be some preference for integration at this chromosomal location. 
There are also differences in the relative prevalence of CI-HHV-6A and -6B with respect to 
their circulating counterparts. In American, European and Japanese populations, 
epidemiological studies have identified HHV-6B as the initial infection responsible for the 
fever and exanthem subitum disease typically associated with infection with a HHV-6 
species [Yamanishi et al., 1988; Dewhurst et al., 1993; Zerr et al., 2005a; Hall et al., 2006]. 
While estimates vary, the prevalence of HHV-6B in these populations is much higher than 
HHV-6A [Hall et al., 2006; 2008]. However, the screening here of a key viral 
immunomodulatory gene from one of the largest groups of CI-HHV-6A/-6B samples 
collated to date suggested that the prevalence of the integrated forms are in fact similar 
to one another. A feature which was further confirmed in this laboratory through the 
screening of additional loci from in these samples [Tweedy et al., 2015a] and previous 
observations about the prevalence of CI-HHV-6A and -6B [Hall et al., 2006; 2008; Leong et 
al., 2007; Hubacek et al., 2009]. 
While effects on detection may play a role in prevalence differences observed between 
HHV-6A and -6B [Leibovitch et al., 2014]. There still appears to be clear distinctions 
between the relative prevalence of the germ-line CI-HHV-6A/-6B compared to acute HHV-
6A/-6B infections. If HHV-6A and -6B possess the same integration capabilities, the 
prevalence of the integrated forms would be expected to reflect those of the circulating 
forms. These relative prevalence distinctions may reflect differences in germ-line 
integration efficiency between the two species. In this regard, HHV-6A has been shown to 
be the predominant cause of symptomatic primary infection in an African population yet 
to date CI-HHV-6A has yet to be detected in screens in African populations, although one 
CI-HHV-6B case has been defined in North Africa [Bates et al., 2009 ; Faten et al., 2012; 
Tembo et al., 2015]. While a number of factors, including human genetics could account 
for this, it may also have implications for germ-line integration efficiency. 
An additional explanation may lie in the shared origins of integrated samples implicated 
above. The higher relative prevalence of CI-HHV-6A could result from HHV-6A integration 
events which predate those of CI-HHV-6B, allowing a greater length of time for expansion 
in the population. Additionally since integration at chromosome 17p seems to be 
prevalent for CI-HHV-6A, at least in Europe, this may represent an early HHV-6A 
integration event. The multiple loci analysis preformed previously suggested greater 
divergence for CI-HHV-6A from HHV-6A than that seen for CI-HHV-6B [Tweedy et al., 
2015a]. Furthermore, the pattern of gene divergence, including all of the genes which 
define the speciation of HHV-6A and HHV-6B [Dominguez et al., 1999; Gompels & Kasolo, 
2006; Ablashi et al., 2014], observed in the chromosome 17p integrated isolate, 5055, 
could also be seen to support the idea of integration of an ancestral HHV-6A strain. 
Further screening in this, and additional geographic regions will allow differences to be 
identified. Additionally, attempts to date the integration events at chromosome 17p could
also provide insight into the origins of this integration. 
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CI-HHV-6A genome
Utilising the established NGS methods, genomic analysis of three CI-HHV-6A isolates was 
performed, representing the first characterisation of these chromosomally integrated viral
genomes. The complete UL region was derived for one strain, 2284, and conserved and 
divergent sets of genes for comparison in two further CI-HHV-6A genomes. Completion of 
the DR regions of the genomes was confounded by repetitive sequences, but the two 
genes DR1 and DR6, encoded in these regions were characterised. While these genome 
sequences remain to be fully completed, all CDS features of HHV-6A strain, as currently 
defined, are retained in CI-HHV-6A isolates with no evidence for indels outside of the 
previously identified loss of the distal pac sites from both genomic termini [Ohye et al., 
2014; Huang et al., 2014]. Additionally, retention of a number of cis acting signals required 
for lytic viral replication, and likely any potential reactivation mechanism, was also 
confirmed. Together these suggest that CI-HHV-6A isolates remain intact, thus alongside 
gene expression from the integrated genomes, lytic replication of the viral genomes is 
likely possible if a reactivation/excision mechanism exists. With one of these isolates, 5055,
confirmed to be integrated at chromosome 17p and the implications above that 
integration at this site may represent an early CI-HHV-6A integration event; there is a 
possibility that many if not all of these integrated HHV-6A/-6B genomes remain intact and 
replication competent. During the work towards this thesis, the sequencing of a CI-HHV-
6B isolate was reported, similarly indicating the integrated viral genomes remain intact 
with no disruption to defined ORFs [Huang et al., 2014]. However, this genome shared 
much closer relation to circulating HHV-6B strains, with overall less than 0.2% divergence, 
while CI-HHV-6A genomes had 3-6% divergence in some genes. The methods established 
here should be useful to further characterise CI-HHV-6A/-6B genomes directly from clinical
samples, in order to understand their genetic content and pathological associations.
Comparisons of the integrated genomes to circulating viral strains highlighted increased 
divergence at 16 genes. This was in marked contrast to the sequenced CI-HHV-6B genome,
where less than 300 SNPs were observed across the genome [Huang et al., 2014]. These 
CI-HHV-6A divergent genes included all the genes which have recently been used to define
the speciation of HHV-6A from HHV-6B [Dominguez et al., 1999; Gompels & Kasolo, 2006; 
Ablashi et al., 2014]. Including genes with roles in transcriptional regulation, virus 
infection, as well as cell cycle and immune modulation. The phylogenetic grouping of 
these genes, ancestral to HHV-6A with divergence towards that observed in sequenced 
HHV-6B strains, supports the interpretation here that the CI-HHV-6A genomes could 
represent integration events of ancestral HHV-6A isolates.
Minor variant analysis indicated the possibility of superinfection with circulating viral 
strains in two of the CI-HHV-6A samples examined. Genomic DNA from the integrated 
genomes would be in all cells, while lytic replication will produces high viral titres but this 
would only be in a minority of cells. As such the predominant sequence should be that of 
the integrated genome. However, the potential to confound sequence resolution remains,
especially in the case of low genome coverage. Sample choice should be considered in 
further characterisation of the integrated forms of these viral species.
Role of Germ-line Chromosomal Integration
The analysis of these CI-HHV-6A genomes suggests a series of rare integration events in 
the germline. In a number of ways, these germ-line integration events of HHV-6A/-6B can 
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be seen as analogous to the integration which has occurred amongst certain members of 
the Retroviridae, known as the human endogenous retroviruses (HERVs). Within the 
Retroviridae family, viral genome integration represents an obligatory step in viral 
replication. Following host cell entry of infectious virions, reverse transcription of the 
ssRNA(+) genome produces a linear dsDNA copy. A virally encoded integrase, then 
mediates random integration of the dsDNA copy into the host chromosome [Li et al., 
2006]. Unlike integration events seen in a number of other viruses, excision of the provirus
is not required for continuation of the viral life cycle, instead the provirus remains 
integrated into the cellular chromosome. This somatic integration with horizontal 
transmission via infectious virions, represents the exogenous form of retroviruses.
However, retroviruses can also be seen to exist in a vertically transmissable endogenous 
form, resulting from the integration of ancient retroviruses into the germ-line [Weiss, 
2006]. Indeed, in humans it is believed that ~8% of the human genome consists of the 
remnants of germ-line integration of ancient retroviruses [Li et al., 2001]. The majority of 
these HERVs are defective resulting from the accumulative effects of nonsense mutations,
insertions, deletions and recombination events since their original integration. However, a 
number of HERVs, primarily those representing more recent integration events such as 
the HERV-K family, retain intact ORFs with active gene expression and some even forming 
viral-like particles in certain tissues and pathologies including MS [Dewannieux et al., 2005;
Boller et al., 2008; Contreras-Galindo et al., 2015; Kurth & Bannert, 2010; Balada et al., 
2010]. Upregulation of expression from HERVs has also been noted following infection by 
other viruses, such as exogenous retroviruses [van der Kuyl, 2012; Toufaily et al., 2011; 
Perzova et al., 2011], but also notably following infection with herpesviruses, including 
HHV6A and -6B [Bergallo et al., 2015; Turcanova et al., 2009; Tai etal., 2009]. Indeed the 
simultaneous presence of HHV-6A and HERV antigens has been linked to increased cellular
immune responses, the implication being that such responses may have a role in MS 
progression [Brudek et al., 2004].
Unlike the HERVs, the integrated CI-HHV-6A genomes, at least in the case of those 
examined here, appear to be intact with regard to currently defined coding content and 
many of the cis acting signals required for viral replication, and likely any reactivation 
mechanism. The only loss being the pac 2 site from DRR, and likely the pac 1 site from DRL 
as previously observed [Ohye et al., 2014; Huang et al., 2014], which have implications for 
any proposed mechanisms of integration and possible reactivation.
Like the HERVs it appears that expression from CI-HHV-6A/-6B genomes is possible, there 
are now multiple reports of the detection of transcripts from integrated genomes 
including studies from this laboratory concerning the patients analysed in this thesis 
[Daibata et al.,1998a; Clark et al., 2006a; Strenger et al., 2014 Huang et al., 2014; Tweedy 
et al., 2015a]. Similarly, other pathogens may be able to provide a trans-activating function
to activate the integrated HHV-6A/-6B genomes [Katsafanas et al., 1996; Tanaka-Taya et 
al., 2000; Prusty et al., 2013a; Prusty et al., 2013b]. Since vertical transmission leads to the 
presence of the viral genome in every nucleated cell, gene expression and/or reactivation 
from the integrated virus has the potential to affect early development. Recent reports on
the length of the CI-HHV-6A/-6B associated telomere suggest it is frequently amongst the 
shortest in somatic cells, with the implication the integrated viral genome may be 
perturbing telomeric function resulting in rapid telomeric shortening [Huang et al., 2014]. 
Such events may have implications for reactivation of integrated genomes, discussed 
further in section 6.7. But they could also have effects on expression from the integrated 
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viral genome. For example, it has been shown that the transcription of telomeric repeat 
containing non-coding RNAs (TERRA) which start in the subtelomeric region [Azzalin et al., 
2007] can be induced by telomeric shortening [Cusanelli et al., 2013]. Which could mediate
expression from the viral genome. Furthermore, the ubiquitous presence of the 
integrated viral genome implies gene expression may also be possible in tissues normally 
non-permissive for viral replication in vivo. These and other implications of CI-HHV-6A/-6B 
for disease is considered in more detail in section 6.8.
In this context the findings here support the notion that integration of CI-HHV-6A/-6B into 
the germ-line represent a series of rare events. If reactivation of these integrated forms is 
possible, this vertical transmission could be viewed as providing a replicative advantage 
through an additional transmission route. However, the evidence points towards these 
being aberrant or artifactual events. The recent findings suggestive of somatic integration 
of HHV-6A/-6B as a mechanism of latency [Arbuckle et al., 2010; 2013], alongside those 
identifying the ability of HHV-6A/-6B to bind to the sperm acrosome [Kaspersen et al., 
2012], provide a mechanism for how these germ-line integration events may have 
occurred.
6.6 Somatic Chromosomal Integration of HHV-6A and -6B
While the focus of this work has been to characterise the inherited forms of HHV-6A and 
-6B, the mechanism underlying the germ-line integration events that gave rise to these 
inherited forms may stem from a naturally occurring mechanism utilising homologous 
recombination between cognate telomeric repeat sequences and employed during 
infection of somatic cells. As the two are likely intrinsically linked, the potential for viral 
integration during somatic infection will be considered here.
Currently, in vivo evidence for the somatic cell chromosomal integration of HHV-6A/-6B 
does not exist. However, the recent work on integration and reactivation of HHV-6A/-6B in
vitro has led to suggestions that in contrast to the formation of nuclear episomes 
observed amongst many members of the Herpesviridae, chromosomal integration 
represents an alternative mechanism for the establishment of latency by HHV-6A and -6B 
[Arbuckle et al., 2010; 2013]. This would not represent a unique feature, as similar 
strategies of host chromosomal integration for the establishment of a dormant form can 
be observed in a number of other viral groups. Indeed, as a result of early work on 
bacteriophages during the 1950s, it has long been recognised that viral genetic material 
can integrate into the genome of host cells [Lederberg & Lederberg, 1953]. Upon infection
of host cells, the viral reproduction cycle of temperate phages can proceed in two major 
ways: the lytic cycle or the lysogenic cycle. In contrast to the active production of progeny 
phages in the lytic cycle; during the lysogenic cycle integration of the viral genome into 
the bacterial chromosome results in a quiescent form of the phage genome known as a 
prophage. Periodically environmental cues act as signals of favourable viral replication 
conditions resulting in induction, whereby the integrated phage genome is excised from 
the host cell chromosome and re-enters the lytic cycle [Hendrix, 2013]. Additionally 
reproduction of a bacterium following phage integration, results in the presence of the 
prophage in both daughter cells. Theoretically allowing for indefinite replication of the 
prophage by prokaryotic replication. Thus the lysogenic cyle can be seen to provide a 
replicative advantage to the virus through the induction of a latent state until adequate 
conditions for viral replication occur. As well as an alternative route of transmission to new
host cells.
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Since the discovery of genomic integration in bacteriophages, there has been recognition 
that a number of animal viruses can also integrate into cellular genomic DNA [Choo et al., 
1987; Feng et al., 2008; Murakami et al., 2004; Belyi et al., 2010; Delecluse & 
Hammerschmidt, 1993; Kripalani-Joshi & Law 1994; Pellet et al., 2012]. As exemplified by 
the Human Papillomaviruses, many of these represent occasional aberrant integration, 
with no defined role in viral replication, noted mainly through roles in oncogenesis [Choo 
et al., 1987; Moody & Laimins, 2010]. However, for a number of viral groups cellular 
integration represents a prerequisite for viral replication or an occasional feature which 
appears to play a role in the viral replication cycle. Two in particular, Gallid herpesvirus 2 
(GaHV-2), more commonly known as Marek's Disease Virus (MDV), and the Adeno-
associated viruses (AAV), share notable similarities to the integration observed in HHV-6A 
and -6B.
Gallid herpesvirus 2 /Marek's Disease Virus
MDV is responsible for Marek's disease in chickens, which is characterised by the rapid 
development of malignant T-cell lymphomas. Due to its oncogenic nature it was originally 
classified within the Gammaherpesvirinae, however, sequencing of the viral genome 
revealed it was in fact closely related to HSV-1 and VZV and led to the classification as the 
type species of a new genus, Mardivirus, within the Alphaherpesvirinae [Tullman et al., 
2000; Osterrieder et al., 2006]. The current model of MDV pathogenesis proposes 
inhalation of virus containing dander leads to the infection of phagocytic cells in lung 
tissue and transport to main lymphoid organs [Baaten et al., 2009]. At these sites infection 
of B cells leads to transfer of the virus to activated T cells, the targets for lytic replication 
and latency, respectively. Reactivation and lytic replication of the virus following transport 
of infected cells to feather follicles permits horizontal transmission of the virus via 
shedding [Calnek 2001; Osterrieder et al., 2006]. However, in a minority of the latently 
infected CD4+ T cells transformation occurs, which are the source of the lymphoma. 
During the course of latent infection, integration of the full length genomic DNA into the 
host cell chromosome has been observed to be a common occurrence, with suggestion 
that it is potentially a requirement for the establishment of latency in MDV [Delecluse & 
Hammerschmidt, 1993; Delecluse et al., 1993; Kaufer et al., 2011]. The latent integrated 
state in turn appears to be a prerequisite for cellular transformation, as the number of 
cells harboring latent genome directly correlates with efficiency of lymphoma formation 
[Kaufer et al., 2011]. Integration preferentially occurs in the telomeric region of the host 
chromosome, although the exact location with the telomere i.e. subtelomeric, 
intratelomeric or distal remain to be determined, with no observed preference for a 
particular chromosome [Delecluse & Hammerschmidt, 1993; Delecluse et al., 1993; Kaufer 
et al., 2011]. While the mechanism still remains elusive the presence of host telomeric 
repeat sequences in the genomic terminal repeat structures [Kishi et al., 1991] and a virally
encoded telomerase subunit [Fragnet et al., 2003] likely play a role. The genomic termini 
of MDV contain arrays of telomeric repeats. In MDV, two arrays of repeats have been 
identified within the terminal repeat regions found at the ends of the genome, a short 
telomeric repeat region invariably consisting of 6 repeat units and a long telomeric repeat 
unit consisting of a variable number of repeats up to 100. Indeed, recent work utilising 
MDV telomeric repeat mutants found that the shorter of the repeat arrays was not 
essential for integration, although did affect integration efficiency. However, the longer 
variable copy number array is essential for directed insertion into host telomeres in vivo,  
[Kaufer et al., 2011; Greco et al., 2014]. In the same studies, complete deletion of the viral 
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telomeric repeat sequences still permitted integration, albeit less efficiently, into the host 
genome at non-telomeric sites suggesting an importance to this mechanism rather than 
merely a consequence of the presence of telomeric repeats. Furthermore, the evidence 
available suggests that this integration does not represent a replicative dead end with viral
replication leading to production of linear genomic DNA [Delecluse et al., 1993; Kaufer et 
al., 2011; Schermuly et al., 2015]. Again, with the viral telomeric repeats implicated for a 
key role in this process as viral repeat mutants displayed reduced reactivation efficiency 
[Kaufer et al., 2011; Greco et al., 2014]. However, the mechanism for this reactivation from
the latent integrated form remains unknown.
Adeno-Associated Viruses
The ubiquitous human parvoviruses, the adeno-associated viruses (AAVs), have also been 
shown to integrate into the host chromosome [Cheung et al.,1980; Calcedo et al., 2009]. 
These small single-stranded, linear DNA genome containing viruses possess two major 
ORFs, rep encoding four replication proteins and cap encoding three capsid protein 
[Srivastava et al., 1983]. In isolation AAVs are replication incompetent, instead for the 
production of infectious virions they require a helper virus, typically an adenovirus, 
although other viruses including the herpesviruses, HSV-1 and HHV-6A/-6B can also 
provide helper functions [Geoffroy & Salvetti, 2005; Stutika et al., 2015; Thomson et al., 
1994b]. In the absence of a helper virus, AAVs establish a latent infection, permitting long-
term persistence of the viral genome [Berns et al., 1975]. There are differing reports on 
the primary mode of how this persistence is achieved, with studies in culture indicating 
efficient integration of the viral genome into host cellular DNA, while others suggest that 
in vivo AAV genomes persist predominantly in an episomal form [Kotin et al., 1990; 
Samulski et al., 1991; Schnepp et al., 2005]. Whichever is the case, it is clear that AAV can 
establish latency through integration into the host genome following natural infection 
[Mehrle et al., 2004]. This integration has largely thought to have been highly site-specific, 
with preferential integration into a site within the protein phosphatase 1 regulatory 
subunit 12C gene found on chromosome 19q13.42, a site known as AAVS1 [Kotin et al., 
1990; Giraud et al., 1994; Linden et al., 1996]. However, more recently additional AAV 
integration sites have been noted on different chromosomes, 1q31.1, 3p24.3 and 5p13.3 
[Schnepp et al., 2005; Huser et al., 2010]. The integration of AAV is dependent upon two 
major non-cellular factors. The two largest of the replication proteins, Rep68 and Rep78 
[Weitzman et al., 1994]. In addition to Rep binding and endonuclease sites, consisting of 
GAGC repeats, found in the inverted terminal repeats located at the viral genomic termini, 
as well as present at sites in the human genome [Giraud et al., 1994; Feng et al., 2006]. The
two large Rep proteins possess a range of functions, including DNA binding, ATPase, 
endonuclease and helicase activities [McCarty et al., 1994; Wonderling et al., 1995; Im & 
Muzyckza, 1990], playing integral roles in many other aspects of viral replication. During 
the process of integration, the large Rep proteins form a complex through the binding of 
Rep binding sites present in both the viral and the cellular genome sequences [Weitzman 
et al., 1994]. Rep68 through its helicase and endonuclease activity, mediates the specific 
introduction of nick at homologous motifs found within the viral and cellular Rep binding 
sites [Lamartina et al., 2000]. The remainder of the integration mechanism has yet to be 
elucidated but has been proposed to occur through a series of DNA synthesis and strand 
switching steps involving components of the non-homologous end joining pathway 
[Henckaerts et al., 2009; Daya et al., 2009]. Following integration, certain Rep transcripts 
act to suppress viral gene expression, permitting persistence of the viral genome until 
helper virus is present [Tratschin et al., 1986]. In the presence of helper virus Rep proteins 
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switch roles to act as activators of viral gene expression, with Rep expression likely playing 
a role in release of the AAV genome from the cellular chromosome allowing active 
replication to proceed [Pereira et al., 1997; Samulski et al., 1982; Ward et al., 1994]. While 
the mechanics of this rescue mechanism remain to be determined there is some evidence 
that it may occur through a Rep mediated nick in an inverted terminal repeat of the 
integrated AAV genome followed by DNA replication [Ward et al., 2003]. Additionally, 
while not specifically associated with any human disease states, it is clear that AAV 
infection has pronounced effects on host cells, including cell cycle arrest, induction of 
apoptosis and cellular gene repression, many of which involve the viral Rep proteins 
[Berthet et al., 2005; Schmidt et al., 2000; Dutheil et al., 2014].
HHV-6A and HHV-6B
Like MDV, HHV-6A and-6B contains telomeric repeat arrays within repeat regions at their 
genomic termini and genomic integration occurs at telomeric regions of the host 
chromosome. This integration occurs at a location close to the subtelomere, with 
suggestions that it potentially occurs through a homologous recombination event 
between the perfect TTAGGG telomeric repeat arrays encoded in the T2 region of the DRR 
of the viral genome and the host chromosomal telomeric repeats. The integration event 
results in insertion of the HHV-6A or -6B genome in an orientation, where U100 is located 
towards the centromere and U1 towards the telomeric cap, as well as the loss of the pac2 
site from the DRR [Arbuckle et al., 2010; Ohyne et al., 2014; Huang et al., 2014]. The pac1 
site of the DRL is also lost during the integration event, suggesting either a second 
recombination event in the T1 region of the DRL or erosion of the pac site followed by 
telomere elongation. [Ohye et al., 2014; Huang et al., 2014]. Therefore as demonstrated 
for MDV, this implies an importance for the virally encoded telomeric repeat arrays in HHV-
6A/-6B chromosomal integration.
However, to date evidence suggests that the presence of human telomeric repeat 
sequences alone does not promote integration. Indeed genomic termini-like telomeric 
repeat sequences are also retained in a number of other distantly related herpesviruses, 
including members of the alphaherpesvirnae [Kishi et al., 1991; Tyler etal., 2011; Telford et 
al., 1995]. The conservation of these sequences could suggest an important role in viral 
function outside of integration, such as protection of the linear viral genome from cellular 
nucleases or linkage of episomal forms to the cellular chromosome. Although additionally, 
it could mean that telomeric integration events may be a feature in additional 
herpesviruses besides MDV, HHV-6A and HHV-6B. The other human roseolovirus, HHV-7, 
also possesses similar telomeric repeat sequences but to date, integration into host 
chromosomal DNA has not been noted [Hall et al., 2004]. However, the narrow tropism of 
HHV-7, preventing germ-line integration, and the minority of cells which become latently 
infected, or even just a minority of latently infected cells if multiple latency strategies can 
be employed, would make identification of possible integrated cells challenging. Such is 
the case for the identification of somatically integrated HHV-6A/-6B from clinical samples.
Observation of the insertion of a telomeric repeat lacking MDV mutants, albeit 
inefficiently, into the host chromosome [Kaufer et al., 2011] implies other factors play a 
role in the viral integration events. Likewise, there is a report of CI-HHV-6B integration at a 
non-telomeric region of chromosome 12 (12q14) [Goel at el., 2013], which could also 
suggest factors outside of the presence of telomeric repeats also play a role in HHV-6A/-
6B integration events. One likely possibility is the product of the U94 ORF, an ORF 
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encoded by both HHV-6A and -6B yet absent amongst other human herpesviruses, which 
may play a role in the promotion of integration [Thomson et al., 1991; Rapp et al., 2000]. 
U94 encodes a protein with homology (~24% amino acid identity) to the 
integrase/replicative AAV-2 Rep 68/78 proteins [Thomson et al., 1991]. The ability of HHV-
6A/-6B to act as a helper virus for AAV replication [Thomson et al., 1994b], in addition to a 
number of cases of suspected gene piracy, notably the viral chemokine and chemokine 
receptors, U83, U12 and U51 [Gompels et al 1995; Vischer et al., 2006]. Indicate a 
mechanism by which an ancestral HHV-6 member could have acquired a rep gene 
homologue. With the U94 ORF being highly conserved among HHV-6A and -B strains [Rapp
et al., 2000], expressed at high levels during latency [Rotola et al., 1998], and pU94 
possessing a role in the inhibition of viral replication [Rotola et al., 1998; Caselli et al., 
2006], it has been suggested that it may play an essential role in the establishment of 
latency. Indeed, U94 retains many of the activities of the AAV Rep proteins, namely single 
stranded DNA binding activities to telomeric repeat containg regions [Mori et al., 2000; 
Dhepakson et al., 2002; Caselli et al., 2006; Trempe et al., 2015], 3'-5' exonuclease, ATPase 
and helicase activities [Trempe et al., 2015] and can functionally complement a AAV-2 Rep 
deletion mutant [Thomson et al., 1994b]. Additionally, there is some indication that these 
activities of U94 can also disrupt the host chromosome telomeric D-loop [Trempe et al., 
2015], the displacement loop created by strand invasion of the G-overhang found at the 
chromosomal terminus, to allow formation the T-loop structures that protect the 
chromsome ends [O'Sullivan & Karlseder, 2010]. Thus U94 may play a similar role in the 
HHV-6A and HHV-6B replication cycle, including the possibility of involvement in 
integration of viral genomic DNA.
Thus like the integration observed for MDV and AAV, somatic integration could play a role 
in HHV-6A/-6B latency. Chromosomal integration could be seen to be particularly 
advantageous in HHV-6A/-6B due to the high turnover rate of many of productively 
infected cell types. Ensuring maintenance of the viral genome during cell division. The site 
of integration of the telomeres has also been suggested to be important for latency. For 
example, silencing of genes in close proximity to telomeres has been noted [Baur et al., 
2001]. Aiding to limit expression of viral transcripts which could trigger immune 
responses. However, telomeres also represent dynamic structures and the transcription of 
telomeric repeat containing non-coding RNAs (TERRA) is a feature of this [Azzalin et al., 
2007]. Additionally U94 is expressed at high levels during latency and inhibits viral 
replication [Rotola et al., 1998; Caselli et al., 2006]. So analogous to the AAV Rep transcript
mediated suppression of viral gene expression, U94 may play an important role. Finally if 
HHV-6A/-6B integration does represent a bona fide mechanism of latency, a reactivation 
mechanism must exist for excision of the viral genome from the cellular chromosome in a 
form that would permit lytic replication to proceed.   
6.7 Reactivation of Integrated HHV-6A/-6B
In addition to the gene expression shown in the cohort of CI-HHV-6A/-6B patients analysed
in this laboratory, there is increasing evidence emerging with regard to the reactivation of 
CI-HHV-6A and -6B. Treatment of PBMCs from CI-HHV-6 patients and a CI-HHV-6 cell line 
with trichostatin A (TSA) and to a lesser extent 12-O-tetradecanoyl-13 acetate (TPA), 
compounds known to reactivate latent herpesviruses, could reactivate both CI-HHV-6A 
and -B to produce infectious virions [Arbuckle et al., 2010; Arbuckle & Medveczky, 2011; 
Arbuckle et al., 2013]. The sequence of the gB gene in transplacentally acquired HHV-6A 
cases was shown to be identical to that of the mothers CI-HHV-6A yet divergent from 
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other known HHV-6 isolates, implicating transmission of reactivated CI-HHV-6A [Gravel et 
al., 2013b]. Similarly, in the case of a patient with X-linked severe combined 
immunodeficiency (X-SCID) and inherited CI-HHV-6A on chromosome 22, both RT-PCR 
detection of viral RNA and isolated virus were identical to the integrated virus from both 
the patient and father, yet distinct from known circulating strains [Endo et al., 2014]. 
Extra-chromosomal HHV-6A/-6B DNA has also been noted following Chlamydia 
trachomatis infection of CI-HHV-6A/-6B cells lines and PBMCs from patients with CI-HHV-
6A/-6B [Prusty et al., 2013a; Prusty et al., 2013b]. While frequent detection of transcripts 
from an inhibitor of viral replication, U94, during latency [Rotola et al., 1998; Caselli et al., 
2006], as well as spliced transcripts from the the IE transactivator, U90 [Kondo et al., 2002; 
Kondo et al., 2003; Huang et al., 2014], also support a role for integration as a mechanism 
of latency.
Thus like MDV and AAV, there appears to be a mechanism for excision of the viral genome 
from the cellular chromosome, and circularisation of the genome that would permit active
viral replication in permissive cells. This is similar to the involvement of the Rep proteins of
AAV in reactivation. HHV-6A/-6B U94 could potentially play a role in excision of the viral 
genome. There is evidence that U94 can disrupt the host chromosome telomeric D-loop 
[Trempe et al., 2015]. However, Rep mediated excision requires endonuclease activity, 
which was not detected for U94 [Ward et al., 2003; Trempe et al., 2015]. Also with AAV 
possessing a ssDNA genome, the proposed mechanism does not seem to fit for the 
excision of the dsDNA HHV-6A/-6B genome. Similarly, the dsDNA genome of MDV is 
excised from a telomeric region in the apparent absence of a Rep homologue [Delecluse 
et al., 1993; Kaufer et al., 2011; Schermuly et al., 2015]. While this mechanism of MDV 
reactivation is yet to be defined, the viral telomeric repeats appear to play a key role 
[Kaufer et al., 2011; Greco et al., 2014]. 
Two groups have noted extra-chromosomal circular molecules consisting of viral genomic 
DNA with a single complete DR [Huang et al., 2014; Prusty et al., 2013b]. Providing 
compelling evidence supporting the hypothesis that a t-loop/t-circle excision mechanism, 
could permit viral reactivation. In this model, strand invasion into the T1 region of DRR 
mediated by the telomeric repeats permits the excision of a circular viral genomic 
structure which has the potential to act as a template for rolling circle replication 
generating concatameric genomes with intact DRs and pac sites, as observed in infectious 
virions. Implying an importance to the virally encoded telomeric repeat sequences for 
reactivation, like that seen in MDV. Additionally, even if viral replication cannot be 
completed, the possibility for excision and re-integration into the cellular chromosome as 
a transposable element cannot be ruled out.
There was implication that this t-circle formation may be increased by telomere shortening
[Prusty et al., 2013b]. As suggested earlier, TERRA transcripts could play a role in 
expression from the integrated viral genome through induction at shortened telomeres 
[Cusanelli et al., 2013]. However, certain TERRA transcripts or aberrant TERRA 
transcription has also been associated with telomere shortening [Pfeiffer & Lingner, 2012; 
Maicher et al., 2012]. Thus the integrated viral genome may actually be interfering with 
TERRA associated mechanisms alongside inducing them, in turn facilitating excision via the
proposed t-circle excision mechanism through a feedback loop. 
Prusty and colleagues also found that telomere shortening was induced by Chlamydia 
trachomatis infection [Prusty et al., 2013a; Prusty et al., 2013b]. Superinfection with HHV-7 
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has also been shown to reactivate latent HHV-6B [Katsafanas et al., 1996; Tanaka-Taya et 
al., 2000]. Additionally, the minor variant analysis performed here also suggested that 
superinfection with HHV-6A/-6B was associated with expression from the integrated 
genomes. Thus infection with exogenous viruses could also promote reactivation by a 
similar mechanism. Even in the absence of reactivation, co-infection of CI-HHV-6A/-6B cells
with a circulating HHV-6A/-6B strain could have the potential for recombination. In this 
regard, the multiple loci analysis performed previously in this laboratory on these 
integrated genomes noted cases of intra- and inter-genic recombination [Tweedy et al., 
2015a]. Recombination with superinfecting virus could potentially provide sources of 
divergent genes/variation for exogenous HHV-6A/-6B strains.
6.8 Functional Consequences of CI-HHV-6A/-6B
Pathological associations with CI-HHV-6A/-6B are only beginning to be assessed. To date, 
the most apparent consequence of germ-line integrated HHV-6A/-6B appears to be the 
misdiagnosis of active HHV-6 infection with subsequent unnecessary treatment [Clark & 
Ward, 2008]. With regard to directly associated pathologies, while there have been some 
implications due to the higher presence of CIHHV-6A/-6B in certain conditions, other 
studies have provided conflicting results [Pellet et al., 2012; Morissette & Flamand, 2010; 
Hubacek et al., 2009; Hill et al., 2015]. As such definitive links between many pathologies 
and CI-HHV-6A/-6B remain largely undefined.
However, there is speculation about a number of possible consequences of CI-HHV-6A/-6B,
although these might not be present in each CI-HHV-6A/-6B individual. Firstly, integration 
of the virus into the telomeric regions of the host chromosome may have profound effects
on the integrity of the chromosome. Indeed in somatic cells disruption of the telomere 
function on the integrated chromosome appears to be associated with telomeric 
shortening [Huang et al., 2014]. Thus hastening of the onset of cellular senescence may be
a feature directly related to the integration of the viral genome [Shay & Wright, 2005]. 
Dysfunction of the telomeric region is also linked to a number of different disease states 
[O'Sullivan et al., 2002; Sahin et al., 2011], while a role in chromosomal instability could 
also be a factor in progression to cancer [Jefford & Irminger-Finger, 2006]. These would 
also likely be a factor in somatic cell integration for latency, in non-CI-HHV-6A/-6B 
individuals. Second there could be gene expression. Studies in addition to those on the 
cohort reported here have shown that expression of genes from all of the different kinetic
classes can occur from CI-HHV-6A/-6B genomes, including some potentially important 
inflammatory modulators, U51 and U83 [Daibata et al.,1998a; Clark et al., 2006a; Strenger 
et al., 2014; Tweedy et al., 2015a]. Third, reactivation of the integrated viral genomes 
could occur, as discussed above. Thus effects may be mediated by viral gene expression 
and/or replication, alongside any disruption of the host chromosome. Although, whether 
infectious virus is produced is still under evaluation.
Since CI-HHV-6A/-6B is transmitted vertically there may also be development implications. 
Recent evidence has led to suggestions of the existence of a condition termed inherited 
herpesvirus 6 syndrome (IHS) [Pantry et al., 2013]. Individuals with CI-HHV-6A/-6B had 
previously been noted as possessing a decreased humoural response to an important 
HHV-6 antigen, gB, in comparison to a healthy population sample [Tanaka-Taya et al., 
2004]. In addition, antiviral use for the successful resolution of clinical symptoms (and 
subsequent relapses upon cessation of treatment) in two CI-HHV-6A patients displaying 
cognitive dysfunction, suggested symptomatic reactivation of CI-HHV-6A or a reduced 
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resistance to circulating HHV-6A/-6B strains could play a role in disease [Montoya et al., 
2012]. Subsequently, the demonstration that the sequence of late HHV-6 mRNAs from CI-
HHV-6A patients presenting with neurological disease differed markedly from the 
sequence of the inherited viral genome, led to the suggestions of the existence of IHS 
[Pantry et al., 2013]. In which individuals with inherited CI-HHV-6A may possess a level of 
immune tolerance or a weakened immune response to HHV-6A antigens, resulting in an 
increased risk of persistent exogenous infections and associated disease states. 
Additionally, evidence has been presented that congenital HHV-6A/-6B, occuring primarily 
from vertical transmission of CI-HHV-6A/-6B, has negative effects on neurodevelopment 
[Hall et al., 2008; 2010; Caserta et al., 2014].
HHV-6A/-6B infection has long been associated with inflammatory pathology. Similarly, CI-
HHV-6A/-6B also has links to inflammatory disease states. A recent study has found links 
between persistent myocardial complications and CI-HHV-6A/-6B, with symptomatic 
episodes associated with viral gene expression and detection of viral particles in 
degenerating myocytes and interstitial cells [Kuhl et al., 2015]. Both symptoms and 
detection of viral mRNA were abolished with antiviral treatment. This was in the same 
patient cohort analysed here. Furthermore, a recent large scale analysis has also found CI-
HHV-6A/-6B to be a risk factor in the development of angina, with the prevalence more 
than three times greater in CI-HHV-6A/-6B than control groups [Gravel et al., 2015]. The 
implication being that expression from the integrated viral genome and/or reactivation 
leads to immune activation with cellular damage that promotes myocardial complications.
Finally, there may also be implications for the use of samples from donors with inherited 
CI-HHV-6A and/or -6B [Flamand et al., 2010]. Where highly immunsuppressive states may 
permit more frequent viral reactivation.
6.9 CI-HHV-6A U51
While many are regarded as dispensable for viral replication in vitro, the extensive 
presence of genes which share homology to chemokine and chemokine receptors 
amongst the β- and γ- herpesviruses suggests a key significance to these genes to in vivo 
replication of these viruses. It is also clear that these virally encoded modulators of the 
chemokine system are all highly divergent in both sequence and signalling activities. 
Implying specific roles for these genes in each individual viral species related to their 
respective tissue tropisms and replication cycles, rather than a more generalised function 
amongst all herpesviruses. For example, even between the two closely related HHV-6 
species, significant variation can be observed in function with U83B an agonist of CCR2 
[Zou et al., 1999; Luttichau et al., 2003; Clark et al., 2013], while U83A is a highly potency 
agonist for CCR1, CCR4, CCR5, CCR6 and CCR8 [Dewin et al., 2006; Catusse et al., 2007; 
Clark et al., 2013].
Although clearly distinct analogies can be noted between U51 and one of the viral GPCRs 
encoded by the betaherpesvirus HCMV. HCMV encodes four chemokine-like GPCRs, US27, 
US28, UL33 and UL78 [Chee et al., 1990; Gompels et al., 1995]. While HHV-6A/-6B U51 is a 
positional homologue of HCMV UL78, there are significant differences between these 
GPCRs. Notably, the lack of constitutive signalling and apparent ligand binding displayed 
by UL78. Instead, HHV-6A U51 appears to share more similarities with the most extensively
studied of these HCMV GPCRs, US28, notably in its multiple ligand specificity across 
different chemokine ligand classes.
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HCMV US28
US28 is transcribed as an early lytic gene with the ability to act as a high affinity 
promiscuous β-chemokine (CCL2, CCL3, CCL4 and CCL5) [Neote et al., 1993; Gao & Murphy,
1994; Kuhn et al., 1995; Vieira et al., 1998; Billstrom et al., 1998] and δ-chemokine 
(CX3CL1) binding GPCR [Casarosa et al., 2001]. This feature in conjunction with its ability to
undergo constitutive endocytosis and recycling via multiple routes [Fraile-Ramos et al., 
2001; Droese et al., 2004] has led to the suggestion that pUS28 can sequester CC 
chemokines from the microenvironment thereby acting as a chemokine sink for immune 
evasion [Bodaghi et al., 1998; Vieira et al., 1998; Randolph-Habecker et al., 2002]. 
However, others have challenged this notion by suggesting that physiological 
concentrations of chemokines are too high to be efficiently scavenged by US28 [Boomker 
et al., 2006a].
The signalling capabilities of pUS28 are highly complex. It is a constitutively active vGPCR 
[Casarosa et al., 2001; Minisin et al., 2003], with two recent crystal structures of US28 
suggesting the evolution of an amino acid network in the transmembrane domain of the 
receptor which destabilises the receptors inactive state [Burg et al., 2015]. This 
constitutive activity can be differentially modulated by binding of its β- and  δ-chemokine 
ligands [Vomaske et al., 2009a]. Leading to ligand-specific and cell type-specific activation 
of alternative signalling pathways [Vomaske et al., 2009b], through coupling to multiple 
subclasses of G proteins (Gαi, Gα16, Gαq/11 and Gα12 ) [Billstrom et al., 1998; Casarosa et al., 
2001; Melnychuk et al., 2004] and Gβγ signalling [Casarosa et al., 2001]. The signaling 
pathways utilised by US28, have been extensively reviewed recently [Vischer et al., 2014] 
so will not be fully discussed here, however, some of the major functions attributed to this
signalling by pUS28 will be described below. 
Constitutive signalling activity has been shown to be directly linked to modulation of the 
intracellular environment for activation of the HCMV lytic cycle, through transactivation of
the HCMV major immediate-early promoter [Boomker et al., 2006b]. The constitutive 
signalling activity of pUS28 has also been implicated in an oncomodulatory role which 
promotes tumourigenesis. pUS28 expression upregulates the expression of vascular 
endothelial growth factor (VEGF) and Interleukin-6 (IL-6) and positively modulates β-
catenin signalling leading to enhanced cell cycle progression and transformation of cells in
vitro and the promotion of tumour formation in vivo which may be further enhanced by 
inflammatory chemokines (CCL2) [Maussang et al., 2006; Maussang et al., 2009; Bongers et
al., 2010; Slinger et al., 2010; Langemeijer et al., 2012]. pUS28 is also an important 
mediator of the movement of infected cells. Its signalling capabilities can directly promote
chemotaxis of primary arterial smooth muscle cells (SMCs) in the presence of 
constitutively produced CCL2 [Streblow et al., 1999]. It is hypothesised this virus mediated 
chemotaxis of infected cells to sites of inflammation provides a mechanism for the 
transmission of HCMV to macrophages and subsequent dissemination throughout the 
body. However, the migration of virally infected cells to inflammatory sites also provides a 
molecular basis for the link between HCMV infection and acceleration of vascular disease 
[Streblow et al., 1999]. In addition, pUS28 has been demonstrated to increase the motility 
of infected cells on a CX3CL1-modified surface, used to simulate an activated endothelial 
surface, thereby potentially modifying their recruitment and dispersal in vivo [Hjorto et al., 
2013]. The expression of pUS28 in latently infected monocytes has also led to suggestions 
of a role HCMV mediated manipulation of the dissemination of latently infected cells 
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[Beisser et al., 2001]. Finally the fact that pUS28 can bind different viral proteins has led to 
suggestions it may serve a role in HCMV dissemination through the enhancement of cell-
cell fusion [Pleskoff et al., 1998].
HHV-6A U51
The aim in this work was to assess the functional significance of variation in the amino-
terminal domain of U51A noted in all CI-HHV-6A samples examined here, in addition to 
HHV-6A strains GS and AJ. The implication being that the ligand binding profile of this 
U51A variant in the integrated genomes may differ from that of strain U1102, which has 
been used almost exclusively in the characterisation of U51A, to date. This may be 
important since HHV-6A is frequently associated with inflammatory pathology, which in 
part likely stems from dysregulation of the chemokine system, therefore in CI-HHV-6A 
patients there could be distinct immunomodulatory effects, such as the case of the 
myocarditis patients characterised here.
Similar to US28, U51A displays high levels of constitutive activity not frequently observed 
amongst human GPCRs [Fitzsimons et al., 2006; Catusse et al., 2008; Smit et al., 2007]. 
Constitutive activity which can be modulated to multiple subclasses of G proteins through 
differential binding of a promiscuous ligand binding profile, encompassing ligands from 
multiple chemokine groups [Milne et al., 2000; Fitzsimons et al., 2006; Catusse et al., 
2008]. Constitutive activity by HHV-6A pU51 has been shown to specifically lead to the 
transcriptional down-regulation of two cellular targets. Firstly, CCL5, which has been 
demonstrated in both epithelial and haematopoietic cell lines, where its roles have been 
hypothesised to include immune evasion or modulation of recruitment of circulating 
inflammatory cells for systemic spread of the virus [Milne et al., 2000; Caruso et al. 2003; 
Catusse et al., 2008]. The second cellular target specifically down-regulated by HHV-6A 
pU51 is FOG-2 in a haematopoietic cell line, FOG-2 is a transcriptional repressor which may 
have a role in influencing the Th1/Th2 balance by repressing Th2 development, which may 
also contribute to cardiac and inflammatory complications [Catusse et al., 2008]. RNAi 
studies have also implicated constitutive signalling of U51 to have role in aiding viral 
replication through a role in direct cell-to-cell fusion [Zhen et al., 2005]. 
The functions of ligand binding and differential signalling remain largely undefined. 
However, decreased PLC activation and abolishment of the inhibition of CRE-mediated 
gene transcription, compared to levels seen for the constitutively active receptor state are
noted [Fitzsimons et al., 2006]. Making it clear that distinct changes to the intracellular 
environment occur in response to ligand binding, perhaps as an immune evasion strategy. 
Or alternatively like US28, to permit chemotactic responses to ligands for dissemination, 
such as that proposed for the CCL11 and CCL19 activity of U51 in dissemination to the 
lung and lymph nodes, respectively [Catusse et al., 2008]. Additionally, a 'chemokine sink' 
role as suggested for many other vGPCRs, also cannot be ruled out.
Therefore changes to the ligand binding specificity or even affinity of U51A have the 
potential to have significant effects on function in the viral life cycle or virally mediated 
pathology. While the functional significance of this amino-terminal variation could not be 
determined here. A panel of mutant receptor expression vectors has been constructed, 
which can hopefully shed light on this in the future. Additionally, the amino terminal 
alanine-scanning mutants may also have utility in the investigation of potential post-
translational modifications. Since tyrosine sulfation and N- and O-linked glycosylation are 
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frequent features on this domain of a number of human and viral chemokine receptors 
[Szpakowskaet al., 2012; Paulsen et al., 2005; Marguilies & Gibson, 2007; Feng et al., 2010; 
Wu et al., 2015]. Finally since RNAi downregulation of U51 negatively impacts viral 
replication, understanding the binding interactions may have utility in the design of novel 
therapeutics. Recently, the receptor-ligand interaction properties of US28 have been 
utilised to direct toxin fusion proteins to HCMV infected cells, with promising anti-viral 
activity in vitro and in vivo [Spiess et al., 2015].
6.10 Future Work
Completion of the genome sequences of the CI-HHV-6A isolates examined here should be 
one of the first major goals. For the UL region of the genomes, this represents an easily 
obtainable goal through the inclusion of the under represented amplicons in further NGS 
runs. While the completed UL region of isolate 2284 could also be utilised as a reference 
template for assembly. Resolution of the DRs and the repeat regions found amongst the 
UL region likely requires more extensive Sanger sequencing, however, the de novo 
assembly information available for these regions should help to guide such efforts. 
Further genome sequences of both CI-HHV-6A/-6B and HHV-6A/-6B will be able to give a 
clearer understanding of the relationships of these integrated forms to both exogenous 
viral strains as well as amongst the integrated isolates themselves. Information that will 
help in confirming many of the assertions made here about ancestral relationships 
between integrated viral genomes as well as the observed divergence. Attempts to 
finalise these sequences within this laboratory are currently ongoing.
Since analysis of integration site junctions at the subtelomeric region of chromosome 17p 
here, suggested a shared genetic lineage. NGS sequencing of any of the 18 further isolates
suspected to be integrated at this chromosomal with subsequent phylogentic analyses 
would help to further confirm this suggestions. Confirmation of this would then hopefully 
open the avenue to attempts to date the timing of the integration event at this 
chromosomal location. However, differing host and viral mutation rates, plus the potential
for recombination with exogenous HHV-6A strains may prove problematic, in such 
attempts.
It would also be of merit to determine the chromosomal location of integration for the 
remainder of isolates subjected to whole genomes NGS. Inverse PCR from locations within
the viral DRR, as previously utilised for CI-HHV-6A/-6B [Arbuckle et al., 2010; Huang et al., 
2014], likely represents the best method to achieve characterisation of previously 
undefined chromosomal integration sites. This would allow better characterisation of the 
genetic relationships between the CI-HHV-6A/-6B viral genomes, potentially integrated at 
different chromosomal locations. As well as defining the sequence of further integration 
site junctions, which may prove valuable in providing insight into the mechanism of viral 
integration into the subtelomeric region in both germ-line integration events as well as 
potential somatic integration for the establishment of latency.
Additionally, such analyses could be extended to the whole set of CI-HHV-6A/6B isolates. 
Since multi loci analysis has previously been performed on this set of isolates, reported in 
Tweedy et al., 2015a, comparisons of the chromosomal integration site location with 
phylogentic analyses at these loci could also help to determine if there are relationships 
between integrated genomes at different chromosomal locations. Although the possibility
of the derivation of more complete genomes utilising the methodology described here 
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would provide a much greater level of insight.
Further characterisation of integrated genomes can be achieved by the application of NGS 
methodology, such as that described here, to sequencing of additional CI-HHV-6A/-6B or 
HHV-6A/-6B isolates, alongside more extensive deep sequencing techniques to analyse 
viral populations, and expression of small protein and small RNA species. This will be key in
determining the mechanisms underlying the control of viral latency and subsequent 
switches to a reactivated state. An additional consideration will be understanding the 
implication of the increasing complexity to the control of HHV-6A/-6B gene expression 
which is just beginning to be appreciated for other herpesviruses [Arias et al., 2014; Stern-
Ginossar et al., 2012; Dolken et al., 2009]. Further, much of the mechanisms underlying 
both viral integration and reactivation are still to be elucidated. With the viral telomeric 
repeats and U94 identified as likely contributing factors attempts, targeted genetic 
manipulation of these features utilising previously generated HHV-6A/-6B BACs 
[Borenstein & Frenkel, 2009; Tang et al., 2010] will be important in functional assessment 
of their roles in integration, latency and reactivation mechanisms.
With regard to U51, there remains a panel of U51 mutants which remain to be functionally
assessed if levels of surface expression can be improved. Alternatively assessment of the 
amino-terminal domain in isolation remains a possibility, for example with analyses 
utilising surface plasmon resonance [Majka & Speck, 2007]. While this would not permit 
determination of receptor activation, the affinity and kinetics of the interactions between 
the amino-terminal domain and various ligands could be assessed. Additionally there is still
likely importance in investigating the consequences of the charge changes noted in the 
ECL regions of the receptor, since recent reports on the crystal structures of US28 bound 
to its chemokine ligand CX3CL1 implicated found such residues to be involved in the 'site 
2' interactions that determine receptor activation [Burg et al., 2015]. Thus understanding 
of the mechanism of U51A binding and activation could help to with the development of 
small molecule inhibitors which could be utilised as intervention strategies due to the 
noted ability of U51 knockdown having significant impact on viral replication [Zhen et al., 
2005].
6.11 Concluding Remarks
The work described in this thesis has begun to characterise the germ-line chromosomally 
integrated form of HHV-6A/-6B. Methods were established to allow the NGS of CI-HHV-
6A/-6B genomic DNA directly from clinical samples, with confirmation through sequencing
of HHV-6A strain AJ. Analyses of CI-HHV-6A integration sites on chromosome 17 supports 
the interpretation of a single ancestral germ-line integration event. While genomic 
analyses revealed CI-HHV-6A retains the full HHV-6A gene complement and cis acting 
signals required for viral replication/reactivation. However, the CI-HHV-6A genomes 
diverged as a set of genes which are markers of speciation amongst roseoloviruses. 
Overall, the results define unique characters of these germ-line integrated genomes 
compared to circulating viral strains. 
Gene expression appears possible from these integrated genomes. Additionally, there is 
ever increasing support to the notion that somatic integration of HHV-6A/-6B may 
represent a mechanism for viral latency. In which case a mechanism for viral reactivation 
from the chromosomally integrated forms must exist. Therefore reactivation/gene 
expression with possible recombination with exogenous strains suggest that the 
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expansion of the integrated form in the human population could serve as source of 
emergent infection. The potential effects of this gene expression/reactivation on human 
health are only beginning to be understood. Further understanding of the mechanisms 
underlying this integration and reactivation may help in the development of therapeutic 
strategies to perturb the health effects of both CI-HHV-6A/-6B and HHV-6A/-6B.
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Chapter 7: Appendices
7.1 The Human Chemokine System
7.1.1 Introduction
Chemotaxis describes the directional movement of leukocytes in response to a 
concentration gradient of an environmental stimulus. Chemokines, chemotactic 
cytokines, are a specific class of small, low molecular weight cytokines which when 
released from a cell establish a concentration gradient, along which a responding cell can 
move. For chemokines it is engagement of a cell surface receptor of the rhodopsin-like G 
protein-coupled receptor (GPCR) family, known as a chemokine receptor, that initiates 
intracellular signalling in the responding cell. This signalling through the orchestrated 
polymerisation of cytoskeletal actin filaments, myosin-mediated contraction and increased
adhesive interactions with the extracellular matrix and adhesion molecules, ultimately 
leads to movement of the cell up the established chemokine concentration gradient; that 
is from a region of low concentration towards a region of high concentration in the vicinity
of the source of the chemokine production. This mechanism thereby allows the targeted 
movement, or chemotaxis, of specific cells to specific sites or tissues within the host based
upon both the expression of a chemokine gene at the source and the expression of 
relevant chemokine receptor genes by responding cells. While this definition still stands, it 
is becoming increasingly clear that the chemokine system plays an array of different roles 
in the responding cells alongside directing motility.
The chemokine superfamily represents a large, diverse and rapidly evolving gene family. 
Since their emergence numerous en bloc and tandem gene duplication events and 
subsequent divergence have given rise to a large number of genes encoding both 
chemokines and chemokine receptors [Zlotnik et al. 2006; Nomiyama et al. 2010]. In 
humans this has led to a chemokine gene family consisting of over 40 members and a 
chemokine receptor family with over 20 members [Pease & Williams, 2006]. Within the 
chemokine system there appears to be a high level of redundancy as receptors are often 
highly promiscuous, binding multiple ligands and ligands also binding to multiple 
receptors (figure 1.6). However, in recent years a number of challenges to the notion of 
this high level of redundancy have arisen. It has been proposed that responding cells are 
often expressing multiple chemokine receptors and will be responding to a multiplicity of 
chemokine ligands within their environment, the signals of which in turn are integrated 
into the appropriate response. As such this apparent redundancy may represent a 
mechanism for fine-tuning the regulation of chemotactic responses [Rajagopalan & 
Rajarathnam 2006]. Regardless, the potential promiscuous binding and differential 
expression profiles create great complexity in the understanding of the chemokine 
system, which is further compounded by factors such as post-translational modifications 
of chemokines, the differential affinities of ligands at a specific receptor or between a 
ligands receptors, the ability of different chemokines to initiate differential signalling 
pathways through the same receptor, and again the components of these signalling 
pathways may vary in a cell type specific manner [Schall & Proudfoot, 2011].
While the chemokine system was originally recognised as a pro-inflammatory mediator for 
its role in the control of haematopoietic cell migration during immune challenge. The 
advent and utilisation of genome sequencing and bioinformatics in particular, in 
combination with a number of readily identifiable characteristic features of chemokines 
145
and their receptors, as described in sections 7.1.2 and 7.1.3, led to the discovery of many 
new chemokines and chemokine receptors, and the subsequent identification of a number
of additional roles they play in physiological processes such as leukocyte homing and 
development, immune surveillance, angiogenesis/angiostasis, wound healing, cell 
activation, maturation and differentiation. As well as roles in a huge variety of pathological
processes including autoimmune diseases, cancer, transplant rejections and microbial 
infections [Rossi & Zlotnik, 2000; Mackay, 2001; Fernandez & Lolis, 2002].
7.1.2 Chemokines
Chemokines are the largest family of cytokines identified. They are secreted proteins, with
the noted exceptions of CX3CL1 and CXCL16 which have membrane anchored forms 
allowing them to also act as adhesion molecules [Bazan et al., 1997; Matloubian et al., 
2000]. Mature chemokines are 8-14 kDa, basic proteins which even in cases of low overall 
sequence identity adopt a similar tertiary folding as determined by X-ray crystallography 
and/or NMR [Allen et al., 2007]. This tertiary structure is maintained by the presence of 
disulphide bonds between four conserved cysteine residues. (figure 7.1). The spacing 
between the first and second of these cysteine residues is used to classify the mammalian 
chemokines into four groups: CXC (a.k.a. α), CC (a.k.a. β), XC (a.k.a. γ) and CX3C (a.k.a. δ); 
with each chemokine being assigned an 'L' as signifier for 'ligand' and an identifying arabic 
number. Currently there are 17 α-chemokines designated CXCL1-CXCL17; 28 β-
chemokines designated CCL1-CCL28; 2 γ-chemokines designated XCL1-XCL2 and a single 
δ-chemokine CX3CL1, formally recognised [Zlotnik & Yoshie, 2000; Bacon et al., 2002; 
Zlotnik & Yoshie, 2012]. However, the existence of isoforms and alternatively spliced 
variants plus the possibility of post-translational modifications can be considered to 
greatly increase the number of functional chemokines.
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Figure 7.1 Schematic representation of the structural motifs which retain chemokine tertiary
structure and define the four chemokine subfamilies. Beta sheet structures are depicted as arrows.
Disulphide bonds between the conserved cysteine residues are represented by dashed lines. The
CX3C chemokine is depicted with a transmembrane domain [Figure from Frederick & Clayman,
2001].
In addition to these structural criteria, chemokines may also be classified into two groups 
upon the basis of function: homeostatic and inflammatory chemokines (figure 1.6). The 
homeostatic chemokines are typically constitutively expressed in organs and tissues in the 
absence of inflammatory stimuli, resulting in leukocyte trafficking important during 
normally occurring processes such as immune cell maturation or immune surveillance. 
While inflammatory chemokines are predominantly only expressed by monocytic, 
epithelial, endothelial or fibroblastic cells in response to pro-inflammatory stimuli, to 
initiate the migration of leukocytes to inflammatory sites as well as activating other 
mediators of immune responses and wound healing. Typically, chemokines belonging to 
the homeostatic category are considered to bind a single receptor to exert their 
function(s), while the inflammatory chemokines display a more promiscuous receptor 
binding profile. However, as with many aspects of the chemokine system, the division of 
chemokines into these groups is not absolute, with a number falling into both categories 
[Allen et al., 2007].
While the interaction of chemokines with their respective receptors is the major 
interaction defining chemokine activity it is not the only interaction important for 
chemokine function. In vivo, predominantly on luminal surface of endothelial cells, certain 
chemokines also undergo essential lower-affinity interactions with glycosaminoglycan 
(GAG) moieties of proteoglycans; although the affinities and GAG specificities can vary 
widely, representing another mechanisms for the control of their site specific expression 
[Proudfoot et al., 2003; Witt & Lander, 1994; Kuschert et al., 1999]. GAGs are highly 
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charged, highly sulfated and heterogeneous polysaccharides which, while expressed by 
nearly all mammalian cells, possess expression patterns which can be varied, for example, 
upon a different pathological state [Mortier et al., 2012]. It is an electrostatic interaction 
between the negative charge on GAGs and the predominantly basic chemokine protein 
which is thought to be primarily be responsible for binding [Hileman et al., 1998; 
Proudfoot, 2006]. While these GAG interactions are essential for the activity of certain 
chemokines in vivo, the exact mechanism still remains uncertain. It is believed that in vivo 
the secretion of chemokines alone, especially in presence of shear forces of blood flow, is 
not sufficient for the establishment and maintenance of the gradient required for 
leukocyte chemotaxis. As such the chemokine-GAG interaction permits a mechanism for 
localisation through establishment of the chemokine gradient [Handel et al., 2005]. 
However, the possibility that chemokine-GAG interactions may contribute to other 
important chemotactic processes, such as leukocyte arrest, protection from proteolysis 
and transcytosis of chemokines across the endothelium, still remains [Middleton et al., 
2002; Salanga & Handel 2011].
In addition to the interaction with GAGs, many chemokines also possess the ability to form 
both homo- and hetero-oligomers both in solution at high concentrations and in the 
presence of GAGs [Handel et al., 2005; Proudfoot, 2006; Salanga & Handel 2011]. It should 
be noted that a number of chemokines exist in naturally occurring obligate monomeric 
forms, such as CCL1, CCL7 and CCL11[Proudfoot et al., 2003]. While there is some 
evidence suggesting that these higher order oligomers may play a role in vivo, such as by 
increasing the affinity for GAGs or potentially modulating chemokine function, the true 
role of such structures remains unclear [Salanga & Handel 2011]. However, despite the 
existence of oligomeric forms, it is now generally accepted that the interaction of the 
chemokine with the receptor responsible for receptor activation and chemotaxis, occurs 
via the monomeric form. This was elucidated through the generation of obligate 
mononmeric mutants of a number of chemokines, CCL2, CCL3, CCL4, CCL5 and CXCL8. 
These obligate monomeric mutants failed to induce chemotaxis in in vivo migration assays 
however, they retained wild-type receptor binding affinities and chemotactic activity in 
vitro [Paavola et al., 1998; Handel et al., 2008; Avalos et al., 1994; Laurence et al., 2000; 
Proudfoot et al., 2003; Rajarathnam et al., 1994]. Thus it seems while oligomeric forms 
may to play a role in chemotactic responses in vivo, at least in the case of some 
chemokines, the actual chemokine-chemokine receptor interaction which leads to 
receptor activation and induction of cellular movement occurs via the monomeric 
chemokine form.
7.1.3 G Protein-Coupled Chemokine Receptors
Chemokine signals are transduced across the plasma membrane of responding cells 
through engagement of cell surface receptors of the G protein-coupled receptor 
superfamily (GPCRs). One of the predominant features for inclusion in the GPCR 
superfamily is the presence of a characteristic structure, consisting of seven 
predominantly hydrophobic stretches of 20-35 amino acids representing transmembrane 
α-helical domains, designated transmembrane domain 1-7 (TM1-TM7) [Allen et al., 2007]. 
These hydrophobic domains insert into the plasma membrane resulting in a protein which 
passes through the membrane seven times in an anti-clockwise manner to form an α-
helical bundle. The location of these hydrophobic domains creates a structure with an 
extracellular region consisting of an N-terminal domain and three extracellular loops 
(ECL1-ECL3), which form a pocket for interaction with the extracellular ligand; and an 
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intracellular region consisting of three intracellular loops (ICL1-ICL3) and a C-terminal 
domain, which interact with intracellular proteins to transduce the extracellular signal 
from ligand binding to the interior of the cell, figure 7.2. 
Figure 7.2 Schematic representations of chemokine receptor topology. Abbreviations: TM,
transmembrane domain; ECL, extracellular domain. [Figures from Fernandez & Lolis, 2002 and
Szpakowska et al., 2012].
With roughly 800 members in humans alone, GPCRs constitute the largest group of cell 
surface proteins involved in signal transduction [Fredriksson et al., 2003]. The sequence of 
these GPCRs ranges from a few hundred amino acids up to thousands in length, with most 
consisting of ~300-500 amino acids [Latek et al., 2012]. Generally speaking the 
extracellular region of GPCRs shows greater diversity in sequence length and identity, 
reflecting the diverse array of ligands which interact with members of this superfamily, 
such as hormones, peptides, amines, lipid mediators and photons [Allen et al., 2007]. While
the intracellular regions show greater similarity due to their interaction with a smaller 
subset of signal transduction and regulatory proteins [Latek et al., 2012]. Based around 
sequence similarities and the presence of different characteristic motifs a number of 
different classification schemes have been proposed for the GPCR superfamily, however, 
for human GPCRs the most widely accepted is the GRAFS system which involves the 
division into five main families: Glutamate (G), Rhodopsin (R), Adhesion (A), Frizzled/Taste2
(F) and Secretin (S) [Fredriksson et al., 2003]. The Rhodopsin family is by far the largest of 
these families with characteristic features of this family including comparatively short N-
terminal domains, a DRYLAIV or related motif at the TM3-ICL2 boundary, a CwxP motif in 
TM6 and a NPxxY motif in TM7 [Mirzadegan et al., 2003; Schioth & Fredriksson, 2005]. The 
Rhodopsin family can be further subdivided into four groups: α, β, γ and δ; and it is to the 
γ-Rhodopsin group which the chemokine receptors belong [Fredriksson et al., 2003].
Chemokine receptors can be broadly classified into two categories, firstly, the 'classical' 
chemokine receptors defined as those signalling via G proteins; while more recently there 
has been increased recognition of chemokine receptors which apparently lack signalling 
capabilities or signal in a G protein-independent manner which are now referred to as 
atypical chemokine receptors [Bachelerie et al, 2013].
The Chemokine receptor group has been further subdivided by the class of chemokine 
ligand they bind: CXC (α), CC (β), XC (γ) and CX3C (δ); since although they may bind 
multiple chemokine ligands, human chemokine receptors are generally considered 
restricted to binding ligands from a single chemokine class [Bacon et al., 2002; Zlotnik et 
149
A B
al. 2006]. In addition to this, generally speaking functional human chemokines act as 
agonists at their respective receptors [Murphy et al., 2000]. In much the same manner as 
chemokine nomenclature, the chemokine receptors are named according to the class of 
chemokine they bind followed by an 'R' denoting receptor and a distinguishing arabic 
numeral. [Murphy et al., 2000]. To date there has been formal recognition of 18 distinct 
chemokine receptors: 6 CXC class receptors designated CXCR1-CXCR6; 10 CC class 
receptors designated CCR1-CCR10; 1 XC class receptor designated XCR1 and 1 CX3C class 
receptor designated CX3CR1 [Bachelerie et al., 2013]. The binding profiles and commonly 
expressing cell types can be seen in figure 1.6 and table 1.2. As highlighted in table 1.2, 
while chemokine receptor expression is primarily regarded as a characteristic of 
leukocytes, it is not solely limited to them, indeed chemokine receptor expression has 
been noted on a wide variety of cell types including: epithelial cells [Dwinell et al., 1999; 
Jordan et al., 1999; Khurram et al., 2010], endothelial cells [Gupta et al., 1998], and a 
number of neuronal cell types [Bajetto et al., 1999; Flynn et al., 2003; Kremlev et al., 2004].
There is a second group of human receptors which retain chemokine binding properties 
and share structural homology to the G protein-coupled chemokine receptors but lack the 
ability to initiate 'classical' G protein signalling pathways upon ligand binding. In addition, 
these receptors generally also differ from their human G protein-coupled chemokine 
receptor counterparts in their unusual expression profiles, limited conservation of the 
important DRYLAIV G-protein signalling motif, and abilities to bind a broader range of 
chemokine ligands [Mantovani et al., 2006; Graham et al., 2012; Bachelerie et al, 2013]. 
While previously known under a variety of names (decoy/regulatory/silent/scavenger 
receptors), recently the nomenclature for this group of receptors has been standardised 
to atypical chemokine receptors (ACKRs) along with the formal recognition of four 
members of this group, designated ACKR1-ACKR4, and the provisional recognition of two 
further members [Bachelerie et al, 2013]. These receptors appear to play a vital role in the 
regulation of many aspects of the chemokine system through a 'fine tuning' of the 
chemokine levels at specific sites/tissues [Nibbs & Graham, 2013]. As such, dysregulation 
of these ACKRs has also been linked to important infectious disease and cancer 
pathologies.
7.1.4 Chemokine-Chemokine Receptor Interactions
Atomic structures of chemokine ligands in complex with their cognate receptors will be 
the key to fully understanding the basis of the interactions which define chemokine 
receptor binding and activation. However, structural determination of GPCRs has only 
really become viable in the past decade and still remains an ardours task. Therefore to 
date, mutagenesis studies and structural determination of peptide complexes have been 
the most readily employed methods  to gain insight into chemokine-receptor interaction. 
Such studies on a variety of different CC, CXC and CX3C chemokines and receptors have 
been key to providing insight into the interactions of the chemokines with their receptors. 
These studies have revealed a number of generalised concepts regarding the binding and 
signalling epitopes present on chemokines and chemokine receptors. 
The first of these is the the flexible N-terminal region preceding the first conserved 
cysteine residue contains the determinants which are primarily responsible for the 
signalling/receptor activation event subsequent to receptor recognition/binding. This is 
demonstrated by the fact that N-terminal truncation mutants, addition mutants or 
modification of residues within the first 10 amino acids of numerous chemokines have 
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frequently been found to result in molecules which maintain high affinity binding to the 
ligands native receptor while diminishing or completely abolishing receptor activation and 
signalling [Gong & Clark-Lewis, 1995; Jarnagin et al., 1999; Laurence et al., 2000; Bondue 
et al., 2002; Struyf et al., 1998; Proudfoot et al., 1996; Simmons et al., 1997; Pakianathan 
et al., 1997; McQuibban et al., 2002; Struyf et al., 1999; Ott et al., 2004; Liston et al., 2009; 
Ott et al., 2006; Shinkai et al., 2002; Moser et al., 1993; Campanella et al., 2003; Crump et 
al., 1997; McQuibban et al., 2001; Inoue et al., 2005]. In fact in vivo it seems chemokines 
may undergo natural post-translational proteolysis resulting in N-terminal truncations, as 
one means of modulating or regulating chemokine activity. [Berahovich et al., 2005; 
Proost et al., 2006; Mortier et al., 2012; Moelants et al., 2013]. Similarly the N-loop region 
that follows the first two conserved cysteine residues, connecting the N-terminus to the 
first of the three β-sheets, is the predominant region responsible for receptor specificity 
and high affinity binding [Hemmerich et al., 1999; Mayer & Stone, 2001; Lowman et al., 
1996; Schraufstatter et al., 1993; Hammond et al., 1996; Williams et al., 1996; Sarmiento et
al., 2011; Campanella et al., 2003].
The use of extracellular region mutant receptors, receptor chimeras and extracellular 
region peptides has been heavily employed to investigate the ligand interacting sites on 
chemokine receptors. From these, the receptors N-terminal domain has generally 
emerged as a strong candidate for the determination of the affinity and specificity of the 
chemokine binding interaction [Pease et al., 1998; Monteclaro & Charo, 1997; Ye et al., 
2000; Blanpain et al., 1999; Duma et al., 2007; Love et al., 2012; LaRosa et al., 1992; Hebert
et al., 1993; Clubb et al., 1994; Wu et al., 1996; Skelton et al., 1999; Rajagopalan & 
Rajarathnam, 2004; Prado et al., 2007; Park et al., 2011; Colvin et al., 2006; Gozansky et al., 
2005; Veldkamp et al., 2006; Veldkamp et al., 2008; Mizoue et al., 1999; Kokkoli et al., 
2005; Chen et al., 2006]. While regions in the receptors three ECLs and the ECL-TM 
boundaries have generally been implicated in the interactions which result in receptor 
activation and consequent signal transduction [Pease et al., 1998; Zoffmann et al., 2002; 
Han et al., 1999; Blanpain et al., 2003; Schnur et al., 2013; Ai et al., 2004; Wu et al., 1996; 
Katancik et al., 2000; Brelot et al., 2000; Chen et al., 2006].
As such this led to the proposition of a “two-site” model for the interaction of chemokines 
with their receptors, figure 7.3. In such a model the core globular domain of the 
chemokine initially interacts with sites in the N-terminal domain of the chemokine 
receptor (site I) an interaction which determines the affinity and specificity of the binding. 
This initial interaction positions the chemokine in such a manner allowing for a second set 
of interactions to occur between the receptors ECLs and the chemokines N-terminus (site 
II) and it is this interaction which was proposed to result in receptor activation. 
However, in many cases the ligand binding affinity, specificity and activation cannot be 
readily separated out into these two distinct sites [Rajagopalan & Rajarathnam, 2006; 
Chevigne et al., 2011]. In addition N-termini-N-loop derived peptides frequently display 
reduced activity when compared to the full length wild type counterparts, suggesting 
other regions of the chemokine must also be participating in the interactions that 
maintain wild-type activity [Fernandez & Lolis, 2002; Chevigne et al., 2011]. As such it 
seems that while still valid, this simplistic “two-site” model cannot fully explain the 
chemokine-receptor interactions. Regardless, from the observations it is clear that the N-
terminus of chemokine receptors represents an important interacting partner with the 
chemokine ligand, playing a role in shaping the affinity, specificity and/or receptor 
activation potential of the chemokine-receptor interaction. 
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Figure 7.3 Hypothetical model of the chemokine-receptor interaction [Figure from Allen et al.,
2007].
7.1.5 Chemokine Receptor Structure and Activation
While high resolution structures of soluble proteins, such as chemokines, have been 
comparatively easy to obtain, those of membrane proteins, such as the chemokine 
receptor GPCRs, has posed a much greater challenge. Purification of the proteins from the
membrane in their native state and crystallisation, especially of flexible GPCRs, has posed 
a great deal of problems. However, recent advances in a number of methodologies 
required to obtain high resolution structures of membrane proteins such as membrane 
extraction, protein stabilisation, and obtaining structures without crystals, have allowed a 
number of GPCR structures to be obtained [Baker, 2010]. These include the high 
resolution structures of three chemokine receptors, CXCR4, CXCR1 and CCR5 [Wu et al., 
2010; Park et al., 2012; Tan et al., 2013]. These structures have helped to provide huge 
insight into the mechanism of action of the members of the Rhodopsin-like family.
GPCRs possess 7 transmembrane (TM) hydrophobic α-helical domains, corresponding in 
size to the thickness of the plasma membrane. These insert into the membrane resulting 
in a protein passing through the membrane 7 times in an anti-clockwise manner to form an
α-helical bundle with an extracellular ligand binding pocket and an intracellular signal 
transduction interface. Binding of a ligand to the extracellular surface induces and 
stabilises small conformational changes in the extracellular binding pocket. These 
conformational changes are propagated through the transmembrane portion of the 
receptor due to rotation and rearrangement of the TM helices of the receptor bundle 
relative to one another [Katrich et al., 2013]. These movements represent receptor 
activation and this modification of the tertiary structure results in larger conformational 
changes on the intracellular side of the receptor exposing previously masked binding sites 
on the intracellular side of the receptor. Interaction with signal transduction proteins at 
these intracellular binding sites, allows for relay of the external signal of ligand binding 
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across the membrane to proteins to initiate signalling cascades and bring about the 
relevant responses [Katrich et al., 2013].  GPCRs, therefore represent fluid structures 
which can adopt a number of different conformational states. The binding of an agonist 
shifts the conformation towards an active conformation. However, for some GPCRs, 
predominantly those, like chemokine receptors, which possess the ability to interact and 
be activated by a number of different ligands, there is often not just a single activation 
conformation. There is increasing recognition of so called 'functional selectivity' or 'biased 
agonism' in a number of GPCRs whereby the different agonists of a single GPCR can 
stabilise distinct active receptor conformations permitting more favourable interactions 
with different downstream effectors, thus allowing alternative downstream effects to be 
mediated through a single GPCR [Rajagopal et al., 2013]. In addition, there is also 
increasing evidence that the availability of downstream effectors in the cell can also play a 
role in determining ligand binding [Sprang, 2011]. As such, the notion of GPCRs being 
simple on/off switches is now largely dismissed.
The N-termini of the chemokine receptors have a number of common characteristics. In 
comparison to other GPCRs, chemokine receptors possess relatively short N-terminal 
regions (generally predicted N-terminal sequences are 25-60 amino acids in length) 
[Szpakowska et al., 2012]. The majority of chemokine receptors also contain conserved 
cysteine and proline residues in the N-terminal domain, the cysteine likely participates in a 
disulphide bond with another conserved cysteine found in ECL3 linking TM1 and TM7, and 
interaction which is aided by the presence of the proline and its conformational effects on 
protein structure [Rana & Baranski, 2010; Wu et al., 2010; Park et al., 2012]. This conserved
cysteine has also been the basis for a division of the N-terminus into two functional 
domains. Firstly the 5' region from the starting methionine to the conserved cysteine and 
the 3' region from the conserved cysteine to the start of TM1. The 5' region is believed to 
be much more flexible than the 3', consistent with this being the region for which 
structural data has yet to be resolved. This 5' region also possesses an overall negative 
charge and is much more variable than the 3' region, both in sequence identity and length 
[Szpakowska et al., 2012]. Features which seem to be consistent with the notion of ligand 
binding and the selectivity of this ligand binding. Finally this 5' region also generally 
contains residues which has been shown or are predicted to be post-translationally 
modified. Such as be the presence of sulfated tyrosines [Farzan et al., 1999, 2002;  
Preobrazhensky et al., 2000; Fong et al., 2002; Colvin et al., 2006] and glycosylation sites 
[Ludwig et al., 2000; Preobrazhensky et al., 2000; Bannert et al., 2001], again features 
which have at least in part been linked to protein-protein interactions.
7.1.6 G proteins
The classically recognised means of GPCR signal transduction involves the activated 
receptor engaging and acting as a guanine nucleotide exchange factor for heterotrimeric 
G proteins. These proteins, as the name suggests, are formed from the association of 
three subunits designated Gα, Gβ and Gγ, of which there are a number of different types. 
To date, 16  Gα, 5 Gβ and 12 Gγ genes have been identified in the human genome, many of
which can be subject to alternative splicing and post-translational modification providing 
further diversity [Downes & Gautam, 1999]. Typically, G proteins are classified into four 
groups, Gαi/o Gαs Gαq/11 Gα12/13, based upon sequence homology of the Gα subunit and 
abilities to regulate distinct classes of downstream regulators [Simon et al., 1991]. The 
majority of chemokine receptors have been found to mediate their signals through Gα i/o 
group proteins with regard to chemotactic responses, although signalling via alternative G 
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proteins has been suggested for some human receptors [Neptune & Bourne, 1997; New & 
Wong, 2003; Shi et al., 2007].
While the mechanics of the G protein-receptor interactions and the molecular basis for G 
protein selectivity remain hotly debated topics, there is a relatively well established 
'classical' view of G protein signalling. In their inactive state G proteins exist as GDP 
associated trimer anchored to the intracellular face of the plasma membrane, placing 
them in close proximity to the GPCR. Receptor activation allows for interaction with the 
heterotrimeric G protein, the receptor acting as a guanine exchange factor induces 
conformational changes in the Gα subunit causing an exchange of its bound GDP for a GTP
which is present in much higher concentrations in the cytosol [Offermanns, 2003]. This 
binding of GTP represents initiation of the G protein activation cycle and it is believed to 
cause the Gα subunit to dissociate from the Gβγ dimer, which remain as an undissociable 
complex at physiological conditions. The separated Gα-GTP and Gβγ subunits are then free
to modulate a variety of different cytosolic effectors, in addition to promoting increases in
the intracellular concentration of Ca2+ and the opening or closing of ion channels 
[Wettschureck & Offermanns, 2005]. The Gα subunit possesses a GTPase domain whose 
inherent activity leads to the hydrolysis of the bound GTP to GDP. This hydrolysis leads to 
an increase in the affinity of the Gβγ for the Gα-GDP subunit, in turn leading to 
reassociation of the two subunits to reform the heterotrimer. The heterotrimeric G 
protein is then available for initiation of a new activation cycle  [Offermanns, 2003]. 
However, as outlined below in section 7.1.7 a number of cytosolic accessory proteins are 
also intimately involved in control of the G protein activation, signalling and termination.
A broad array of downstream effectors have been found to be stimulated by these 
activated G protein subunits including PI3K, phospholipase Cβ2 and β3, phospholipase A3, 
and phospholipase D; mitogen-activated protein kinases (MAPK); ion channels and tyrosine
kinases [Bachelerie et al., 2013]. With importance of these effectors varying in receptor 
and cell type dependent manners. In addition a multitude of cellular regulatory 
mechanisms are in place to ensure tight control of receptor signalling following activation.
In addition, G protein mediated stimulation of downstream effectors does not represent 
the only signalling consequence of chemokine receptor activation. More recently, there 
has also been an increased appreciation of G protein independent GPCR signalling, 
primarily mediated by β-arrestins. Initially these arrestin proteins were though to act as 
signal terminators, discussed in section 7.1.7. However, through scaffolding of various 
signalling molecules both the stimulatory and inhibitory capacity of this β-arrestin 
mediated signalling is becoming apparent, adding a further level of complexity to 
chemokine receptor signalling [Musnier et al., 2010].
7.1.7 Regulation of Chemokine Receptor Signalling
Signalling from a chemokine receptor represents a transient event. While the GTPase 
activity of the G protein Gα subunit is one of the major determinants of signal termination,
the extent and duration of signalling is tightly regulated by a number of other 
mechanisms. These processes prevent both excessive stimulation of cells as well as 
insensitivity to ligands.
Firstly, the GTPase activity of the Gα subunit can be modulated by members of the 
regulators of G-protein signalling (RGS) protein family. These proteins act to increase or 
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decrease the rate of GTPase activity of the G protein Gα subunit, thus accelerating or 
inhibiting the termination of the G-protein signalling [Bowman et al., 1998; Ross & Wilkie, 
2000]. Secondly, following ligand induced activation receptors are generally considered to 
be rapidly desensitised and internalised [Sorkin & von Zastrow, 2002]. However, this 
paradigm may not hold true as there is now increasing recognition that G protein 
dependent and independent GPCR signalling can occur from endosomal compartments 
[Irannejad et al., 2013]. Regardless, this internalisation downregulates the level of 
receptor surface expression, thereby attenuating further ligand induced receptor 
activation, in a manner that has been shown to be independent of G protein signalling [van
Koppen & Jakobs, 2004]. Activated receptors are rapidly phosphorylated by GPCR kinases 
(GRKs) on intracellular domains, predominantly found in the C-terminal tail and ICL3 [Ritter
& Hall, 2009]. Phosphorylation of the receptors permits their association with arrestin 
proteins, which play a variety of roles in the modulation of GPCR activity. The binding of 
arrestin proteins sterically inhibits the association of the receptor with G proteins [Vroon 
et al., 2006]. Arrestins themselves can also initiate signalling pathways distinct from those 
of the G proteins [Violin & Lefkowitz, 2007]. But their most well known role is to act as 
adapters, coupling the receptor to the machinery of the clathrin-mediated endocytosis 
pathway  thus permitting endocytosis of the activated receptor to an endosomal 
compartment [Wolfe & Trejo 2007]. Following endocytosis the receptor can follow 
divergent pathways, the endosome may be targeted to lysosomes for receptor 
degradation or alternatively resensitisation of the receptor through ligand removal, 
dephosphorylation and recycling back to the cell surface [Kelly et al., 2008]. Thirdly, 
heterologous desensitisation may occur, whereby the downstream signalling responses to 
ligand stimulated activation at one receptor acts to desensitise other activated or 
unactivated receptors on the responding cell [Richardson et al., 1995; Kelly et al., 2008]. 
7.1.8 Chemokine Receptor Dimerisation
In addition to their association with downstream signalling and regulatory components in 
lipid rafts. It is becoming increasingly clear that chemokine receptors are also capable of 
associating with other chemokine receptors in cell membranes. Predominantly through 
the methods of co-immunoprecipation, fluorescence resonance energy transfer (FRET) 
and bioluminescence resonance energy transfer (BRET) it has now been demonstrated 
that a number of CC (CCR2 and CCR5) [Percherancier et al., 2005; Hernanz-Falcon et al., 
2004; Springael et al., 2006] and CXC (CXCR1, CXCR2, CXCR4) [Wilson et al., 2005; 
Hamatake et al., 2009; Levoye et al., 2009] chemokine receptors possess the ability to 
form homo- and hetero- dimers/oligomers. To date, the full significance of such 
dimerisation with regards to functional consequences remains uncertain, however, a 
number of theories have been proposed.
The detection of dimerised receptors in the ER/Golgi [Issafras et al., 2002; Singer et al., 
2001] has led to suggestions that receptor dimerisation may play a role in the regulation 
of receptor trafficking to the cell surface. Support is added to this idea, through the 
finding that the co-expression of cytoplasmically retained mutant chemokine receptors 
with wild-type receptors leads to significant downregulation of the the wild-type receptor 
expression via retention in the ER [Wilson et al., 2005; Chelli & Alizon, 2001].  
A large amount of evidence also appears to suggest heterodimerisation may represent a 
means of allosteric modulation, whereby the ligands of one receptor in the heterodimer, 
reduce or prevent binding of the ligands of the other receptor in the heterodimer. This has
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been shown most extensively with CCR2 and its dimerisation with CCR5 and CXCR4, in 
which CCR5 and CXCR4 ligands acting at their respective receptors in the heterodimer 
with CCR2 actually inhibit the action of CCR2 ligands at CCR2 [El-Asmar et al., 2005; 
Springael et al., 2006; Sohy et al., 2007]. But similar results have also been demonstrated 
for some of the ACKRs, ACKR1 and its inhibition of CCR5 activation [Chakera et al., 2008] 
and ACKR3 and CXCR4 [Levoye et al., 2009]. Chemokine receptors have also been found to
form heterodimers with other non chemokine receptor GPCRs, both CXCR2 and CXCR4 
have been found to heterodimerise with opioid receptors again with the potential for 
allosteric modulation [Parenty et al., 2008; Pello et al., 2008]. Finally, while not explicitly 
demonstrated amongst the chemokine receptors, studies on other GPCRs have also 
implicated dimerisation in the modulation of both ligand binding affinities and the 
activation of downstream signalling pathways [Jordan & Devi, 1999; Terrillon & Bouvier, 
2004]. While the true functional consequences of dimerisation have yet to be determined, 
it is clear that dimerisation is likely to play another important regulatory role in 
chemotactic responses, as well as adding yet further complexities to be overcome in the 
understanding of the chemokine system.
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7.2 HHV-6A strain AJ Gene List

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.3 Nucleotide Sequence Alignment of Suspected Chromosome 17p13.3 CI-HHV-
6A Integration Site Junctions
Clustal W2 [Larkin et al., 2007] alignment with manual adjustments of the nucleotide 
sequences of the 12 amplified CI-HHV-6A integration site junctions, as described in section
4.2 and summarised in figure 4.2. Grey shading indicates readily identifiable subtelomeric 

























































































































































































































































7.4  Alignments for Determination of Practical Level of Read Coverage for 
Accurate Sequence Resolution
The parameters used for both variant call methods required any variants to be present in a
minimum of 5 reads for variant calling to occur, a value chosen to minimise false positive 
results. This defined a theoretical read coverage limit required for accurate sequence 
generation from the mapped assemblies. The work sequencing HHV-6A strain AJ, shown 
in section 3.2 and table 3.1, indicated that a minimum read coverage of 16 was sufficient 
to accurately call variants across the CDS one of the most diverse genes in the HHV-6A 
genome, U100. However, the fact that a number of genes from the CI-HHV-6A samples 
had been subjected to Sanger capillary sequencing for alternative lines of work described 
in Tweedy et al., 2015a, using the primer sequences outlined in section 2.3.3, provided 
further means to ascertain a practical level of read coverage required for accurate variant 
calling in these samples. For this, read coverage was calculated across each of these genes,
while the nucleotide identity of the consensus sequence generated by NGS was compared 
to that obtained via Sanger capillary sequencing, table 7.1.
Table 7.1 Determination of practical level of read coverage for accurate genome sequence
resolution. Pairwise comparisons of the nucleotide sequence of genes subjected to both NGS and
Sanger sequencing. Differences in sequence identity are indicated in red. Full alignments of these
genes are below.
This indicated that a minimum read coverage of 10, seen in the U51 gene from CI-HHV-6A 
sample 2284, still permitted accurate variant calling. While U51 represents a relatively 
conserved gene amongst HHV-6A, there are clear differences in the gene between strain 
U1102 and the Sanger amplification from CI-HHV-6A 2284 (99.67% nucleotide identity 
between the sequences, variation in this gene is also discussed further in section 5.2). All 
these sites of variation were accurately called by the NGS protocol used here, full 
alignment of these sequences alongside the U1102 reference used for the mapping 
assembly is shown below. 
To further define this level, the read coverage required for the correct identification of 
SNPs in the U47 gene, the variable glycoprotein O, was further investigated for CI-HHV-6A 
isolate 5055, alignment shown in appendix 7.4.7. This showed accurate resolution at a 
read depth of greater than 7 reads utilising the read assembly and variant analyses 
methods here. Thus for the purposes of the work with these CI-HHV-6A genomes 
described below, a minimum read coverage of 8 or greater across a genes CDS was applied
as a cut-off for inclusion in further analysis. Table 4.3 highlights 14 genes where one or 
more of CI-HHV-6A genomes possessed read coverage below this defined limit. Therefore 
while reads covered these CDS features, sequencing errors  had the potential to confound 
these sequence, as such these genes were excluded from downstream analyses. 
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CI-HHV-6A 2284 CI-HHV-6A 5055 CI-HHV-6A 5814
CDS
U38 119.46 44 100 7710.53 2614 100 1566.01 628 100
U46 202.74 182 100 7.04 4 99.61 4124.52 3774 100
U47 184.77 51 100 7.61 2 98.16 3707.86 1396 100
U51 18.06 10 100 3.57 0 99.67 1.04 0 99.56
U65 100.41 72 100 5.64 0 97.72 40.03 26 100

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.7 Alignment of the Origin of Lytic Replication of CI-HHV-6A
The origin of lytic replication [Turner et al., 2002] of ciHHV-6A isolates 2284, 5055 and 
























































































































































































7.8 Optimisation of CCR5 Surface Expression 
Steps were taken to optimise transient surface expression through investigation of several
factors affecting electroporation and subsequent recombinant gene expression. Optimal 
gene expression is typically achieved with electroporation during early log phase. 
Therefore the growth rate of the cell lines was assessed under the defined equipment and
laboratory conditions from Vaidehi et al., 2009, figure 7.4. Additionally the duration of 
time following transfection and amount of receptor construct plasmid DNA transfected 
were also considered with regards to there effects on construct cell surface expression, 
figures 7.5 and 7.6. Due to reagent constraints these were tested with expression of the 
human chemokine receptor CCR5 and an anti-CCR5 antibody. These defined a set of 
conditions which would be utilised to allow for maximal surface expression of the receptor
constructs, reproducibility between assays but also take into consideration practical 
requirements of total cell numbers required for the downstream applications. Cells were 
subsequently electroporated when cultured cell density was ~0.9  x 106 cells/ml, to ensure 
they were in early log phase. Electroporation occurred with 2 μg of plasmid DNA/1 x 106 
cells, then cells were cultured for a further 48hrs before downstream analysis
Figure 7.4 L1.2 cell growth time curve. Log phase indicated by dashed lines.
Figure 7.5 Surface expression of CCR5 at time points following transfection. Shaded with
black outline indicates no stain. Orange indicated isotype control staining. Blue indicates
anti-CCR5 staining. Times indicate number of hours post transfection.
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Log phase
24 hrs 48 hrs 72 hrs
Figure 7.6 Effect of transfected DNA on surface expression of CCR5 at 48 hours post
transfection. Shaded with black outline indicates no stain. Orange indicated isotype
control staining. Blue indicates anti-CCR5 staining. Quantities represent the total amount
of CCR5 plasmid DNA transfected. 2 μg DNA/1x106 cells was the maximum tested due to
concerns about altering the electroporation buffer, due to the low overal volume.
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0.5 µg DNA/1x106 cells 1 µg DNA/1x106 cells 2 µg DNA/1x106 cells 
7.9 Generation of Stably Expressing Cell Lines
Cells were transfected, as described in section 2.12.4, concurrently with an experimental 
vector or the pEGFP vector (Clontech, Mountain View, California, USA). Transfected cells 
were then grown, as described in section 2.12.1, but additionally placed under selection 
through the addition of 400 μg/ml Geneticin (G418) (Life Techologies, Paisley, UK). Cells 
were grown for ~3 weeks in selective media until complete selection, as determined by 
100% live cell EGFP expression. Cell stocks of experimentally transfected cells were then 
prepared as described in section 2.12.2. 
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7.10 Actin Polymerisation Assay
Actin polymerisation assays were performed based on those described previously [Burger 
et al., 2005; Udi et al., 2013]. 1.5 x 106 cells/ml or receptor transfected cells were 
centrifuged and resuspended in RPMI 1640/0.5% BSA (both  Sigma Aldrich, Gillingham, 
UK). Cells were then stimulated with relevant chemokine, at 0, 15, 60, and 120 second 
time points 400 μl of the stimulated cells was mixed with 100 μl of a dying solution and 
incubated for 20 minutes at room emperature. The dying solution consisted of 50 μg/ml  
fluorescein isothiocyanate (FITC)-labeled phalloidin, 1 mg/ml L-α-lysophosphatidylcholine 
and 37% formaldehyde in phosphate-buffered saline (all from Sigma Aldrich, Gillingham, 
UK). Cells were then washed twice by centrifugation at 400 g for 4 minutes in a Mistral 
3000i centrifuge (MSE, Lower Sydenham, UK) and resuspension in PBS 1640/0.1% BSA 
(both Sigma Aldrich, Gillingham, UK). Intracellular F-actin was analysed by flow cytometry 
by comparison to a baseline of mean fluorescence prior to chemokine addition.
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